1	Gene	gene	NN	_	3	compound
2	expression	expression	NN	_	3	compound
3	analysis	analysis	NN	_	4	nsubj
4	indicated	indicate	VBD	_	0	ROOT
5	an	a	DT	_	6	det
6	association	association	NN	_	4	dobj
7	between	between	IN	_	8	case
8	genotypes	genotype	NNS	_	6	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	drug1	drug1	NN	_	12	compound
12	variant	variant	NN	_	8	nmod
13	and	and	CC	_	12	cc
14	CHRNA5	chrna5	NN	_	12	conj
15	expression	expression	NN	_	12	dep
16	in	in	IN	_	17	case
17	brain	brain	NN	_	12	nmod
18	and	and	CC	_	17	cc
19	peripheral	peripheral	JJ	_	20	amod
20	drug2	drug2	NN	_	17	conj
21	,	,	,	_	4	punct
22	and	and	CC	_	4	cc
23	with	with	IN	_	28	case
24	the	the	DT	_	28	det
25	rs16969968	rs16969968	NN	_	28	compound
26	and	and	CC	_	25	cc
27	rs17477223	rs17477223	NN	_	25	conj
28	variants	variant	NNS	_	4	conj
29	in	in	IN	_	30	case
30	brain	brain	NN	_	28	nmod
31	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	aim	aim	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	assess	assess	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	effect	effect	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	6	punct
14	the	the	DT	_	15	det
15	intake	intake	NN	_	13	root
16	of	of	IN	_	19	case
17	saturated	saturated	JJ	_	19	amod
18	fatty	fatty	JJ	_	19	amod
19	acids	acid	NNS	_	15	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	SFA	sfa	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	,	,	,	_	15	punct
24	and	and	CC	_	15	cc
25	drug2	drug2	NN	_	15	conj
26	on	on	IN	_	29	case
27	serum	serum	NN	_	29	compound
28	lipid	lipid	NN	_	29	compound
29	levels	level	NNS	_	25	nmod
30	in	in	IN	_	33	case
31	Lithuanian	lithuanian	JJ	_	33	amod
32	adult	adult	JJ	_	33	amod
33	population	population	NN	_	15	nmod
34	.	.	.	_	15	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	11	nsubjpass
4	,	,	,	_	3	punct
5	SFA	sfa	NN	_	6	compound
6	intake	intake	NN	_	3	conj
7	,	,	,	_	3	punct
8	and	and	CC	_	3	cc
9	drug2	drug2	NN	_	3	conj
10	were	be	VBD	_	11	auxpass
11	found	find	VBN	_	1	appos
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	auxpass
14	associated	associate	VBN	_	11	xcomp
15	with	with	IN	_	18	case
16	blood	blood	NN	_	18	compound
17	lipid	lipid	NN	_	18	compound
18	levels	level	NNS	_	14	nmod
19	in	in	IN	_	22	case
20	Lithuanian	lithuanian	JJ	_	22	amod
21	adult	adult	JJ	_	22	amod
22	population	population	NN	_	18	nmod
23	.	.	.	_	1	punct

1	Analysis	analysis	NN	_	9	nsubj
2	of	of	IN	_	6	case
3	gene-diet	gene-diet	JJ	_	6	amod
4	and	and	CC	_	3	cc
5	gene-obesity	gene-obesity	JJ	_	3	conj
6	interactions	interaction	NNS	_	1	nmod
7	did	do	VBD	_	9	aux
8	not	not	RB	_	9	neg
9	confirm	confirm	VB	_	0	ROOT
10	that	that	IN	_	23	mark
11	the	the	DT	_	12	det
12	effects	effect	NNS	_	23	nsubj
13	of	of	IN	_	14	case
14	diet	diet	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	on	on	IN	_	18	case
18	TC	tc	NN	_	12	nmod
19	and	and	CC	_	18	cc
20	LDL-C	ldl-c	NN	_	21	compound
21	level	level	NN	_	18	conj
22	significantly	significantly	RB	_	23	advmod
23	depended	depend	VBD	_	9	ccomp
24	on	on	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	.	.	.	_	9	punct

1	Inside	inside	IN	_	3	case
2	this	this	DT	_	3	det
3	region	region	NN	_	19	nmod
4	of	of	IN	_	6	case
5	16.3	16.3	CD	_	6	nummod
6	kb	kb	NN	_	3	nmod
7	,	,	,	_	19	punct
8	LD	ld	NN	_	19	nsubjpass
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	r2	r2	NN	_	8	dep
11	=	=	JJ	_	10	amod
12	0.14	0.14	CD	_	11	dep
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	between	between	IN	_	15	case
15	drug1	drug1	NN	_	8	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	was	be	VBD	_	19	auxpass
19	observed	observe	VBN	_	0	ROOT
20	in	in	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	,	,	,	_	21	punct
23	but	but	CC	_	21	cc
24	not	not	RB	_	26	neg
25	in	in	IN	_	26	case
26	drug4	drug4	NN	_	21	conj
27	and	and	CC	_	26	cc
28	in	in	IN	_	29	case
29	controls	control	NNS	_	26	conj
30	.	.	.	_	19	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	the	the	DT	_	6	det
5	discovery	discovery	NN	_	6	compound
6	population	population	NN	_	9	nmod
7	,	,	,	_	9	punct
8	we	we	PRP	_	9	nsubj
9	observed	observe	VBD	_	1	dep
10	an	a	DT	_	11	det
11	association	association	NN	_	9	dobj
12	between	between	IN	_	16	case
13	SIRT2	sirt2	NN	_	16	compound
14	drug1	drug1	NN	_	16	compound
15	T	t	NN	_	16	compound
16	allele	allele	NN	_	11	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	adjusted	adjust	VBN	_	22	amod
21	odds	odds	NNS	_	22	compound
22	ratio	ratio	NN	_	9	dep
23	-LSB-	-lsb-	-LRB-	_	24	punct
24	OR	or	NN	_	22	appos
25	-RSB-	-rsb-	-RRB-	_	24	punct
26	=	=	JJ	_	22	amod
27	1.23	1.23	CD	_	26	dep
28	,	,	,	_	22	punct
29	95	95	CD	_	30	compound
30	%	%	NN	_	32	amod
31	confidence	confidence	NN	_	32	compound
32	interval	interval	NN	_	22	appos
33	-LSB-	-lsb-	-LRB-	_	34	punct
34	CI	ci	NN	_	32	appos
35	-RSB-	-rsb-	-RRB-	_	34	punct
36	:	:	:	_	22	punct
37	1.02-1	1.02-1	CD	_	38	compound
38	.50	.50	CD	_	22	dep
39	,	,	,	_	38	punct
40	P	p	NN	_	41	nsubj
41	=	=	JJ	_	38	acl:relcl
42	.02	.02	CD	_	41	dobj
43	,	,	,	_	38	punct
44	after	after	IN	_	45	case
45	correction	correction	NN	_	38	nmod
46	for	for	IN	_	47	case
47	sex	sex	NN	_	45	nmod
48	,	,	,	_	47	punct
49	age	age	NN	_	47	conj
50	,	,	,	_	47	punct
51	and	and	CC	_	47	cc
52	APOE	APOE	NNP	_	54	compound
53	e4	e4	NN	_	54	compound
54	genotype	genotype	NN	_	47	conj
55	-RRB-	-rrb-	-RRB-	_	22	punct
56	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	association	association	NN	_	12	nsubj
3	between	between	IN	_	4	case
4	drug2	drug2	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	SIRT2	sirt2	NN	_	9	compound
7	drug1	drug1	NN	_	9	compound
8	T	t	NN	_	9	compound
9	allele	allele	NN	_	4	conj
10	was	be	VBD	_	12	cop
11	only	only	RB	_	12	advmod
12	present	present	JJ	_	0	ROOT
13	in	in	IN	_	16	case
14	APOE	APOE	NNP	_	16	compound
15	e4	e4	NN	_	16	compound
16	noncarriers	noncarrier	NNS	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	adjusted	adjust	VBN	_	19	amod
19	OR	or	NN	_	16	dep
20	=	=	JJ	_	19	amod
21	1.29	1.29	CD	_	20	dep
22	,	,	,	_	19	punct
23	95	95	CD	_	24	compound
24	%	%	NN	_	25	amod
25	CI	ci	NN	_	19	appos
26	:	:	:	_	19	punct
27	1.03-1	1.03-1	CD	_	28	compound
28	.61	.61	CD	_	19	dep
29	,	,	,	_	19	punct
30	P	p	NN	_	31	nsubj
31	=	=	JJ	_	19	dep
32	.03	.03	CD	_	31	dobj
33	-RRB-	-rrb-	-RRB-	_	19	punct
34	.	.	.	_	12	punct

1	Over	over	IN	_	4	case
2	an	a	DT	_	4	det
3	average	average	JJ	_	4	amod
4	period	period	NN	_	19	nmod
5	of	of	IN	_	7	case
6	three	three	CD	_	7	nummod
7	years	year	NNS	_	4	nmod
8	,	,	,	_	19	punct
9	participants	participant	NNS	_	19	nsubj
10	with	with	IN	_	14	case
11	the	the	DT	_	14	det
12	risk-conferring	risk-conferring	JJ	_	14	amod
13	TT	tt	NN	_	14	compound
14	genotype	genotype	NN	_	9	nmod
15	at	at	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	were	be	VBD	_	19	cop
18	more	more	RBR	_	19	advmod
19	likely	likely	JJ	_	0	ROOT
20	to	to	TO	_	21	mark
21	have	have	VB	_	19	xcomp
22	progression	progression	NN	_	21	dobj
23	from	from	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	to	to	TO	_	26	case
26	drug3	drug3	NN	_	22	nmod
27	than	than	IN	_	28	dep
28	were	be	VBD	_	19	dep
29	CC	cc	NN	_	30	compound
30	homozygotes	homozygote	NNS	_	28	nsubj
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	hazard	hazard	NN	_	33	compound
33	ratio	ratio	NN	_	30	dep
34	,	,	,	_	33	punct
35	1.55	1.55	CD	_	33	amod
36	;	;	:	_	33	punct
37	95	95	CD	_	40	nummod
38	percent	percent	NN	_	40	compound
39	confidence	confidence	NN	_	40	compound
40	interval	interval	NN	_	33	dep
41	,	,	,	_	40	punct
42	1.20	1.20	CD	_	44	compound
43	to	to	TO	_	44	dep
44	2.01	2.01	CD	_	40	appos
45	;	;	:	_	33	punct
46	P	p	NN	_	33	dep
47	<	<	JJR	_	46	amod
48	0.001	0.001	CD	_	47	dep
49	-RRB-	-rrb-	-RRB-	_	33	punct
50	.	.	.	_	19	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	frequency	frequency	NN	_	9	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	did	do	VBD	_	9	aux
8	not	not	RB	_	9	neg
9	differ	differ	VB	_	1	dep
10	between	between	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	controls	control	NNS	_	13	conj
16	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicated	indicate	VBD	_	0	ROOT
4	that	that	IN	_	13	mark
5	homozygous	homozygous	JJ	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	carriers	carrier	NNS	_	13	nsubj
8	aged	aged	JJ	_	7	acl
9	35	35	CD	_	10	nummod
10	years	year	NNS	_	8	dobj
11	or	or	CC	_	10	cc
12	older	older	JJR	_	10	conj
13	had	have	VBD	_	3	ccomp
14	worse	worse	JJR	_	15	amod
15	drug2	drug2	NN	_	13	dobj
16	than	than	IN	_	18	case
17	heterozygous	heterozygous	JJ	_	18	amod
18	carriers	carrier	NNS	_	15	nmod
19	and	and	CC	_	18	cc
20	noncarriers	noncarrier	NNS	_	18	conj
21	.	.	.	_	3	punct

1	Nine	nine	CD	_	2	nummod
2	loci	locus	NNS	_	5	nsubjpass
3	were	be	VBD	_	5	auxpass
4	statistically	statistically	RB	_	5	advmod
5	associated	associate	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	incident	incident	NN	_	9	compound
8	drug10	drug10	NN	_	9	compound
9	events	event	NNS	_	5	nmod
10	in	in	IN	_	12	case
11	white	white	JJ	_	12	amod
12	participants	participant	NNS	_	9	nmod
13	:	:	:	_	5	punct
14	9p21	9p21	NN	_	5	dep
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug1	drug1	NN	_	14	dep
17	;	;	:	_	16	punct
18	P	p	NN	_	19	nsubj
19	=	=	JJ	_	16	dep
20	4.7	4.7	CD	_	22	nummod
21	*	*	SYM	_	22	dep
22	10	10	CD	_	19	dobj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	-41	-41	CD	_	19	dep
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	-RRB-	-rrb-	-RRB-	_	16	punct
27	,	,	,	_	14	punct
28	16q23	16q23	NN	_	29	compound
29	.1	.1	NN	_	14	conj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	drug2	drug2	NN	_	29	dep
32	;	;	:	_	31	punct
33	P	p	NN	_	34	nsubj
34	=	=	JJ	_	31	dep
35	0.0004	0.0004	CD	_	34	dobj
36	-RRB-	-rrb-	-RRB-	_	31	punct
37	,	,	,	_	14	punct
38	6p24	6p24	JJ	_	39	amod
39	.1	.1	NN	_	14	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	drug3	drug3	NN	_	39	dep
42	;	;	:	_	41	punct
43	P	p	NN	_	44	nsubj
44	=	=	JJ	_	41	dep
45	0.0002	0.0002	CD	_	44	dobj
46	-RRB-	-rrb-	-RRB-	_	41	punct
47	,	,	,	_	14	punct
48	2q36	2q36	JJ	_	49	amod
49	.3	.3	NN	_	14	conj
50	-LRB-	-lrb-	-LRB-	_	51	punct
51	drug4	drug4	NN	_	49	dep
52	;	;	:	_	51	punct
53	P	p	NN	_	54	nsubj
54	=	=	JJ	_	51	dep
55	6.7	6.7	CD	_	57	nummod
56	*	*	SYM	_	57	dep
57	10	10	CD	_	54	dobj
58	-LRB-	-lrb-	-LRB-	_	59	punct
59	-6	-6	CD	_	54	dep
60	-RRB-	-rrb-	-RRB-	_	59	punct
61	-RRB-	-rrb-	-RRB-	_	51	punct
62	,	,	,	_	14	punct
63	MTHFD1L	mthfd1l	NN	_	14	conj
64	-LRB-	-lrb-	-LRB-	_	65	punct
65	drug5	drug5	NN	_	63	dep
66	,	,	,	_	65	punct
67	P	p	NN	_	68	nsubj
68	=	=	JJ	_	65	dep
69	5.1	5.1	CD	_	71	nummod
70	*	*	SYM	_	71	dep
71	10	10	CD	_	68	dobj
72	-LRB-	-lrb-	-LRB-	_	73	punct
73	-10	-10	CD	_	68	dep
74	-RRB-	-rrb-	-RRB-	_	73	punct
75	-RRB-	-rrb-	-RRB-	_	65	punct
76	,	,	,	_	14	punct
77	APOE	apoe	NN	_	14	conj
78	-LRB-	-lrb-	-LRB-	_	79	punct
79	drug6	drug6	NN	_	77	dep
80	;	;	:	_	79	punct
81	P	p	NN	_	82	nsubj
82	=	=	JJ	_	79	dep
83	2.7	2.7	CD	_	85	nummod
84	*	*	SYM	_	85	dep
85	10	10	CD	_	82	dobj
86	-LRB-	-lrb-	-LRB-	_	87	punct
87	-18	-18	CD	_	82	dep
88	-RRB-	-rrb-	-RRB-	_	87	punct
89	-RRB-	-rrb-	-RRB-	_	79	punct
90	,	,	,	_	14	punct
91	ZNF627	znf627	NN	_	14	conj
92	-LRB-	-lrb-	-LRB-	_	93	punct
93	drug7	drug7	NN	_	91	dep
94	;	;	:	_	93	punct
95	P	p	NN	_	96	nsubj
96	=	=	JJ	_	93	dep
97	5.0	5.0	CD	_	99	nummod
98	*	*	SYM	_	99	dep
99	10	10	CD	_	96	dobj
100	-LRB-	-lrb-	-LRB-	_	101	punct
101	-8	-8	CD	_	96	dep
102	-RRB-	-rrb-	-RRB-	_	101	punct
103	-RRB-	-rrb-	-RRB-	_	93	punct
104	,	,	,	_	14	punct
105	CXCL12	cxcl12	NN	_	14	conj
106	-LRB-	-lrb-	-LRB-	_	107	punct
107	drug8	drug8	NN	_	105	dep
108	;	;	:	_	107	punct
109	P	p	NN	_	110	nsubj
110	=	=	JJ	_	107	dep
111	1.4	1.4	CD	_	113	nummod
112	*	*	SYM	_	113	dep
113	10	10	CD	_	110	dobj
114	-LRB-	-lrb-	-LRB-	_	115	punct
115	-6	-6	CD	_	110	dep
116	-RRB-	-rrb-	-RRB-	_	115	punct
117	-RRB-	-rrb-	-RRB-	_	107	punct
118	and	and	CC	_	14	cc
119	LPL	lpl	NN	_	14	conj
120	-LRB-	-lrb-	-LRB-	_	121	punct
121	drug9	drug9	NN	_	119	dep
122	;	;	:	_	121	punct
123	P	p	NN	_	124	nsubj
124	=	=	JJ	_	121	dep
125	2.7	2.7	CD	_	127	nummod
126	*	*	SYM	_	127	dep
127	10	10	CD	_	124	dobj
128	-LRB-	-lrb-	-LRB-	_	129	punct
129	-17	-17	CD	_	124	dep
130	-RRB-	-rrb-	-RRB-	_	129	punct
131	-RRB-	-rrb-	-RRB-	_	121	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Apolipoprotein	apolipoprotein	NN	_	4	compound
4	E	e	NN	_	9	compound
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	APOE	apoe	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	functional	functional	JJ	_	9	amod
9	haplotypes	haplotype	NNS	_	19	nsubjpass
10	determined	determine	VBN	_	9	acl
11	by	by	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	15	compound
15	SNPs	snp	NNS	_	12	conj
16	have	have	VBP	_	19	aux
17	been	be	VBN	_	19	auxpass
18	extensively	extensively	RB	_	19	advmod
19	studied	study	VBN	_	1	dep
20	and	and	CC	_	19	cc
21	found	find	VBN	_	19	conj
22	to	to	TO	_	24	mark
23	be	be	VB	_	24	cop
24	one	one	CD	_	21	xcomp
25	of	of	IN	_	29	case
26	the	the	DT	_	29	det
27	most	most	RBS	_	28	advmod
28	consistent	consistent	JJ	_	29	amod
29	association	association	NN	_	24	nmod
30	in	in	IN	_	33	case
31	human	human	JJ	_	33	amod
32	drug3	drug3	NN	_	33	compound
33	studies	study	NNS	_	29	nmod
34	.	.	.	_	1	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	also	also	RB	_	2	advmod
4	no	no	DT	_	6	neg
5	significant	significant	JJ	_	6	amod
6	effects	effect	NNS	_	2	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	E4	e4	NN	_	11	compound
11	carriers	carrier	NNS	_	8	conj
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	development	development	NN	_	6	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	2	punct
18	but	but	CC	_	2	cc
19	multivariate	multivariate	JJ	_	22	amod
20	logistic	logistic	JJ	_	22	amod
21	regression	regression	NN	_	22	compound
22	testing	testing	NN	_	23	nsubj
23	revealed	reveal	VBD	_	2	conj
24	that	that	IN	_	35	mark
25	the	the	DT	_	26	det
26	duration	duration	NN	_	35	nsubj
27	of	of	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	and	and	CC	_	28	cc
30	triglyceride	triglyceride	NN	_	28	conj
31	and	and	CC	_	28	cc
32	hemoglobin	hemoglobin	NN	_	34	compound
33	A1c	a1c	NN	_	34	compound
34	concentrations	concentration	NNS	_	28	conj
35	had	have	VBD	_	23	ccomp
36	independent	independent	JJ	_	37	amod
37	effects	effect	NNS	_	35	dobj
38	on	on	IN	_	40	case
39	the	the	DT	_	40	det
40	development	development	NN	_	35	nmod
41	of	of	IN	_	42	case
42	drug4	drug4	NN	_	40	nmod
43	.	.	.	_	2	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Significant	significant	JJ	_	4	amod
4	associations	association	NNS	_	8	nsubjpass
5	with	with	IN	_	6	case
6	drug4	drug4	NN	_	4	nmod
7	were	be	VBD	_	8	auxpass
8	observed	observe	VBN	_	1	dep
9	for	for	IN	_	10	case
10	genotypes	genotype	NNS	_	8	nmod
11	drug1	drug1	VBP	_	10	acl
12	A/T	a/t	NN	_	15	compound
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	odds	odds	NNS	_	15	compound
15	ratio	ratio	NN	_	11	dobj
16	-LSB-	-lsb-	-LRB-	_	17	punct
17	OR	or	NN	_	15	appos
18	-RSB-	-rsb-	-RRB-	_	17	punct
19	,	,	,	_	15	punct
20	2.1	2.1	CD	_	15	appos
21	;	;	:	_	15	punct
22	95	95	CD	_	23	compound
23	%	%	NN	_	25	amod
24	confidence	confidence	NN	_	25	compound
25	interval	interval	NN	_	15	conj
26	-LSB-	-lsb-	-LRB-	_	27	punct
27	CI	ci	NN	_	25	appos
28	-RSB-	-rsb-	-RRB-	_	27	punct
29	,	,	,	_	25	punct
30	1.0-4	1.0-4	CD	_	31	nummod
31	.5	.5	CD	_	25	appos
32	-RRB-	-rrb-	-RRB-	_	25	punct
33	,	,	,	_	15	punct
34	drug2	drug2	NN	_	35	compound
35	T/C	t/c	NN	_	15	conj
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	OR	or	NN	_	35	appos
38	,	,	,	_	37	punct
39	4.4	4.4	CD	_	37	appos
40	;	;	:	_	37	punct
41	95	95	CD	_	42	compound
42	%	%	NN	_	43	amod
43	CI	ci	NN	_	37	dep
44	,	,	,	_	43	punct
45	1.9-10	1.9-10	CD	_	46	nummod
46	.2	.2	NN	_	43	appos
47	-RRB-	-rrb-	-RRB-	_	37	punct
48	,	,	,	_	15	punct
49	and	and	CC	_	15	cc
50	drug3	drug3	NN	_	52	compound
51	-LRB-	-lrb-	-LRB-	_	52	punct
52	OR	or	NN	_	15	conj
53	,	,	,	_	52	punct
54	4.1	4.1	CD	_	52	nummod
55	;	;	:	_	15	punct
56	95	95	CD	_	57	compound
57	%	%	NN	_	58	amod
58	CI	ci	NN	_	15	dep
59	,	,	,	_	58	punct
60	1.6-10	1.6-10	CD	_	61	compound
61	.9	.9	CD	_	58	appos
62	-RRB-	-rrb-	-RRB-	_	15	punct

1	The	the	DT	_	5	det
2	nicotinic	nicotinic	JJ	_	5	amod
3	acetylcholine	acetylcholine	NN	_	5	compound
4	receptor	receptor	NN	_	5	compound
5	polymorphism	polymorphism	NN	_	13	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug1	drug1	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	on	on	IN	_	11	case
10	chromosome	chromosome	NN	_	11	compound
11	15q25	15q25	NN	_	5	nmod
12	is	be	VBZ	_	13	auxpass
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	16	case
15	major	major	JJ	_	16	amod
16	drug2	drug2	NN	_	13	nmod
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	general	general	JJ	_	20	amod
20	population	population	NN	_	16	nmod
21	with	with	IN	_	24	case
22	additional	additional	JJ	_	24	amod
23	increased	increase	VBN	_	24	amod
24	risk	risk	NN	_	13	nmod
25	of	of	IN	_	26	case
26	COPD	COPD	NNP	_	24	nmod
27	as	as	RB	_	24	cc
28	well	well	RB	_	27	mwe
29	as	as	IN	_	27	mwe
30	drug3	drug3	NN	_	24	conj
31	.	.	.	_	13	punct

1	Although	although	IN	_	3	mark
2	there	there	EX	_	3	expl
3	was	be	VBD	_	21	advcl
4	only	only	RB	_	5	advmod
5	moderate	moderate	JJ	_	7	amod
6	linkage	linkage	NN	_	7	compound
7	disequilibrium	disequilibrium	NN	_	3	nsubj
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	3	nmod
10	and	and	CC	_	9	cc
11	the	the	DT	_	13	det
12	ApoE	apoe	NN	_	13	compound
13	e4	e4	NN	_	9	conj
14	defining	define	VBG	_	13	acl
15	SNP	snp	NN	_	16	compound
16	drug2	drug2	NN	_	14	dobj
17	,	,	,	_	21	punct
18	we	we	PRP	_	21	nsubj
19	could	could	MD	_	21	aux
20	not	not	RB	_	21	neg
21	find	find	VB	_	0	ROOT
22	an	a	DT	_	24	det
23	APOE-independent	apoe-independent	JJ	_	24	amod
24	effect	effect	NN	_	21	dobj
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	on	on	IN	_	28	case
28	drug4	drug4	NN	_	24	nmod
29	,	,	,	_	21	punct
30	either	either	CC	_	32	cc:preconj
31	in	in	IN	_	32	case
32	cross-sectional	cross-sectional	JJ	_	21	nmod
33	or	or	CC	_	32	cc
34	in	in	IN	_	36	case
35	longitudinal	longitudinal	JJ	_	36	amod
36	analyses	analysis	NNS	_	32	conj
37	.	.	.	_	21	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	19	nmod
3	,	,	,	_	19	punct
4	the	the	DT	_	6	det
5	major	major	JJ	_	6	amod
6	locus	locus	NN	_	19	nsubjpass
7	determining	determine	VBG	_	6	acl
8	familial	familial	JJ	_	9	amod
9	drug2	drug2	NN	_	7	dobj
10	up	up	IN	_	13	case
11	to	to	TO	_	13	case
12	high	high	JJ	_	13	amod
13	age	age	NN	_	7	nmod
14	as	as	IN	_	15	mark
15	detected	detect	VBN	_	7	advcl
16	by	by	IN	_	17	case
17	GWAS	GWAS	NNP	_	15	nmod
18	was	be	VBD	_	19	auxpass
19	marked	mark	VBN	_	0	ROOT
20	by	by	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	,	,	,	_	21	punct
23	which	which	WDT	_	24	nsubj
24	tags	tag	NNS	_	21	acl:relcl
25	the	the	DT	_	27	det
26	deleterious	deleterious	JJ	_	27	amod
27	effects	effect	NNS	_	24	dobj
28	of	of	IN	_	32	case
29	the	the	DT	_	32	det
30	ApoE	apoe	NN	_	32	compound
31	e4	e4	NN	_	32	compound
32	allele	allele	NN	_	27	nmod
33	.	.	.	_	19	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	After	after	IN	_	4	mark
4	correcting	correct	VBG	_	1	acl
5	for	for	IN	_	7	case
6	multiple	multiple	JJ	_	7	amod
7	testing	testing	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	p	p	NN	_	10	dep
10	<	<	JJR	_	4	parataxis
11	0.05	0.05	CD	_	10	nummod
12	-RRB-	-rrb-	-RRB-	_	10	punct
13	and	and	CC	_	4	cc
14	accounting	accounting	NN	_	4	conj
15	for	for	IN	_	17	case
16	significant	significant	JJ	_	17	amod
17	differences	difference	NNS	_	14	nmod
18	in	in	IN	_	22	case
19	the	the	DT	_	22	det
20	association	association	NN	_	22	compound
21	effect	effect	NN	_	22	compound
22	sizes	size	NNS	_	17	nmod
23	between	between	IN	_	24	case
24	subjects	subject	NNS	_	22	nmod
25	with	with	IN	_	47	mark
26	and	and	CC	_	47	cc
27	without	without	IN	_	28	case
28	drug4	drug4	NN	_	47	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	p	p	NN	_	31	dep
31	<	<	JJR	_	28	dep
32	0.05	0.05	CD	_	31	nummod
33	-RRB-	-rrb-	-RRB-	_	31	punct
34	,	,	,	_	47	punct
35	variants	variant	NNS	_	47	nsubjpass
36	of	of	IN	_	37	case
37	APOA5	apoa5	NN	_	35	nmod
38	-LRB-	-lrb-	-LRB-	_	39	punct
39	drug1	drug1	NN	_	37	appos
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	and	and	CC	_	37	cc
42	APOE	apoe	NN	_	37	conj
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	drug2	drug2	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	were	be	VBD	_	47	auxpass
47	associated	associate	VBN	_	24	acl
48	with	with	IN	_	49	case
49	HDL-C	hdl-c	NN	_	47	nmod
50	and	and	CC	_	49	cc
51	LDL-C	ldl-c	NN	_	52	compound
52	responses	response	NNS	_	49	conj
53	in	in	IN	_	55	case
54	MetS	mets	NN	_	55	compound
55	subjects	subject	NNS	_	49	nmod
56	,	,	,	_	4	punct
57	while	while	IN	_	61	mark
58	APOA4	apoa4	NN	_	59	compound
59	drug3	drug3	NN	_	61	nsubjpass
60	was	be	VBD	_	61	auxpass
61	associated	associate	VBN	_	4	advcl
62	with	with	IN	_	64	case
63	TG	tg	NN	_	64	compound
64	response	response	NN	_	61	nmod
65	in	in	IN	_	67	case
66	non-MetS	non-mets	JJ	_	67	amod
67	subjects	subject	NNS	_	64	nmod
68	.	.	.	_	1	punct

1	Our	we	PRP$	_	2	nmod:poss
2	findings	finding	NNS	_	3	nsubj
3	confirm	confirm	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	the	the	DT	_	7	det
6	drug1	drug1	NN	_	7	compound
7	gene	gene	NN	_	8	nsubj
8	represents	represent	VBZ	_	3	ccomp
9	an	a	DT	_	11	det
10	important	important	JJ	_	11	amod
11	locus	locus	NN	_	8	dobj
12	for	for	IN	_	13	mark
13	predicting	predict	VBG	_	11	acl
14	inherited	inherit	VBN	_	15	amod
15	susceptibility	susceptibility	NN	_	13	dobj
16	to	to	TO	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	3	punct

1	Five	five	CD	_	2	nummod
2	polymorphisms	polymorphism	NNS	_	20	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	-491	-491	CD	_	5	nummod
5	drug1	drug1	NN	_	2	dep
6	,	,	,	_	5	punct
7	-427	-427	CD	_	8	nummod
8	drug2	drug2	NN	_	5	appos
9	,	,	,	_	5	punct
10	-219	-219	CD	_	11	nummod
11	drug3	drug3	NN	_	5	conj
12	,	,	,	_	5	punct
13	and	and	CC	_	5	cc
14	e	e	SYM	_	17	dep
15	drug4	drug4	SYM	_	17	dep
16	-	-	:	_	17	punct
17	drug5	drug5	NN	_	5	conj
18	-RRB-	-rrb-	-RRB-	_	5	punct
19	were	be	VBD	_	20	auxpass
20	studied	study	VBN	_	0	ROOT
21	in	in	IN	_	24	case
22	1308	1308	CD	_	24	nummod
23	drug6	drug6	NN	_	24	compound
24	patients	patient	NNS	_	20	nmod
25	and	and	CC	_	24	cc
26	1082	1082	CD	_	28	nummod
27	control	control	NN	_	28	compound
28	individuals	individual	NNS	_	24	conj
29	from	from	IN	_	32	case
30	the	the	DT	_	32	det
31	Central-Northern	Central-Northern	NNP	_	32	compound
32	Italy	Italy	NNP	_	24	nmod
33	.	.	.	_	20	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Apolipoprotein	apolipoprotein	NN	_	4	compound
4	E	e	NN	_	8	compound
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	APOE	apoe	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	genotype	genotype	NN	_	22	nsubjpass
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	e2/e3/e4	e2/e3/e4	NN	_	8	appos
11	:	:	:	_	10	punct
12	drug1	drug1	NN	_	14	compound
13	e4	e4	NN	_	14	compound
14	allele	allele	NN	_	10	dep
15	;	;	:	_	14	punct
16	drug2	drug2	NN	_	18	compound
17	e2	e2	NN	_	18	compound
18	allele	allele	NN	_	14	dep
19	-RRB-	-rrb-	-RRB-	_	10	punct
20	is	be	VBZ	_	22	auxpass
21	strongly	strongly	RB	_	22	advmod
22	associated	associate	VBN	_	1	appos
23	with	with	IN	_	26	case
24	both	both	CC	_	26	cc:preconj
25	lipid	lipid	NN	_	26	compound
26	levels	level	NNS	_	22	nmod
27	and	and	CC	_	26	cc
28	A	a	DT	_	29	det
29	drug3	drug3	NN	_	31	nmod:poss
30	's	's	POS	_	29	case
31	disease	disease	NN	_	26	conj
32	.	.	.	_	1	punct

1	As	as	IN	_	2	mark
2	expected	expect	VBN	_	14	advcl
3	,	,	,	_	14	punct
4	the	the	DT	_	8	det
5	most	most	RBS	_	6	advmod
6	strongly	strongly	RB	_	7	advmod
7	associated	associate	VBN	_	8	amod
8	SNP	snp	NN	_	14	nsubj
9	was	be	VBD	_	14	cop
10	the	the	DT	_	14	det
11	APOE	APOE	NNP	_	14	compound
12	e4	e4	NN	_	14	compound
13	drug1	drug1	NN	_	14	compound
14	variant	variant	NN	_	0	ROOT
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	HR	hr	NN	_	14	dep
17	=	=	JJ	_	16	amod
18	2.47	2.47	CD	_	17	dep
19	-LSB-	-lsb-	-LRB-	_	20	punct
20	1.58	1.58	CD	_	18	dep
21	,	,	,	_	20	punct
22	3.87	3.87	CD	_	20	dep
23	-RSB-	-rsb-	-RRB-	_	20	punct
24	,	,	,	_	16	punct
25	p	p	NN	_	29	dep
26	=	=	JJ	_	29	dep
27	7.52	7.52	CD	_	29	nummod
28	*	*	SYM	_	29	dep
29	10	10	CD	_	16	dep
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	-5	-5	CD	_	29	dep
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	-RRB-	-rrb-	-RRB-	_	16	punct
34	,	,	,	_	14	punct
35	although	although	IN	_	49	mark
36	variants	variant	NNS	_	49	nsubjpass
37	within	within	IN	_	42	case
38	the	the	DT	_	42	det
39	more	more	RBR	_	40	advmod
40	recently	recently	RB	_	41	advmod
41	implicated	implicate	VBN	_	42	amod
42	SORL1	sorl1	NN	_	36	nmod
43	and	and	CC	_	42	cc
44	RUNX1	runx1	NN	_	45	compound
45	genes	gene	NNS	_	42	conj
46	were	be	VBD	_	49	auxpass
47	also	also	RB	_	49	advmod
48	strongly	strongly	RB	_	49	advmod
49	associated	associate	VBN	_	14	advcl
50	with	with	IN	_	51	case
51	drug2	drug2	NN	_	49	nmod
52	in	in	IN	_	53	case
53	drug3	drug3	NN	_	51	nmod
54	-LRB-	-lrb-	-LRB-	_	56	punct
55	HR	hr	NN	_	56	nsubj
56	=	=	JJ	_	49	parataxis
57	0.54	0.54	CD	_	56	dobj
58	-LSB-	-lsb-	-LRB-	_	59	punct
59	0.37	0.37	CD	_	56	dep
60	,	,	,	_	59	punct
61	0.80	0.80	CD	_	59	dep
62	-RSB-	-rsb-	-RRB-	_	59	punct
63	,	,	,	_	56	punct
64	p	p	NN	_	65	nsubj
65	=	=	JJ	_	56	dep
66	0.002	0.002	CD	_	65	dobj
67	and	and	CC	_	65	cc
68	HR	hr	NN	_	69	nsubj
69	=	=	JJ	_	65	conj
70	1.61	1.61	CD	_	69	dobj
71	-LSB-	-lsb-	-LRB-	_	72	punct
72	1.15	1.15	CD	_	65	dep
73	,	,	,	_	72	punct
74	2.26	2.26	CD	_	72	dep
75	-RSB-	-rsb-	-RRB-	_	72	punct
76	,	,	,	_	56	punct
77	p	p	NN	_	78	nsubj
78	=	=	JJ	_	56	parataxis
79	0.006	0.006	CD	_	78	dobj
80	respectively	respectively	RB	_	56	advmod
81	-RRB-	-rrb-	-RRB-	_	56	punct
82	.	.	.	_	14	punct

1	Disease	disease	NN	_	3	compound
2	association	association	NN	_	3	compound
3	analysis	analysis	NN	_	4	nsubj
4	revealed	reveal	VBD	_	0	ROOT
5	a	a	DT	_	8	det
6	susceptibility	susceptibility	NN	_	8	compound
7	haplotype	haplotype	NN	_	8	compound
8	CGTC	cgtc	NN	_	27	nsubj
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	in	in	IN	_	11	case
11	order	order	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug4	drug4	NN	_	13	conj
20	-RRB-	-rrb-	-RRB-	_	11	punct
21	and	and	CC	_	8	cc
22	the	the	DT	_	23	det
23	carriers	carrier	NNS	_	8	conj
24	of	of	IN	_	26	case
25	this	this	DT	_	26	det
26	haplotype	haplotype	NN	_	23	nmod
27	has	have	VBZ	_	4	ccomp
28	higher	higher	JJR	_	29	amod
29	risk	risk	NN	_	27	dobj
30	of	of	IN	_	31	case
31	drug5	drug5	NN	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	OR	or	NN	_	31	dep
34	3.53	3.53	CD	_	33	nummod
35	,	,	,	_	33	punct
36	95	95	CD	_	37	compound
37	%	%	NN	_	38	amod
38	CI	ci	NN	_	33	appos
39	1.21-11	1.21-11	CD	_	40	compound
40	.0	.0	CD	_	38	nummod
41	,	,	,	_	33	punct
42	P	p	NN	_	43	nsubj
43	=	=	JJ	_	33	dep
44	0.017	0.017	CD	_	43	dobj
45	-RRB-	-rrb-	-RRB-	_	33	punct
46	and	and	CC	_	31	cc
47	osteoporosis	osteoporosis	NN	_	31	conj
48	-LRB-	-lrb-	-LRB-	_	49	punct
49	OR	or	NN	_	47	dep
50	3.61	3.61	CD	_	49	nummod
51	,	,	,	_	49	punct
52	95	95	CD	_	53	compound
53	%	%	NN	_	54	amod
54	CI	ci	NN	_	49	appos
55	1.53-9	1.53-9	CD	_	56	compound
56	.48	.48	CD	_	54	nummod
57	,	,	,	_	49	punct
58	P	p	NN	_	59	nsubj
59	=	=	JJ	_	49	dep
60	0.002	0.002	CD	_	59	dobj
61	-RRB-	-rrb-	-RRB-	_	49	punct
62	after	after	IN	_	63	mark
63	adjusting	adjust	VBG	_	27	advcl
64	the	the	DT	_	66	det
65	confounding	confounding	JJ	_	66	amod
66	effect	effect	NN	_	63	dobj
67	of	of	IN	_	68	case
68	age	age	NN	_	66	nmod
69	,	,	,	_	68	punct
70	BMI	bmi	NN	_	68	conj
71	and	and	CC	_	68	cc
72	years	year	NNS	_	68	conj
73	since	since	IN	_	74	case
74	menopause	menopause	NN	_	63	nmod
75	.	.	.	_	4	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	With	with	IN	_	7	case
4	multivariate	multivariate	JJ	_	7	amod
5	generalized	generalize	VBN	_	7	amod
6	linear	linear	JJ	_	7	amod
7	models	model	NNS	_	1	nmod
8	,	,	,	_	7	punct
9	the	the	DT	_	10	det
10	association	association	NN	_	18	nsubjpass
11	of	of	IN	_	13	case
12	TEF	tef	NN	_	13	compound
13	drug1	drug1	NN	_	10	nmod
14	with	with	IN	_	16	case
15	drug2	drug2	NN	_	16	compound
16	symptoms	symptom	NNS	_	10	nmod
17	was	be	VBD	_	18	auxpass
18	confirmed	confirm	VBN	_	7	acl:relcl
19	.	.	.	_	1	punct

1	Several	several	JJ	_	2	amod
2	markers	marker	NNS	_	17	nsubjpass
3	in	in	IN	_	5	case
4	strong	strong	JJ	_	5	amod
5	LD	ld	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	r	r	NN	_	5	dep
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	2	2	CD	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	>	>	JJR	_	7	amod
12	0.7	0.7	CD	_	11	dep
13	-RRB-	-rrb-	-RRB-	_	7	punct
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	2	nmod
16	were	be	VBD	_	17	auxpass
17	found	find	VBN	_	0	ROOT
18	to	to	TO	_	21	mark
19	be	be	VB	_	21	auxpass
20	significantly	significantly	RB	_	21	advmod
21	associated	associate	VBN	_	17	xcomp
22	with	with	IN	_	24	case
23	drug2	drug2	NN	_	24	compound
24	risk	risk	NN	_	21	nmod
25	in	in	IN	_	29	case
26	recent	recent	JJ	_	29	amod
27	genome-wide	genome-wide	JJ	_	29	amod
28	association	association	NN	_	29	compound
29	studies	study	NNS	_	24	nmod
30	with	with	IN	_	33	case
31	similar	similar	JJ	_	33	amod
32	effect	effect	NN	_	33	compound
33	sizes	size	NNS	_	29	nmod
34	,	,	,	_	21	punct
35	providing	provide	VBG	_	21	advcl
36	independent	independent	JJ	_	37	amod
37	support	support	NN	_	35	dobj
38	of	of	IN	_	41	case
39	the	the	DT	_	41	det
40	current	current	JJ	_	41	amod
41	findings	finding	NNS	_	37	nmod
42	.	.	.	_	17	punct

1	The	the	DT	_	2	det
2	frequency	frequency	NN	_	12	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	G	g	NN	_	6	compound
6	genotype	genotype	NN	_	2	nmod
7	in	in	IN	_	9	case
8	COMT	COMT	NNP	_	9	compound
9	drug1	drug1	NN	_	6	nmod
10	was	be	VBD	_	12	cop
11	statistically	statistically	RB	_	12	advmod
12	different	different	JJ	_	0	ROOT
13	between	between	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	controls	control	NNS	_	16	conj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	P	p	NN	_	21	nsubj
21	=	=	JJ	_	12	parataxis
22	.04	.04	CD	_	21	dobj
23	-RRB-	-rrb-	-RRB-	_	21	punct
24	,	,	,	_	12	punct
25	and	and	CC	_	12	cc
26	between	between	IN	_	27	case
27	patients	patient	NNS	_	12	conj
28	with	with	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	and	and	CC	_	29	cc
31	controls	control	NNS	_	29	conj
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	P	p	NN	_	34	nsubj
34	=	=	JJ	_	27	dep
35	.02	.02	CD	_	34	dobj
36	-RRB-	-rrb-	-RRB-	_	34	punct
37	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	frequency	frequency	NN	_	10	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	A	a	NN	_	6	compound
6	genotype	genotype	NN	_	2	nmod
7	in	in	IN	_	9	case
8	PLCH1	plch1	NN	_	9	compound
9	drug1	drug1	NN	_	2	nmod
10	occurred	occur	VBD	_	0	ROOT
11	more	more	RBR	_	12	advmod
12	frequently	frequently	RB	_	10	advmod
13	in	in	IN	_	14	case
14	drug2	drug2	NN	_	10	nmod
15	than	than	IN	_	17	case
16	in	in	IN	_	17	case
17	controls	control	NNS	_	10	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	P	p	NN	_	17	dep
20	=	=	JJ	_	19	amod
21	.02	.02	CD	_	20	dep
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	.	.	.	_	10	punct

1	The	the	DT	_	4	det
2	G/G	g/g	NN	_	4	compound
3	homozygous	homozygous	JJ	_	4	amod
4	genotype	genotype	NN	_	16	nsubjpass
5	in	in	IN	_	7	case
6	COMT	COMT	NNP	_	7	compound
7	drug1	drug1	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	A/A	a/a	NN	_	11	compound
10	homozygous	homozygous	JJ	_	11	amod
11	genotype	genotype	NN	_	7	conj
12	in	in	IN	_	14	case
13	PLCH1	plch1	NN	_	14	compound
14	drug2	drug2	NN	_	4	nmod
15	were	be	VBD	_	16	auxpass
16	associated	associate	VBN	_	0	ROOT
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	,	,	,	_	16	punct
22	respectively	respectively	RB	_	16	advmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	odds	odds	NNS	_	25	compound
25	ratio	ratio	NN	_	16	dep
26	-LSB-	-lsb-	-LRB-	_	27	punct
27	OR	or	NN	_	25	appos
28	-RSB-	-rsb-	-RRB-	_	27	punct
29	0.61	0.61	CD	_	25	nummod
30	and	and	CC	_	25	cc
31	OR	or	NN	_	25	conj
32	2.01	2.01	CD	_	31	nummod
33	,	,	,	_	25	punct
34	respectively	respectively	RB	_	25	advmod
35	-RRB-	-rrb-	-RRB-	_	25	punct
36	.	.	.	_	16	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	6	nmod
4	,	,	,	_	6	punct
5	we	we	PRP	_	6	nsubj
6	found	find	VBD	_	0	ROOT
7	that	that	IN	_	14	mark
8	the	the	DT	_	11	det
9	COMT	COMT	NNP	_	11	compound
10	drug1	drug1	NN	_	11	compound
11	SNP	snp	NN	_	14	nsubjpass
12	was	be	VBD	_	14	auxpass
13	significantly	significantly	RB	_	14	advmod
14	associated	associate	VBN	_	6	ccomp
15	with	with	IN	_	18	case
16	a	a	DT	_	18	det
17	reduced	reduce	VBN	_	18	amod
18	risk	risk	NN	_	14	nmod
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	,	,	,	_	18	punct
22	especially	especially	RB	_	23	advmod
23	drug3	drug3	NN	_	18	appos
24	,	,	,	_	18	punct
25	which	which	WDT	_	26	nsubj
26	suggests	suggest	VBZ	_	18	acl:relcl
27	that	that	IN	_	31	mark
28	this	this	DT	_	29	det
29	SNP	snp	NN	_	31	nsubj
30	may	may	MD	_	31	aux
31	have	have	VB	_	26	ccomp
32	a	a	DT	_	34	det
33	protective	protective	JJ	_	34	amod
34	effect	effect	NN	_	31	dobj
35	.	.	.	_	6	punct

1	Moreover	moreover	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	6	det
4	PLCH1	plch1	NN	_	6	compound
5	drug1	drug1	NN	_	6	compound
6	SNP	snp	NN	_	9	nsubjpass
7	was	be	VBD	_	9	auxpass
8	strongly	strongly	RB	_	9	advmod
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	13	case
11	an	a	DT	_	13	det
12	increased	increase	VBN	_	13	amod
13	risk	risk	NN	_	9	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	9	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	associated	associate	VBN	_	1	appos
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	athero-thrombosis	athero-thrombosis	NN	_	8	conj
11	however	however	RB	_	23	advmod
12	the	the	DT	_	13	det
13	association	association	NN	_	23	nsubjpass
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	AAA	aaa	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	has	have	VBZ	_	23	aux
20	not	not	RB	_	23	neg
21	been	be	VBN	_	23	auxpass
22	previously	previously	RB	_	23	advmod
23	examined	examine	VBN	_	6	ccomp
24	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	We	we	PRP	_	4	nsubj
4	found	find	VBD	_	1	appos
5	no	no	DT	_	7	neg
6	consistent	consistent	JJ	_	7	amod
7	association	association	NN	_	4	dobj
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	.	.	.	_	1	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	As	as	IN	_	5	mark
4	previously	previously	RB	_	5	advmod
5	reported	report	VBN	_	13	advcl
6	in	in	IN	_	7	case
7	Spain	Spain	NNP	_	5	nmod
8	,	,	,	_	13	punct
9	drug1	drug1	NN	_	10	compound
10	allele	allele	NN	_	13	nsubjpass
11	was	be	VBD	_	13	auxpass
12	strongly	strongly	RB	_	13	advmod
13	associated	associate	VBN	_	1	dep
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	in	in	IN	_	18	case
17	our	we	PRP$	_	18	nmod:poss
18	series	series	NN	_	13	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	OR	or	NN	_	18	appos
21	=	=	JJ	_	20	amod
22	2.88	2.88	CD	_	21	dep
23	-LSB-	-lsb-	-LRB-	_	22	punct
24	95	95	CD	_	25	nummod
25	%	%	NN	_	23	root
26	C.I.	C.I.	NNP	_	25	dep
27	2.16	2.16	CD	_	26	nummod
28	-	-	:	_	26	punct
29	3.84	3.84	CD	_	26	nummod
30	-RSB-	-rsb-	-RRB-	_	26	punct
31	,	,	,	_	25	punct
32	p	p	NN	_	25	appos
33	=	=	JJ	_	32	amod
34	7.38E-11	7.38e-11	NN	_	33	dep
35	-RRB-	-rrb-	-RRB-	_	25	punct
36	.	.	.	_	25	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	3	nsubj
3	strengthen	strengthen	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	evidence	evidence	NN	_	3	dobj
6	that	that	IN	_	14	mark
7	one	one	CD	_	10	nummod
8	or	or	CC	_	7	cc
9	more	more	JJR	_	7	conj
10	variants	variant	NNS	_	14	nsubjpass
11	in	in	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	are	be	VBP	_	14	auxpass
14	associated	associate	VBN	_	5	ccomp
15	with	with	IN	_	17	case
16	increased	increase	VBN	_	17	amod
17	risk	risk	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	combined	combined	JJ	_	3	amod
3	effect	effect	NN	_	11	nsubjpass
4	of	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	polymorphisms	polymorphism	NNS	_	3	nmod
7	on	on	IN	_	9	case
8	drug2	drug2	NN	_	9	compound
9	phenotypes	phenotype	NNS	_	3	nmod
10	was	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	n't	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	drug2	drug2	NN	_	4	dobj
6	,	,	,	_	4	punct
7	suggesting	suggest	VBG	_	4	advcl
8	its	its	PRP$	_	11	nmod:poss
9	potential	potential	JJ	_	11	amod
10	modality-specific	modality-specific	JJ	_	11	amod
11	effects	effect	NNS	_	7	dobj
12	on	on	IN	_	14	case
13	human	human	JJ	_	14	amod
14	pain	pain	NN	_	11	nmod
15	.	.	.	_	4	punct

1	We	we	PRP	_	2	nsubj
2	compared	compare	VBD	_	0	ROOT
3	genotype	genotype	NN	_	4	compound
4	frequencies	frequency	NNS	_	2	dobj
5	in	in	IN	_	6	case
6	subjects	subject	NNS	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	with	with	IN	_	10	case
10	those	those	DT	_	8	nmod
11	with	with	IN	_	12	case
12	NGT	ngt	NN	_	10	nmod
13	and	and	CC	_	2	cc
14	found	find	VBD	_	2	conj
15	marginal	marginal	JJ	_	16	amod
16	association	association	NN	_	14	dobj
17	for	for	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	P	p	NN	_	21	nsubj
21	=	=	JJ	_	16	dep
22	0.05	0.05	CD	_	21	dobj
23	;	;	:	_	21	punct
24	odds	odds	NNS	_	25	compound
25	ratio	ratio	NN	_	21	dep
26	-LSB-	-lsb-	-LRB-	_	27	punct
27	OR	or	NN	_	25	appos
28	-RSB-	-rsb-	-RRB-	_	27	punct
29	1.51	1.51	CD	_	25	nummod
30	-RRB-	-rrb-	-RRB-	_	21	punct
31	;	;	:	_	2	punct

1	comparison	comparison	NN	_	14	nsubj
2	between	between	IN	_	5	case
3	NGT	NGT	NNP	_	5	compound
4	control	control	JJ	_	5	amod
5	subjects	subject	NNS	_	1	nmod
6	and	and	CC	_	5	cc
7	the	the	DT	_	9	det
8	combined	combined	JJ	_	9	amod
9	drug5	drug5	NN	_	5	conj
10	/	/	:	_	9	punct
11	IGT	IGT	NNP	_	13	compound
12	case	case	NN	_	13	compound
13	group	group	NN	_	9	dep
14	showed	show	VBD	_	0	ROOT
15	strong	strong	JJ	_	16	amod
16	association	association	NN	_	14	dobj
17	with	with	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	P	p	NN	_	23	nsubj
23	=	=	JJ	_	16	dep
24	0.008-0	0.008-0	CD	_	25	compound
25	.01	.01	CD	_	23	dobj
26	;	;	:	_	23	punct
27	OR	or	NN	_	23	dep
28	1.53-1	1.53-1	CD	_	29	compound
29	.57	.57	CD	_	27	nummod
30	-RRB-	-rrb-	-RRB-	_	23	punct
31	and	and	CC	_	16	cc
32	marginal	marginal	JJ	_	33	amod
33	association	association	NN	_	16	conj
34	with	with	IN	_	35	case
35	drug3	drug3	NN	_	33	nmod
36	and	and	CC	_	35	cc
37	drug4	drug4	NN	_	35	conj
38	-LRB-	-lrb-	-LRB-	_	40	punct
39	P	p	NN	_	40	nsubj
40	=	=	JJ	_	33	dep
41	0.07	0.07	CD	_	40	dobj
42	and	and	CC	_	40	cc
43	P	p	NN	_	44	nsubj
44	=	=	JJ	_	40	conj
45	0.04	0.04	CD	_	44	dobj
46	,	,	,	_	40	punct
47	respectively	respectively	RB	_	40	advmod
48	-RRB-	-rrb-	-RRB-	_	40	punct
49	.	.	.	_	14	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	genotyped	genotype	VBD	_	0	ROOT
4	these	these	DT	_	5	det
5	SNPs	snp	NNS	_	3	dobj
6	in	in	IN	_	3	dep
7	nondiabetic	nondiabetic	JJ	_	6	dep
8	,	,	,	_	7	punct
9	non-Amish	non-amish	JJ	_	10	amod
10	subjects	subject	NNS	_	8	root
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	n	n	NN	_	10	dep
13	=	=	JJ	_	12	amod
14	48	48	CD	_	13	dep
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	,	,	,	_	10	punct
17	in	in	IN	_	18	case
18	whom	whom	WP	_	24	nmod
19	intravenous	intravenous	JJ	_	22	amod
20	glucose	glucose	NN	_	22	compound
21	tolerance	tolerance	NN	_	22	compound
22	tests	test	NNS	_	24	nsubjpass
23	were	be	VBD	_	24	auxpass
24	performed	perform	VBN	_	10	acl:relcl
25	,	,	,	_	24	punct
26	and	and	CC	_	24	cc
27	found	find	VBD	_	24	conj
28	an	a	DT	_	29	det
29	association	association	NN	_	27	dobj
30	between	between	IN	_	31	case
31	drug1	drug1	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	drug2	drug2	NN	_	31	conj
34	and	and	CC	_	33	cc
35	drug3	drug3	NN	_	33	conj
36	-LRB-	-lrb-	-LRB-	_	38	punct
37	P	p	NN	_	38	nsubj
38	=	=	JJ	_	29	dep
39	0.003	0.003	CD	_	38	dobj
40	and	and	CC	_	38	cc
41	P	p	NN	_	42	nsubj
42	=	=	JJ	_	38	conj
43	0.005	0.005	CD	_	42	dobj
44	,	,	,	_	38	punct
45	respectively	respectively	RB	_	38	advmod
46	-RRB-	-rrb-	-RRB-	_	38	punct
47	and	and	CC	_	29	cc
48	drug4	drug4	NN	_	29	conj
49	-LRB-	-lrb-	-LRB-	_	50	punct
50	P	p	NN	_	48	dep
51	=	=	JJ	_	50	amod
52	0.04	0.04	CD	_	51	dep
53	and	and	CC	_	50	cc
54	P	p	NN	_	50	conj
55	=	=	JJ	_	54	amod
56	0.007	0.007	CD	_	55	dep
57	,	,	,	_	50	punct
58	respectively	respectively	RB	_	50	advmod
59	-RRB-	-rrb-	-RRB-	_	50	punct
60	.	.	.	_	10	punct

1	Thus	thus	RB	_	8	advmod
2	,	,	,	_	8	punct
3	the	the	DT	_	5	det
4	drug1	drug1	NN	_	5	compound
5	polymorphism	polymorphism	NN	_	8	nsubjpass
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	Caucasian	caucasian	JJ	_	14	amod
14	population	population	NN	_	10	nmod
15	but	but	CC	_	8	cc
16	acts	act	VBZ	_	8	conj
17	as	as	IN	_	19	case
18	a	a	DT	_	19	det
19	modifier	modifier	NN	_	16	nmod
20	of	of	IN	_	22	case
21	the	the	DT	_	22	det
22	AAO	AAO	NNP	_	19	nmod
23	in	in	IN	_	24	case
24	drug3	drug3	NN	_	16	nmod
25	with	with	IN	_	28	case
26	a	a	DT	_	28	det
27	sexual	sexual	JJ	_	28	amod
28	dimorphism	dimorphism	NN	_	24	nmod
29	:	:	:	_	8	punct
30	the	the	DT	_	32	det
31	Val	val	NN	_	32	compound
32	allele	allele	NN	_	34	nsubjpass
33	is	be	VBZ	_	34	auxpass
34	associated	associate	VBN	_	8	parataxis
35	with	with	IN	_	38	case
36	a	a	DT	_	38	det
37	younger	younger	JJR	_	38	amod
38	AAO	aao	NN	_	34	nmod
39	in	in	IN	_	40	case
40	men	man	NNS	_	38	nmod
41	with	with	IN	_	43	case
42	idiopathic	idiopathic	JJ	_	43	amod
43	PD	pd	NN	_	40	nmod
44	.	.	.	_	8	punct

1	The	the	DT	_	5	det
2	drug1	drug1	NN	_	5	compound
3	at-risk	at-risk	JJ	_	5	amod
4	allele	allele	NN	_	5	compound
5	associates	associate	NNS	_	0	ROOT
6	with	with	IN	_	8	case
7	decreased	decrease	VBN	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	earlier	earlier	JJR	_	11	amod
11	age	age	NN	_	8	conj
12	at	at	IN	_	13	case
13	diagnosis	diagnosis	NN	_	5	nmod
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	drug3	drug3	NN	_	17	compound
17	subjects	subject	NNS	_	13	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	P	p	NN	_	5	dep
20	=	=	JJ	_	19	amod
21	8.0	8.0	CD	_	25	nummod
22	x	x	CC	_	21	cc
23	10	10	CD	_	21	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	-3	-3	CD	_	20	dep
26	-RRB-	-rrb-	-RRB-	_	19	punct
27	and	and	CC	_	5	cc
28	P	p	NN	_	29	nsubj
29	=	=	JJ	_	5	conj
30	3.8	3.8	CD	_	29	dobj
31	x	x	CC	_	30	cc
32	10	10	CD	_	30	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	-4	-4	CD	_	29	dep
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	29	punct
37	respectively	respectively	RB	_	29	advmod
38	-RRB-	-rrb-	-RRB-	_	29	punct
39	,	,	,	_	5	punct
40	which	which	WDT	_	42	nsubjpass
41	is	be	VBZ	_	42	auxpass
42	supported	support	VBN	_	5	acl:relcl
43	by	by	IN	_	47	case
44	quantitative	quantitative	JJ	_	47	amod
45	family-based	family-based	JJ	_	47	amod
46	association	association	NN	_	47	compound
47	tests	test	NNS	_	42	nmod
48	.	.	.	_	5	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	seen	see	VBN	_	1	appos
6	to	to	TO	_	7	mark
7	show	show	VB	_	5	xcomp
8	a	a	DT	_	10	det
9	decreased	decrease	VBN	_	10	amod
10	risk	risk	NN	_	7	dobj
11	for	for	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	in	in	IN	_	15	case
14	Asian	asian	JJ	_	15	amod
15	population	population	NN	_	10	nmod

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	polymorphisms	polymorphism	NNS	_	5	nsubj
5	demonstrated	demonstrate	VBD	_	0	ROOT
6	an	a	DT	_	10	det
7	increased	increase	VBN	_	10	amod
8	and	and	CC	_	7	cc
9	decreased	decrease	VBN	_	7	conj
10	risk	risk	NN	_	5	dobj
11	for	for	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	,	,	,	_	5	punct
14	respectively	respectively	RB	_	5	advmod
15	.	.	.	_	5	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	We	we	PRP	_	4	nsubj
4	found	find	VBD	_	1	dep
5	no	no	DT	_	6	neg
6	association	association	NN	_	4	dobj
7	between	between	IN	_	9	case
8	drug2	drug2	NN	_	9	compound
9	status	status	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	SNP	snp	NN	_	13	compound
12	drug1	drug1	NN	_	13	compound
13	genotype	genotype	NN	_	9	conj
14	nor	nor	CC	_	4	cc
15	did	do	VBD	_	17	aux
16	we	we	PRP	_	17	nsubj
17	find	find	VBP	_	4	conj
18	a	a	DT	_	20	det
19	significant	significant	JJ	_	20	amod
20	association	association	NN	_	17	dobj
21	to	to	TO	_	23	case
22	the	the	DT	_	23	det
23	degree	degree	NN	_	20	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Although	although	IN	_	12	mark
4	prefrontal	prefrontal	JJ	_	9	amod
5	cortical	cortical	JJ	_	9	amod
6	and	and	CC	_	5	cc
7	ventral	ventral	JJ	_	5	conj
8	striatal	striatal	JJ	_	9	amod
9	activity	activity	NN	_	12	nsubj
10	are	be	VBP	_	12	cop
11	highly	highly	RB	_	12	advmod
12	relevant	relevant	JJ	_	32	advcl
13	for	for	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	under	under	IN	_	19	case
18	partial	partial	JJ	_	19	amod
19	control	control	NN	_	12	conj
20	of	of	IN	_	22	case
21	drug1	drug1	NN	_	22	compound
22	genotype	genotype	NN	_	19	nmod
23	,	,	,	_	32	punct
24	no	no	DT	_	25	neg
25	association	association	NN	_	32	nsubjpass
26	between	between	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	and	and	CC	_	27	cc
29	drug4	drug4	NN	_	30	compound
30	behavior	behavior	NN	_	27	conj
31	was	be	VBD	_	32	auxpass
32	observed	observe	VBN	_	1	dep

1	Our	we	PRP$	_	2	nmod:poss
2	data	datum	NNS	_	4	nsubj
3	strongly	strongly	RB	_	4	advmod
4	confirm	confirm	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	7	compound
7	gene	gene	NN	_	8	nsubj
8	contribute	contribute	VBP	_	4	ccomp
9	to	to	TO	_	11	case
10	the	the	DT	_	11	det
11	risk	risk	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	6	nmod
3	,	,	,	_	6	punct
4	our	we	PRP$	_	5	nmod:poss
5	findings	finding	NNS	_	6	nsubj
6	provide	provide	VBP	_	0	ROOT
7	evidence	evidence	NN	_	6	dobj
8	that	that	IN	_	17	mark
9	in	in	IN	_	10	case
10	addition	addition	NN	_	17	nmod
11	to	to	TO	_	13	case
12	other	other	JJ	_	13	amod
13	genes	gene	NNS	_	10	nmod
14	,	,	,	_	17	punct
15	drug1	drug1	NN	_	17	nsubj
16	also	also	RB	_	17	advmod
17	has	have	VBZ	_	7	ccomp
18	a	a	DT	_	20	det
19	significant	significant	JJ	_	20	amod
20	role	role	NN	_	17	dobj
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	development	development	NN	_	17	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	,	,	,	_	17	punct
27	and	and	CC	_	17	cc
28	demonstrate	demonstrate	VBP	_	17	conj
29	that	that	IN	_	43	mark
30	analysing	analyse	VBG	_	43	csubj
31	the	the	DT	_	34	det
32	complex	complex	NN	_	34	compound
33	phenotype	phenotype	NN	_	34	compound
34	associations	association	NNS	_	30	dobj
35	of	of	IN	_	36	case
36	genes	gene	NNS	_	34	nmod
37	by	by	IN	_	39	case
38	haplotype	haplotype	NN	_	39	compound
39	tagging	tagging	NN	_	30	nmod
40	is	be	VBZ	_	43	cop
41	a	a	DT	_	43	det
42	powerful	powerful	JJ	_	43	amod
43	method	method	NN	_	28	ccomp
44	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	11	nmod
3	to	to	TO	_	5	case
4	previous	previous	JJ	_	5	amod
5	findings	finding	NNS	_	2	nmod
6	,	,	,	_	11	punct
7	analysis	analysis	NN	_	11	nsubj
8	by	by	IN	_	10	case
9	logistic	logistic	JJ	_	10	amod
10	regression	regression	NN	_	7	nmod
11	failed	fail	VBD	_	0	ROOT
12	to	to	TO	_	13	mark
13	find	find	VB	_	11	xcomp
14	any	any	DT	_	15	det
15	associations	association	NNS	_	13	dobj
16	between	between	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	20	compound
20	symptoms	symptom	NNS	_	17	conj
21	.	.	.	_	11	punct

1	Although	although	IN	_	10	mark
2	prefrontal	prefrontal	JJ	_	7	amod
3	cortical	cortical	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	ventral	ventral	JJ	_	3	conj
6	striatal	striatal	JJ	_	7	amod
7	activity	activity	NN	_	10	nsubj
8	are	be	VBP	_	10	cop
9	highly	highly	RB	_	10	advmod
10	relevant	relevant	JJ	_	29	advcl
11	for	for	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	,	,	,	_	10	punct
14	and	and	CC	_	10	cc
15	under	under	IN	_	17	case
16	partial	partial	JJ	_	17	amod
17	control	control	NN	_	10	conj
18	of	of	IN	_	20	case
19	drug1	drug1	NN	_	20	compound
20	genotype	genotype	NN	_	17	nmod
21	,	,	,	_	29	punct
22	no	no	DT	_	23	neg
23	association	association	NN	_	29	nsubjpass
24	between	between	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	drug4	drug4	NN	_	25	conj
28	was	be	VBD	_	29	auxpass
29	observed	observe	VBN	_	0	ROOT
30	.	.	.	_	29	punct

1	A	a	DT	_	3	det
2	significant	significant	JJ	_	3	amod
3	association	association	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	between	between	IN	_	29	case
7	,	,	,	_	29	punct
8	drug1	drug1	NN	_	29	compound
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	OR	or	NN	_	8	dep
11	=	=	JJ	_	10	amod
12	1.95	1.95	CD	_	11	dep
13	,	,	,	_	10	punct
14	C.I.	C.I.	NNP	_	10	appos
15	1.13-3	1.13-3	CD	_	16	nummod
16	.36	.36	CD	_	14	dep
17	-RRB-	-rrb-	-RRB-	_	10	punct
18	and	and	CC	_	8	cc
19	drug2	drug2	NN	_	8	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	OR	or	NN	_	19	dep
22	=	=	JJ	_	21	amod
23	2.39	2.39	CD	_	22	dep
24	,	,	,	_	21	punct
25	C.I.	C.I.	NNP	_	21	appos
26	1.24-4	1.24-4	CD	_	27	nummod
27	.24	.24	CD	_	25	dep
28	-RRB-	-rrb-	-RRB-	_	21	punct
29	polymorphisms	polymorphism	NNS	_	5	nmod
30	with	with	IN	_	32	case
31	the	the	DT	_	32	det
32	risk	risk	NN	_	29	nmod
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	32	nmod
35	.	.	.	_	5	punct

1	We	we	PRP	_	2	nsubj
2	observed	observe	VBD	_	0	ROOT
3	a	a	DT	_	6	det
4	strong	strong	JJ	_	6	amod
5	association	association	NN	_	6	compound
6	drug4	drug4	NN	_	2	dobj
7	with	with	IN	_	10	case
8	all	all	PDT	_	10	det:predet
9	the	the	DT	_	10	det
10	polymorphisms	polymorphism	NNS	_	6	nmod
11	,	,	,	_	10	punct
12	including	include	VBG	_	13	case
13	drug1	drug1	NN	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	odds	odds	NNS	_	16	compound
16	ratio	ratio	NN	_	13	dep
17	-LSB-	-lsb-	-LRB-	_	18	punct
18	OR	or	NN	_	16	appos
19	-RSB-	-rsb-	-RRB-	_	18	punct
20	1.50	1.50	CD	_	16	nummod
21	-LSB-	-lsb-	-LRB-	_	24	punct
22	95	95	CD	_	23	compound
23	%	%	NN	_	24	amod
24	CI	ci	NN	_	16	dep
25	=	=	JJ	_	24	amod
26	1.24-1	1.24-1	CD	_	27	nummod
27	.82	.82	CD	_	25	dep
28	-RSB-	-rsb-	-RRB-	_	24	punct
29	,	,	,	_	16	punct
30	p	p	NN	_	16	appos
31	=	=	JJ	_	30	amod
32	4.0	4.0	CD	_	31	dep
33	x	x	CC	_	32	cc
34	10	10	CD	_	32	conj
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	-5	-5	CD	_	32	dep
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	-RRB-	-rrb-	-RRB-	_	16	punct
39	,	,	,	_	13	punct
40	drug2	drug2	NN	_	13	conj
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	OR	or	NN	_	40	dep
43	1.48	1.48	CD	_	42	nummod
44	-LSB-	-lsb-	-LRB-	_	47	punct
45	95	95	CD	_	46	compound
46	%	%	NN	_	47	amod
47	CI	ci	NN	_	42	dep
48	=	=	JJ	_	47	amod
49	1.24-1	1.24-1	CD	_	50	nummod
50	.77	.77	CD	_	48	dep
51	-RSB-	-rsb-	-RRB-	_	47	punct
52	,	,	,	_	42	punct
53	p	p	NN	_	59	dep
54	=	=	JJ	_	59	dep
55	2.0	2.0	CD	_	59	nummod
56	x	x	CC	_	55	cc
57	10	10	CD	_	55	conj
58	-LRB-	-lrb-	-LRB-	_	59	punct
59	-5	-5	CD	_	42	dep
60	-RRB-	-rrb-	-RRB-	_	42	punct
61	-RRB-	-rrb-	-RRB-	_	13	punct
62	and	and	CC	_	13	cc
63	drug3	drug3	NN	_	13	conj
64	-LRB-	-lrb-	-LRB-	_	65	punct
65	OR	or	NN	_	63	dep
66	1.46	1.46	CD	_	65	nummod
67	-LSB-	-lsb-	-LRB-	_	70	punct
68	95	95	CD	_	69	compound
69	%	%	NN	_	70	amod
70	CI	ci	NN	_	65	dep
71	=	=	JJ	_	70	amod
72	1.22-1	1.22-1	CD	_	73	nummod
73	.75	.75	CD	_	71	dep
74	-RSB-	-rsb-	-RRB-	_	70	punct
75	,	,	,	_	65	punct
76	p	p	NN	_	82	dep
77	=	=	JJ	_	82	dep
78	3.0	3.0	CD	_	82	nummod
79	x	x	CC	_	78	cc
80	10	10	CD	_	78	conj
81	-LRB-	-lrb-	-LRB-	_	82	punct
82	-5	-5	CD	_	65	dep
83	-RRB-	-rrb-	-RRB-	_	65	punct
84	-RRB-	-rrb-	-RRB-	_	2	punct
85	.	.	.	_	2	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	association	association	NN	_	2	dobj
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	TCF7L2	tcf7l2	NN	_	8	compound
8	genotypes	genotype	NNS	_	4	nmod
9	with	with	IN	_	10	case
10	age	age	NN	_	4	nmod
11	at	at	IN	_	12	case
12	diagnosis	diagnosis	NN	_	4	nmod
13	,	,	,	_	12	punct
14	BMI	bmi	NN	_	12	conj
15	or	or	CC	_	12	cc
16	WHR	whr	NN	_	12	conj
17	,	,	,	_	2	punct
18	but	but	CC	_	2	cc
19	the	the	DT	_	21	det
20	risk	risk	NN	_	21	compound
21	genotype	genotype	NN	_	25	nsubjpass
22	at	at	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	was	be	VBD	_	25	auxpass
25	associated	associate	VBN	_	2	conj
26	with	with	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	p	p	NN	_	30	nsubj
30	=	=	JJ	_	27	dep
31	0.001	0.001	CD	_	30	dobj
32	-RRB-	-rrb-	-RRB-	_	30	punct
33	,	,	,	_	27	punct
34	drug3	drug3	NN	_	27	conj
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	p	p	NN	_	37	nsubj
37	=	=	JJ	_	34	dep
38	0.0002	0.0002	CD	_	37	dobj
39	-RRB-	-rrb-	-RRB-	_	37	punct
40	and	and	CC	_	27	cc
41	drug4	drug4	NN	_	43	compound
42	model	model	NN	_	43	compound
43	assessment	assessment	NN	_	27	conj
44	of	of	IN	_	45	case
45	drug5	drug5	NN	_	43	nmod
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	HOMA-R	homa-r	NN	_	45	dep
48	;	;	:	_	47	punct
49	p	p	NN	_	50	nsubj
50	=	=	JJ	_	47	dep
51	0.012	0.012	CD	_	50	dobj
52	-RRB-	-rrb-	-RRB-	_	47	punct
53	in	in	IN	_	55	case
54	non-diabetic	non-diabetic	JJ	_	55	amod
55	subjects	subject	NNS	_	25	nmod
56	.	.	.	_	2	punct

1	However	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	found	find	VBD	_	0	ROOT
5	an	a	DT	_	6	det
6	association	association	NN	_	4	dobj
7	between	between	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	genotype	genotype	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	Val/Val	val/val	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	and	and	CC	_	9	cc
14	A	a	DT	_	17	det
15	drug2	drug2	NN	_	17	compound
16	carrier	carrier	NN	_	17	compound
17	status	status	NN	_	9	conj
18	and	and	CC	_	9	cc
19	the	the	DT	_	20	det
20	risk	risk	NN	_	9	conj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	.	.	.	_	4	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	4	compound
4	polymorphisms	polymorphism	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	found	find	VBN	_	0	ROOT
7	to	to	TO	_	9	mark
8	significantly	significantly	RB	_	9	advmod
9	affect	affect	VB	_	6	xcomp
10	drug3	drug3	NN	_	11	compound
11	risk	risk	NN	_	9	dobj
12	,	,	,	_	6	punct
13	and	and	CC	_	6	cc
14	the	the	DT	_	16	det
15	drug2	drug2	NN	_	16	compound
16	polymorphism	polymorphism	NN	_	17	nsubj
17	helped	help	VBD	_	6	conj
18	determine	determine	VB	_	17	ccomp
19	drug4	drug4	NN	_	18	dobj
20	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	association	association	NN	_	12	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	10	case
6	the	the	DT	_	10	det
7	drug2	drug2	NN	_	10	compound
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	combination	combination	NN	_	2	nmod
11	could	could	MD	_	12	aux
12	help	help	VB	_	0	ROOT
13	to	to	TO	_	14	mark
14	explain	explain	VB	_	12	xcomp
15	the	the	DT	_	17	det
16	contradictory	contradictory	JJ	_	17	amod
17	results	result	NNS	_	14	dobj
18	of	of	IN	_	20	case
19	previous	previous	JJ	_	20	amod
20	studies	study	NNS	_	17	nmod
21	.	.	.	_	12	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	associations	association	NNS	_	2	nsubj
6	between	between	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	genotypes	genotype	NNS	_	2	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	or	or	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	allele	allele	NN	_	8	nsubj
4	of	of	IN	_	7	case
5	the	the	DT	_	7	det
6	COMT	COMT	NNP	_	7	compound
7	gene	gene	NN	_	3	nmod
8	confers	confer	VBZ	_	0	ROOT
9	a	a	DT	_	12	det
10	significantly	significantly	RB	_	11	advmod
11	increased	increase	VBN	_	12	amod
12	risk	risk	NN	_	8	dobj
13	for	for	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	in	in	IN	_	18	case
18	drug4	drug4	NN	_	8	nmod
19	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	a	a	DT	_	6	det
5	statistical	statistical	JJ	_	6	amod
6	association	association	NN	_	3	dobj
7	and	and	CC	_	3	cc
8	suggest	suggest	VBP	_	3	conj
9	biological	biological	JJ	_	10	amod
10	plausibility	plausibility	NN	_	8	dobj
11	that	that	IN	_	18	mark
12	the	the	DT	_	17	det
13	drug1	drug1	NN	_	17	compound
14	T	t	NN	_	17	compound
15	>	>	JJR	_	17	amod
16	C	c	NN	_	17	compound
17	polymorphism	polymorphism	NN	_	18	nsubj
18	contributed	contribute	VBD	_	10	ccomp
19	to	to	TO	_	21	case
20	increased	increase	VBN	_	21	amod
21	risks	risk	NNS	_	18	nmod
22	and	and	CC	_	21	cc
23	poor	poor	JJ	_	24	amod
24	prognosis	prognosis	NN	_	21	conj
25	of	of	IN	_	27	case
26	both	both	CC	_	27	cc:preconj
27	drug2	drug2	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	drug3	drug3	NN	_	27	conj
30	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	increased	increase	VBN	_	3	amod
3	volumes	volume	NNS	_	17	nsubjpass
4	in	in	IN	_	6	case
5	the	the	DT	_	6	det
6	genu	genu	NN	_	3	nmod
7	,	,	,	_	6	punct
8	splenium	splenium	NN	_	6	conj
9	and	and	CC	_	6	cc
10	total	total	JJ	_	11	amod
11	CC	cc	NN	_	6	conj
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	drug3	drug3	NN	_	15	compound
15	group	group	NN	_	3	nmod
16	were	be	VBD	_	17	auxpass
17	associated	associate	VBN	_	0	ROOT
18	with	with	IN	_	19	case
19	polymorphisms	polymorphism	NNS	_	17	nmod
20	within	within	IN	_	23	case
21	the	the	DT	_	23	det
22	candidate	candidate	NN	_	23	compound
23	genes	gene	NNS	_	19	nmod
24	:	:	:	_	17	punct
25	drug1	drug1	NN	_	17	dep
26	,	,	,	_	25	punct
27	drug2	drug2	NN	_	25	conj
28	and	and	CC	_	25	cc
29	UFD1L	ufd1l	NN	_	25	conj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	drug4	drug4	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	.	.	.	_	17	punct

1	The	the	DT	_	4	det
2	OPRM1	oprm1	NN	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	genotype	genotype	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	11	case
8	patients	patient	NNS	_	11	nmod:poss
9	'	'	POS	_	8	case
10	drug2	drug2	NN	_	11	compound
11	ratings	rating	NNS	_	6	nmod
12	at	at	IN	_	14	case
13	15	15	CD	_	14	nummod
14	min	min	NN	_	11	nmod
15	in	in	IN	_	19	case
16	the	the	DT	_	19	det
17	postanesthesia	postanesthesia	NN	_	19	compound
18	care	care	NN	_	19	compound
19	unit	unit	NN	_	14	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	PACU	pacu	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	p	p	NN	_	25	nsubj
25	=	=	JJ	_	11	dep
26	.01	.01	CD	_	25	dobj
27	-RRB-	-rrb-	-RRB-	_	25	punct
28	and	and	CC	_	11	cc
29	patients	patient	NNS	_	31	nmod:poss
30	'	'	POS	_	29	case
31	drug3	drug3	NN	_	11	conj
32	at	at	IN	_	34	case
33	15	15	CD	_	34	nummod
34	min	min	NN	_	31	nmod
35	in	in	IN	_	37	case
36	the	the	DT	_	37	det
37	PACU	PACU	NNP	_	34	nmod
38	-LRB-	-lrb-	-LRB-	_	40	punct
39	p	p	NN	_	40	nsubj
40	=	=	JJ	_	31	dep
41	.02	.02	CD	_	40	dobj
42	-RRB-	-rrb-	-RRB-	_	40	punct
43	.	.	.	_	6	punct

1	COMT	COMT	NNP	_	3	compound
2	genotype	genotype	NN	_	3	compound
3	drug1	drug1	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	associated	associate	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	in	in	IN	_	12	case
9	the	the	DT	_	12	det
10	first	first	JJ	_	12	amod
11	45	45	CD	_	12	nummod
12	min	min	NN	_	5	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	PACU	PACU	NNP	_	12	nmod
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	p	p	NN	_	18	nsubj
18	=	=	JJ	_	12	dep
19	.04	.04	CD	_	18	dobj
20	-RRB-	-rrb-	-RRB-	_	18	punct
21	.	.	.	_	5	punct

1	Our	we	PRP$	_	4	nmod:poss
2	haplotype	haplotype	NN	_	4	compound
3	trend	trend	NN	_	4	compound
4	analysis	analysis	NN	_	5	nsubj
5	identified	identify	VBD	_	0	ROOT
6	a	a	DT	_	7	det
7	drug1	drug1	NN	_	5	dobj
8	significantly	significantly	RB	_	9	advmod
9	associated	associate	VBN	_	7	acl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	p	p	NN	_	14	nsubj
14	=	=	JJ	_	11	dep
15	.0013	.0013	CD	_	14	dobj
16	-RRB-	-rrb-	-RRB-	_	14	punct
17	,	,	,	_	11	punct
18	drug3	drug3	NN	_	11	conj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	p	p	NN	_	21	nsubj
21	=	=	JJ	_	18	dep
22	.0024	.0024	CD	_	21	dobj
23	-RRB-	-rrb-	-RRB-	_	21	punct
24	,	,	,	_	11	punct
25	and	and	CC	_	11	cc
26	drug4	drug4	NN	_	11	conj
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	p	p	NN	_	29	nsubj
29	=	=	JJ	_	26	dep
30	.017	.017	CD	_	29	dobj
31	-RRB-	-rrb-	-RRB-	_	29	punct
32	.	.	.	_	5	punct

1	Allele	allele	NN	_	5	compound
2	G	g	NN	_	5	compound
3	fromCOMT	fromcomt	NN	_	5	compound
4	SNPs	snp	NNS	_	5	compound
5	drug1	drug1	NN	_	9	nsubj
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	may	may	MD	_	9	aux
9	represent	represent	VB	_	0	ROOT
10	reliable	reliable	JJ	_	12	amod
11	state-dependent	state-dependent	JJ	_	12	amod
12	predictors	predictor	NNS	_	9	dobj
13	of	of	IN	_	15	case
14	global	global	JJ	_	15	amod
15	drug3	drug3	NN	_	12	nmod
16	during	during	IN	_	20	case
17	manic	manic	JJ	_	20	amod
18	and	and	CC	_	17	cc
19	mixed	mixed	JJ	_	17	conj
20	episodes	episode	NNS	_	9	nmod
21	in	in	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	.	.	.	_	9	punct

1	Moreover	moreover	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	5	det
4	T	t	NN	_	5	compound
5	allele	allele	NN	_	10	nsubjpass
6	at	at	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	was	be	VBD	_	10	auxpass
9	inversely	inversely	RB	_	10	advmod
10	associated	associate	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	log-transformed	log-transformed	JJ	_	10	nmod
13	,	,	,	_	12	punct
14	HOMA	homa	NN	_	12	appos
15	-	-	:	_	12	punct
16	%	%	NN	_	19	compound
17	B	b	NN	_	19	compound
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	beta	beta	NN	_	12	dep
20	=	=	JJ	_	19	amod
21	-0.07	-0.07	CD	_	20	dep
22	,	,	,	_	19	punct
23	p	p	NN	_	24	nsubj
24	=	=	JJ	_	19	dep
25	0.005	0.005	CD	_	24	dobj
26	-RRB-	-rrb-	-RRB-	_	19	punct
27	as	as	IN	_	29	case
28	a	a	DT	_	29	det
29	measure	measure	NN	_	12	nmod
30	of	of	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	,	,	,	_	10	punct
33	and	and	CC	_	10	cc
34	drug3	drug3	NN	_	10	conj
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	beta	beta	NN	_	37	nsubj
37	=	=	JJ	_	34	dep
38	-0.06	-0.06	CD	_	37	dobj
39	,	,	,	_	37	punct
40	p	p	NN	_	41	nsubj
41	=	=	JJ	_	37	parataxis
42	0.02	0.02	CD	_	41	dobj
43	-RRB-	-rrb-	-RRB-	_	37	punct
44	.	.	.	_	10	punct

1	The	the	DT	_	6	det
2	nicotinic	nicotinic	JJ	_	6	amod
3	acetylcholine	acetylcholine	NN	_	6	compound
4	receptor	receptor	NN	_	6	compound
5	polymorphism	polymorphism	NN	_	6	compound
6	drug1	drug1	NN	_	11	nsubjpass
7	on	on	IN	_	9	case
8	chromosome	chromosome	NN	_	9	compound
9	15q25	15q25	NN	_	6	nmod
10	is	be	VBZ	_	11	auxpass
11	associated	associate	VBN	_	0	ROOT
12	with	with	IN	_	14	case
13	major	major	JJ	_	14	amod
14	drug2	drug2	NN	_	11	nmod
15	in	in	IN	_	18	case
16	the	the	DT	_	18	det
17	general	general	JJ	_	18	amod
18	population	population	NN	_	14	nmod
19	with	with	IN	_	22	case
20	additional	additional	JJ	_	22	amod
21	increased	increase	VBN	_	22	amod
22	risk	risk	NN	_	11	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	as	as	RB	_	24	cc
26	well	well	RB	_	25	mwe
27	as	as	IN	_	25	mwe
28	drug4	drug4	NN	_	24	conj
29	.	.	.	_	11	punct

1	Variant	variant	JJ	_	2	amod
2	alleles	allele	NNS	_	13	nsubj
3	of	of	IN	_	4	case
4	polymorphisms	polymorphism	NNS	_	2	nmod
5	of	of	IN	_	7	case
6	TLR2	tlr2	NN	_	7	compound
7	drug1	drug1	NN	_	4	nmod
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug3	drug3	NN	_	7	conj
13	demonstrated	demonstrate	VBD	_	0	ROOT
14	a	a	DT	_	16	det
15	consistent	consistent	JJ	_	16	amod
16	association	association	NN	_	13	dobj
17	with	with	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	p	p	NN	_	21	nsubj
21	=	=	JJ	_	16	dep
22	0.008	0.008	CD	_	21	dobj
23	,	,	,	_	21	punct
24	p	p	NN	_	25	nsubj
25	=	=	JJ	_	21	parataxis
26	0.006	0.006	CD	_	25	dobj
27	and	and	CC	_	21	cc
28	p	p	NN	_	29	nsubj
29	=	=	JJ	_	21	conj
30	0.029	0.029	CD	_	29	dobj
31	respectively	respectively	RB	_	29	advmod
32	-RRB-	-rrb-	-RRB-	_	21	punct
33	.	.	.	_	13	punct

1	Variant	variant	JJ	_	2	amod
2	alleles	allele	NNS	_	13	nsubj
3	of	of	IN	_	4	case
4	polymorphisms	polymorphism	NNS	_	2	nmod
5	of	of	IN	_	7	case
6	TLR2	tlr2	NN	_	7	compound
7	drug1	drug1	NN	_	4	nmod
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug3	drug3	NN	_	7	conj
13	demonstrated	demonstrate	VBD	_	0	ROOT
14	a	a	DT	_	16	det
15	consistent	consistent	JJ	_	16	amod
16	association	association	NN	_	13	dobj
17	with	with	IN	_	19	case
18	drug4	drug4	NN	_	19	compound
19	severity	severity	NN	_	16	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	p	p	NN	_	22	nsubj
22	=	=	JJ	_	19	dep
23	0.008	0.008	CD	_	22	dobj
24	,	,	,	_	22	punct
25	p	p	NN	_	26	nsubj
26	=	=	JJ	_	22	parataxis
27	0.006	0.006	CD	_	26	dobj
28	and	and	CC	_	22	cc
29	p	p	NN	_	30	nsubj
30	=	=	JJ	_	22	conj
31	0.029	0.029	CD	_	30	dobj
32	respectively	respectively	RB	_	30	advmod
33	-RRB-	-rrb-	-RRB-	_	22	punct

1	Patients	patient	NNS	_	3	compound
2	homozygous	homozygous	JJ	_	3	amod
3	AA	aa	NN	_	11	nsubjpass
4	for	for	IN	_	7	case
5	TLR1	tlr1	NN	_	7	compound
6	polymorphism	polymorphism	NN	_	7	compound
7	drug1	drug1	NN	_	3	nmod
8	are	be	VBP	_	11	auxpass
9	more	more	RBR	_	10	advmod
10	frequently	frequently	RB	_	11	advmod
11	associated	associate	VBN	_	0	ROOT
12	with	with	IN	_	14	case
13	faster	faster	JJR	_	14	amod
14	decline	decline	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	compared	compare	VBN	_	20	case
18	to	to	TO	_	20	case
19	heterozygous	heterozygous	JJ	_	20	amod
20	genotype	genotype	NN	_	14	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	OR	or	NN	_	20	dep
23	:7.33	:7.33	CD	_	22	nummod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	95	95	CD	_	26	compound
26	%	%	NN	_	27	amod
27	CI	ci	NN	_	22	appos
28	:1.63	:1.63	CD	_	29	compound
29	-33.11	-33.11	CD	_	27	nummod
30	-RRB-	-rrb-	-RRB-	_	27	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	4	expl
4	is	be	VBZ	_	1	dep
5	a	a	DT	_	7	det
6	close	close	JJ	_	7	amod
7	relationship	relationship	NN	_	4	nsubj
8	between	between	IN	_	10	case
9	the	the	DT	_	10	det
10	presence	presence	NN	_	7	nmod
11	of	of	IN	_	13	case
12	TLR3	tlr3	NN	_	13	compound
13	drug1	drug1	NN	_	10	nmod
14	/	/	:	_	13	punct
15	CT	ct	NN	_	13	dep
16	and	and	CC	_	15	cc
17	an	a	DT	_	19	det
18	increased	increase	VBN	_	19	amod
19	risk	risk	NN	_	15	conj
20	of	of	IN	_	21	case
21	pneumonia	pneumonia	NN	_	19	nmod
22	in	in	IN	_	23	case
23	children	child	NNS	_	10	nmod
24	infected	infect	VBN	_	23	acl
25	by	by	IN	_	30	case
26	the	the	DT	_	30	det
27	pandemic	pandemic	NN	_	30	compound
28	A	a	NN	_	30	compound
29	/	/	:	_	30	punct
30	drug2	drug2	NN	_	24	nmod
31	/	/	:	_	4	punct
32	2009	2009	CD	_	34	nummod
33	drug3	drug3	NN	_	34	compound
34	virus	virus	NN	_	4	dep
35	.	.	.	_	1	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Overall	overall	JJ	_	12	dep
4	,	,	,	_	12	punct
5	150	150	CD	_	6	nummod
6	patients	patient	NNS	_	12	nsubjpass
7	with	with	IN	_	8	case
8	drug6	drug6	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	ascites	ascite	NNS	_	8	conj
11	were	be	VBD	_	12	auxpass
12	genotyped	genotype	VBN	_	1	dep
13	for	for	IN	_	16	case
14	TLR2	tlr2	NN	_	16	compound
15	gene	gene	NN	_	16	compound
16	variants	variant	NNS	_	12	nmod
17	drug1	drug1	NN	_	16	dep
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug2	drug2	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	17	punct
22	drug3	drug3	NN	_	17	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug4	drug4	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	17	punct
27	Pro631His	pro631his	NN	_	17	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug5	drug5	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	and	and	CC	_	17	cc
32	the	the	DT	_	35	det
33	TLR2GT	tlr2gt	NN	_	35	compound
34	microsatellite	microsatellite	NN	_	35	compound
35	polymorphism	polymorphism	NN	_	17	conj
36	in	in	IN	_	37	case
37	intron	intron	NN	_	35	nmod
38	2	2	CD	_	37	nummod
39	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	study	study	NN	_	5	nsubj
5	extends	extend	VBZ	_	1	appos
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	observation	observation	NN	_	5	nmod
9	of	of	IN	_	13	case
10	a	a	DT	_	13	det
11	strong	strong	JJ	_	13	amod
12	multiethnic	multiethnic	JJ	_	13	amod
13	association	association	NN	_	8	nmod
14	of	of	IN	_	15	case
15	polymorphisms	polymorphism	NNS	_	13	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	drug1	drug1	NN	_	13	nmod
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	with	with	IN	_	22	case
22	drug4	drug4	NN	_	13	nmod
23	,	,	,	_	5	punct
24	but	but	CC	_	5	cc
25	does	do	VBZ	_	27	aux
26	not	not	RB	_	27	neg
27	confirm	confirm	VB	_	5	conj
28	the	the	DT	_	29	det
29	association	association	NN	_	27	dobj
30	of	of	IN	_	31	case
31	CPT1B/CHKB	cpt1b/chkb	NN	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	drug3	drug3	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	in	in	IN	_	38	case
36	the	the	DT	_	38	det
37	Chinese	chinese	JJ	_	38	amod
38	population	population	NN	_	29	nmod
39	.	.	.	_	1	punct

1	Common	common	JJ	_	2	amod
2	variation	variation	NN	_	7	nsubjpass
3	at	at	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	7	auxpass
6	robustly	robustly	RB	_	7	advmod
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	smoking	smoking	NN	_	10	compound
10	quantity	quantity	NN	_	7	nmod
11	and	and	CC	_	7	cc
12	was	be	VBD	_	14	auxpass
13	recently	recently	RB	_	14	advmod
14	shown	show	VBN	_	7	conj
15	to	to	TO	_	16	mark
16	influence	influence	VB	_	14	xcomp
17	drug2	drug2	NN	_	16	dobj
18	during	during	IN	_	19	case
19	pregnancy	pregnancy	NN	_	16	nmod
20	,	,	,	_	7	punct
21	but	but	CC	_	7	cc
22	its	its	PRP$	_	23	nmod:poss
23	influence	influence	NN	_	29	nsubj
24	on	on	IN	_	26	case
25	birth	birth	NN	_	26	compound
26	weight	weight	NN	_	23	nmod
27	is	be	VBZ	_	29	cop
28	not	not	RB	_	29	neg
29	clear	clear	JJ	_	7	conj
30	.	.	.	_	7	punct

1	Stepwise	stepwise	JJ	_	4	amod
2	multiple	multiple	JJ	_	4	amod
3	regression	regression	NN	_	4	compound
4	analysis	analysis	NN	_	5	nsubj
5	revealed	reveal	VBD	_	0	ROOT
6	that	that	IN	_	18	mark
7	the	the	DT	_	9	det
8	risk	risk	NN	_	9	compound
9	allele	allele	NN	_	18	nsubjpass
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	C	c	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	for	for	IN	_	15	case
14	SNP	snp	NN	_	15	compound
15	drug1	drug1	NN	_	9	nmod
16	was	be	VBD	_	18	auxpass
17	significantly	significantly	RB	_	18	advmod
18	associated	associate	VBN	_	5	ccomp
19	with	with	IN	_	23	case
20	decreased	decrease	VBN	_	23	amod
21	CPT1B	cpt1b	NN	_	23	compound
22	mRNA	mrna	NN	_	23	compound
23	expression	expression	NN	_	18	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	P	p	NN	_	26	nsubj
26	=	=	JJ	_	23	dep
27	1.0	1.0	CD	_	29	nummod
28	*	*	SYM	_	29	dep
29	10	10	CD	_	26	dobj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	-9	-9	CD	_	26	parataxis
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	-RRB-	-rrb-	-RRB-	_	26	punct
34	,	,	,	_	18	punct
35	and	and	CC	_	18	cc
36	the	the	DT	_	38	det
37	CPT1B	cpt1b	NN	_	38	compound
38	expression	expression	NN	_	40	nsubj
39	was	be	VBD	_	40	cop
40	higher	higher	JJR	_	18	conj
41	in	in	IN	_	44	case
42	the	the	DT	_	44	det
43	drug2	drug2	NN	_	44	compound
44	patients	patient	NNS	_	40	nmod
45	than	than	IN	_	48	case
46	in	in	IN	_	48	case
47	the	the	DT	_	48	det
48	controls	control	NNS	_	40	advcl
49	-LRB-	-lrb-	-LRB-	_	50	punct
50	P	p	NN	_	48	dep
51	=	=	JJ	_	50	amod
52	0.005	0.005	CD	_	51	dep
53	-RRB-	-rrb-	-RRB-	_	50	punct
54	.	.	.	_	5	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	significantly	significantly	RB	_	6	advmod
6	associated	associate	VBN	_	1	appos
7	with	with	IN	_	9	case
8	SNP	snp	NN	_	9	compound
9	drug1	drug1	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	P	p	NN	_	9	dep
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	allele	allele	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	=	=	JJ	_	11	amod
16	3.6	3.6	CD	_	17	nummod
17	x10	x10	NN	_	15	dep
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	-3	-3	CD	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	;	;	:	_	11	punct
22	OR	or	NN	_	11	dep
23	=	=	JJ	_	22	amod
24	1.56	1.56	CD	_	23	dep
25	;	;	:	_	11	punct
26	95	95	CD	_	27	nummod
27	%	%	NN	_	11	dep
28	c.i.	c.i.	NN	_	27	dep
29	:	:	:	_	27	punct
30	1.12-2	1.12-2	CD	_	31	nummod
31	.15	.15	CD	_	27	dep
32	-RRB-	-rrb-	-RRB-	_	11	punct
33	and	and	CC	_	9	cc
34	HLA-DRB1	hla-drb1	NN	_	39	compound
35	*	*	SYM	_	38	dep
36	1501-DQB1	1501-dqb1	CD	_	38	compound
37	*	*	SYM	_	38	dep
38	0602	0602	CD	_	39	nummod
39	haplotype	haplotype	NN	_	9	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	P	p	NN	_	39	dep
42	-LRB-	-lrb-	-LRB-	_	43	punct
43	positivity	positivity	NN	_	41	appos
44	-RRB-	-rrb-	-RRB-	_	43	punct
45	=	=	JJ	_	41	amod
46	9.2	9.2	CD	_	47	nummod
47	x10	x10	NN	_	45	dep
48	-LRB-	-lrb-	-LRB-	_	49	punct
49	-11	-11	CD	_	47	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	;	;	:	_	41	punct
52	OR	or	NN	_	41	dep
53	=	=	JJ	_	52	amod
54	3.97	3.97	CD	_	53	dep
55	;	;	:	_	41	punct
56	95	95	CD	_	57	nummod
57	%	%	NN	_	41	dep
58	c.i.	c.i.	NN	_	57	dep
59	:	:	:	_	57	punct
60	2.55-6	2.55-6	CD	_	61	nummod
61	.19	.19	CD	_	57	dep
62	-RRB-	-rrb-	-RRB-	_	41	punct
63	.	.	.	_	1	punct

1	drug1	drug1	NN	_	12	nsubjpass
2	,	,	,	_	1	punct
3	a	a	DT	_	4	det
4	SNP	snp	NN	_	1	appos
5	located	located	JJ	_	4	amod
6	between	between	IN	_	7	case
7	CPT1B	cpt1b	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	CHKB	chkb	NN	_	7	conj
10	,	,	,	_	1	punct
11	was	be	VBD	_	12	auxpass
12	associated	associate	VBN	_	0	ROOT
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	in	in	IN	_	44	case
16	Japanese	japanese	JJ	_	28	dep
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	drug2	drug2	NN	_	20	compound
19	-LSB-	-lsb-	-LRB-	_	20	punct
20	C	c	NN	_	16	appos
21	-RSB-	-rsb-	-RRB-	_	20	punct
22	,	,	,	_	28	punct
23	odds	odds	NNS	_	24	compound
24	ratio	ratio	NN	_	28	nsubj
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	OR	or	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	=	=	JJ	_	44	amod
29	1.79	1.79	CD	_	28	dep
30	,	,	,	_	28	punct
31	combined	combine	VBN	_	32	amod
32	P	p	NN	_	33	nsubj
33	=	=	JJ	_	28	conj
34	4.4	4.4	CD	_	33	dobj
35	x	x	CC	_	34	cc
36	10	10	CD	_	34	conj
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	-7	-7	CD	_	33	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	-RRB-	-rrb-	-RRB-	_	28	punct
41	and	and	CC	_	28	cc
42	other	other	JJ	_	28	conj
43	ancestry	ancestry	NN	_	44	compound
44	groups	group	NNS	_	14	nmod
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	OR	or	NN	_	44	dep
47	=	=	JJ	_	46	amod
48	1.40	1.40	CD	_	47	dep
49	,	,	,	_	46	punct
50	P	p	NN	_	51	nsubj
51	=	=	JJ	_	46	dep
52	0.02	0.02	CD	_	51	dobj
53	-RRB-	-rrb-	-RRB-	_	46	punct
54	.	.	.	_	12	punct

1	drug1	drug1	NN	_	12	nsubjpass
2	,	,	,	_	1	punct
3	a	a	DT	_	4	det
4	SNP	snp	NN	_	1	appos
5	located	located	JJ	_	4	amod
6	between	between	IN	_	7	case
7	CPT1B	cpt1b	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	CHKB	chkb	NN	_	7	conj
10	,	,	,	_	1	punct
11	was	be	VBD	_	12	auxpass
12	associated	associate	VBN	_	0	ROOT
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	in	in	IN	_	44	case
16	Japanese	japanese	JJ	_	28	dep
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	drug2	drug2	NN	_	20	compound
19	-LSB-	-lsb-	-LRB-	_	20	punct
20	C	c	NN	_	16	appos
21	-RSB-	-rsb-	-RRB-	_	20	punct
22	,	,	,	_	28	punct
23	odds	odds	NNS	_	24	compound
24	ratio	ratio	NN	_	28	nsubj
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	OR	or	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	=	=	JJ	_	44	amod
29	1.79	1.79	CD	_	28	dep
30	,	,	,	_	28	punct
31	combined	combine	VBN	_	32	amod
32	P	p	NN	_	33	nsubj
33	=	=	JJ	_	28	conj
34	4.4	4.4	CD	_	33	dobj
35	x	x	CC	_	34	cc
36	10	10	CD	_	34	conj
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	-7	-7	CD	_	33	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	-RRB-	-rrb-	-RRB-	_	28	punct
41	and	and	CC	_	28	cc
42	other	other	JJ	_	28	conj
43	ancestry	ancestry	NN	_	44	compound
44	groups	group	NNS	_	14	nmod
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	OR	or	NN	_	44	dep
47	=	=	JJ	_	46	amod
48	1.40	1.40	CD	_	47	dep
49	,	,	,	_	46	punct
50	P	p	NN	_	51	nsubj
51	=	=	JJ	_	46	dep
52	0.02	0.02	CD	_	51	dobj
53	-RRB-	-rrb-	-RRB-	_	46	punct
54	.	.	.	_	12	punct

1	Case-control	case-control	JJ	_	2	amod
2	comparisons	comparison	NNS	_	3	nsubj
3	revealed	reveal	VBD	_	0	ROOT
4	higher	higher	JJR	_	5	amod
5	prevalence	prevalence	NN	_	3	dobj
6	of	of	IN	_	9	case
7	short	short	JJ	_	9	amod
8	CAG	cag	NN	_	9	compound
9	alleles	allele	NNS	_	5	nmod
10	as	as	RB	_	5	cc
11	well	well	RB	_	10	mwe
12	as	as	IN	_	10	mwe
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	A	a	NN	_	16	compound
16	allele	allele	NN	_	5	conj
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	drug1	drug1	NN	_	20	compound
20	SNP	snp	NN	_	16	nmod
21	in	in	IN	_	24	case
22	female	female	JJ	_	24	amod
23	drug3	drug3	NN	_	24	compound
24	cases	case	NNS	_	16	nmod
25	than	than	IN	_	27	case
26	in	in	IN	_	27	case
27	controls	control	NNS	_	16	nmod
28	,	,	,	_	3	punct
29	but	but	CC	_	3	cc
30	revealed	reveal	VBD	_	3	conj
31	no	no	DT	_	33	neg
32	significant	significant	JJ	_	33	amod
33	differences	difference	NNS	_	30	dobj
34	with	with	IN	_	35	case
35	respect	respect	NN	_	33	nmod
36	to	to	TO	_	38	case
37	the	the	DT	_	38	det
38	drug2	drug2	NN	_	35	nmod
39	.	.	.	_	3	punct

1	We	we	PRP	_	2	nsubj
2	identified	identify	VBD	_	0	ROOT
3	drug1	drug1	NN	_	2	dobj
4	as	as	IN	_	6	mark
5	strongly	strongly	RB	_	6	advmod
6	associated	associate	VBN	_	2	advcl
7	with	with	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	,	,	,	_	8	punct
10	In	in	IN	_	11	case
11	particular	particular	JJ	_	8	nmod
12	,	,	,	_	2	punct
13	we	we	PRP	_	14	nsubj
14	found	find	VBD	_	2	parataxis
15	that	that	IN	_	24	mark
16	drug2	drug2	NN	_	24	nsubj
17	located	located	JJ	_	16	amod
18	8	8	CD	_	19	nummod
19	kb	kb	NN	_	17	dobj
20	from	from	IN	_	23	case
21	the	the	DT	_	23	det
22	EDA2R	eda2r	NN	_	23	compound
23	gene	gene	NN	_	19	nmod
24	showed	show	VBD	_	14	ccomp
25	the	the	DT	_	27	det
26	best	best	JJS	_	27	amod
27	result	result	NN	_	24	dobj
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	P	p	NN	_	30	nsubj
30	=	=	JJ	_	27	dep
31	7.77	7.77	CD	_	30	dobj
32	e	e	SYM	_	30	dep
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	-7	-7	CD	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	-RRB-	-rrb-	-RRB-	_	30	punct
37	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	conditional	conditional	JJ	_	4	amod
3	logistic	logistic	JJ	_	4	amod
4	regression	regression	NN	_	7	nmod
5	,	,	,	_	7	punct
6	there	there	EX	_	7	expl
7	was	be	VBD	_	0	ROOT
8	no	no	DT	_	9	neg
9	association	association	NN	_	7	nsubj
10	between	between	IN	_	12	case
11	the	the	DT	_	12	det
12	number	number	NN	_	9	nmod
13	of	of	IN	_	14	case
14	alleles	allele	NNS	_	12	nmod
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	>	>	JJR	_	16	dep
18	or	or	CC	_	17	cc
19	=	=	JJ	_	17	conj
20	21	21	CD	_	19	dep
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	or	or	CC	_	23	cc
23	>	>	JJR	_	20	dep
24	or	or	CC	_	23	cc
25	=	=	JJ	_	23	conj
26	22	22	CD	_	25	dep
27	-RRB-	-rrb-	-RRB-	_	23	punct
28	and	and	CC	_	16	cc
29	risk	risk	NN	_	16	conj
30	of	of	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	,	,	,	_	31	punct
33	drug3	drug3	NN	_	31	conj
34	or	or	CC	_	31	cc
35	drug4	drug4	NN	_	31	conj
36	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	2001	2001	CD	_	5	nmod
3	,	,	,	_	5	punct
4	we	we	PRP	_	5	nsubj
5	published	publish	VBD	_	0	ROOT
6	the	the	DT	_	9	det
7	first	first	JJ	_	9	amod
8	significant	significant	JJ	_	9	amod
9	evidence	evidence	NN	_	5	dobj
10	of	of	IN	_	13	case
11	a	a	DT	_	13	det
12	genetic	genetic	JJ	_	13	amod
13	association	association	NN	_	9	nmod
14	between	between	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	a	a	DT	_	21	det
18	synonymous	synonymous	JJ	_	21	amod
19	coding	code	VBG	_	21	amod
20	SNP	snp	NN	_	21	compound
21	drug1	drug1	NN	_	15	conj
22	in	in	IN	_	26	case
23	the	the	DT	_	26	det
24	androgen	androgen	NN	_	26	compound
25	receptor	receptor	NN	_	26	compound
26	gene	gene	NN	_	21	nmod
27	,	,	,	_	26	punct
28	AR	ar	NN	_	26	appos
29	.	.	.	_	5	punct

1	We	we	PRP	_	2	nsubj
2	utilised	utilise	VBD	_	0	ROOT
3	statistical	statistical	JJ	_	4	amod
4	methods	method	NNS	_	2	dobj
5	appropriate	appropriate	JJ	_	4	amod
6	for	for	IN	_	9	case
7	the	the	DT	_	9	det
8	categorical	categorical	JJ	_	9	amod
9	nature	nature	NN	_	5	nmod
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	phenotype	phenotype	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	familial	familial	JJ	_	15	amod
15	structure	structure	NN	_	12	conj
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	cohort	cohort	NN	_	12	nmod
19	,	,	,	_	2	punct
20	and	and	CC	_	2	cc
21	determined	determine	VBD	_	2	conj
22	that	that	IN	_	21	dobj
23	whilst	whilst	IN	_	28	mark
24	SNP	snp	NN	_	25	compound
25	drug1	drug1	NN	_	28	nsubjpass
26	was	be	VBD	_	28	auxpass
27	strongly	strongly	RB	_	28	advmod
28	associated	associate	VBN	_	22	dep
29	with	with	IN	_	30	case
30	drug2	drug2	NN	_	28	nmod
31	-LRB-	-lrb-	-LRB-	_	34	punct
32	P	p	NN	_	34	nsubj
33	<	<	JJR	_	34	dep
34	0.0001	0.0001	CD	_	30	dep
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	28	punct
37	the	the	DT	_	40	det
38	GGN	ggn	NN	_	40	compound
39	triplet	triplet	NN	_	40	compound
40	repeat	repeat	NN	_	36	root
41	was	be	VBD	_	40	acl
42	not	not	RB	_	41	advmod
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	P	p	NN	_	42	dep
45	=	=	JJ	_	44	amod
46	0.13	0.13	CD	_	45	dep
47	-RRB-	-rrb-	-RRB-	_	44	punct
48	.	.	.	_	40	punct

1	We	we	PRP	_	2	nsubj
2	genotyped	genotype	VBD	_	0	ROOT
3	the	the	DT	_	5	det
4	CAG	cag	NN	_	5	compound
5	microsatellite	microsatellite	NN	_	2	dobj
6	and	and	CC	_	5	cc
7	six	six	CD	_	11	nummod
8	haplotype-tagging	haplotype-tagging	JJ	_	11	amod
9	single	single	JJ	_	11	amod
10	nucleotide	nucleotide	NN	_	11	compound
11	polymorphisms	polymorphism	NNS	_	5	conj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug1	drug1	NN	_	11	dep
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug4	drug4	NN	_	13	conj
20	,	,	,	_	13	punct
21	drug5	drug5	NN	_	13	conj
22	,	,	,	_	13	punct
23	drug6	drug6	NN	_	13	appos
24	-RRB-	-rrb-	-RRB-	_	13	punct
25	of	of	IN	_	29	case
26	the	the	DT	_	29	det
27	androgen	androgen	NN	_	29	compound
28	receptor	receptor	NN	_	29	compound
29	gene	gene	NN	_	5	nmod
30	in	in	IN	_	33	case
31	987	987	CD	_	33	nummod
32	drug7	drug7	NN	_	33	compound
33	cases	case	NNS	_	2	nmod
34	and	and	CC	_	33	cc
35	1,034	1,034	CD	_	36	nummod
36	controls	control	NNS	_	33	conj
37	from	from	IN	_	39	case
38	a	a	DT	_	39	det
39	study	study	NN	_	2	nmod
40	conducted	conduct	VBN	_	39	acl
41	in	in	IN	_	43	case
42	New	New	NNP	_	43	compound
43	Hampshire	Hampshire	NNP	_	40	nmod
44	and	and	CC	_	43	cc
45	eastern	eastern	JJ	_	46	amod
46	Massachusetts	Massachusetts	NNP	_	43	conj
47	between	between	IN	_	48	case
48	May	May	NNP	_	40	nmod
49	1992	1992	CD	_	48	nummod
50	and	and	CC	_	48	cc
51	July	July	NNP	_	48	conj
52	2003	2003	CD	_	51	nummod
53	.	.	.	_	2	punct

1	We	we	PRP	_	2	nsubj
2	observed	observe	VBD	_	0	ROOT
3	that	that	IN	_	15	mark
4	carriage	carriage	NN	_	15	nsubjpass
5	of	of	IN	_	7	case
6	two	two	CD	_	7	nummod
7	alleles	allele	NNS	_	4	nmod
8	with	with	IN	_	13	case
9	>	>	JJR	_	12	advmod
10	or	or	CC	_	9	cc
11	=	=	JJ	_	9	conj
12	22	22	CD	_	13	nummod
13	drug1	drug1	NN	_	4	nmod
14	was	be	VBD	_	15	auxpass
15	associated	associate	VBN	_	2	ccomp
16	with	with	IN	_	19	case
17	an	a	DT	_	19	det
18	increased	increase	VBN	_	19	amod
19	risk	risk	NN	_	15	nmod
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	compared	compare	VBN	_	24	case
23	with	with	IN	_	24	case
24	carriage	carriage	NN	_	19	nmod
25	of	of	IN	_	27	case
26	two	two	CD	_	27	nummod
27	alleles	allele	NNS	_	24	nmod
28	with	with	IN	_	32	case
29	<	<	JJR	_	30	advmod
30	22	22	CD	_	32	nummod
31	CAG	cag	NN	_	32	compound
32	repeats	repeat	NNS	_	27	nmod
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	covariate-adjusted	covariate-adjusted	JJ	_	36	amod
35	odds	odds	NNS	_	36	compound
36	ratios	ratio	NNS	_	32	dep
37	,	,	,	_	36	punct
38	1.31	1.31	CD	_	36	appos
39	;	;	:	_	36	punct
40	95	95	CD	_	41	compound
41	%	%	NN	_	43	amod
42	confidence	confidence	NN	_	43	compound
43	intervals	interval	NNS	_	36	dep
44	,	,	,	_	43	punct
45	1.01-1	1.01-1	CD	_	46	nummod
46	.69	.69	CD	_	43	appos
47	-RRB-	-rrb-	-RRB-	_	36	punct
48	.	.	.	_	2	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	14	mark
5	possession	possession	NN	_	14	nsubjpass
6	of	of	IN	_	11	case
7	two	two	CD	_	11	nummod
8	long	long	JJ	_	11	amod
9	AR	ar	NNS	_	11	compound
10	alleles	allele	NNS	_	11	compound
11	drug1	drug1	NN	_	5	nmod
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	associated	associate	VBN	_	3	ccomp
15	with	with	IN	_	17	case
16	increased	increase	VBN	_	17	amod
17	risk	risk	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	compared	compare	VBN	_	22	case
21	with	with	IN	_	22	case
22	women	woman	NNS	_	17	nmod
23	with	with	IN	_	27	case
24	two	two	CD	_	27	nummod
25	short	short	JJ	_	27	amod
26	AR	ar	NNS	_	27	compound
27	alleles	allele	NNS	_	22	nmod
28	-LRB-	-lrb-	-LRB-	_	32	punct
29	<	<	JJR	_	30	advmod
30	22	22	CD	_	32	nummod
31	CAG	cag	NN	_	32	compound
32	repeats	repeat	NNS	_	27	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	.	.	.	_	3	punct

1	Recently	recently	RB	_	20	advmod
2	,	,	,	_	20	punct
3	TCF7L2	tcf7l2	NN	_	4	compound
4	variants	variant	NNS	_	20	nsubjpass
5	,	,	,	_	4	punct
6	including	include	VBG	_	10	case
7	the	the	DT	_	10	det
8	microsatellite	microsatellite	NN	_	10	compound
9	marker	marker	NN	_	10	compound
10	drug1	drug1	NN	_	4	nmod
11	and	and	CC	_	10	cc
12	the	the	DT	_	17	det
13	nearly	nearly	RB	_	14	advmod
14	perfectly	perfectly	RB	_	15	advmod
15	linked	link	VBN	_	17	amod
16	SNP	snp	NN	_	17	compound
17	drug2	drug2	NN	_	10	conj
18	,	,	,	_	4	punct
19	were	be	VBD	_	20	auxpass
20	identified	identify	VBN	_	0	ROOT
21	to	to	TO	_	22	mark
22	associate	associate	VB	_	20	xcomp
23	with	with	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod

1	The	the	DT	_	3	det
2	T	t	NN	_	3	compound
3	allele	allele	NN	_	6	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	showed	show	VBD	_	0	ROOT
7	an	a	DT	_	8	det
8	association	association	NN	_	6	dobj
9	with	with	IN	_	11	case
10	borderline	borderline	JJ	_	11	amod
11	significance	significance	NN	_	8	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	OR	or	NN	_	11	dep
14	=	=	JJ	_	13	amod
15	1.19	1.19	CD	_	14	dep
16	,	,	,	_	13	punct
17	95	95	CD	_	18	compound
18	%	%	NN	_	19	amod
19	C.I.	c.i.	NN	_	13	appos
20	=	=	JJ	_	19	amod
21	1.01-1	1.01-1	CD	_	22	nummod
22	.42	.42	CD	_	20	dep
23	,	,	,	_	13	punct
24	P	p	NN	_	25	nsubj
25	=	=	JJ	_	13	dep
26	0.04	0.04	CD	_	25	dobj
27	-RRB-	-rrb-	-RRB-	_	13	punct
28	,	,	,	_	6	punct
29	and	and	CC	_	6	cc
30	the	the	DT	_	32	det
31	Cochran-Armitage	cochran-armitage	JJ	_	32	amod
32	test	test	NN	_	35	nsubj
33	for	for	IN	_	34	case
34	trend	trend	NN	_	32	nmod
35	revealed	reveal	VBD	_	6	conj
36	an	a	DT	_	39	det
37	allele	allele	NN	_	39	compound
38	dose-dependent	dose-dependent	JJ	_	39	amod
39	association	association	NN	_	35	dobj
40	of	of	IN	_	41	case
41	drug2	drug2	NN	_	39	nmod
42	with	with	IN	_	43	case
43	drug3	drug3	NN	_	39	nmod
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	Ptrend	ptrend	NN	_	43	dep
46	=	=	JJ	_	45	amod
47	0.04	0.04	CD	_	46	dep
48	-RRB-	-rrb-	-RRB-	_	45	punct
49	.	.	.	_	6	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	a	a	DT	_	6	det
5	possible	possible	JJ	_	6	amod
6	influence	influence	NN	_	3	dobj
7	of	of	IN	_	9	case
8	TCF7L2	tcf7l2	NN	_	9	compound
9	drug1	drug1	NN	_	6	nmod
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	risk	risk	NN	_	6	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	3	punct

1	Further	further	RB	_	41	advmod
2	,	,	,	_	41	punct
3	effects	effect	NNS	_	41	nsubjpass
4	of	of	IN	_	8	case
5	a	a	DT	_	8	det
6	stronger	stronger	JJR	_	8	amod
7	beneficial	beneficial	JJ	_	8	amod
8	association	association	NN	_	3	nmod
9	between	between	IN	_	11	case
10	n-3	n-3	JJ	_	11	amod
11	drug4	drug4	NN	_	8	nmod
12	in	in	IN	_	13	case
13	RBCs	rbc	NNS	_	11	nmod
14	and	and	CC	_	13	cc
15	plasma	plasma	NN	_	17	compound
16	lipid	lipid	NN	_	17	compound
17	parameters	parameter	NNS	_	13	conj
18	-	-	:	_	8	punct
19	including	include	VBG	_	21	case
20	lower	lower	JJR	_	21	amod
21	totalcholesterol	totalcholesterol	NN	_	8	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	TC	tc	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	,	,	,	_	21	punct
26	drug5	drug5	NN	_	21	conj
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	LDL-C	ldl-c	NN	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	or	or	CC	_	21	cc
31	higher	higher	JJR	_	34	amod
32	high-density	high-density	JJ	_	34	amod
33	lipoprotein	lipoprotein	NN	_	34	compound
34	cholesterol	cholesterol	NN	_	21	conj
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	HDL-C	hdl-c	NN	_	34	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	concentrations	concentration	NNS	_	21	dep
39	-	-	:	_	21	punct
40	were	be	VBD	_	41	auxpass
41	associated	associate	VBN	_	0	ROOT
42	with	with	IN	_	44	case
43	AGT	agt	NN	_	44	compound
44	M235T	m235t	NN	_	41	nmod
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	drug1	drug1	NN	_	44	appos
47	-RRB-	-rrb-	-RRB-	_	46	punct
48	TT	tt	NN	_	49	compound
49	genotype	genotype	NN	_	44	dep
50	,	,	,	_	49	punct
51	CETP	cetp	NN	_	52	compound
52	G-971A	g-971a	NN	_	57	compound
53	-LRB-	-lrb-	-LRB-	_	54	punct
54	drug2	drug2	NN	_	52	appos
55	-RRB-	-rrb-	-RRB-	_	54	punct
56	AG	AG	NNP	_	57	compound
57	genotype	genotype	NN	_	49	conj
58	,	,	,	_	49	punct
59	T	t	NN	_	61	compound
60	allele	allele	NN	_	61	compound
61	carriers	carrier	NNS	_	49	conj
62	of	of	IN	_	64	case
63	CETP	cetp	NN	_	64	compound
64	C-4502T	c-4502t	NN	_	61	nmod
65	-LRB-	-lrb-	-LRB-	_	66	punct
66	drug3	drug3	NN	_	64	appos
67	-RRB-	-rrb-	-RRB-	_	66	punct
68	,	,	,	_	49	punct
69	and	and	CC	_	49	cc
70	T	t	NN	_	72	compound
71	allele	allele	NN	_	72	compound
72	carriers	carrier	NNS	_	49	conj
73	ofCETP	ofcetp	VBP	_	41	dep
74	Ile405Val	ile405val	NN	_	73	dobj
75	-LRB-	-lrb-	-LRB-	_	76	punct
76	rs5882	rs5882	NN	_	74	appos
77	-RRB-	-rrb-	-RRB-	_	76	punct
78	.	.	.	_	41	punct

1	Based	base	VBN	_	4	case
2	on	on	IN	_	4	case
3	12	12	CD	_	4	nummod
4	studies	study	NNS	_	0	ROOT
5	with	with	IN	_	8	case
6	5,573	5,573	CD	_	8	nummod
7	MetS	mets	NN	_	8	compound
8	cases	case	NNS	_	4	nmod
9	and	and	CC	_	8	cc
10	8,290	8,290	CD	_	11	nummod
11	controls	control	NNS	_	8	conj
12	from	from	IN	_	16	case
13	5	5	CD	_	16	nummod
14	East	east	JJ	_	15	amod
15	Asian	asian	JJ	_	16	amod
16	studies	study	NNS	_	4	nmod
17	,	,	,	_	4	punct
18	5	5	CD	_	20	nummod
19	European	european	JJ	_	20	amod
20	studies	study	NNS	_	17	root
21	and	and	CC	_	20	cc
22	2	2	CD	_	23	nummod
23	studies	study	NNS	_	20	conj
24	of	of	IN	_	27	case
25	other	other	JJ	_	27	amod
26	ethnic	ethnic	JJ	_	27	amod
27	groups	group	NNS	_	23	nmod
28	,	,	,	_	20	punct
29	the	the	DT	_	30	det
30	drug1	drug1	NN	_	32	nsubjpass
31	was	be	VBD	_	32	auxpass
32	associated	associate	VBN	_	20	acl:relcl
33	with	with	IN	_	35	case
34	increased	increase	VBN	_	35	amod
35	risk	risk	NN	_	32	nmod
36	of	of	IN	_	37	case
37	drug2	drug2	NN	_	35	nmod
38	with	with	IN	_	40	case
39	an	a	DT	_	40	det
40	OR	or	NN	_	35	nmod
41	-LRB-	-lrb-	-LRB-	_	44	punct
42	95	95	CD	_	43	compound
43	%	%	NN	_	44	amod
44	CI	ci	NN	_	40	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	=	=	JJ	_	40	amod
47	1.33	1.33	CD	_	46	dep
48	-LRB-	-lrb-	-LRB-	_	51	punct
49	1.16	1.16	CD	_	51	nummod
50	,	,	,	_	51	punct
51	1.53	1.53	CD	_	47	appos
52	-RRB-	-rrb-	-RRB-	_	51	punct
53	in	in	IN	_	56	case
54	the	the	DT	_	56	det
55	overall	overall	JJ	_	56	amod
56	population	population	NN	_	40	nmod
57	,	,	,	_	56	punct
58	1.43	1.43	CD	_	56	conj
59	-LRB-	-lrb-	-LRB-	_	62	punct
60	1.29	1.29	CD	_	62	nummod
61	,	,	,	_	62	punct
62	1.58	1.58	CD	_	58	appos
63	-RRB-	-rrb-	-RRB-	_	62	punct
64	in	in	IN	_	66	case
65	East	east	JJ	_	66	amod
66	Asian	asian	JJ	_	58	nmod
67	and	and	CC	_	56	cc
68	1.30	1.30	CD	_	56	conj
69	-LRB-	-lrb-	-LRB-	_	70	punct
70	0.94	0.94	CD	_	68	dep
71	,	,	,	_	70	punct
72	1.78	1.78	CD	_	70	appos
73	-RRB-	-rrb-	-RRB-	_	70	punct
74	in	in	IN	_	76	case
75	European	european	JJ	_	76	amod
76	populations	population	NNS	_	40	nmod
77	.	.	.	_	20	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	8	nmod
3	,	,	,	_	8	punct
4	the	the	DT	_	5	det
5	drug1	drug1	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	elevated	elevated	JJ	_	11	amod
11	levels	level	NNS	_	8	nmod
12	of	of	IN	_	14	case
13	fasting	fast	VBG	_	14	amod
14	TG	tg	NN	_	11	nmod
15	,	,	,	_	14	punct
16	TC	tc	NN	_	14	conj
17	,	,	,	_	14	punct
18	LDL-C	ldl-c	NN	_	14	conj
19	and	and	CC	_	14	cc
20	decreased	decrease	VBD	_	21	amod
21	HDL-C	hdl-c	NN	_	14	conj
22	,	,	,	_	8	punct
23	and	and	CC	_	8	cc
24	increased	increase	VBD	_	25	amod
25	risk	risk	NN	_	8	conj
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	,	,	,	_	25	punct
29	especially	especially	RB	_	32	advmod
30	in	in	IN	_	32	case
31	East	East	NNP	_	32	compound
32	Asians	Asians	NNPS	_	25	nmod
33	.	.	.	_	8	punct

1	Conclusion	conclusion	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	This	this	DT	_	4	det
4	study	study	NN	_	5	nsubj
5	highlights	highlight	VBZ	_	1	dep
6	the	the	DT	_	10	det
7	gender-specific	gender-specific	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	weight-sensitive	weight-sensitive	JJ	_	7	conj
10	effects	effect	NNS	_	5	dobj
11	of	of	IN	_	13	case
12	APOA5	apoa5	NN	_	13	compound
13	drug1	drug1	NN	_	10	nmod
14	on	on	IN	_	16	case
15	central	central	JJ	_	16	amod
16	drug2	drug2	NN	_	10	nmod
17	in	in	IN	_	19	case
18	Taiwanese	taiwanese	JJ	_	19	amod
19	individuals	individual	NNS	_	16	nmod
20	,	,	,	_	5	punct
21	and	and	CC	_	5	cc
22	that	that	IN	_	26	mark
23	these	these	DT	_	24	det
24	effects	effect	NNS	_	26	nsubj
25	are	be	VBP	_	26	cop
26	dyslipidemia-independent	dyslipidemia-independent	JJ	_	5	conj
27	and	and	CC	_	26	cc
28	weight-loss	weight-loss	JJ	_	29	amod
29	responsive	responsive	JJ	_	26	conj
30	.	.	.	_	1	punct

1	Though	though	IN	_	8	mark
2	drug1	drug1	NN	_	6	compound
3	/	/	:	_	6	punct
4	C3/A4/A5	c3/a4/a5	NN	_	6	compound
5	genetic	genetic	JJ	_	6	amod
6	polymorphisms	polymorphism	NNS	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	associated	associate	VBN	_	19	advcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	19	punct
12	their	they	PRP$	_	13	nmod:poss
13	effect	effect	NN	_	19	nsubjpass
14	on	on	IN	_	16	case
15	central	central	JJ	_	16	amod
16	drug3	drug3	NN	_	13	nmod
17	is	be	VBZ	_	19	auxpass
18	less	less	RBR	_	19	advmod
19	known	know	VBN	_	0	ROOT

1	The	the	DT	_	3	det
2	present	present	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	demonstrated	demonstrate	VBD	_	0	ROOT
5	that	that	IN	_	4	dobj
6	carrying	carry	VBG	_	5	dep
7	rare	rare	JJ	_	8	amod
8	alleles	allele	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	10	punct
12	-1131	-1131	CD	_	13	nummod
13	T	t	NN	_	14	nmod:npmod
14	>	>	JJR	_	21	advmod
15	C	c	NN	_	14	dep
16	and	and	CC	_	15	cc
17	G185C	g185c	NN	_	15	conj
18	alone	alone	RB	_	15	advmod
19	do	do	VBP	_	21	aux
20	not	not	RB	_	21	neg
21	constitute	constitute	VB	_	10	dep
22	a	a	DT	_	23	det
23	risk	risk	NN	_	21	dobj
24	for	for	IN	_	26	case
25	ischemic	ischemic	JJ	_	26	amod
26	drug2	drug2	NN	_	23	nmod
27	in	in	IN	_	31	case
28	the	the	DT	_	31	det
29	studied	study	VBN	_	31	amod
30	Turkish	turkish	JJ	_	31	amod
31	subjects	subject	NNS	_	21	nmod
32	.	.	.	_	4	punct

1	Multivariable	multivariable	JJ	_	4	amod
2	logistic	logistic	JJ	_	4	amod
3	regression	regression	NN	_	4	compound
4	analysis	analysis	NN	_	17	nsubj
5	of	of	IN	_	7	case
6	combined	combined	JJ	_	7	amod
7	genotypes	genotype	NNS	_	4	nmod
8	with	with	IN	_	9	case
9	adjustment	adjustment	NN	_	7	nmod
10	for	for	IN	_	11	case
11	age	age	NN	_	9	nmod
12	,	,	,	_	11	punct
13	gender	gender	NN	_	11	conj
14	and	and	CC	_	11	cc
15	drug3	drug3	NN	_	16	compound
16	mellitus	mellitus	NN	_	11	conj
17	revealed	reveal	VBD	_	0	ROOT
18	that	that	IN	_	25	mark
19	drug1	drug1	NN	_	25	nsubj
20	and	and	CC	_	19	cc
21	drug2	drug2	NN	_	19	conj
22	significantly	significantly	RB	_	23	advmod
23	and	and	CC	_	25	advmod
24	synergistically	synergistically	RB	_	23	advmod
25	affected	affect	VBN	_	17	ccomp
26	drug4	drug4	NN	_	25	dobj
27	.	.	.	_	17	punct

1	Genetic	genetic	JJ	_	2	amod
2	variants	variant	NNS	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	9	aux
8	synergistically	synergistically	RB	_	9	advmod
9	affect	affect	VB	_	0	ROOT
10	the	the	DT	_	11	det
11	prevalence	prevalence	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	in	in	IN	_	17	case
15	East	east	JJ	_	17	amod
16	Asian	asian	JJ	_	17	amod
17	populations	population	NNS	_	9	nmod
18	and	and	CC	_	17	cc
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	17	conj
21	in	in	IN	_	23	case
22	Japanese	japanese	JJ	_	23	amod
23	individuals	individual	NNS	_	20	nmod
24	.	.	.	_	9	punct

1	Our	we	PRP$	_	3	nmod:poss
2	cross-sectional	cross-sectional	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	confirmed	confirm	VBD	_	0	ROOT
5	the	the	DT	_	7	det
6	essential	essential	JJ	_	7	amod
7	roles	role	NNS	_	4	dobj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	polymorphisms	polymorphism	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	drug1	drug1	NN	_	10	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	and	and	CC	_	13	cc
17	drug3	drug3	NN	_	13	conj
18	in	in	IN	_	23	case
19	the	the	DT	_	23	det
20	lipid	lipid	NN	_	23	compound
21	or	or	CC	_	20	cc
22	drug4	drug4	NN	_	20	conj
23	disorders	disorder	NNS	_	7	nmod
24	,	,	,	_	4	punct
25	and	and	CC	_	4	cc
26	suggested	suggest	VBD	_	4	conj
27	the	the	DT	_	28	det
28	importance	importance	NN	_	26	dobj
29	of	of	IN	_	32	case
30	fat	fat	JJ	_	32	amod
31	intake	intake	NN	_	32	compound
32	control	control	NN	_	28	nmod
33	in	in	IN	_	36	case
34	the	the	DT	_	36	det
35	individualized	individualized	JJ	_	36	amod
36	prevention	prevention	NN	_	28	nmod
37	of	of	IN	_	38	case
38	drug5	drug5	NN	_	36	nmod
39	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	examined	examine	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	associations	association	NNS	_	3	dobj
6	of	of	IN	_	9	case
7	the	the	DT	_	9	det
8	APOA5	apoa5	NN	_	9	compound
9	T-1131C	t-1131c	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug1	drug1	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	,	,	,	_	9	punct
14	G553T	g553t	NN	_	9	appos
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug2	drug2	NN	_	14	dep
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	,	,	,	_	9	punct
21	GCK	gck	NN	_	22	compound
22	G-30A	g-30a	NN	_	9	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug4	drug4	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	9	punct
27	GCKR	gckr	NN	_	28	compound
28	A/G	a/g	NN	_	9	conj
29	at	at	IN	_	30	case
30	intron16	intron16	NN	_	28	nmod
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	drug5	drug5	NN	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	and	and	CC	_	30	cc
35	T1403C	t1403c	NN	_	30	conj
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	Leu446Pro	leu446pro	NN	_	35	dep
38	,	,	,	_	37	punct
39	drug6	drug6	NN	_	37	appos
40	-RRB-	-rrb-	-RRB-	_	37	punct
41	polymorphisms	polymorphism	NNS	_	30	dep
42	with	with	IN	_	43	case
43	drug7	drug7	NN	_	30	nmod
44	and	and	CC	_	43	cc
45	drug8	drug8	NN	_	43	conj
46	in	in	IN	_	47	case
47	Japanese	japanese	JJ	_	43	nmod
48	,	,	,	_	9	punct
49	considering	consider	VBG	_	9	acl
50	lifestyle	lifestyle	NN	_	51	compound
51	factors	factor	NNS	_	49	dobj

1	Moreover	moreover	RB	_	28	advmod
2	,	,	,	_	28	punct
3	a	a	DT	_	6	det
4	significant	significant	JJ	_	6	amod
5	positive	positive	JJ	_	6	amod
6	interaction	interaction	NN	_	28	nsubjpass
7	between	between	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	G/T	g/t	NN	_	6	nmod
10	+	+	CC	_	9	cc
11	T/T	t/t	NN	_	12	compound
12	genotypes	genotype	NNS	_	9	conj
13	and	and	CC	_	9	cc
14	fat	fat	JJ	_	15	amod
15	intake	intake	NN	_	9	conj
16	>	>	JJR	_	17	advmod
17	25	25	CD	_	18	nummod
18	%	%	NN	_	15	dep
19	of	of	IN	_	21	case
20	total	total	JJ	_	21	amod
21	energy	energy	NN	_	18	nmod
22	for	for	IN	_	24	case
23	the	the	DT	_	24	det
24	risk	risk	NN	_	6	nmod
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	was	be	VBD	_	28	auxpass
28	observed	observe	VBN	_	0	ROOT
29	.	.	.	_	28	punct

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	polymorphisms	polymorphism	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	serve	serve	VB	_	0	ROOT
7	as	as	IN	_	8	case
8	biomarkers	biomarker	NNS	_	6	nmod
9	in	in	IN	_	13	case
10	the	the	DT	_	13	det
11	South	South	NNP	_	13	compound
12	Indian	Indian	NNP	_	13	compound
13	population	population	NN	_	8	nmod
14	to	to	TO	_	15	mark
15	identify	identify	VB	_	6	xcomp
16	drug3	drug3	NN	_	17	compound
17	patients	patient	NNS	_	15	dobj
18	who	who	WP	_	21	nsubj
19	are	be	VBP	_	21	cop
20	at	at	IN	_	21	case
21	risk	risk	NN	_	17	acl:relcl
22	of	of	IN	_	23	mark
23	developing	develop	VBG	_	21	acl
24	drug4	drug4	NN	_	23	dobj
25	.	.	.	_	6	punct

1	Two	two	CD	_	2	nummod
2	SNPs	snp	NNS	_	11	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug1	drug1	NN	_	2	dep
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	in	in	IN	_	9	case
9	IREB2	ireb2	NN	_	2	nmod
10	were	be	VBD	_	11	auxpass
11	associated	associate	VBN	_	0	ROOT
12	with	with	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	P	p	NN	_	13	dep
16	=	=	JJ	_	15	amod
17	0.045	0.045	CD	_	16	dep
18	and	and	CC	_	15	cc
19	0.032	0.032	CD	_	15	conj
20	,	,	,	_	15	punct
21	respectively	respectively	RB	_	15	advmod
22	-RRB-	-rrb-	-RRB-	_	15	punct
23	in	in	IN	_	24	case
24	non-smoker	non-smoker	NN	_	13	nmod
25	.	.	.	_	11	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Our	we	PRP$	_	4	nmod:poss
4	findings	finding	NNS	_	5	nsubj
5	extend	extend	VBP	_	1	dep
6	and	and	CC	_	5	cc
7	add	add	VBP	_	5	conj
8	new	new	JJ	_	9	amod
9	information	information	NN	_	7	dobj
10	to	to	TO	_	13	case
11	the	the	DT	_	13	det
12	existing	exist	VBG	_	13	amod
13	data	datum	NNS	_	7	nmod
14	regarding	regard	VBG	_	16	case
15	the	the	DT	_	16	det
16	association	association	NN	_	13	nmod
17	between	between	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	TG	tg	NN	_	21	compound
21	regulation	regulation	NN	_	18	conj
22	during	during	IN	_	26	case
23	long-term	long-term	JJ	_	26	amod
24	atypical	atypical	JJ	_	26	amod
25	drug2	drug2	NN	_	26	compound
26	treatment	treatment	NN	_	16	nmod
27	.	.	.	_	1	punct

1	significant	significant	JJ	_	2	amod
2	differences	difference	NNS	_	0	ROOT
3	in	in	IN	_	7	case
4	the	the	DT	_	7	det
5	association	association	NN	_	7	compound
6	effect	effect	NN	_	7	compound
7	sizes	size	NNS	_	2	nmod
8	between	between	IN	_	9	case
9	subjects	subject	NNS	_	7	nmod
10	with	with	IN	_	32	mark
11	and	and	CC	_	32	cc
12	without	without	IN	_	13	case
13	MetS	mets	NN	_	32	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	p	p	NN	_	16	dep
16	<	<	JJR	_	13	dep
17	0.05	0.05	CD	_	16	nummod
18	-RRB-	-rrb-	-RRB-	_	16	punct
19	,	,	,	_	32	punct
20	variants	variant	NNS	_	32	nsubjpass
21	of	of	IN	_	22	case
22	APOA5	apoa5	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug1	drug1	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	and	and	CC	_	22	cc
27	APOE	apoe	NN	_	22	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug2	drug2	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	were	be	VBD	_	32	auxpass
32	associated	associate	VBN	_	9	acl
33	with	with	IN	_	34	case
34	drug4	drug4	NN	_	32	nmod
35	in	in	IN	_	37	case
36	drug5	drug5	NN	_	37	compound
37	subjects	subject	NNS	_	34	nmod
38	,	,	,	_	2	punct
39	while	while	IN	_	45	mark
40	APOA4	apoa4	NN	_	45	nsubjpass
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	drug3	drug3	NN	_	40	appos
43	-RRB-	-rrb-	-RRB-	_	42	punct
44	was	be	VBD	_	45	auxpass
45	associated	associate	VBN	_	2	dep
46	with	with	IN	_	47	case
47	drug6	drug6	NN	_	45	nmod
48	in	in	IN	_	50	case
49	non-MetS	non-mets	JJ	_	50	amod
50	subjects	subject	NNS	_	47	nmod
51	.	.	.	_	2	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	drug1	drug1	NN	_	5	compound
5	allele	allele	NN	_	15	nsubj
6	,	,	,	_	5	punct
7	associated	associate	VBN	_	5	acl
8	with	with	IN	_	12	case
9	higher	higher	JJR	_	12	amod
10	fasting	fasting	NN	_	12	compound
11	triglyceride	triglyceride	NN	_	12	compound
12	levels	level	NNS	_	7	nmod
13	,	,	,	_	5	punct
14	strongly	strongly	RB	_	15	advmod
15	affects	affect	VBZ	_	1	appos
16	the	the	DT	_	17	det
17	risk	risk	NN	_	15	dobj
18	for	for	IN	_	20	case
19	early-onset	early-onset	JJ	_	20	amod
20	drug2	drug2	NN	_	17	nmod
21	,	,	,	_	15	punct
22	even	even	RB	_	24	advmod
23	after	after	IN	_	24	mark
24	adjusting	adjust	VBG	_	15	advcl
25	for	for	IN	_	26	case
26	triglycerides	triglyceride	NNS	_	24	nmod
27	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	association	association	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	number	number	NN	_	2	nmod
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	drug2	drug2	NN	_	11	compound
11	components	component	NNS	_	7	nmod
12	was	be	VBD	_	13	cop
13	significant	significant	JJ	_	0	ROOT
14	regardless	regardless	RB	_	13	advmod
15	of	of	IN	_	16	case
16	age	age	NN	_	14	nmod
17	,	,	,	_	16	punct
18	sex	sex	NN	_	16	conj
19	,	,	,	_	16	punct
20	obesity	obesity	NN	_	16	conj
21	and	and	CC	_	16	cc
22	alcohol	alcohol	NN	_	23	compound
23	drinking	drinking	NN	_	16	conj
24	,	,	,	_	13	punct
25	but	but	CC	_	13	cc
26	almost	almost	RB	_	27	advmod
27	disappeared	disappear	VBD	_	13	conj
28	after	after	IN	_	30	mark
29	further	further	RB	_	30	advmod
30	adjusting	adjust	VBG	_	27	advcl
31	for	for	IN	_	33	case
32	plasma	plasma	NN	_	33	compound
33	triglycerides	triglyceride	NNS	_	30	nmod
34	.	.	.	_	13	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	While	while	IN	_	8	mark
4	previous	previous	JJ	_	5	amod
5	studies	study	NNS	_	8	nsubj
6	in	in	IN	_	7	case
7	adults	adult	NNS	_	5	nmod
8	demonstrated	demonstrate	VBD	_	1	dep
9	,	,	,	_	8	punct
10	that	that	IN	_	17	mark
11	the	the	DT	_	16	det
12	drug1	drug1	NN	_	16	compound
13	-1131	-1131	CD	_	16	nummod
14	C	c	NN	_	16	compound
15	minor	minor	JJ	_	16	amod
16	allele	allele	NN	_	17	nsubj
17	confers	confer	VBZ	_	8	ccomp
18	risk	risk	NN	_	17	dobj
19	for	for	IN	_	20	case
20	drug2	drug2	NN	_	17	nmod
21	,	,	,	_	8	punct
22	here	here	RB	_	24	advmod
23	we	we	PRP	_	24	nsubj
24	show	show	VBP	_	8	parataxis
25	,	,	,	_	8	punct
26	that	that	IN	_	8	dep
27	the	the	DT	_	29	det
28	susceptibility	susceptibility	NN	_	29	compound
29	nature	nature	NN	_	26	dep
30	of	of	IN	_	32	case
31	this	this	DT	_	32	det
32	SNP	snp	NN	_	29	nmod
33	restricted	restricted	JJ	_	32	amod
34	to	to	TO	_	36	case
35	the	the	DT	_	36	det
36	APOA5	apoa5	NN	_	33	nmod
37	*	*	SYM	_	39	dep
38	2	2	CD	_	39	nummod
39	haplotype	haplotype	NN	_	29	dep
40	in	in	IN	_	43	case
41	pediatric	pediatric	JJ	_	43	amod
42	obese	obese	JJ	_	43	amod
43	subjects	subject	NNS	_	39	nmod
44	.	.	.	_	1	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Apolipoprotein	apolipoprotein	NN	_	4	compound
4	A5	a5	NN	_	1	dep
5	-LRB-	-lrb-	-LRB-	_	9	punct
6	drug1	drug1	NN	_	9	compound
7	-RRB-	-rrb-	-RRB-	_	9	punct
8	gene	gene	NN	_	9	compound
9	variants	variant	NNS	_	12	nsubjpass
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	shown	show	VBN	_	4	acl:relcl
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	auxpass
15	associated	associate	VBN	_	12	xcomp
16	with	with	IN	_	19	case
17	elevated	elevated	JJ	_	19	amod
18	TG	tg	NN	_	19	compound
19	levels	level	NNS	_	15	nmod
20	;	;	:	_	4	punct
21	the	the	DT	_	26	det
22	T-1131C	t-1131c	NN	_	26	compound
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug2	drug2	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	variant	variant	NN	_	29	nsubjpass
27	has	have	VBZ	_	29	aux
28	been	be	VBN	_	29	auxpass
29	reported	report	VBN	_	4	parataxis
30	to	to	TO	_	31	mark
31	confer	confer	VB	_	29	xcomp
32	risk	risk	NN	_	31	dobj
33	for	for	IN	_	35	case
34	the	the	DT	_	35	det
35	drug3	drug3	NN	_	31	nmod
36	in	in	IN	_	38	case
37	adult	adult	JJ	_	38	amod
38	populations	population	NNS	_	35	nmod
39	.	.	.	_	29	punct

1	Single	single	JJ	_	3	amod
2	nucleotide	nucleotide	NN	_	3	compound
3	polymorphisms	polymorphism	NNS	_	17	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	SNPs	snp	NNS	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	in	in	IN	_	14	case
8	the	the	DT	_	14	det
9	apolipoprotein	apolipoprotein	NN	_	10	compound
10	A5	a5	NN	_	14	compound
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug1	drug1	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	gene	gene	NN	_	3	nmod
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	associated	associate	VBN	_	0	ROOT
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	17	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug4	drug4	NN	_	12	nsubj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	HTG	htg	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	is	be	VBZ	_	12	cop
8	a	a	DT	_	12	det
9	well-established	well-established	JJ	_	12	amod
10	independent	independent	JJ	_	12	amod
11	risk	risk	NN	_	12	compound
12	factor	factor	NN	_	1	dep
13	for	for	IN	_	15	case
14	drug5	drug5	NN	_	15	compound
15	disease	disease	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	the	the	DT	_	18	det
18	influence	influence	NN	_	35	nsubjpass
19	of	of	IN	_	23	case
20	several	several	JJ	_	23	amod
21	geneti	genetus	NNS	_	23	compound
22	c	c	NN	_	23	compound
23	variants	variant	NNS	_	18	nmod
24	in	in	IN	_	25	case
25	genes	gene	NNS	_	23	nmod
26	related	relate	VBN	_	25	acl
27	with	with	IN	_	28	case
28	triglyceride	triglyceride	NN	_	26	nmod
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	TG	tg	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	metabolism	metabolism	NN	_	28	dep
33	has	have	VBZ	_	35	aux
34	been	be	VBN	_	35	auxpass
35	described	describe	VBN	_	12	conj
36	,	,	,	_	35	punct
37	including	include	VBG	_	38	case
38	drug1	drug1	NN	_	35	nmod
39	,	,	,	_	38	punct
40	drug2	drug2	NN	_	38	conj
41	and	and	CC	_	38	cc
42	drug3	drug3	NN	_	38	conj
43	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Our	we	PRP$	_	4	nmod:poss
4	results	result	NNS	_	5	nsubj
5	showed	show	VBD	_	1	dep
6	a	a	DT	_	10	det
7	significant	significant	JJ	_	10	amod
8	independent	independent	JJ	_	10	amod
9	additive	additive	JJ	_	10	amod
10	effect	effect	NN	_	5	dobj
11	on	on	IN	_	12	case
12	drug5	drug5	NN	_	10	nmod
13	of	of	IN	_	17	case
14	the	the	DT	_	17	det
15	LPL	LPL	NNP	_	17	compound
16	polymorphisms	polymorphism	NNS	_	17	compound
17	drug1	drug1	NN	_	12	nmod
18	,	,	,	_	17	punct
19	drug2	drug2	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug3	drug3	NN	_	17	conj
22	and	and	CC	_	17	cc
23	drug4	drug4	NN	_	17	conj
24	;	;	:	_	5	punct
25	the	the	DT	_	26	det
26	S19W	s19w	NN	_	5	dep
27	and	and	CC	_	26	cc
28	-1131	-1131	CD	_	30	nummod
29	T/C	t/c	NN	_	30	compound
30	variants	variant	NNS	_	26	conj
31	of	of	IN	_	32	case
32	APOA5	apoa5	NN	_	26	nmod
33	,	,	,	_	26	punct
34	and	and	CC	_	26	cc
35	the	the	DT	_	37	det
36	epsilon4	epsilon4	NN	_	37	compound
37	allele	allele	NN	_	26	conj
38	of	of	IN	_	39	case
39	APOE	APOE	NNP	_	37	nmod
40	in	in	IN	_	43	case
41	our	we	PRP$	_	43	nmod:poss
42	study	study	NN	_	43	compound
43	population	population	NN	_	37	nmod
44	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	12	mark
5	different	different	JJ	_	6	amod
6	SNPs	snp	NNS	_	12	nsubjpass
7	in	in	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	polymorphisms	polymorphism	NNS	_	6	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	associated	associate	VBN	_	3	ccomp
13	with	with	IN	_	15	case
14	triglyceride	triglyceride	NN	_	15	compound
15	concentration	concentration	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	in	in	IN	_	19	case
19	each	each	DT	_	15	nmod
20	of	of	IN	_	23	case
21	these	these	DT	_	23	det
22	ethnic	ethnic	JJ	_	23	amod
23	origins	origin	NNS	_	19	nmod
24	.	.	.	_	3	punct

1	Homozygosity	Homozygosity	NNP	_	12	nsubj
2	for	for	IN	_	5	case
3	the	the	DT	_	5	det
4	minor	minor	JJ	_	5	amod
5	allele	allele	NN	_	1	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	TT	tt	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	of	of	IN	_	11	case
10	SNP	snp	NN	_	11	compound
11	drug1	drug1	NN	_	5	nmod
12	occurred	occur	VBD	_	0	ROOT
13	in	in	IN	_	15	case
14	9	9	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	of	of	IN	_	17	case
17	individuals	individual	NNS	_	15	nmod
18	and	and	CC	_	12	cc
19	was	be	VBD	_	20	auxpass
20	associated	associate	VBN	_	12	conj
21	with	with	IN	_	25	case
22	a	a	DT	_	25	det
23	31	31	CD	_	24	compound
24	%	%	NN	_	25	amod
25	reduction	reduction	NN	_	20	nmod
26	in	in	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	in	in	IN	_	31	case
29	a	a	DT	_	31	det
30	recessive	recessive	JJ	_	31	amod
31	model	model	NN	_	25	nmod
32	.	.	.	_	12	punct

1	whereas	whereas	IN	_	6	mark
2	drug1	drug1	NN	_	3	compound
3	genotype	genotype	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	not	not	RB	_	6	neg
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	measures	measure	NNS	_	6	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	6	punct

1	le	le	DT	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	as	as	IN	_	6	mark
5	also	also	RB	_	6	advmod
6	associated	associate	VBN	_	1	advcl
7	with	with	IN	_	9	case
8	increased	increase	VBN	_	9	amod
9	prevalence	prevalence	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	1	punct

1	Genotypes	genotype	NNS	_	6	nsubjpass
2	at	at	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	were	be	VBD	_	6	auxpass
5	not	not	RB	_	6	neg
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	any	any	DT	_	9	det
9	drug2	drug2	NN	_	6	nmod
10	.	.	.	_	6	punct

1	Singlenucleotide	singlenucleotide	JJ	_	2	amod
2	polymorphisms	polymorphism	NNS	_	16	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	SNPs	snp	NNS	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	and	and	CC	_	2	cc
7	haplotypes	haplotype	NNS	_	2	conj
8	in	in	IN	_	14	case
9	the	the	DT	_	14	det
10	drug1	drug1	NN	_	14	compound
11	/	/	:	_	14	punct
12	C3/A4/A5	c3/a4/a5	NN	_	14	compound
13	gene	gene	NN	_	14	compound
14	cluster	cluster	NN	_	2	nmod
15	are	be	VBP	_	16	auxpass
16	associated	associate	VBN	_	0	ROOT
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	in	in	IN	_	20	case
20	Caucasians	Caucasians	NNPS	_	18	nmod
21	and	and	CC	_	18	cc
22	with	with	IN	_	23	case
23	elevatedtriglycerides	elevatedtriglyceride	NNS	_	18	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	TG	tg	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	in	in	IN	_	30	case
28	various	various	JJ	_	30	amod
29	ethnic	ethnic	JJ	_	30	amod
30	groups	group	NNS	_	23	nmod
31	.	.	.	_	16	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	that	that	IN	_	2	dobj
4	:	:	:	_	8	punct
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	i	i	LS	_	8	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	genotypes	genotype	NNS	_	3	dep
9	,	,	,	_	8	punct
10	including	include	VBG	_	11	case
11	those	those	DT	_	8	nmod
12	of	of	IN	_	14	case
13	drug1	drug1	NN	_	14	compound
14	S19W	s19w	NN	_	11	nmod
15	,	,	,	_	14	punct
16	APOA5	apoa5	NN	_	14	appos
17	-1131	-1131	CD	_	16	dep
18	T	t	NN	_	32	dep
19	>	>	JJR	_	32	dep
20	C	c	NN	_	32	dep
21	,	,	,	_	32	punct
22	APOE	APOE	NNP	_	32	nsubjpass
23	,	,	,	_	22	punct
24	GCKR	GCKR	NNP	_	22	conj
25	,	,	,	_	22	punct
26	drug2	drug2	NN	_	22	conj
27	and	and	CC	_	22	cc
28	TBL2/MLXIPL	tbl2/mlxipl	NN	_	22	conj
29	,	,	,	_	22	punct
30	were	be	VBD	_	32	auxpass
31	significantly	significantly	RB	_	32	advmod
32	associated	associate	VBN	_	17	acl
33	with	with	IN	_	35	case
34	severe	severe	JJ	_	35	amod
35	drug3	drug3	NN	_	32	nmod
36	;	;	:	_	8	punct
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	ii	ii	LS	_	41	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	odds	odds	NNS	_	41	compound
41	ratios	ratio	NNS	_	47	nsubj
42	for	for	IN	_	45	case
43	these	these	DT	_	45	det
44	genetic	genetic	JJ	_	45	amod
45	variables	variable	NNS	_	41	nmod
46	were	be	VBD	_	47	cop
47	significant	significant	JJ	_	8	parataxis
48	in	in	IN	_	53	case
49	both	both	CC	_	50	cc:preconj
50	univariate	univariate	JJ	_	53	amod
51	and	and	CC	_	50	cc
52	multivariate	multivariate	JJ	_	50	conj
53	regressionanalyses	regressionanalys	NNS	_	47	nmod
54	,	,	,	_	47	punct
55	irrespective	irrespective	RB	_	47	dep
56	of	of	IN	_	58	case
57	the	the	DT	_	58	det
58	presence	presence	NN	_	55	nmod
59	or	or	CC	_	55	cc
60	absence	absence	NN	_	55	conj
61	of	of	IN	_	62	case
62	drug4	drug4	NN	_	60	nmod
63	or	or	CC	_	62	cc
64	drug5	drug5	NN	_	62	conj
65	;	;	:	_	8	punct
66	-LRB-	-lrb-	-LRB-	_	67	punct
67	iii	iii	LS	_	8	parataxis
68	-RRB-	-rrb-	-RRB-	_	67	punct
69	a	a	DT	_	72	det
70	significant	significant	JJ	_	72	amod
71	fraction-about	fraction-about	JJ	_	72	amod
72	one-quarter-of	one-quarter-of	JJ	_	67	dep
73	the	the	DT	_	75	det
74	explained	explain	VBN	_	75	amod
75	variation	variation	NN	_	80	nsubjpass
76	in	in	IN	_	78	case
77	disease	disease	NN	_	78	compound
78	status	status	NN	_	75	nmod
79	was	be	VBD	_	80	auxpass
80	associated	associate	VBN	_	72	ccomp
81	with	with	IN	_	83	case
82	these	these	DT	_	83	det
83	genotypes	genotype	NNS	_	80	nmod
84	.	.	.	_	2	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	no	no	DT	_	4	neg
4	relationships	relationship	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	found	find	VBN	_	0	ROOT
7	between	between	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	genotype	genotype	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	in	in	IN	_	14	case
13	2	2	CD	_	14	nummod
14	cohorts	cohort	NNS	_	9	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	n	n	NN	_	9	dep
17	=	=	JJ	_	16	amod
18	1648	1648	CD	_	17	dep
19	and	and	CC	_	16	cc
20	n	n	NN	_	16	conj
21	=	=	JJ	_	20	amod
22	1039	1039	CD	_	21	dep
23	-RRB-	-rrb-	-RRB-	_	16	punct
24	of	of	IN	_	27	case
25	healthy	healthy	JJ	_	27	amod
26	middle-aged	middle-aged	JJ	_	27	amod
27	carriers	carrier	NNS	_	9	nmod
28	of	of	IN	_	32	case
29	the	the	DT	_	32	det
30	APOE	APOE	NNP	_	32	compound
31	e3/e3	e3/e3	NN	_	32	compound
32	genotype	genotype	NN	_	27	nmod
33	.	.	.	_	6	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	7	nsubj
4	is	be	VBZ	_	7	cop
5	a	a	DT	_	7	det
6	functional	functional	JJ	_	7	amod
7	polymorphism	polymorphism	NN	_	1	dep
8	involved	involve	VBN	_	7	acl
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	regulation	regulation	NN	_	8	nmod
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug2	drug2	NN	_	11	nmod
15	.	.	.	_	1	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Single	single	JJ	_	5	amod
4	nucleotide	nucleotide	NN	_	5	compound
5	polymorphisms	polymorphism	NNS	_	38	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	SNPs	snp	NNS	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	drug1	drug1	NN	_	5	dep
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	e4	e4	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	and	and	CC	_	9	cc
14	drug2	drug2	NN	_	9	conj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	e2	e2	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	5	punct
19	both	both	DT	_	21	det
20	invoking	invoke	VBG	_	21	amod
21	changes	change	NNS	_	5	appos
22	in	in	IN	_	25	case
23	the	the	DT	_	25	det
24	amino-acid	amino-acid	JJ	_	25	amod
25	sequence	sequence	NN	_	21	nmod
26	of	of	IN	_	33	case
27	the	the	DT	_	33	det
28	apolipoprotein	apolipoprotein	NN	_	29	compound
29	E	e	NN	_	33	compound
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	APOE	apoe	NN	_	33	compound
32	-RRB-	-rrb-	-RRB-	_	33	punct
33	gene	gene	NN	_	25	nmod
34	,	,	,	_	5	punct
35	have	have	VBP	_	38	aux
36	previously	previously	RB	_	38	advmod
37	been	be	VBN	_	38	auxpass
38	tested	test	VBN	_	1	dep
39	for	for	IN	_	40	case
40	association	association	NN	_	38	nmod
41	with	with	IN	_	43	case
42	drug3	drug3	NN	_	43	compound
43	risk	risk	NN	_	40	nmod
44	.	.	.	_	1	punct

1	Despite	despite	IN	_	3	case
2	sufficient	sufficient	JJ	_	3	amod
3	power	power	NN	_	21	nmod
4	to	to	TO	_	5	mark
5	detect	detect	VB	_	3	acl
6	associations	association	NNS	_	5	dobj
7	at	at	IN	_	10	case
8	genome-wide	genome-wide	JJ	_	10	amod
9	significance	significance	NN	_	10	compound
10	thresholds	threshold	NNS	_	5	nmod
11	across	across	IN	_	13	case
12	a	a	DT	_	13	det
13	range	range	NN	_	10	nmod
14	of	of	IN	_	15	case
15	ORs	or	NNS	_	13	nmod
16	,	,	,	_	21	punct
17	our	we	PRP$	_	18	nmod:poss
18	analyses	analysis	NNS	_	21	nsubj
19	did	do	VBD	_	21	aux
20	not	not	RB	_	21	neg
21	support	support	VB	_	0	ROOT
22	a	a	DT	_	23	det
23	role	role	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	or	or	CC	_	25	cc
27	drug2	drug2	NN	_	25	conj
28	on	on	IN	_	29	case
29	drug3	drug3	NN	_	23	nmod
30	.	.	.	_	21	punct

1	Furthermore	furthermore	RB	_	26	advmod
2	,	,	,	_	26	punct
3	studies	study	NNS	_	26	nsubjpass
4	of	of	IN	_	6	case
5	APOE	APOE	NNP	_	6	compound
6	drug1	drug1	NN	_	3	nmod
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	appos
9	,	,	,	_	6	punct
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	defining	define	VBG	_	6	dep
12	e2/e3/e4	e2/e3/e4	NN	_	13	compound
13	alleles	allele	NNS	_	11	dobj
14	;	;	:	_	11	punct
15	12	12	CD	_	16	nummod
16	studies	study	NNS	_	11	dep
17	-RRB-	-rrb-	-RRB-	_	11	punct
18	and	and	CC	_	6	cc
19	APOB	apob	NN	_	20	compound
20	drug3	drug3	NN	_	6	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	eight	eight	CD	_	23	nummod
23	studies	study	NNS	_	20	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	were	be	VBD	_	26	auxpass
26	included	include	VBN	_	0	ROOT
27	in	in	IN	_	28	case
28	meta-analyses	meta-analysis	NNS	_	26	nmod
29	,	,	,	_	28	punct
30	the	the	DT	_	33	det
31	observational	observational	JJ	_	33	amod
32	hazard	hazard	NN	_	33	compound
33	ratio	ratio	NN	_	54	nsubj
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	HR	hr	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	for	for	IN	_	39	case
38	symptomatic	symptomatic	JJ	_	39	amod
39	drug4	drug4	NN	_	33	nmod
40	for	for	IN	_	45	case
41	the	the	DT	_	45	det
42	fifth	fifth	JJ	_	45	amod
43	versus	versus	CC	_	42	cc
44	first	first	JJ	_	42	conj
45	quintile	quintile	NN	_	39	nmod
46	of	of	IN	_	47	case
47	LDL-C	ldl-c	NN	_	45	nmod
48	was	be	VBD	_	54	cop
49	0.94	0.94	CD	_	54	nummod
50	-LRB-	-lrb-	-LRB-	_	54	punct
51	95	95	CD	_	52	compound
52	%	%	NN	_	54	amod
53	confidence	confidence	NN	_	54	compound
54	interval	interval	NN	_	28	appos
55	:	:	:	_	54	punct
56	0.76-1	0.76-1	CD	_	57	nummod
57	.17	.17	CD	_	54	dep
58	-RRB-	-rrb-	-RRB-	_	54	punct
59	,	,	,	_	28	punct
60	despite	despite	IN	_	65	case
61	a	a	DT	_	65	det
62	corresponding	corresponding	JJ	_	65	amod
63	134	134	CD	_	64	compound
64	%	%	NN	_	65	amod
65	increase	increase	NN	_	26	nmod
66	in	in	IN	_	67	case
67	LDL-C	ldl-c	NN	_	65	nmod
68	.	.	.	_	26	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	associations	association	NNS	_	2	nsubj
5	between	between	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	polymorphisms	polymorphism	NNS	_	4	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	9	punct
11	drug3	drug3	NN	_	9	conj
12	and	and	CC	_	9	cc
13	drug4	drug4	NN	_	9	conj

1	In	in	IN	_	3	case
2	drug2	drug2	NN	_	3	compound
3	patients	patient	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	genetic	genetic	JJ	_	6	amod
6	heterogeneity	heterogeneity	NN	_	14	nsubjpass
7	in	in	IN	_	11	case
8	the	the	DT	_	11	det
9	drug1	drug1	NN	_	11	compound
10	genomic	genomic	JJ	_	11	amod
11	region	region	NN	_	6	nmod
12	is	be	VBZ	_	14	auxpass
13	significantly	significantly	RB	_	14	advmod
14	associated	associate	VBN	_	0	ROOT
15	with	with	IN	_	16	case
16	variation	variation	NN	_	14	nmod
17	in	in	IN	_	19	case
18	serum	serum	NN	_	19	compound
19	ApoE	apoe	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	ApoB	apob	NN	_	22	compound
22	levels	level	NNS	_	19	conj
23	,	,	,	_	14	punct
24	and	and	CC	_	14	cc
25	also	also	RB	_	27	advmod
26	with	with	IN	_	27	case
27	fibrosis	fibrosis	NN	_	14	conj
28	suggesting	suggest	VBG	_	27	acl
29	a	a	DT	_	31	det
30	pleiotropic	pleiotropic	JJ	_	31	amod
31	attribute	attribute	NN	_	28	dobj
32	of	of	IN	_	35	case
33	this	this	DT	_	35	det
34	genomic	genomic	JJ	_	35	amod
35	region	region	NN	_	31	nmod
36	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	aim	aim	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	assess	assess	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	effect	effect	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	6	punct
14	the	the	DT	_	15	det
15	intake	intake	NN	_	13	root
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	drug3	drug3	NN	_	15	conj
21	in	in	IN	_	24	case
22	Lithuanian	lithuanian	JJ	_	24	amod
23	adult	adult	JJ	_	24	amod
24	population	population	NN	_	15	nmod
25	.	.	.	_	15	punct

1	drug1	drug1	NN	_	9	nsubjpass
2	,	,	,	_	1	punct
3	SFA	sfa	NN	_	4	compound
4	intake	intake	NN	_	1	conj
5	,	,	,	_	1	punct
6	and	and	CC	_	1	cc
7	drug2	drug2	NN	_	1	conj
8	were	be	VBD	_	9	auxpass
9	found	find	VBN	_	0	ROOT
10	to	to	TO	_	12	mark
11	be	be	VB	_	12	auxpass
12	associated	associate	VBN	_	9	xcomp
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	in	in	IN	_	18	case
16	Lithuanian	lithuanian	JJ	_	18	amod
17	adult	adult	JJ	_	18	amod
18	population	population	NN	_	14	nmod
19	.	.	.	_	9	punct

1	Multivariate	multivariate	JJ	_	2	amod
2	analysis	analysis	NN	_	3	nsubj
3	showed	show	VBD	_	0	ROOT
4	association	association	NN	_	3	dobj
5	between	between	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	4	punct
10	independently	independently	RB	_	13	advmod
11	from	from	IN	_	13	case
12	the	the	DT	_	13	det
13	effect	effect	NN	_	4	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	3	punct

1	Pooled	pool	VBN	_	3	amod
2	DNA	dna	NN	_	3	compound
3	GWAS	gwas	NN	_	4	nsubj
4	enabled	enable	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	identification	identification	NN	_	4	dobj
7	of	of	IN	_	13	case
8	a	a	DT	_	13	det
9	novel	novel	JJ	_	13	amod
10	drug2	drug2	NN	_	13	compound
11	candidate	candidate	NN	_	13	compound
12	risk	risk	NN	_	13	compound
13	variant	variant	NN	_	6	nmod
14	,	,	,	_	13	punct
15	drug1	drug1	NN	_	13	appos
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	9q21	9q21	NN	_	15	appos
18	.33	.33	CD	_	17	nummod
19	-RRB-	-rrb-	-RRB-	_	17	punct
20	,	,	,	_	13	punct
21	tagging	tag	VBG	_	13	acl
22	a	a	DT	_	25	det
23	possible	possible	JJ	_	25	amod
24	genomic	genomic	JJ	_	25	amod
25	enhancer	enhancer	NN	_	21	dobj
26	affecting	affect	VBG	_	25	acl
27	proximal	proximal	JJ	_	29	amod
28	transcribed	transcribe	VBN	_	29	amod
29	elements	element	NNS	_	26	dobj
30	including	include	VBG	_	32	case
31	DAPK1	dapk1	NN	_	32	compound
32	gene	gene	NN	_	29	nmod
33	.	.	.	_	4	punct

1	the	the	DT	_	3	det
2	minor	minor	JJ	_	3	amod
3	alleles	allele	NNS	_	18	nsubjpass
4	of	of	IN	_	8	case
5	cholesteryl	cholesteryl	NN	_	8	compound
6	ester	ester	NN	_	8	compound
7	transfer	transfer	NN	_	8	compound
8	protein	protein	NN	_	3	nmod
9	-LRB-	-lrb-	-LRB-	_	13	punct
10	CETP	cetp	NN	_	13	compound
11	-RRB-	-rrb-	-RRB-	_	13	punct
12	gene	gene	NN	_	13	compound
13	SNPs	snp	NNS	_	8	dep
14	drug1	drug1	NN	_	13	dep
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	were	be	VBD	_	18	auxpass
18	associated	associate	VBN	_	0	ROOT
19	with	with	IN	_	20	case
20	drug12	drug12	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	with	with	IN	_	24	case
24	drug13	drug13	NN	_	20	nmod
25	;	;	:	_	18	punct
26	CETP	cetp	NN	_	28	compound
27	SNPs	snp	NNS	_	28	compound
28	drug4	drug4	NN	_	18	dep
29	,	,	,	_	28	punct
30	drug5	drug5	NN	_	28	conj
31	,	,	,	_	28	punct
32	and	and	CC	_	28	cc
33	drug6	drug6	NN	_	28	conj
34	and	and	CC	_	33	cc
35	apolipoprotein	apolipoprotein	NN	_	36	compound
36	B	b	NN	_	33	conj
37	-LRB-	-lrb-	-LRB-	_	42	punct
38	APOB	apob	NN	_	42	compound
39	-RRB-	-rrb-	-RRB-	_	42	punct
40	gene	gene	NN	_	42	compound
41	SNP	snp	NN	_	42	compound
42	drug7	drug7	NN	_	36	dep
43	with	with	IN	_	44	case
44	drug14	drug14	NN	_	42	nmod
45	;	;	:	_	42	punct
46	APOE	APOE	NNP	_	48	compound
47	SNP	snp	NN	_	48	compound
48	drug8	drug8	NN	_	42	dep
49	,	,	,	_	48	punct
50	peroxisome	peroxisome	NN	_	53	compound
51	proliferator-activated	proliferator-activated	JJ	_	53	amod
52	receptor	receptor	NN	_	53	compound
53	gamma	gamma	NN	_	48	appos
54	-LRB-	-lrb-	-LRB-	_	59	punct
55	PPARG	pparg	NN	_	59	compound
56	-RRB-	-rrb-	-RRB-	_	59	punct
57	gene	gene	NN	_	59	compound
58	SNP	snp	NN	_	59	compound
59	drug9	drug9	NN	_	53	dep
60	with	with	IN	_	61	case
61	drug15	drug15	NN	_	59	nmod
62	,	,	,	_	59	punct
63	and	and	CC	_	59	cc
64	CETP	CETP	NNP	_	66	compound
65	SNP	snp	NN	_	66	compound
66	drug10	drug10	NN	_	59	conj
67	with	with	IN	_	68	case
68	drug16	drug16	NN	_	59	nmod
69	;	;	:	_	59	punct
70	and	and	CC	_	59	cc
71	APOE/C1/C4	apoe/c1/c4	NN	_	76	compound
72	/	/	:	_	76	punct
73	C2	c2	NN	_	76	compound
74	cluster	cluster	NN	_	76	compound
75	SNP	snp	NN	_	76	compound
76	drug11	drug11	NN	_	59	conj
77	with	with	IN	_	80	case
78	lower	lower	JJR	_	80	amod
79	serum	serum	NN	_	80	compound
80	TG	tg	NN	_	76	nmod
81	.	.	.	_	18	punct

1	For	for	IN	_	2	case
2	example	example	NN	_	14	nmod
3	,	,	,	_	14	punct
4	the	the	DT	_	5	det
5	association	association	NN	_	14	nsubj
6	of	of	IN	_	7	case
7	polymorphisms	polymorphism	NNS	_	5	nmod
8	drug1	drug1	NN	_	7	dep
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	5	nmod
13	was	be	VBD	_	14	cop
14	heterogeneous	heterogeneous	JJ	_	0	ROOT
15	between	between	IN	_	16	case
16	Caucasians	caucasian	NNS	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	OR	or	NN	_	16	dep
19	=	=	JJ	_	18	amod
20	1.32	1.32	CD	_	19	dep
21	and	and	CC	_	20	cc
22	1.22	1.22	CD	_	20	conj
23	;	;	:	_	18	punct
24	95	95	CD	_	25	compound
25	%	%	NN	_	26	amod
26	CI	ci	NN	_	18	dep
27	:	:	:	_	26	punct
28	1.25-1	1.25-1	CD	_	29	compound
29	.44	.44	CD	_	26	dep
30	and	and	CC	_	29	cc
31	1.05-1	1.05-1	CD	_	32	compound
32	.42	.42	CD	_	29	conj
33	;	;	:	_	18	punct
34	P	p	NN	_	18	dep
35	<	<	JJR	_	34	amod
36	0.0005	0.0005	CD	_	35	dep
37	and	and	CC	_	36	cc
38	0.008	0.008	CD	_	36	conj
39	,	,	,	_	34	punct
40	respectively	respectively	RB	_	34	advmod
41	-RRB-	-rrb-	-RRB-	_	18	punct
42	and	and	CC	_	16	cc
43	East	East	NNP	_	44	compound
44	Asians	Asians	NNPS	_	16	conj
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	OR	or	NN	_	44	dep
47	=	=	JJ	_	46	amod
48	1.51	1.51	CD	_	47	dep
49	and	and	CC	_	48	cc
50	1.03	1.03	CD	_	48	conj
51	;	;	:	_	46	punct
52	95	95	CD	_	53	compound
53	%	%	NN	_	54	amod
54	CI	ci	NN	_	46	dep
55	:	:	:	_	54	punct
56	0.76-3	0.76-3	CD	_	54	dep
57	and	and	CC	_	56	cc
58	0.47-2	0.47-2	CD	_	59	compound
59	.27	.27	CD	_	56	conj
60	;	;	:	_	46	punct
61	P	p	NN	_	62	nsubj
62	=	=	JJ	_	46	dep
63	0.237	0.237	CD	_	62	dobj
64	and	and	CC	_	63	cc
65	0.934	0.934	CD	_	63	conj
66	,	,	,	_	62	punct
67	respectively	respectively	RB	_	62	advmod
68	-RRB-	-rrb-	-RRB-	_	46	punct
69	under	under	IN	_	71	case
70	theallelic	theallelic	JJ	_	71	amod
71	model	model	NN	_	14	nmod
72	,	,	,	_	14	punct
73	and	and	CC	_	14	cc
74	this	this	DT	_	75	det
75	association	association	NN	_	78	nsubjpass
76	was	be	VBD	_	78	auxpass
77	relatively	relatively	RB	_	78	advmod
78	strengthened	strengthen	VBN	_	14	conj
79	under	under	IN	_	82	case
80	the	the	DT	_	82	det
81	dominant	dominant	JJ	_	82	amod
82	model	model	NN	_	78	nmod
83	.	.	.	_	14	punct

1	Inside	inside	IN	_	3	case
2	this	this	DT	_	3	det
3	region	region	NN	_	25	nmod
4	of	of	IN	_	6	case
5	26.9	26.9	CD	_	6	nummod
6	kb	kb	NN	_	3	nmod
7	,	,	,	_	25	punct
8	LD	ld	NN	_	25	nsubjpass
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	r2	r2	NN	_	8	appos
11	>	>	JJR	_	12	advmod
12	0.50	0.50	CD	_	10	nummod
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	between	between	IN	_	15	case
15	TOMM40	tomm40	NN	_	8	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug1	drug1	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	and	and	CC	_	15	cc
20	APOE	apoe	NN	_	15	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug2	drug2	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	was	be	VBD	_	25	auxpass
25	observed	observe	VBN	_	0	ROOT
26	in	in	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	and	and	CC	_	27	cc
29	in	in	IN	_	30	case
30	controls	control	NNS	_	27	conj
31	,	,	,	_	27	punct
32	but	but	CC	_	27	cc
33	not	not	RB	_	35	neg
34	in	in	IN	_	35	case
35	drug4	drug4	NN	_	27	conj

1	The	the	DT	_	5	det
2	SIRT2	sirt2	NN	_	5	compound
3	drug1	drug1	NN	_	5	compound
4	T	t	NN	_	5	compound
5	allele	allele	NN	_	6	nsubj
6	deserves	deserve	VBZ	_	0	ROOT
7	further	further	JJ	_	8	amod
8	investigation	investigation	NN	_	6	dobj
9	as	as	IN	_	15	case
10	a	a	DT	_	15	det
11	novel	novel	JJ	_	15	amod
12	minor	minor	JJ	_	15	amod
13	genetic	genetic	JJ	_	15	amod
14	risk	risk	NN	_	15	compound
15	factor	factor	NN	_	6	nmod
16	for	for	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	in	in	IN	_	23	case
19	the	the	DT	_	23	det
20	APOE	APOE	NNP	_	23	compound
21	e4-negative	e4-negative	JJ	_	23	amod
22	Caucasian	caucasian	JJ	_	23	amod
23	population	population	NN	_	17	nmod
24	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	moderate	moderate	JJ	_	4	amod
4	consistency	consistency	NN	_	2	nsubj
5	between	between	IN	_	10	case
6	the	the	DT	_	10	det
7	cross-sectional	cross-sectional	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	longitudinal	longitudinal	JJ	_	7	conj
10	findings	finding	NNS	_	4	nmod
11	,	,	,	_	2	punct
12	with	with	IN	_	14	case
13	eight	eight	CD	_	14	nummod
14	SNP	snp	NN	_	2	nmod
15	:	:	:	_	14	punct
16	drug8	drug8	NN	_	17	compound
17	associations	association	NNS	_	19	nsubj
18	consistently	consistently	RB	_	19	advmod
19	identified	identify	VBD	_	14	dep
20	across	across	IN	_	22	case
21	both	both	DT	_	22	det
22	study	study	NN	_	19	nmod
23	designs	design	VBZ	_	19	dep
24	:	:	:	_	23	punct
25	-LSB-	-lsb-	-LRB-	_	27	punct
26	APOE	APOE	NNP	_	27	compound
27	.2	.2	NN	_	23	dep
28	and	and	CC	_	27	cc
29	APOE	apoe	NN	_	30	compound
30	.4	.4	NN	_	27	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	drug1	drug1	NN	_	30	dep
33	and	and	CC	_	32	cc
34	drug2	drug2	NN	_	32	conj
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	-RSB-	-rsb-	-RRB-	_	27	punct
37	:	:	:	_	19	punct
38	TC	tc	NN	_	19	dep
39	;	;	:	_	38	punct
40	HL/LIPC	hl/lipc	NN	_	38	dep
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	drug3	drug3	NN	_	40	appos
43	-RRB-	-rrb-	-RRB-	_	42	punct
44	:	:	:	_	40	punct
45	HDL	hdl	NN	_	40	dep
46	;	;	:	_	38	punct
47	-LSB-	-lsb-	-LRB-	_	48	punct
48	APOB	apob	NN	_	38	dep
49	-LRB-	-lrb-	-LRB-	_	50	punct
50	drug4	drug4	NN	_	48	appos
51	-RRB-	-rrb-	-RRB-	_	50	punct
52	,	,	,	_	48	punct
53	APOE	APOE	NNP	_	54	compound
54	.2	.2	NN	_	48	appos
55	and	and	CC	_	54	cc
56	APOE	apoe	NN	_	57	compound
57	.4	.4	NN	_	54	conj
58	-LRB-	-lrb-	-LRB-	_	59	punct
59	drug5	drug5	NN	_	48	dep
60	and	and	CC	_	59	cc
61	drug6	drug6	NN	_	59	conj
62	-RRB-	-rrb-	-RRB-	_	59	punct
63	-RSB-	-rsb-	-RRB-	_	48	punct
64	:	:	:	_	38	punct
65	LDL	ldl	NN	_	38	dep
66	;	;	:	_	19	punct
67	-LSB-	-lsb-	-LRB-	_	68	punct
68	APOA5	apoa5	NN	_	19	dep
69	-LRB-	-lrb-	-LRB-	_	70	punct
70	drug7	drug7	NN	_	68	appos
71	-RRB-	-rrb-	-RRB-	_	70	punct
72	and	and	CC	_	68	cc
73	APOC	APOC	NNP	_	74	compound
74	III	III	NNP	_	68	conj
75	-LRB-	-lrb-	-LRB-	_	76	punct
76	drug9	drug9	NN	_	74	appos
77	-RRB-	-rrb-	-RRB-	_	76	punct
78	-RSB-	-rsb-	-RRB-	_	68	punct
79	:	:	:	_	19	punct
80	TG	tg	NN	_	19	dep
81	.	.	.	_	2	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	frequency	frequency	NN	_	10	nsubj
5	of	of	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	polymorphisms	polymorphism	NNS	_	4	nmod
8	did	do	VBD	_	10	aux
9	not	not	RB	_	10	neg
10	differ	differ	VB	_	1	dep
11	between	between	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	controls	control	NNS	_	14	conj
17	.	.	.	_	1	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	investigated	investigate	VBD	_	0	ROOT
8	whether	whether	IN	_	11	mark
9	drug1	drug1	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	associated	associate	VBN	_	7	ccomp
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	in	in	IN	_	17	case
15	predominantly	predominantly	RB	_	16	advmod
16	middle-aged	middle-aged	JJ	_	17	amod
17	persons	person	NNS	_	11	nmod
18	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicated	indicate	VBD	_	0	ROOT
4	that	that	IN	_	13	mark
5	homozygous	homozygous	JJ	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	carriers	carrier	NNS	_	13	nsubj
8	aged	aged	JJ	_	7	acl
9	35	35	CD	_	10	nummod
10	years	year	NNS	_	8	dobj
11	or	or	CC	_	10	cc
12	older	older	JJR	_	10	conj
13	had	have	VBD	_	3	ccomp
14	worse	worse	JJR	_	15	amod
15	drug2	drug2	NN	_	13	dobj
16	than	than	IN	_	18	case
17	heterozygous	heterozygous	JJ	_	18	amod
18	carriers	carrier	NNS	_	15	nmod
19	and	and	CC	_	18	cc
20	noncarriers	noncarrier	NNS	_	18	conj
21	.	.	.	_	3	punct

1	Collectively	collectively	RB	_	6	advmod
2	,	,	,	_	6	punct
3	these	these	DT	_	4	det
4	results	result	NNS	_	6	nsubj
5	also	also	RB	_	6	advmod
6	suggest	suggest	VBP	_	0	ROOT
7	and	and	CC	_	6	cc
8	claim	claim	VBP	_	6	conj
9	for	for	IN	_	11	case
10	further	further	JJ	_	11	amod
11	investigations	investigation	NNS	_	8	nmod
12	on	on	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	/	/	:	_	13	punct
15	HP	HP	NNP	_	16	compound
16	interaction	interaction	NN	_	13	dep
17	in	in	IN	_	20	case
18	other	other	JJ	_	20	amod
19	age-related	age-related	JJ	_	20	amod
20	diseases	disease	NNS	_	16	nmod
21	such	such	JJ	_	25	case
22	as	as	IN	_	21	mwe
23	drug2	drug2	NN	_	25	nmod:poss
24	's	's	POS	_	25	case
25	disease	disease	NN	_	20	nmod
26	,	,	,	_	25	punct
27	drug3	drug3	NN	_	25	conj
28	and	and	CC	_	25	cc
29	drug4	drug4	NN	_	31	nmod:poss
30	's	's	POS	_	29	case
31	disease	disease	NN	_	25	conj
32	.	.	.	_	6	punct

1	Apolipoprotein	apolipoprotein	NN	_	2	compound
2	E	e	NN	_	7	compound
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	APOE	apoe	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	functional	functional	JJ	_	7	amod
7	haplotypes	haplotype	NNS	_	17	nsubjpass
8	determined	determine	VBN	_	7	acl
9	by	by	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	13	compound
13	SNPs	snp	NNS	_	10	conj
14	have	have	VBP	_	17	aux
15	been	be	VBN	_	17	auxpass
16	extensively	extensively	RB	_	17	advmod
17	studied	study	VBN	_	0	ROOT
18	and	and	CC	_	17	cc
19	found	find	VBN	_	17	conj
20	to	to	TO	_	22	mark
21	be	be	VB	_	22	cop
22	one	one	CD	_	19	xcomp
23	of	of	IN	_	27	case
24	the	the	DT	_	27	det
25	most	most	RBS	_	26	advmod
26	consistent	consistent	JJ	_	27	amod
27	association	association	NN	_	22	nmod
28	in	in	IN	_	31	case
29	human	human	JJ	_	31	amod
30	drug3	drug3	NN	_	31	compound
31	studies	study	NNS	_	27	nmod
32	.	.	.	_	17	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	4	compound
4	haplotypes	haplotype	NNS	_	7	nsubjpass
5	are	be	VBP	_	7	auxpass
6	significantly	significantly	RB	_	7	advmod
7	associated	associate	VBN	_	1	appos
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	in	in	IN	_	12	case
11	our	we	PRP$	_	12	nmod:poss
12	population	population	NN	_	9	nmod
13	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Although	although	IN	_	13	mark
4	the	the	DT	_	6	det
5	physiological	physiological	JJ	_	6	amod
6	role	role	NN	_	13	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	in	in	IN	_	10	case
10	drug3	drug3	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	drug4	drug4	NN	_	10	conj
13	needs	need	VBZ	_	19	advcl
14	further	further	JJ	_	15	amod
15	investigations	investigation	NNS	_	13	dobj
16	,	,	,	_	19	punct
17	our	we	PRP$	_	18	nmod:poss
18	results	result	NNS	_	19	nsubj
19	suggest	suggest	VBP	_	1	appos
20	an	a	DT	_	21	det
21	involvement	involvement	NN	_	19	dobj
22	of	of	IN	_	26	case
23	the	the	DT	_	26	det
24	drug2	drug2	NN	_	26	compound
25	gene	gene	NN	_	26	compound
26	locus	locus	NN	_	21	nmod
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	genetics	genetics	NNS	_	21	nmod
30	of	of	IN	_	31	case
31	drug5	drug5	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	drug6	drug6	NN	_	31	conj
34	.	.	.	_	1	punct

1	Individuals	individual	NNS	_	3	nsubjpass
2	were	be	VBD	_	3	auxpass
3	genotyped	genotype	VBN	_	0	ROOT
4	for	for	IN	_	6	case
5	PCSK9	pcsk9	NN	_	6	compound
6	R46L	r46l	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug1	drug1	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	6	punct
11	ABCG8	abcg8	NN	_	12	compound
12	D19H	d19h	NN	_	6	conj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug2	drug2	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	6	punct
17	and	and	CC	_	6	cc
18	APOE	APOE	NNP	_	19	compound
19	R112C	r112c	NN	_	6	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	drug3	drug3	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	and	and	CC	_	19	cc
24	R158C	r158c	NN	_	28	compound
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	drug4	drug4	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	polymorphisms	polymorphism	NNS	_	19	conj
29	,	,	,	_	6	punct
30	all	all	DT	_	34	nsubjpass
31	of	of	IN	_	32	case
32	which	which	WDT	_	30	nmod
33	are	be	VBP	_	34	auxpass
34	associated	associate	VBN	_	6	acl:relcl
35	with	with	IN	_	37	case
36	lifelong	lifelong	JJ	_	37	amod
37	drug5	drug5	NN	_	34	nmod
38	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	paper	paper	NN	_	3	nsubj
3	addresses	address	VBZ	_	0	ROOT
4	a	a	DT	_	5	det
5	tenet	tenet	NN	_	3	dobj
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	literature	literature	NN	_	5	nmod
9	on	on	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	10	punct
12	i.e.	i.e.	FW	_	10	conj
13	,	,	,	_	10	punct
14	the	the	DT	_	15	det
15	relationship	relationship	NN	_	10	appos
16	between	between	IN	_	18	case
17	the	the	DT	_	18	det
18	effects	effect	NNS	_	15	nmod
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	e4	e4	NN	_	18	nmod
22	,	,	,	_	21	punct
23	one	one	CD	_	21	appos
24	of	of	IN	_	29	case
25	the	the	DT	_	29	det
26	established	established	JJ	_	29	amod
27	genetic	genetic	JJ	_	29	amod
28	risk	risk	NN	_	29	compound
29	factor	factor	NN	_	23	nmod
30	for	for	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	,	,	,	_	21	punct
33	and	and	CC	_	18	cc
34	its	its	PRP$	_	36	nmod:poss
35	expression	expression	NN	_	36	compound
36	levels	level	NNS	_	18	conj
37	as	as	IN	_	38	mark
38	determined	determine	VBN	_	15	dep
39	by	by	IN	_	42	case
40	APOE	apoe	NN	_	42	compound
41	promoter	promoter	NN	_	42	compound
42	polymorphisms	polymorphism	NNS	_	38	nmod
43	.	.	.	_	3	punct

1	Three	three	CD	_	2	nummod
2	SNPs	snp	NNS	_	18	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug1	drug1	NN	_	2	dep
5	in	in	IN	_	6	case
6	IREB2	ireb2	NN	_	4	nmod
7	,	,	,	_	4	punct
8	drug2	drug2	NN	_	4	conj
9	in	in	IN	_	10	case
10	LOC123688	loc123688	NN	_	8	nmod
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	drug3	drug3	NN	_	4	conj
14	in	in	IN	_	15	case
15	CHRNA3	chrna3	NN	_	4	nmod
16	-RRB-	-rrb-	-RRB-	_	4	punct
17	were	be	VBD	_	18	auxpass
18	associated	associate	VBN	_	0	ROOT
19	with	with	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	of	of	IN	_	22	mark
22	predicted	predict	VBN	_	20	acl
23	in	in	IN	_	28	case
24	the	the	DT	_	28	det
25	AAT	AAT	NNP	_	28	compound
26	Genetic	Genetic	NNP	_	28	compound
27	Modifiers	Modifiers	NNP	_	28	compound
28	Study	Study	NNP	_	22	nmod
29	.	.	.	_	18	punct

1	Two	two	CD	_	2	nummod
2	SNPs	snp	NNS	_	9	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug1	drug1	NN	_	2	dep
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	were	be	VBD	_	9	auxpass
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	12	case
11	the	the	DT	_	12	det
12	drug3	drug3	NN	_	9	nmod
13	of	of	IN	_	14	case
14	predicted	predict	VBN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug4	drug4	NN	_	14	conj
17	;	;	:	_	9	punct
18	SNP-by-gender	snp-by-gender	JJ	_	19	amod
19	interactions	interaction	NNS	_	21	nsubjpass
20	were	be	VBD	_	21	auxpass
21	observed	observe	VBN	_	9	parataxis
22	.	.	.	_	9	punct

1	In	in	IN	_	6	case
2	the	the	DT	_	6	det
3	UK	UK	NNP	_	6	compound
4	National	National	NNP	_	6	compound
5	Registry	Registry	NNP	_	6	compound
6	dataset	dataset	NNP	_	11	nmod
7	,	,	,	_	11	punct
8	drug1	drug1	NN	_	11	nsubjpass
9	was	be	VBD	_	11	auxpass
10	significantly	significantly	RB	_	11	advmod
11	associated	associate	VBN	_	0	ROOT
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	male	male	JJ	_	17	amod
17	subgroup	subgroup	NN	_	13	nmod
18	;	;	:	_	11	punct
19	significant	significant	JJ	_	21	amod
20	SNP-by-smoking	snp-by-smoking	JJ	_	21	amod
21	interactions	interaction	NNS	_	23	nsubjpass
22	were	be	VBD	_	23	auxpass
23	observed	observe	VBN	_	11	parataxis
24	.	.	.	_	11	punct

1	We	we	PRP	_	2	nsubj
2	investigated	investigate	VBD	_	0	ROOT
3	thecausal	thecausal	JJ	_	4	amod
4	relationship	relationship	NN	_	2	dobj
5	between	between	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	symptoms	symptom	NNS	_	6	conj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	drug4	drug4	NN	_	10	conj
13	in	in	IN	_	17	case
14	the	the	DT	_	17	det
15	Norwegian	norwegian	JJ	_	17	amod
16	HUNT	hunt	NN	_	17	compound
17	study	study	NN	_	6	nmod
18	using	use	VBG	_	2	xcomp
19	the	the	DT	_	22	det
20	drug1	drug1	NN	_	22	compound
21	single	single	JJ	_	22	amod
22	nucleotidepolymorphism	nucleotidepolymorphism	NN	_	18	dobj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	SNP	snp	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	variant	variant	JJ	_	22	amod
27	located	located	JJ	_	26	dep
28	in	in	IN	_	34	case
29	the	the	DT	_	34	det
30	nicotine	nicotine	NN	_	34	compound
31	acetylcholine	acetylcholine	NN	_	34	compound
32	receptor	receptor	NN	_	34	compound
33	gene	gene	NN	_	34	compound
34	cluster	cluster	NN	_	27	nmod
35	on	on	IN	_	36	case
36	chromosome	chromosome	NN	_	34	nmod
37	15	15	CD	_	36	nummod
38	as	as	IN	_	41	case
39	an	a	DT	_	41	det
40	instrumental	instrumental	JJ	_	41	amod
41	variable	variable	NN	_	27	nmod
42	for	for	IN	_	43	case
43	smokingphenotypes	smokingphenotype	NNS	_	41	nmod

1	Our	we	PRP$	_	2	nmod:poss
2	data	datum	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	compatible	compatible	JJ	_	0	ROOT
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	hypothesis	hypothesis	NN	_	4	nmod
8	of	of	IN	_	11	case
9	a	a	DT	_	11	det
10	complex	complex	JJ	_	11	amod
11	role	role	NN	_	7	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	drug2	drug2	NN	_	17	compound
17	pathogenesis	pathogenesis	NN	_	11	nmod
18	,	,	,	_	4	punct
19	with	with	IN	_	23	case
20	positive	positive	JJ	_	23	amod
21	and	and	CC	_	20	cc
22	negative	negative	JJ	_	20	conj
23	effects	effect	NNS	_	4	nmod
24	occurring	occur	VBG	_	23	acl
25	concomitantly	concomitantly	RB	_	24	advmod
26	according	accord	VBG	_	30	case
27	to	to	TO	_	26	mwe
28	its	its	PRP$	_	30	nmod:poss
29	expression	expression	NN	_	30	compound
30	levels	level	NNS	_	24	nmod
31	and	and	CC	_	30	cc
32	its	its	PRP$	_	34	nmod:poss
33	protein-protein	protein-protein	JJ	_	34	amod
34	interactions	interaction	NNS	_	36	nsubj
35	largely	largely	RB	_	36	advmod
36	unclarified	unclarified	JJ	_	30	conj
37	.	.	.	_	4	punct

1	VKORC1	vkorc1	NN	_	3	compound
2	3673	3673	CD	_	3	nummod
3	AA	aa	NN	_	0	ROOT
4	or	or	CC	_	3	cc
5	GA	ga	NN	_	6	compound
6	genotype	genotype	NN	_	3	conj
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	P	p	NN	_	10	nsubj
9	<	<	JJR	_	10	dep
10	0.0001	0.0001	CD	_	6	dep
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	3	punct
13	one	one	CD	_	17	nummod
14	or	or	CC	_	13	cc
15	two	two	CD	_	13	conj
16	variant	variant	JJ	_	17	amod
17	alleles	allele	NNS	_	3	conj
18	of	of	IN	_	20	case
19	CYP2C9	cyp2c9	NN	_	20	compound
20	gene	gene	NN	_	17	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	P	p	NN	_	17	dep
23	=	=	JJ	_	22	amod
24	0.0004	0.0004	CD	_	23	dep
25	-RRB-	-rrb-	-RRB-	_	22	punct
26	,	,	,	_	3	punct
27	drug1	drug1	NN	_	29	compound
28	e2	e2	NN	_	29	compound
29	haplotype	haplotype	NN	_	3	conj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	P	p	NN	_	29	dep
32	=	=	JJ	_	31	amod
33	0.01	0.01	CD	_	32	dep
34	-RRB-	-rrb-	-RRB-	_	31	punct
35	,	,	,	_	3	punct
36	and	and	CC	_	3	cc
37	increasing	increase	VBG	_	38	amod
38	age	age	NN	_	3	conj
39	-LRB-	-lrb-	-LRB-	_	46	punct
40	P	p	NN	_	46	nsubjpass
41	<	<	JJR	_	40	amod
42	0.0001	0.0001	CD	_	41	dep
43	-RRB-	-rrb-	-RRB-	_	46	punct
44	were	be	VBD	_	46	auxpass
45	all	all	DT	_	46	dep
46	associated	associate	VBN	_	38	dep
47	with	with	IN	_	50	case
48	lower	lower	JJR	_	50	amod
49	warfarin	warfarin	NN	_	50	compound
50	dose	dose	NN	_	46	nmod
51	,	,	,	_	46	punct
52	whereas	whereas	IN	_	46	dep
53	drug2	drug2	NN	_	66	nsubj
54	-LRB-	-lrb-	-LRB-	_	56	punct
55	P	p	NN	_	56	nsubj
56	=	=	JJ	_	53	dep
57	0.025	0.025	CD	_	56	dobj
58	-RRB-	-rrb-	-RRB-	_	56	punct
59	and	and	CC	_	53	cc
60	drug3	drug3	NN	_	53	conj
61	-LRB-	-lrb-	-LRB-	_	62	punct
62	P	p	NN	_	60	dep
63	=	=	JJ	_	62	amod
64	0.0059	0.0059	CD	_	63	dep
65	-RRB-	-rrb-	-RRB-	_	62	punct
66	showed	show	VBD	_	46	parataxis
67	association	association	NN	_	66	dobj
68	with	with	IN	_	71	case
69	higher	higher	JJR	_	71	amod
70	warfarin	warfarin	NN	_	71	compound
71	doses	dose	NNS	_	67	nmod
72	.	.	.	_	3	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	study	study	NN	_	5	nsubj
5	shows	show	VBZ	_	1	appos
6	that	that	IN	_	22	mark
7	drug1	drug1	NN	_	22	nsubj
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	10	compound
10	polymorphisms	polymorphism	NNS	_	7	conj
11	,	,	,	_	7	punct
12	APOE	APOE	NNP	_	14	compound
13	e2	e2	NN	_	14	compound
14	variant	variant	NN	_	7	conj
15	,	,	,	_	7	punct
16	and	and	CC	_	7	cc
17	several	several	JJ	_	19	amod
18	clinical/demographic	clinical/demographic	JJ	_	19	amod
19	variables	variable	NNS	_	7	conj
20	are	be	VBP	_	22	cop
21	important	important	JJ	_	22	amod
22	determinants	determinant	NNS	_	5	ccomp
23	of	of	IN	_	26	case
24	drug3	drug3	NN	_	26	compound
25	dose	dose	NN	_	26	compound
26	requirements	requirement	NNS	_	22	nmod
27	in	in	IN	_	29	case
28	Egyptian	egyptian	JJ	_	29	amod
29	patients	patient	NNS	_	26	nmod
30	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Although	although	IN	_	7	mark
4	drug1	drug1	NN	_	5	compound
5	genotype	genotype	NN	_	7	nsubj
6	does	do	VBZ	_	7	aux
7	have	have	VB	_	19	advcl
8	strong	strong	JJ	_	9	amod
9	associations	association	NNS	_	7	dobj
10	with	with	IN	_	12	case
11	lipid	lipid	NN	_	12	compound
12	levels	level	NNS	_	9	nmod
13	in	in	IN	_	14	case
14	childhood	childhood	NN	_	12	nmod
15	,	,	,	_	19	punct
16	there	there	EX	_	19	expl
17	does	do	VBZ	_	19	aux
18	not	not	RB	_	19	neg
19	seem	seem	VB	_	1	dep
20	to	to	TO	_	23	mark
21	be	be	VB	_	23	cop
22	meaningful	meaningful	JJ	_	23	amod
23	effects	effect	NNS	_	19	xcomp
24	on	on	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	,	,	,	_	19	punct
27	suggesting	suggest	VBG	_	19	xcomp
28	that	that	IN	_	41	mark
29	any	any	DT	_	31	det
30	detrimental	detrimental	JJ	_	31	amod
31	effects	effect	NNS	_	41	nsubj
32	of	of	IN	_	35	case
33	the	the	DT	_	35	det
34	e4	e4	NN	_	35	compound
35	allele	allele	NN	_	31	nmod
36	on	on	IN	_	38	case
37	cognitive	cognitive	JJ	_	38	amod
38	function	function	NN	_	31	nmod
39	are	be	VBP	_	41	cop
40	not	not	RB	_	41	neg
41	important	important	JJ	_	27	ccomp
42	until	until	IN	_	44	case
43	later	later	JJ	_	44	amod
44	life	life	NN	_	41	nmod
45	.	.	.	_	19	punct

1	drug1	drug1	NN	_	4	nsubj
2	alone	alone	RB	_	1	advmod
3	is	be	VBZ	_	4	cop
4	responsible	responsible	JJ	_	0	ROOT
5	for	for	IN	_	7	case
6	the	the	DT	_	7	det
7	association	association	NN	_	4	nmod
8	of	of	IN	_	9	case
9	APOE	apoe	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	7	nmod
12	;	;	:	_	4	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	present	present	JJ	_	5	amod
5	study	study	NN	_	6	nsubj
6	exposed	expose	VBD	_	1	parataxis
7	a	a	DT	_	10	det
8	susceptibility	susceptibility	NN	_	10	compound
9	haplotype	haplotype	NN	_	10	compound
10	drug1	drug1	NN	_	6	dobj
11	,	,	,	_	6	punct
12	within	within	IN	_	14	case
13	drug2	drug2	NN	_	14	compound
14	gene	gene	NN	_	6	nmod
15	,	,	,	_	14	punct
16	which	which	WDT	_	18	nsubjpass
17	was	be	VBD	_	18	auxpass
18	found	find	VBN	_	14	acl:relcl
19	to	to	TO	_	21	mark
20	be	be	VB	_	21	auxpass
21	associated	associate	VBN	_	18	xcomp
22	with	with	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	and	and	CC	_	23	cc
25	risk	risk	NN	_	23	conj
26	of	of	IN	_	27	case
27	drug4	drug4	NN	_	23	nmod
28	and	and	CC	_	27	cc
29	drug5	drug5	NN	_	27	conj
30	in	in	IN	_	32	case
31	postmenopausal	postmenopausal	JJ	_	32	amod
32	females	female	NNS	_	27	nmod
33	of	of	IN	_	34	case
34	India	India	NNP	_	32	nmod
35	.	.	.	_	1	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	association	association	NN	_	23	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	APOE	apoe	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	genotypes	genotype	NNS	_	6	dep
11	with	with	IN	_	14	case
12	bone	bone	NN	_	14	compound
13	mineral	mineral	NN	_	14	compound
14	density	density	NN	_	4	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	BMD	bmd	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	and	and	CC	_	14	cc
19	risk	risk	NN	_	14	conj
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	have	have	VBP	_	23	aux
23	remained	remain	VBN	_	1	dep
24	unclear	unclear	JJ	_	23	xcomp
25	.	.	.	_	23	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Hypertriglyceridemia	hypertriglyceridemia	NN	_	12	nsubj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	HTG	htg	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	is	be	VBZ	_	12	cop
8	a	a	DT	_	12	det
9	well-established	well-established	JJ	_	12	amod
10	independent	independent	JJ	_	12	amod
11	risk	risk	NN	_	12	compound
12	factor	factor	NN	_	1	dep
13	for	for	IN	_	15	case
14	drug4	drug4	NN	_	15	compound
15	disease	disease	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	the	the	DT	_	18	det
18	influence	influence	NN	_	34	nsubjpass
19	of	of	IN	_	22	case
20	several	several	JJ	_	22	amod
21	genetic	genetic	JJ	_	22	amod
22	variants	variant	NNS	_	18	nmod
23	in	in	IN	_	24	case
24	genes	gene	NNS	_	22	nmod
25	related	relate	VBN	_	24	acl
26	with	with	IN	_	27	case
27	triglyceride	triglyceride	NN	_	25	nmod
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	TG	tg	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	metabolism	metabolism	NN	_	27	dep
32	has	have	VBZ	_	34	aux
33	been	be	VBN	_	34	auxpass
34	described	describe	VBN	_	12	conj
35	,	,	,	_	34	punct
36	including	include	VBG	_	37	case
37	drug1	drug1	NN	_	34	nmod
38	,	,	,	_	37	punct
39	drug2	drug2	NN	_	37	conj
40	and	and	CC	_	37	cc
41	drug3	drug3	NN	_	37	conj
42	.	.	.	_	1	punct

1	Among	among	IN	_	2	case
2	SNPs	snp	NNS	_	19	nmod
3	tested	test	VBN	_	2	acl
4	with	with	IN	_	7	case
5	an	a	DT	_	7	det
6	allele	allele	NN	_	7	compound
7	frequency	frequency	NN	_	3	nmod
8	of	of	IN	_	12	case
9	at	at	IN	_	10	case
10	least	least	JJS	_	11	nmod:npmod
11	5	5	CD	_	12	nummod
12	%	%	NN	_	7	nmod
13	,	,	,	_	19	punct
14	only	only	RB	_	15	advmod
15	SNPs	snp	NNS	_	19	nsubjpass
16	in	in	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	are	be	VBP	_	19	auxpass
19	found	find	VBN	_	0	ROOT
20	to	to	TO	_	21	mark
21	influence	influence	VB	_	19	xcomp
22	drug2	drug2	NN	_	21	dobj
23	significantly	significantly	RB	_	21	advmod
24	.	.	.	_	19	punct

1	Of	of	IN	_	4	case
2	the	the	DT	_	4	det
3	3	3	CD	_	4	nummod
4	SNPs	snp	NNS	_	21	nmod
5	most	most	RBS	_	6	advmod
6	significantly	significantly	RB	_	7	advmod
7	associated	associate	VBN	_	4	acl
8	with	with	IN	_	9	case
9	MI	MI	NNP	_	7	nmod
10	,	,	,	_	9	punct
11	drug1	drug1	NN	_	9	appos
12	,	,	,	_	9	punct
13	which	which	WDT	_	14	nsubj
14	defines	define	VBZ	_	9	acl:relcl
15	the	the	DT	_	18	det
16	Apo	apo	NN	_	18	compound
17	E2	e2	NN	_	18	compound
18	isoform	isoform	NN	_	14	dobj
19	,	,	,	_	21	punct
20	was	be	VBD	_	21	auxpass
21	associated	associate	VBN	_	0	ROOT
22	with	with	IN	_	28	case
23	both	both	CC	_	28	cc:preconj
24	a	a	DT	_	28	det
25	lower	lower	JJR	_	28	amod
26	Apo	apo	NN	_	28	compound
27	B/A1	b/a1	NN	_	28	compound
28	ratio	ratio	NN	_	21	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	P	p	NN	_	31	nsubj
31	=	=	JJ	_	28	dep
32	1.0	1.0	CD	_	33	nummod
33	x10	x10	NN	_	31	dobj
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	-7	-7	CD	_	31	parataxis
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	-RRB-	-rrb-	-RRB-	_	31	punct
38	and	and	CC	_	28	cc
39	lower	lower	JJR	_	41	amod
40	drug2	drug2	NN	_	41	compound
41	risk	risk	NN	_	28	conj
42	-LRB-	-lrb-	-LRB-	_	44	punct
43	P	p	NN	_	44	nsubj
44	=	=	JJ	_	41	dep
45	0.0004	0.0004	CD	_	44	dobj
46	-RRB-	-rrb-	-RRB-	_	44	punct
47	.	.	.	_	21	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	We	we	PRP	_	4	nsubj
4	reviewed	review	VBD	_	1	dep
5	the	the	DT	_	6	det
6	literature	literature	NN	_	4	dobj
7	relating	relate	VBG	_	6	acl
8	to	to	TO	_	10	case
9	SNPs	snp	NNS	_	10	compound
10	drug1	drug1	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	4	punct
16	and	and	CC	_	4	cc
17	clinical	clinical	JJ	_	20	amod
18	and	and	CC	_	17	cc
19	preclinical	preclinical	JJ	_	17	conj
20	studies	study	NNS	_	4	conj
21	,	,	,	_	20	punct
22	which	which	WDT	_	23	nsubj
23	shed	shed	VBD	_	20	acl:relcl
24	light	light	NN	_	23	dobj
25	on	on	IN	_	27	case
26	the	the	DT	_	27	det
27	mechanisms	mechanism	NNS	_	23	nmod
28	underlying	underlie	VBG	_	27	acl
29	these	these	DT	_	30	det
30	associations	association	NNS	_	28	dobj

1	Two	two	CD	_	2	nummod
2	polymorphisms	polymorphism	NNS	_	23	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug1	drug1	NN	_	2	dep
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	that	that	WDT	_	9	nsubj
9	define	define	VBP	_	2	acl:relcl
10	the	the	DT	_	17	det
11	epsilon2	epsilon2	NN	_	17	compound
12	,	,	,	_	11	punct
13	epsilon3	epsilon3	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	epsilon4	epsilon4	NN	_	11	conj
17	isoforms	isoform	NNS	_	9	dobj
18	of	of	IN	_	20	case
19	apolipoprotein	apolipoprotein	NN	_	20	compound
20	E	e	NN	_	17	nmod
21	were	be	VBD	_	23	auxpass
22	significantly	significantly	RB	_	23	advmod
23	associated	associate	VBN	_	0	ROOT
24	with	with	IN	_	26	case
25	percent	percent	NN	_	26	compound
26	reduction	reduction	NN	_	23	nmod
27	in	in	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	epsilon2	epsilon2	NN	_	31	compound
31	carriers	carrier	NNS	_	26	dep
32	53.8	53.8	CD	_	33	nummod
33	%	%	NN	_	31	dep
34	,	,	,	_	31	punct
35	epsilon3/epsilon3	epsilon3/epsilon3	NN	_	37	compound
36	48.1	48.1	CD	_	37	nummod
37	%	%	NN	_	31	conj
38	,	,	,	_	31	punct
39	and	and	CC	_	31	cc
40	epsilon4	epsilon4	NN	_	41	compound
41	carriers	carrier	NNS	_	31	conj
42	46.4	46.4	CD	_	43	nummod
43	%	%	NN	_	41	dep
44	,	,	,	_	31	punct
45	respectively	respectively	RB	_	31	advmod
46	,	,	,	_	31	punct
47	P	p	NN	_	48	nsubj
48	=	=	JJ	_	31	dep
49	0.00039	0.00039	CD	_	48	dobj
50	-RRB-	-rrb-	-RRB-	_	31	punct
51	and	and	CC	_	23	cc
52	replicated	replicate	VBN	_	23	conj
53	in	in	IN	_	55	case
54	the	the	DT	_	55	det
55	drug4	drug4	NN	_	52	nmod
56	-LRB-	-lrb-	-LRB-	_	58	punct
57	epsilon2	epsilon2	NN	_	58	compound
58	carriers	carrier	NNS	_	55	dep
59	22.1	22.1	CD	_	60	nummod
60	%	%	NN	_	58	dep
61	,	,	,	_	58	punct
62	epsilon3/epsilon3	epsilon3/epsilon3	NN	_	58	conj
63	21.8	21.8	CD	_	64	nummod
64	%	%	NN	_	62	dep
65	,	,	,	_	58	punct
66	and	and	CC	_	58	cc
67	epsilon4	epsilon4	NN	_	68	compound
68	carriers	carrier	NNS	_	58	conj
69	16.6	16.6	CD	_	70	nummod
70	%	%	NN	_	68	dep
71	,	,	,	_	58	punct
72	respectively	respectively	RB	_	58	advmod
73	,	,	,	_	58	punct
74	P	p	NN	_	75	nsubj
75	=	=	JJ	_	58	dep
76	0.00038	0.00038	CD	_	75	dobj
77	-RRB-	-rrb-	-RRB-	_	58	punct
78	.	.	.	_	23	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	3	nsubj
3	support	support	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	hypothesis	hypothesis	NN	_	3	dobj
6	that	that	IN	_	8	mark
7	drug1	drug1	NN	_	8	nsubj
8	influence	influence	VBP	_	5	ccomp
9	the	the	DT	_	10	det
10	prevalence	prevalence	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	8	cc
14	possibly	possibly	RB	_	15	advmod
15	overweight	overweight	JJ	_	8	conj
16	in	in	IN	_	18	case
17	drug3	drug3	NN	_	18	compound
18	patients	patient	NNS	_	15	nmod
19	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	associations	association	NNS	_	3	nsubj
3	warrant	warrant	VBP	_	0	ROOT
4	prospective	prospective	JJ	_	5	amod
5	study	study	NN	_	3	dobj
6	to	to	TO	_	7	mark
7	assess	assess	VB	_	5	acl
8	interaction	interaction	NN	_	7	dobj
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	the	the	DT	_	13	det
13	propensity	propensity	NN	_	10	conj
14	of	of	IN	_	15	case
15	antipsychotics	antipsychotic	NNS	_	13	nmod
16	to	to	TO	_	17	mark
17	induce	induce	VB	_	8	acl
18	drug2	drug2	NN	_	17	dobj
19	.	.	.	_	3	punct

1	Lower	lower	JJR	_	4	amod
2	lipid	lipid	NN	_	4	compound
3	profile	profile	NN	_	4	compound
4	values	value	NNS	_	19	nsubj
5	among	among	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	,	,	,	_	19	punct
8	even	even	RB	_	9	advmod
9	those	those	DT	_	19	nsubj
10	on	on	IN	_	12	case
11	lipid-rich	lipid-rich	JJ	_	12	amod
12	diets	diet	NNS	_	9	nmod
13	associated	associate	VBN	_	12	acl
14	with	with	IN	_	17	case
15	the	the	DT	_	17	det
16	drug1	drug1	NN	_	17	compound
17	allele	allele	NN	_	13	nmod
18	,	,	,	_	19	punct
19	suggest	suggest	VBP	_	0	ROOT
20	alterations	alteration	NNS	_	19	dobj
21	in	in	IN	_	24	case
22	the	the	DT	_	24	dep
23	lipid	lipid	NN	_	24	compound
24	synthesis	synthesis	NN	_	20	nmod
25	and	and	CC	_	24	cc
26	metabolism	metabolism	NN	_	27	compound
27	pathways	pathway	NNS	_	24	conj
28	in	in	IN	_	29	case
29	drug2	drug2	NN	_	24	nmod
30	.	.	.	_	19	punct

1	GAB2	gab2	NN	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	marker	marker	NN	_	6	nsubj
4	does	do	VBZ	_	6	aux
5	not	not	RB	_	6	neg
6	modify	modify	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	risk	risk	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	in	in	IN	_	16	case
12	Spanish	spanish	JJ	_	16	amod
13	APOE	apoe	NN	_	16	compound
14	epsilon	epsilon	NN	_	16	compound
15	4	4	CD	_	16	nummod
16	carriers	carrier	NNS	_	6	nmod
17	.	.	.	_	6	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Although	although	IN	_	7	mark
4	several	several	JJ	_	5	amod
5	studies	study	NNS	_	7	nsubj
6	have	have	VBP	_	7	aux
7	reported	report	VBN	_	1	dep
8	an	a	DT	_	9	det
9	association	association	NN	_	7	dobj
10	between	between	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	OSA	osa	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	11	cc
16	the	the	DT	_	18	det
17	chromosomal	chromosomal	JJ	_	18	amod
18	region	region	NN	_	11	conj
19	containing	contain	VBG	_	18	acl
20	the	the	DT	_	22	det
21	Apolipoprotein	apolipoprotein	NN	_	22	compound
22	E	e	NN	_	19	dobj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	drug1	drug1	NN	_	26	compound
25	-RRB-	-rrb-	-RRB-	_	26	punct
26	gene	gene	NN	_	39	nsubj
27	,	,	,	_	26	punct
28	findings	finding	NNS	_	26	appos
29	about	about	IN	_	32	case
30	the	the	DT	_	32	det
31	exact	exact	JJ	_	32	amod
32	location	location	NN	_	28	nmod
33	in	in	IN	_	36	case
34	the	the	DT	_	36	det
35	ApoE	apoe	NN	_	36	compound
36	gene	gene	NN	_	32	nmod
37	have	have	VBP	_	39	aux
38	been	be	VBN	_	39	cop
39	inconsistent	inconsistent	JJ	_	22	acl:relcl
40	.	.	.	_	1	punct

1	The	the	DT	_	7	det
2	sliding	slide	VBG	_	7	amod
3	window	window	NN	_	7	compound
4	haplotype	haplotype	NN	_	7	compound
5	trend	trend	NN	_	7	compound
6	regression	regression	NN	_	7	compound
7	test	test	NN	_	8	nsubj
8	revealed	reveal	VBD	_	0	ROOT
9	that	that	IN	_	13	mark
10	SNP	snp	NN	_	11	compound
11	drug1	drug1	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	included	include	VBN	_	8	ccomp
14	in	in	IN	_	16	case
15	all	all	DT	_	16	det
16	haplotypes	haplotype	NNS	_	13	nmod
17	that	that	WDT	_	20	nsubjpass
18	are	be	VBP	_	20	auxpass
19	significantly	significantly	RB	_	20	advmod
20	associated	associate	VBN	_	16	acl:relcl
21	with	with	IN	_	23	case
22	drug2	drug2	NN	_	23	compound
23	status	status	NN	_	20	nmod
24	.	.	.	_	8	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	clinical	clinical	JJ	_	4	amod
4	setting	setting	NN	_	8	nmod
5	,	,	,	_	8	punct
6	drug1	drug1	NN	_	8	nsubj
7	could	could	MD	_	8	aux
8	offer	offer	VB	_	0	ROOT
9	additional	additional	JJ	_	11	amod
10	biological	biological	JJ	_	11	amod
11	evidence	evidence	NN	_	8	dobj
12	of	of	IN	_	17	mark
13	whether	whether	IN	_	17	mark
14	a	a	DT	_	15	det
15	subject	subject	NN	_	17	nsubj
16	may	may	MD	_	17	aux
17	develop	develop	VB	_	11	acl
18	drug2	drug2	NN	_	17	dobj
19	,	,	,	_	8	punct
20	but	but	CC	_	8	cc
21	it	it	PRP	_	24	nsubj
22	is	be	VBZ	_	24	cop
23	not	not	RB	_	24	neg
24	robust	robust	JJ	_	8	conj
25	enough	enough	JJ	_	24	xcomp
26	to	to	TO	_	27	mark
27	serve	serve	VB	_	25	xcomp
28	as	as	IN	_	31	case
29	an	a	DT	_	31	det
30	independent	independent	JJ	_	31	amod
31	screening	screening	NN	_	27	nmod
32	or	or	CC	_	31	cc
33	predictive	predictive	JJ	_	34	amod
34	test	test	NN	_	31	conj
35	in	in	IN	_	36	case
36	thediagnosis	thediagnosis	NN	_	31	nmod
37	of	of	IN	_	38	case
38	drug3	drug3	NN	_	36	nmod

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	6	nmod
4	,	,	,	_	6	punct
5	we	we	PRP	_	6	nsubj
6	investigated	investigate	VBD	_	0	ROOT
7	whether	whether	IN	_	23	mark
8	variants	variant	NNS	_	23	nsubjpass
9	in	in	IN	_	13	case
10	three	three	CD	_	13	nummod
11	key	key	JJ	_	13	amod
12	pigmentation	pigmentation	NN	_	13	compound
13	genes	gene	NNS	_	8	nmod
14	-	-	:	_	13	punct
15	drug1	drug1	NN	_	13	dep
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	drug3	drug3	NN	_	15	conj
21	--	--	:	_	13	punct
22	were	be	VBD	_	23	auxpass
23	involved	involve	VBN	_	6	ccomp
24	in	in	IN	_	26	case
25	drug4	drug4	NN	_	26	compound
26	predisposition	predisposition	NN	_	23	nmod

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	variants	variant	NNS	_	5	nsubj
5	had	have	VBD	_	0	ROOT
6	additive	additive	JJ	_	7	amod
7	effects	effect	NNS	_	5	dobj
8	on	on	IN	_	10	case
9	drug3	drug3	NN	_	10	compound
10	risk	risk	NN	_	5	nmod
11	,	,	,	_	5	punct
12	and	and	CC	_	5	cc
13	after	after	IN	_	14	mark
14	adjusting	adjust	VBG	_	22	advcl
15	for	for	IN	_	17	case
16	pigmentation	pigmentation	NN	_	17	compound
17	characteristics	characteristic	NNS	_	14	nmod
18	,	,	,	_	22	punct
19	the	the	DT	_	20	det
20	risk	risk	NN	_	22	nsubj
21	was	be	VBD	_	22	cop
22	persistent	persistent	JJ	_	5	conj
23	,	,	,	_	22	punct
24	even	even	RB	_	28	advmod
25	though	though	IN	_	28	mark
26	both	both	DT	_	27	det
27	genes	gene	NNS	_	28	nsubj
28	had	have	VBD	_	22	advcl
29	a	a	DT	_	31	det
30	strong	strong	JJ	_	31	amod
31	impact	impact	NN	_	28	dobj
32	on	on	IN	_	33	case
33	pigmentation	pigmentation	NN	_	31	nmod

1	We	we	PRP	_	2	nsubj
2	conducted	conduct	VBD	_	0	ROOT
3	additional	additional	JJ	_	4	amod
4	genotyping	genotyping	NN	_	2	dobj
5	to	to	TO	_	6	mark
6	clarify	clarify	VB	_	2	advcl
7	the	the	DT	_	8	det
8	role	role	NN	_	6	dobj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	drug1	drug1	NN	_	12	compound
12	locus	locus	NN	_	8	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	inheritance	inheritance	NN	_	8	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	other	other	JJ	_	21	amod
20	pigmentary	pigmentary	JJ	_	21	amod
21	traits	trait	NNS	_	17	conj
22	associated	associate	VBN	_	17	acl
23	with	with	IN	_	27	case
24	drug3	drug3	NN	_	27	compound
25	risk	risk	NN	_	27	compound
26	inwhite	inwhite	NN	_	27	compound
27	populations	population	NNS	_	22	nmod

1	The	the	DT	_	3	det
2	minor	minor	JJ	_	3	amod
3	alleles	allele	NNS	_	64	nsubjpass
4	of	of	IN	_	8	case
5	drug1	drug1	NN	_	7	nmod:npmod
6	T	t	NN	_	7	nmod:npmod
7	=	=	JJ	_	8	amod
8	TF	tf	NN	_	3	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	TCF7L2	tcf7l2	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	8	punct
13	drug2	drug2	NN	_	15	nmod:npmod
14	T	t	NN	_	15	nmod:npmod
15	=	=	JJ	_	8	amod
16	TF	tf	NN	_	15	dep
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	TCF7L2	tcf7l2	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	,	,	,	_	8	punct
21	drug3	drug3	NN	_	8	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	-30	-30	CD	_	24	nummod
24	G/A	g/a	NN	_	21	dep
25	,	,	,	_	24	punct
26	GCK	gck	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	24	punct
28	,	,	,	_	8	punct
29	drug4	drug4	NN	_	8	conj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	E23K	e23k	NN	_	29	dep
32	,	,	,	_	31	punct
33	KCNJ11	kcnj11	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	31	punct
35	,	,	,	_	8	punct
36	drug5	drug5	NN	_	8	conj
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	CDKAL1	cdkal1	NN	_	36	appos
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	,	,	,	_	8	punct
41	drug6	drug6	NN	_	8	conj
42	-LRB-	-lrb-	-LRB-	_	43	punct
43	IGF2BP2	igf2bp2	NN	_	41	appos
44	-RRB-	-rrb-	-RRB-	_	43	punct
45	,	,	,	_	8	punct
46	drug7	drug7	NN	_	8	conj
47	-LRB-	-lrb-	-LRB-	_	48	punct
48	MTNR1B	mtnr1b	NN	_	46	appos
49	-RRB-	-rrb-	-RRB-	_	48	punct
50	,	,	,	_	8	punct
51	drug8	drug8	NN	_	8	conj
52	-LRB-	-lrb-	-LRB-	_	53	punct
53	MTNR1B	mtnr1b	NN	_	51	appos
54	-RRB-	-rrb-	-RRB-	_	53	punct
55	and	and	CC	_	8	cc
56	drug9	drug9	NN	_	8	conj
57	-LRB-	-lrb-	-LRB-	_	58	punct
58	Gly972Arg	gly972arg	NN	_	56	dep
59	,	,	,	_	58	punct
60	IRS1	irs1	NN	_	58	appos
61	-RRB-	-rrb-	-RRB-	_	58	punct
62	were	be	VBD	_	64	auxpass
63	significantly	significantly	RB	_	64	advmod
64	associated	associate	VBN	_	0	ROOT
65	with	with	IN	_	68	case
66	a	a	DT	_	68	det
67	higher	higher	JJR	_	68	amod
68	risk	risk	NN	_	64	nmod
69	of	of	IN	_	70	case
70	drug10	drug10	NN	_	68	nmod
71	.	.	.	_	64	punct

1	Among	among	IN	_	2	case
2	them	they	PRP	_	8	nmod
3	,	,	,	_	8	punct
4	genetic	genetic	JJ	_	5	amod
5	variants	variant	NNS	_	8	nsubj
6	in	in	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	showed	show	VBD	_	0	ROOT
9	the	the	DT	_	11	det
10	strongest	strongest	JJS	_	11	amod
11	association	association	NN	_	8	dobj
12	with	with	IN	_	14	case
13	drug4	drug4	NN	_	14	compound
14	risk	risk	NN	_	11	nmod
15	,	,	,	_	11	punct
16	with	with	IN	_	17	case
17	ORs	or	NNS	_	11	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	95	95	CD	_	20	compound
20	%	%	NN	_	21	amod
21	CIs	ci	NNS	_	17	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	of	of	IN	_	24	case
24	1.44	1.44	CD	_	17	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	1.29-1	1.29-1	CD	_	27	nummod
27	.60	.60	CD	_	24	dep
28	,	,	,	_	27	punct
29	P	p	NN	_	31	dep
30	<	<	JJR	_	31	dep
31	0.001	0.001	CD	_	27	dep
32	-RRB-	-rrb-	-RRB-	_	27	punct
33	per	per	IN	_	35	case
34	T	t	NN	_	35	compound
35	allele	allele	NN	_	17	nmod
36	of	of	IN	_	37	case
37	drug2	drug2	NN	_	35	nmod
38	and	and	CC	_	37	cc
39	1.46	1.46	CD	_	37	conj
40	-LRB-	-lrb-	-LRB-	_	42	punct
41	1.15-1	1.15-1	CD	_	42	nummod
42	.84	.84	NN	_	39	dep
43	,	,	,	_	42	punct
44	P	p	NN	_	45	nsubj
45	=	=	JJ	_	42	dep
46	0.002	0.002	CD	_	45	dobj
47	-RRB-	-rrb-	-RRB-	_	42	punct
48	per	per	IN	_	50	case
49	T	t	NN	_	50	compound
50	allele	allele	NN	_	37	nmod
51	of	of	IN	_	52	case
52	drug3	drug3	NN	_	50	nmod

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Two	two	CD	_	5	nummod
4	single-nucleotide	single-nucleotide	JJ	_	5	amod
5	polymorphisms	polymorphism	NNS	_	25	nsubjpass
6	,	,	,	_	5	punct
7	drug1	drug1	NN	_	5	appos
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	5	punct
11	located	located	JJ	_	5	amod
12	within	within	IN	_	18	case
13	the	the	DT	_	18	det
14	nicotinic	nicotinic	JJ	_	18	amod
15	acetylcholine	acetylcholine	NN	_	18	compound
16	receptor	receptor	NN	_	18	compound
17	gene	gene	NN	_	18	compound
18	cluster	cluster	NN	_	11	nmod
19	on	on	IN	_	22	case
20	chromosome	chromosome	NN	_	22	compound
21	15q25	15q25	NN	_	22	compound
22	locus	locus	NN	_	18	nmod
23	,	,	,	_	5	punct
24	are	be	VBP	_	25	auxpass
25	associated	associate	VBN	_	1	dep
26	with	with	IN	_	27	case
27	heaviness	heaviness	NN	_	25	nmod
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	,	,	,	_	25	punct
31	risk	risk	NN	_	25	conj
32	for	for	IN	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	,	,	,	_	25	punct
35	and	and	CC	_	25	cc
36	other	other	JJ	_	39	amod
37	smoking-related	smoking-related	JJ	_	39	amod
38	health	health	NN	_	39	compound
39	outcomes	outcome	NNS	_	25	conj
40	.	.	.	_	1	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	We	we	PRP	_	4	nsubj
4	aimed	aim	VBD	_	1	appos
5	to	to	TO	_	6	mark
6	replicate	replicate	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	association	association	NN	_	6	dobj
9	of	of	IN	_	20	case
10	the	the	DT	_	20	det
11	drug1	drug1	NN	_	20	compound
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	IVS3C/T	ivs3c/t	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	11	cc
16	drug2	drug2	NN	_	11	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	IVS3C/T	ivs3c/t	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	polymorphisms	polymorphism	NNS	_	8	nmod
21	of	of	IN	_	23	case
22	transcription	transcription	NN	_	23	compound
23	factor	factor	NN	_	20	nmod
24	7-like	7-like	JJ	_	23	amod
25	2	2	CD	_	24	dep
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	TCF7L2	tcf7l2	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	and	and	CC	_	25	cc
30	drug3	drug3	NN	_	25	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	drug4	drug4	NN	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	in	in	IN	_	37	case
35	Han	Han	NNP	_	37	compound
36	Chinese	Chinese	NNPS	_	37	compound
37	people	people	NNS	_	8	nmod
38	in	in	IN	_	40	case
39	Henan	Henan	NNP	_	40	compound
40	province	province	NN	_	37	nmod
41	,	,	,	_	40	punct
42	China	China	NNP	_	40	appos
43	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	CC	cc	NN	_	5	compound
5	genotype	genotype	NN	_	33	nsubjpass
6	and	and	CC	_	5	cc
7	the	the	DT	_	9	det
8	recessive	recessive	JJ	_	9	amod
9	model	model	NN	_	5	conj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	variant	variant	JJ	_	13	amod
13	drug1	drug1	NN	_	9	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	IVS3C/T	ivs3c/t	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	and	and	CC	_	13	cc
18	CC	cc	NN	_	19	compound
19	haplotype	haplotype	NN	_	13	conj
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	13	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	IVS3C/T	ivs3c/t	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	and	and	CC	_	21	cc
26	drug3	drug3	NN	_	21	conj
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	IVS3C/T	ivs3c/t	NN	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	in	in	IN	_	31	case
31	TCF7L2may	tcf7l2may	NN	_	5	nmod
32	be	be	VB	_	33	auxpass
33	associated	associate	VBN	_	1	appos
34	with	with	IN	_	35	case
35	drug4	drug4	NN	_	33	nmod
36	in	in	IN	_	39	case
37	Han	Han	NNP	_	39	compound
38	Chinese	Chinese	NNPS	_	39	compound
39	people	people	NNS	_	35	nmod
40	in	in	IN	_	42	case
41	Henan	Henan	NNP	_	42	compound
42	province	province	NN	_	39	nmod
43	,	,	,	_	42	punct
44	China	China	NNP	_	42	appos
45	.	.	.	_	1	punct
46	.	.	.	_	1	punct

1	Here	here	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	report	report	VBP	_	0	ROOT
5	replication	replication	NN	_	4	dobj
6	of	of	IN	_	7	case
7	association	association	NN	_	5	nmod
8	between	between	IN	_	9	case
9	drug6	drug6	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	three	three	CD	_	12	nummod
12	SNPs	snp	NNS	_	9	conj
13	in	in	IN	_	39	case
14	the	the	DT	_	39	det
15	case-control	case-control	JJ	_	39	amod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug1	drug1	NN	_	15	dep
18	,	,	,	_	17	punct
19	P	p	NN	_	20	nsubj
20	=	=	JJ	_	17	dep
21	0.003	0.003	CD	_	20	dobj
22	;	;	:	_	17	punct
23	drug2	drug2	NN	_	17	dep
24	,	,	,	_	23	punct
25	P	p	NN	_	26	nsubj
26	=	=	JJ	_	23	dep
27	0.00002	0.00002	CD	_	26	dobj
28	;	;	:	_	17	punct
29	and	and	CC	_	17	cc
30	.	.	.	_	17	punct
31	drug3	drug3	NN	_	17	conj
32	,	,	,	_	17	punct
33	P	p	NN	_	34	nsubj
34	=	=	JJ	_	17	dep
35	0.000004	0.000004	CD	_	34	dobj
36	-RRB-	-rrb-	-RRB-	_	17	punct
37	and	and	CC	_	15	cc
38	two	two	CD	_	15	conj
39	SNPs	snp	NNS	_	5	nmod
40	in	in	IN	_	56	case
41	the	the	DT	_	56	det
42	family-based	family-based	JJ	_	56	amod
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	drug4	drug4	NN	_	42	dep
45	,	,	,	_	44	punct
46	P	p	NN	_	47	nsubj
47	=	=	JJ	_	44	dep
48	0.01	0.01	CD	_	47	dobj
49	and	and	CC	_	48	cc
50	drug5	drug5	NN	_	48	conj
51	,	,	,	_	44	punct
52	P	p	NN	_	53	nsubj
53	=	=	JJ	_	44	dep
54	0.04	0.04	CD	_	53	dobj
55	-RRB-	-rrb-	-RRB-	_	44	punct
56	samples	sample	NNS	_	39	nmod
57	from	from	IN	_	59	case
58	northern	northern	JJ	_	59	amod
59	Sweden	Sweden	NNP	_	56	nmod
60	.	.	.	_	4	punct

1	This	this	DT	_	3	det
2	263	263	CD	_	3	nummod
3	indel	indel	NN	_	9	nsubj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug1	drug1	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	is	be	VBZ	_	9	aux
8	</ModMar>	</ModMar>	NNP	_	9	nsubj
9	reported	report	VBD	_	0	ROOT
10	</ModMar>	</modmar>	NN	_	9	dobj
11	to	to	TO	_	16	mark
12	be	be	VB	_	16	cop
13	in	in	IN	_	16	case
14	strong	strong	JJ	_	16	amod
15	linkage	linkage	NN	_	16	compound
16	disequilibrium	disequilibrium	NN	_	10	xcomp
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	LD	ld	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	with	with	IN	_	24	case
21	a	a	DT	_	24	det
22	single	single	JJ	_	24	amod
23	nucleotide	nucleotide	NN	_	24	compound
24	polymorphism	polymorphism	NN	_	16	nmod
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	SNP	snp	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	35	35	CD	_	29	nummod
29	kilobases	kilobase	NNS	_	30	nmod:npmod
30	upstream	upstream	RB	_	24	advmod
31	of	of	IN	_	32	case
32	HLA-C	hla-c	NN	_	30	nmod
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	-35	-35	CD	_	35	nummod
35	T/C	t/c	NN	_	24	dep
36	;	;	:	_	35	punct
37	rs9264942	rs9264942	NN	_	35	dep
38	-RRB-	-rrb-	-RRB-	_	35	punct
39	in	in	IN	_	41	case
40	Caucasian	caucasian	JJ	_	41	amod
41	individuals	individual	NNS	_	24	nmod
42	,	,	,	_	16	punct
43	making	make	VBG	_	16	advcl
44	this	this	DT	_	45	det
45	SNP	snp	NN	_	48	nsubj
46	a	a	DT	_	48	det
47	potential	potential	JJ	_	48	amod
48	marker	marker	NN	_	43	xcomp
49	for	for	IN	_	52	case
50	both	both	DT	_	52	cc:preconj
51	HLA-C	hla-c	NN	_	52	compound
52	expression	expression	NN	_	48	nmod
53	and	and	CC	_	52	cc
54	drug2	drug2	NN	_	56	compound
55	disease	disease	NN	_	56	compound
56	progression	progression	NN	_	52	conj

1	Two	two	CD	_	2	nummod
2	polymorphisms	polymorphism	NNS	_	14	nsubjpass
3	affecting	affect	VBG	_	2	acl
4	HLA-Csurface	hla-csurface	JJ	_	5	amod
5	expression	expression	NN	_	3	dobj
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug1	drug1	NN	_	5	dep
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	-RRB-	-rrb-	-RRB-	_	7	punct
11	have	have	VBP	_	14	aux
12	recently	recently	RB	_	14	advmod
13	been	be	VBN	_	14	auxpass
14	identified	identify	VBN	_	0	ROOT
15	,	,	,	_	14	punct
16	and	and	CC	_	14	cc
17	shown	show	VBN	_	14	conj
18	to	to	TO	_	19	mark
19	influence	influence	VB	_	17	xcomp
20	progression	progression	NN	_	19	dobj
21	of	of	IN	_	23	case
22	drug3	drug3	NN	_	23	compound
23	infection	infection	NN	_	20	nmod
24	.	.	.	_	14	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Heterozygosity	heterozygosity	NN	_	46	nsubjpass
4	for	for	IN	_	9	case
5	a	a	DT	_	9	det
6	32	32	CD	_	9	nummod
7	base	base	NN	_	9	compound
8	pair	pair	NN	_	9	compound
9	deletion	deletion	NN	_	3	nmod
10	in	in	IN	_	13	case
11	the	the	DT	_	13	det
12	CCR5	ccr5	NN	_	13	compound
13	gene	gene	NN	_	9	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	CCR5wt/d32	ccr5wt/d32	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	and	and	CC	_	9	cc
18	the	the	DT	_	20	det
19	minor	minor	JJ	_	20	amod
20	alleles	allele	NNS	_	9	conj
21	of	of	IN	_	24	case
22	a	a	DT	_	24	det
23	single-nucleotide	single-nucleotide	JJ	_	24	amod
24	polymorphism	polymorphism	NN	_	20	nmod
25	in	in	IN	_	28	case
26	the	the	DT	_	28	det
27	HCP5	hcp5	NN	_	28	compound
28	gene	gene	NN	_	24	nmod
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	drug1	drug1	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	and	and	CC	_	28	cc
33	in	in	IN	_	37	case
34	the	the	DT	_	37	det
35	HLA-C	hla-c	NN	_	37	compound
36	gene	gene	NN	_	37	compound
37	region	region	NN	_	28	conj
38	-LRB-	-lrb-	-LRB-	_	40	punct
39	-35	-35	CD	_	40	nummod
40	HLA-C	hla-c	NN	_	37	dep
41	;	;	:	_	40	punct
42	drug2	drug2	NN	_	40	dep
43	-RRB-	-rrb-	-RRB-	_	40	punct
44	has	have	VBZ	_	46	aux
45	been	be	VBN	_	46	auxpass
46	associated	associate	VBN	_	1	appos
47	with	with	IN	_	49	case
48	a	a	DT	_	49	det
49	drug3	drug3	NN	_	46	nmod

1	A	a	DT	_	4	det
2	single	single	JJ	_	4	amod
3	nucleotide	nucleotide	NN	_	4	compound
4	polymorphism	polymorphism	NN	_	19	nsubj
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	SNP	snp	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	35	35	CD	_	9	nummod
9	kb	kb	NN	_	10	nmod:npmod
10	upstream	upstream	RB	_	4	amod
11	of	of	IN	_	12	case
12	HLA-C	hla-c	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug1	drug1	NN	_	12	dep
15	;	;	:	_	14	punct
16	termed	term	VBN	_	14	acl
17	-35	-35	CD	_	16	xcomp
18	-RRB-	-rrb-	-RRB-	_	14	punct
19	associates	associate	VBZ	_	0	ROOT
20	with	with	IN	_	21	case
21	control	control	NN	_	19	nmod
22	of	of	IN	_	23	case
23	drug2	drug2	NN	_	21	nmod
24	,	,	,	_	19	punct
25	and	and	CC	_	19	cc
26	with	with	IN	_	27	case
27	levels	level	NNS	_	19	conj
28	of	of	IN	_	32	case
29	HLA-C	hla-c	NN	_	32	compound
30	messenger	messenger	NN	_	32	compound
31	RNA	rna	NN	_	32	compound
32	transcripts	transcript	NNS	_	27	nmod
33	and	and	CC	_	32	cc
34	cell-surface	cell-surface	JJ	_	35	amod
35	expression	expression	NN	_	32	conj
36	,	,	,	_	27	punct
37	but	but	CC	_	27	cc
38	the	the	DT	_	39	det
39	mechanism	mechanism	NN	_	45	nsubj
40	underlying	underlie	VBG	_	39	acl
41	its	its	PRP$	_	43	nmod:poss
42	varied	varied	JJ	_	43	amod
43	expression	expression	NN	_	40	dobj
44	is	be	VBZ	_	45	cop
45	unknown	unknown	JJ	_	27	conj
46	.	.	.	_	19	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Significant	significant	JJ	_	4	amod
4	associations	association	NNS	_	27	nsubjpass
5	between	between	IN	_	9	case
6	the	the	DT	_	9	det
7	minor	minor	JJ	_	9	amod
8	allele	allele	NN	_	9	compound
9	variants	variant	NNS	_	4	nmod
10	of	of	IN	_	13	case
11	SNPs	snp	NNS	_	13	compound
12	HLA-C	hla-c	NN	_	13	compound
13	drug1	drug1	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	HCP5	hcp5	NN	_	16	compound
16	drug2	drug2	NN	_	13	conj
17	and	and	CC	_	9	cc
18	a	a	DT	_	21	det
19	lower	lower	JJR	_	21	amod
20	viral	viral	JJ	_	21	amod
21	load	load	NN	_	9	conj
22	at	at	IN	_	24	case
23	set	set	VBN	_	24	amod
24	point	point	NN	_	21	nmod
25	could	could	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	replicated	replicate	VBN	_	1	dep
28	in	in	IN	_	30	case
29	the	the	DT	_	30	det
30	drug3	drug3	NN	_	27	nmod
31	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	adiposity-matched	adiposity-matched	JJ	_	5	nmod
3	,	,	,	_	5	punct
4	normal-weight	normal-weight	JJ	_	5	amod
5	humans	human	NNS	_	8	ccomp
6	,	,	,	_	8	punct
7	we	we	PRP	_	8	nsubj
8	showed	show	VBD	_	0	ROOT
9	that	that	IN	_	20	mark
10	subjects	subject	NNS	_	20	nsubj
11	homozygous	homozygous	JJ	_	10	amod
12	for	for	IN	_	18	case
13	the	the	DT	_	18	det
14	FTO	FTO	NNP	_	18	compound
15	drug2	drug2	NN	_	18	compound
16	drug1	drug1	NN	_	18	compound
17	A	a	NN	_	18	compound
18	allele	allele	NN	_	11	nmod
19	have	have	VBP	_	20	aux
20	dysregulated	dysregulate	VBN	_	8	ccomp
21	circulating	circulate	VBG	_	22	amod
22	levels	level	NNS	_	20	dobj
23	of	of	IN	_	27	case
24	the	the	DT	_	27	det
25	orexigenic	orexigenic	JJ	_	27	amod
26	hormone	hormone	NN	_	27	compound
27	acyl-ghrelin	acyl-ghrelin	NN	_	22	nmod
28	and	and	CC	_	20	cc
29	attenuated	attenuate	VBD	_	20	conj
30	drug3	drug3	NN	_	29	dobj
31	.	.	.	_	8	punct

1	Through	through	IN	_	4	case
2	an	a	DT	_	4	det
3	exhaustive	exhaustive	JJ	_	4	amod
4	search	search	NN	_	25	nmod
5	of	of	IN	_	7	case
6	pair-wise	pair-wise	JJ	_	7	amod
7	interactions	interaction	NNS	_	4	nmod
8	and	and	CC	_	7	cc
9	a	a	DT	_	11	det
10	selected	select	VBN	_	11	amod
11	search	search	NN	_	7	conj
12	of	of	IN	_	13	case
13	three	three	CD	_	11	nmod
14	-	-	:	_	4	punct
15	to	to	TO	_	17	case
16	five-way	five-way	JJ	_	17	amod
17	interactions	interaction	NNS	_	4	nmod
18	conditioned	condition	VBN	_	17	acl
19	on	on	IN	_	22	case
20	significant	significant	JJ	_	22	amod
21	pair-wise	pair-wise	JJ	_	22	amod
22	results	result	NNS	_	18	nmod
23	,	,	,	_	25	punct
24	we	we	PRP	_	25	nsubj
25	identified	identify	VBD	_	0	ROOT
26	24	24	CD	_	28	nummod
27	core	core	NN	_	28	compound
28	SNPs	snp	NNS	_	25	dobj
29	in	in	IN	_	31	case
30	six	six	CD	_	31	nummod
31	genes	gene	NNS	_	28	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	FTO	fto	NN	_	31	dep
34	:	:	:	_	33	punct
35	drug1	drug1	NN	_	33	dep
36	,	,	,	_	35	punct
37	drug2	drug2	NN	_	35	conj
38	,	,	,	_	35	punct
39	drug3	drug3	NN	_	35	conj
40	,	,	,	_	35	punct
41	drug4	drug4	NN	_	35	conj
42	,	,	,	_	35	punct
43	drug5	drug5	NN	_	35	conj
44	,	,	,	_	35	punct
45	drug6	drug6	NN	_	35	conj
46	;	;	:	_	35	punct
47	TSPAN8	tspan8	NN	_	35	dep
48	:	:	:	_	47	punct
49	drug7	drug7	NN	_	47	dep
50	;	;	:	_	33	punct
51	TCF7L2	tcf7l2	NN	_	33	dep
52	:	:	:	_	51	punct
53	drug8	drug8	NN	_	51	dep
54	,	,	,	_	53	punct
55	drug9	drug9	NN	_	53	conj
56	,	,	,	_	53	punct
57	drug10	drug10	NN	_	53	conj
58	,	,	,	_	53	punct
59	drug11	drug11	NN	_	53	conj
60	,	,	,	_	53	punct
61	drug12	drug12	NN	_	53	conj
62	,	,	,	_	53	punct
63	drug13	drug13	NN	_	53	conj
64	,	,	,	_	53	punct
65	drug14	drug14	NN	_	53	conj
66	,	,	,	_	53	punct
67	drug15	drug15	NN	_	53	conj
68	;	;	:	_	53	punct
69	L3MBTL3	l3mbtl3	NN	_	53	dep
70	:	:	:	_	69	punct
71	drug16	drug16	NN	_	69	dep
72	,	,	,	_	71	punct
73	drug17	drug17	NN	_	71	appos
74	;	;	:	_	71	punct
75	CELF4	celf4	NN	_	71	dep
76	:	:	:	_	75	punct
77	drug18	drug18	NN	_	75	dep
78	,	,	,	_	77	punct
79	drug19	drug19	NN	_	77	appos
80	;	;	:	_	77	punct
81	RUNX1	runx1	NN	_	77	dep
82	:	:	:	_	81	punct
83	drug20	drug20	NN	_	81	dep
84	,	,	,	_	83	punct
85	drug21	drug21	NN	_	83	conj
86	,	,	,	_	83	punct
87	drug22	drug22	NN	_	83	conj
88	,	,	,	_	83	punct
89	drug23	drug23	NN	_	83	conj
90	,	,	,	_	83	punct
91	drug24	drug24	NN	_	83	appos
92	-RRB-	-rrb-	-RRB-	_	83	punct
93	that	that	WDT	_	94	nsubj
94	appear	appear	VBP	_	81	dep
95	to	to	TO	_	97	mark
96	be	be	VB	_	97	cop
97	important	important	JJ	_	94	xcomp
98	for	for	IN	_	99	case
99	drug25	drug25	CD	_	97	nmod
100	.	.	.	_	25	punct

1	The	the	DT	_	2	det
2	increase	increase	NN	_	6	nsubj
3	in	in	IN	_	5	case
4	cotinine	cotinine	NN	_	5	compound
5	levels	level	NNS	_	2	nmod
6	indicated	indicate	VBD	_	0	ROOT
7	an	a	DT	_	9	det
8	increased	increase	VBN	_	9	amod
9	risk	risk	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	with	with	IN	_	15	case
13	each	each	DT	_	15	det
14	additional	additional	JJ	_	15	amod
15	copy	copy	NN	_	9	nmod
16	of	of	IN	_	22	case
17	the	the	DT	_	22	det
18	drug1	drug1	NN	_	22	compound
19	-	-	:	_	22	punct
20	drug2	drug2	NN	_	22	compound
21	risk	risk	NN	_	22	compound
22	allele	allele	NN	_	15	nmod

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	We	we	PRP	_	4	nsubj
4	investigated	investigate	VBD	_	1	appos
5	if	if	IN	_	9	mark
6	the	the	DT	_	8	det
7	FTO	FTO	NNP	_	8	compound
8	drug1	drug1	NN	_	9	nsubj
9	associates	associate	VBZ	_	4	advcl
10	with	with	IN	_	12	case
11	food	food	NN	_	12	compound
12	preferences	preference	NNS	_	9	nmod
13	in	in	IN	_	15	case
14	healthy	healthy	JJ	_	15	amod
15	adults	adult	NNS	_	9	nmod
16	with	with	IN	_	18	case
17	no	no	DT	_	18	neg
18	drug2	drug2	NN	_	9	nmod
19	,	,	,	_	9	punct
20	drug3	drug3	NN	_	21	compound
21	disease	disease	NN	_	9	dobj
22	,	,	,	_	21	punct
23	or	or	CC	_	21	cc
24	drug4	drug4	NN	_	21	conj
25	.	.	.	_	1	punct

1	Conclusions	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	present	present	JJ	_	5	amod
5	study	study	NN	_	6	nsubj
6	demonstrated	demonstrate	VBD	_	1	appos
7	that	that	IN	_	15	mark
8	FTO	FTO	NNP	_	9	compound
9	drug1	drug1	NN	_	15	nsubjpass
10	and	and	CC	_	9	cc
11	combined	combined	JJ	_	12	amod
12	SNPs	snp	NNS	_	9	conj
13	were	be	VBD	_	15	auxpass
14	significantly	significantly	RB	_	15	advmod
15	associated	associate	VBN	_	6	ccomp
16	with	with	IN	_	17	case
17	risk	risk	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	,	,	,	_	17	punct
21	which	which	WDT	_	22	nsubj
22	seems	seem	VBZ	_	17	acl:relcl
23	to	to	TO	_	25	mark
24	be	be	VB	_	25	cop
25	dependent	dependent	JJ	_	22	xcomp
26	on	on	IN	_	27	case
27	BMI	BMI	NNP	_	25	nmod
28	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	present	present	JJ	_	5	amod
5	study	study	NN	_	6	nsubj
6	demonstrated	demonstrate	VBD	_	1	appos
7	that	that	IN	_	15	mark
8	FTO	FTO	NNP	_	9	compound
9	drug1	drug1	NN	_	15	nsubjpass
10	and	and	CC	_	9	cc
11	combined	combined	JJ	_	12	amod
12	SNPs	snp	NNS	_	9	conj
13	were	be	VBD	_	15	auxpass
14	significantly	significantly	RB	_	15	advmod
15	associated	associate	VBN	_	6	ccomp
16	with	with	IN	_	17	case
17	risk	risk	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	,	,	,	_	17	punct
21	which	which	WDT	_	22	nsubj
22	seems	seem	VBZ	_	17	acl:relcl
23	to	to	TO	_	25	mark
24	be	be	VB	_	25	cop
25	dependent	dependent	JJ	_	22	xcomp
26	on	on	IN	_	27	case
27	BMI	BMI	NNP	_	25	nmod
28	.	.	.	_	1	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	All	all	DT	_	5	det
4	drug2	drug2	NN	_	5	compound
5	patients	patient	NNS	_	7	nsubj
6	were	be	VBD	_	7	cop
7	genotypedfor	genotypedfor	NN	_	1	dep
8	the	the	DT	_	12	det
9	FTO	FTO	NNP	_	12	compound
10	single	single	JJ	_	12	amod
11	nucleotide	nucleotide	NN	_	12	compound
12	polimorphysm	polimorphysm	NN	_	16	compound
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	SNP	snp	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	drug1	drug1	NN	_	7	dep
17	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	investigated	investigate	VBD	_	0	ROOT
3	the	the	DT	_	7	det
4	drug1	drug1	NN	_	7	compound
5	single	single	JJ	_	7	amod
6	nucleotide	nucleotide	NN	_	7	compound
7	polymorphism	polymorphism	NN	_	2	dobj
8	in	in	IN	_	14	case
9	the	the	DT	_	14	det
10	nicotine	nicotine	NN	_	14	compound
11	acetylcholine	acetylcholine	NN	_	14	compound
12	receptor	receptor	NN	_	14	compound
13	gene	gene	NN	_	14	compound
14	cluster	cluster	NN	_	7	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	CHRNA5-CHRNA3-CHRNB4	chrna5-chrna3-chrnb4	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	7	punct
19	associated	associate	VBN	_	7	acl
20	with	with	IN	_	22	case
21	smoking	smoking	NN	_	22	compound
22	phenotypes	phenotype	NNS	_	19	nmod
23	,	,	,	_	7	punct
24	to	to	TO	_	25	mark
25	determine	determine	VB	_	2	advcl
26	whether	whether	IN	_	35	mark
27	women	woman	NNS	_	35	nsubj
28	who	who	WP	_	29	nsubj
29	continued	continue	VBD	_	27	acl:relcl
30	to	to	TO	_	31	mark
31	smoke	smoke	VB	_	29	xcomp
32	were	be	VBD	_	35	cop
33	also	also	RB	_	35	advmod
34	more	more	RBR	_	35	advmod
35	likely	likely	JJ	_	25	ccomp
36	to	to	TO	_	37	mark
37	report	report	VB	_	35	xcomp
38	a	a	DT	_	39	det
39	drug2	drug2	NN	_	37	dobj
40	during	during	IN	_	41	case
41	pregnancy	pregnancy	NN	_	37	nmod
42	.	.	.	_	2	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	among	among	IN	_	4	case
4	women	woman	NNS	_	2	nmod
5	who	who	WP	_	6	nsubj
6	smoked	smoke	VBD	_	4	acl:relcl
7	pre-pregnancy	pre-pregnancy	NN	_	6	dobj
8	,	,	,	_	4	punct
9	those	those	DT	_	15	nsubj
10	with	with	IN	_	14	case
11	the	the	DT	_	14	det
12	drug1	drug1	NN	_	14	compound
13	T	t	NN	_	14	compound
14	allele	allele	NN	_	9	nmod
15	smoked	smoke	VBD	_	4	acl:relcl
16	more	more	JJR	_	15	dobj
17	and	and	CC	_	15	cc
18	were	be	VBD	_	20	cop
19	less	less	RBR	_	20	advmod
20	likely	likely	JJ	_	15	conj
21	to	to	TO	_	22	mark
22	quit	quit	VB	_	20	xcomp
23	drug2	drug2	NN	_	22	dobj
24	during	during	IN	_	25	case
25	pregnancy	pregnancy	NN	_	22	nmod
26	,	,	,	_	2	punct
27	but	but	CC	_	2	cc
28	were	be	VBD	_	31	cop
29	also	also	RB	_	31	advmod
30	less	less	RBR	_	31	advmod
31	likely	likely	JJ	_	2	conj
32	to	to	TO	_	33	mark
33	report	report	VB	_	31	xcomp
34	high	high	JJ	_	35	amod
35	levels	level	NNS	_	33	dobj
36	of	of	IN	_	37	case
37	drug3	drug3	NN	_	35	nmod
38	at	at	IN	_	40	case
39	18	18	CD	_	40	nummod
40	weeks	week	NNS	_	33	nmod
41	of	of	IN	_	42	case
42	pregnancy	pregnancy	NN	_	40	nmod
43	-LRB-	-lrb-	-LRB-	_	52	punct
44	per	per	IN	_	46	case
45	allele	allele	NN	_	46	compound
46	OR	or	NN	_	52	nmod
47	=	=	JJ	_	46	amod
48	0.84	0.84	CD	_	47	dep
49	,	,	,	_	52	punct
50	95	95	CD	_	51	compound
51	%	%	NN	_	52	amod
52	CI	ci	NN	_	40	dep
53	0.72	0.72	CD	_	55	compound
54	to	to	TO	_	55	dep
55	0.99	0.99	CD	_	52	nummod
56	,	,	,	_	52	punct
57	p	p	NN	_	58	nsubj
58	=	=	JJ	_	52	dep
59	0.034	0.034	CD	_	58	dobj
60	-RRB-	-rrb-	-RRB-	_	52	punct
61	.	.	.	_	2	punct

1	The	the	DT	_	4	det
2	drug1	drug1	NN	_	4	compound
3	genetic	genetic	JJ	_	4	amod
4	variant	variant	NN	_	11	nsubjpass
5	within	within	IN	_	9	case
6	the	the	DT	_	9	det
7	CHRNA5-A3-B4	chrna5-a3-b4	NN	_	9	compound
8	gene	gene	NN	_	9	compound
9	cluster	cluster	NN	_	4	nmod
10	is	be	VBZ	_	11	auxpass
11	associated	associate	VBN	_	0	ROOT
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	11	cc
15	has	have	VBZ	_	18	aux
16	recently	recently	RB	_	18	advmod
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	11	conj
19	to	to	TO	_	21	mark
20	be	be	VB	_	21	auxpass
21	associated	associate	VBN	_	18	xcomp
22	with	with	IN	_	23	case
23	likelihood	likelihood	NN	_	21	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	.	.	.	_	11	punct

1	We	we	PRP	_	2	nsubj
2	investigated	investigate	VBD	_	0	ROOT
3	the	the	DT	_	5	det
4	potential	potential	JJ	_	5	amod
5	association	association	NN	_	2	dobj
6	of	of	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	gLLLenotype	glllenotype	NN	_	5	nmod
9	with	with	IN	_	11	case
10	reduced	reduce	VBN	_	11	amod
11	likelihood	likelihood	NN	_	5	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	in	in	IN	_	16	case
15	2	2	CD	_	16	nummod
16	cohorts	cohort	NNS	_	11	nmod
17	of	of	IN	_	19	case
18	treatment-seeking	treatment-seeking	JJ	_	19	amod
19	smokers	smoker	NNS	_	16	nmod
20	in	in	IN	_	22	case
21	primary	primary	JJ	_	22	amod
22	care	care	NN	_	19	nmod
23	in	in	IN	_	26	case
24	the	the	DT	_	26	det
25	United	United	NNP	_	26	compound
26	Kingdom	Kingdom	NNP	_	22	nmod
27	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	evidence	evidence	NN	_	2	nsubj
4	of	of	IN	_	5	case
5	association	association	NN	_	3	nmod
6	of	of	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	genotype	genotype	NN	_	5	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	5	nmod
11	in	in	IN	_	15	case
12	our	we	PRP$	_	15	nmod:poss
13	open-label	open-label	JJ	_	15	amod
14	trial	trial	NN	_	15	compound
15	sample	sample	NN	_	5	nmod
16	but	but	CC	_	15	cc
17	not	not	RB	_	21	neg
18	our	we	PRP$	_	21	nmod:poss
19	placebo-controlled	placebo-controlled	JJ	_	21	amod
20	trial	trial	NN	_	21	compound
21	sample	sample	NN	_	15	conj
22	.	.	.	_	2	punct

1	Moreover	moreover	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	5	det
4	drug1	drug1	NN	_	5	compound
5	variant	variant	NN	_	9	nsubj
6	may	may	MD	_	9	aux
7	not	not	RB	_	9	neg
8	merely	merely	RB	_	9	advmod
9	operate	operate	VB	_	0	ROOT
10	as	as	IN	_	12	case
11	a	a	DT	_	12	det
12	marker	marker	NN	_	9	nmod
13	for	for	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	9	punct

1	Nominally	nominally	RB	_	2	advmod
2	significant	significant	JJ	_	3	amod
3	associations	association	NNS	_	0	ROOT
4	with	with	IN	_	5	case
5	candidateSNPs	candidatesnp	NNS	_	3	nmod
6	within	within	IN	_	8	case
7	cholinergic	cholinergic	JJ	_	8	amod
8	receptors	receptor	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	nicotinic	nicotinic	JJ	_	8	appos
11	,	,	,	_	10	punct
12	alpha	alpha	NN	_	15	compound
13	3/5	3/5	CD	_	12	nummod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	CHRNA3/CHRNA5	chrna3/chrna5	NN	_	10	appos
16	;	;	:	_	3	punct
17	eg	eg	FW	_	20	advmod
18	,	,	,	_	20	punct
19	p	p	NN	_	20	nsubj
20	=	=	JJ	_	3	dep
21	0.00011	0.00011	CD	_	20	dobj
22	for	for	IN	_	24	case
23	SNP	snp	NN	_	24	compound
24	drug1	drug1	NN	_	20	nmod
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	and	and	CC	_	20	cc
27	cytochrome	cytochrome	NN	_	28	compound
28	P450	p450	NN	_	59	nsubjpass
29	,	,	,	_	28	punct
30	family	family	NN	_	28	conj
31	2	2	CD	_	30	nummod
32	,	,	,	_	28	punct
33	subfamily	subfamily	NN	_	34	compound
34	A	a	NN	_	28	conj
35	,	,	,	_	28	punct
36	polypeptide	polypeptide	NN	_	57	compound
37	6	6	CD	_	36	nummod
38	-LRB-	-lrb-	-LRB-	_	39	punct
39	CYP2A6	cyp2a6	NN	_	36	dep
40	;	;	:	_	39	punct
41	eg	eg	FW	_	44	advmod
42	,	,	,	_	44	punct
43	p	p	NN	_	44	nsubj
44	=	=	JJ	_	39	dep
45	2.78	2.78	CD	_	47	nummod
46	*	*	SYM	_	47	dep
47	10	10	CD	_	44	dobj
48	-LRB-	-lrb-	-LRB-	_	49	punct
49	-5	-5	CD	_	47	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	for	for	IN	_	55	case
52	a	a	DT	_	55	det
53	non-synonymous	non-synonymous	JJ	_	55	amod
54	SNP	snp	NN	_	55	compound
55	drug2	drug2	NN	_	44	nmod
56	-RRB-	-rrb-	-RRB-	_	39	punct
57	regions	region	NNS	_	28	appos
58	were	be	VBD	_	59	auxpass
59	observed	observe	VBN	_	20	conj
60	for	for	IN	_	61	case
61	drug3	drug3	NN	_	59	nmod
62	,	,	,	_	20	punct
63	however	however	RB	_	20	advmod
64	only	only	RB	_	65	advmod
65	CYP2A6	cyp2a6	NN	_	66	nsubj
66	showed	show	VBD	_	20	parataxis
67	evidence	evidence	NN	_	66	dobj
68	of	of	IN	_	70	case
69	significant	significant	JJ	_	70	amod
70	association	association	NN	_	67	nmod
71	with	with	IN	_	72	case
72	drug4	drug4	NN	_	70	nmod
73	.	.	.	_	3	punct

1	A	a	DT	_	4	det
2	candidate	candidate	NN	_	4	compound
3	SNP	snp	NN	_	4	compound
4	drug1	drug1	NN	_	14	nsubjpass
5	in	in	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	was	be	VBD	_	14	auxpass
8	significantly	significantly	RB	_	14	advmod
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	p	p	NN	_	11	nsubj
11	=	=	JJ	_	8	dep
12	0.015	0.015	CD	_	11	dobj
13	-RRB-	-rrb-	-RRB-	_	11	punct
14	associated	associate	VBN	_	0	ROOT
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	14	punct

1	We	we	PRP	_	2	nsubj
2	examined	examine	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	associations	association	NNS	_	2	dobj
5	between	between	IN	_	11	case
6	the	the	DT	_	11	det
7	nicotinic	nicotinic	JJ	_	11	amod
8	acetylcholine	acetylcholine	NN	_	11	compound
9	receptor	receptor	NN	_	11	compound
10	polymorphism	polymorphism	NN	_	11	compound
11	drug1	drug1	NN	_	4	nmod
12	on	on	IN	_	13	case
13	chromosome	chromosome	NN	_	4	nmod
14	15q25	15q25	CD	_	13	nummod
15	marking	mark	VBG	_	13	acl
16	thegene	thegene	JJ	_	18	amod
17	cluster	cluster	NN	_	18	compound
18	CHRNA3-CHRNB4-CHRNA5	chrna3-chrnb4-chrna5	NN	_	15	dobj
19	,	,	,	_	18	punct
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	drug3	drug3	NN	_	18	conj
24	and	and	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	in	in	IN	_	29	case
27	the	the	DT	_	29	det
28	general	general	JJ	_	29	amod
29	population	population	NN	_	23	nmod
30	.	.	.	_	2	punct

1	Both	both	CC	_	3	cc:preconj
2	the	the	DT	_	3	det
3	T-allele	t-allele	NN	_	12	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	3	cc
7	the	the	DT	_	8	det
8	T-allele	t-allele	NN	_	3	conj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	significantly	significantly	RB	_	12	advmod
12	increase	increase	VBP	_	0	ROOT
13	drug3	drug3	NN	_	14	compound
14	risk	risk	NN	_	12	dobj
15	with	with	IN	_	19	case
16	an	a	DT	_	19	det
17	allelic	allelic	JJ	_	19	amod
18	odds	odds	NNS	_	19	compound
19	ratio	ratio	NN	_	12	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	OR	or	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	of	of	IN	_	24	case
24	1.69	1.69	CD	_	19	nmod
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	95	95	CD	_	27	compound
27	%	%	NN	_	28	amod
28	CI	ci	NN	_	24	dep
29	1.55-1	1.55-1	CD	_	30	nummod
30	.83	.83	CD	_	28	dep
31	-RRB-	-rrb-	-RRB-	_	28	punct
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	P	p	NN	_	34	nsubj
34	=	=	JJ	_	19	dep
35	6.0	6.0	CD	_	34	dobj
36	x	x	CC	_	35	cc
37	10	10	CD	_	35	conj
38	-LRB-	-lrb-	-LRB-	_	39	punct
39	-35	-35	CD	_	34	parataxis
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	-RRB-	-rrb-	-RRB-	_	34	punct
42	and	and	CC	_	19	cc
43	1.60	1.60	CD	_	19	conj
44	-LRB-	-lrb-	-LRB-	_	46	punct
45	1.47-1	1.47-1	CD	_	46	nummod
46	.74	.74	CD	_	43	appos
47	-RRB-	-rrb-	-RRB-	_	46	punct
48	-LRB-	-lrb-	-LRB-	_	49	punct
49	P	p	NN	_	43	dep
50	=	=	JJ	_	49	amod
51	7.6	7.6	CD	_	50	dep
52	x	x	CC	_	51	cc
53	10	10	CD	_	51	conj
54	-LRB-	-lrb-	-LRB-	_	55	punct
55	-28	-28	CD	_	51	dep
56	-RRB-	-rrb-	-RRB-	_	55	punct
57	-RRB-	-rrb-	-RRB-	_	49	punct
58	,	,	,	_	12	punct
59	respectively	respectively	RB	_	12	advmod
60	.	.	.	_	12	punct

1	The	the	DT	_	6	det
2	drug1	drug1	NN	_	6	compound
3	T	t	NN	_	6	compound
4	at-risk	at-risk	JJ	_	6	amod
5	allele	allele	NN	_	6	compound
6	associates	associate	NNS	_	0	ROOT
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	earlier	earlier	JJR	_	11	amod
11	age	age	NN	_	8	conj
12	at	at	IN	_	13	case
13	diagnosis	diagnosis	NN	_	6	nmod
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	drug3	drug3	NN	_	17	compound
17	subjects	subject	NNS	_	13	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	P	p	NN	_	6	dep
20	=	=	JJ	_	19	amod
21	8.0	8.0	CD	_	25	nummod
22	x	x	CC	_	21	cc
23	10	10	CD	_	21	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	-3	-3	CD	_	20	dep
26	-RRB-	-rrb-	-RRB-	_	19	punct
27	and	and	CC	_	6	cc
28	P	p	NN	_	29	nsubj
29	=	=	JJ	_	6	conj
30	3.8	3.8	CD	_	29	dobj
31	x	x	CC	_	30	cc
32	10	10	CD	_	30	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	-4	-4	CD	_	29	dep
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	29	punct
37	respectively	respectively	RB	_	29	advmod
38	-RRB-	-rrb-	-RRB-	_	29	punct
39	,	,	,	_	6	punct
40	which	which	WDT	_	46	nsubj
41	is	be	VBZ	_	46	cop
42	supportedby	supportedby	JJ	_	46	amod
43	quantitative	quantitative	JJ	_	46	amod
44	family-based	family-based	JJ	_	46	amod
45	association	association	NN	_	46	compound
46	tests	test	NNS	_	6	acl:relcl
47	.	.	.	_	6	punct

1	We	we	PRP	_	2	nsubj
2	genotyped	genotype	VBD	_	0	ROOT
3	four	four	CD	_	2	dobj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	SNPs	snp	NNS	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug1	drug1	NN	_	6	dep
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug3	drug3	NN	_	8	conj
13	,	,	,	_	8	punct
14	and	and	CC	_	8	cc
15	drug4	drug4	NN	_	8	conj
16	-RRB-	-rrb-	-RRB-	_	8	punct
17	in	in	IN	_	19	case
18	Amish	amish	JJ	_	19	amod
19	subjects	subject	NNS	_	6	nmod
20	with	with	IN	_	21	case
21	drug5	drug5	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	n	n	NN	_	21	dep
24	=	=	JJ	_	23	amod
25	137	137	CD	_	24	dep
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	,	,	,	_	21	punct
28	drug6	drug6	NN	_	21	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	IGT	igt	NN	_	28	dep
31	;	;	:	_	30	punct
32	n	n	NN	_	33	nsubj
33	=	=	JJ	_	30	dep
34	139	139	CD	_	33	dobj
35	-RRB-	-rrb-	-RRB-	_	30	punct
36	,	,	,	_	21	punct
37	and	and	CC	_	21	cc
38	drug7	drug7	NN	_	21	conj
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	NGT	ngt	NN	_	38	dep
41	;	;	:	_	40	punct
42	n	n	NN	_	43	nsubj
43	=	=	JJ	_	40	dep
44	342	342	CD	_	43	dobj
45	-RRB-	-rrb-	-RRB-	_	40	punct
46	.	.	.	_	2	punct

1	A-allele	a-allele	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	associated	associate	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	an	a	DT	_	9	det
8	increased	increase	VBN	_	9	amod
9	risk	risk	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	regardless	regardless	RB	_	9	advmod
13	of	of	IN	_	15	case
14	smoking	smoking	NN	_	15	compound
15	exposure	exposure	NN	_	12	nmod
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	pooled	pooled	JJ	_	18	amod
18	OR	or	NN	_	15	dep
19	=	=	JJ	_	18	amod
20	1.26	1.26	CD	_	19	dep
21	,	,	,	_	18	punct
22	95	95	CD	_	23	compound
23	%	%	NN	_	24	amod
24	CI	ci	NN	_	18	appos
25	1.18-1	1.18-1	CD	_	26	compound
26	.34	.34	CD	_	24	nummod
27	,	,	,	_	18	punct
28	p	p	NN	_	18	appos
29	<	<	JJR	_	28	amod
30	10	10	CD	_	31	nummod
31	⁻⁵	⁻⁵	NN	_	29	dep
32	-RRB-	-rrb-	-RRB-	_	18	punct
33	.	.	.	_	5	punct

1	Our	we	PRP$	_	2	nmod:poss
2	findings	finding	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	11	mark
5	drug1	drug1	NN	_	11	nsubj
6	in	in	IN	_	7	case
7	CHRNA	CHRNA	NNP	_	5	nmod
8	is	be	VBZ	_	11	cop
9	a	a	DT	_	11	det
10	susceptibility	susceptibility	NN	_	11	compound
11	variant	variant	NN	_	3	ccomp
12	for	for	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	11	punct
15	in	in	IN	_	16	case
16	terms	term	NNS	_	11	nmod
17	of	of	IN	_	20	case
18	both	both	DT	_	20	cc:preconj
19	airway	airway	NN	_	20	compound
20	obstruction	obstruction	NN	_	16	nmod
21	and	and	CC	_	20	cc
22	parenchyma	parenchyma	NN	_	23	compound
23	destruction	destruction	NN	_	20	conj
24	.	.	.	_	3	punct

1	Recently	recently	RB	_	12	advmod
2	,	,	,	_	12	punct
3	a	a	DT	_	5	det
4	microsatellite	microsatellite	NN	_	5	compound
5	marker	marker	NN	_	12	nsubj
6	in	in	IN	_	7	case
7	intron	intron	NN	_	5	nmod
8	3	3	CD	_	9	nummod
9	drug1	drug1	NN	_	7	dep
10	and	and	CC	_	9	cc
11	five	five	CD	_	9	conj
12	correlated	correlate	VBD	_	0	ROOT
13	single	single	JJ	_	15	amod
14	nucleotide	nucleotide	NN	_	15	compound
15	polymorphisms	polymorphism	NNS	_	20	nsubjpass
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	SNPs	snp	NNS	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	were	be	VBD	_	20	auxpass
20	identified	identify	VBN	_	12	ccomp
21	in	in	IN	_	23	case
22	Icelandic	icelandic	JJ	_	23	amod
23	individuals	individual	NNS	_	20	nmod
24	that	that	WDT	_	25	nsubj
25	showed	show	VBD	_	23	acl:relcl
26	strong	strong	JJ	_	27	amod
27	association	association	NN	_	25	dobj
28	with	with	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	,	,	,	_	29	punct
31	which	which	WDT	_	33	nsubjpass
32	was	be	VBD	_	33	auxpass
33	replicated	replicate	VBN	_	29	acl:relcl
34	in	in	IN	_	38	case
35	Danish	danish	JJ	_	38	amod
36	and	and	CC	_	35	cc
37	European-American	European-American	NNP	_	35	conj
38	cohorts	cohort	NNS	_	33	nmod
39	.	.	.	_	12	punct

1	We	we	PRP	_	2	nsubj
2	genotyped	genotype	VBD	_	0	ROOT
3	four	four	CD	_	2	dobj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	SNPs	snp	NNS	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug1	drug1	NN	_	6	dep
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug3	drug3	NN	_	8	conj
13	,	,	,	_	8	punct
14	and	and	CC	_	8	cc
15	drug4	drug4	NN	_	8	conj
16	-RRB-	-rrb-	-RRB-	_	8	punct
17	in	in	IN	_	19	case
18	Amish	amish	JJ	_	19	amod
19	subjects	subject	NNS	_	6	nmod
20	with	with	IN	_	21	case
21	drug5	drug5	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	n	n	NN	_	21	dep
24	=	=	JJ	_	23	amod
25	137	137	CD	_	24	dep
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	,	,	,	_	21	punct
28	drug6	drug6	NN	_	21	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	IGT	igt	NN	_	28	dep
31	;	;	:	_	30	punct
32	n	n	NN	_	33	nsubj
33	=	=	JJ	_	30	dep
34	139	139	CD	_	33	dobj
35	-RRB-	-rrb-	-RRB-	_	30	punct
36	,	,	,	_	21	punct
37	and	and	CC	_	21	cc
38	drug7	drug7	NN	_	21	conj
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	NGT	ngt	NN	_	38	dep
41	;	;	:	_	40	punct
42	n	n	NN	_	43	nsubj
43	=	=	JJ	_	40	dep
44	342	342	CD	_	43	dobj
45	-RRB-	-rrb-	-RRB-	_	40	punct
46	.	.	.	_	2	punct

1	We	we	PRP	_	2	nsubj
2	compared	compare	VBD	_	0	ROOT
3	genotype	genotype	NN	_	4	compound
4	frequencies	frequency	NNS	_	2	dobj
5	in	in	IN	_	6	case
6	subjects	subject	NNS	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	with	with	IN	_	10	case
10	those	those	DT	_	8	nmod
11	with	with	IN	_	12	case
12	NGT	ngt	NN	_	10	nmod
13	and	and	CC	_	2	cc
14	found	find	VBD	_	2	conj
15	marginal	marginal	JJ	_	16	amod
16	association	association	NN	_	14	dobj
17	for	for	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	P	p	NN	_	21	nsubj
21	=	=	JJ	_	16	dep
22	0.05	0.05	CD	_	21	dobj
23	;	;	:	_	21	punct
24	odds	odds	NNS	_	25	compound
25	ratio	ratio	NN	_	21	dep
26	-LSB-	-lsb-	-LRB-	_	27	punct
27	OR	or	NN	_	25	appos
28	-RSB-	-rsb-	-RRB-	_	27	punct
29	1.51	1.51	CD	_	25	nummod
30	-RRB-	-rrb-	-RRB-	_	21	punct
31	;	;	:	_	2	punct

1	comparison	comparison	NN	_	12	nsubj
2	between	between	IN	_	5	case
3	NGT	NGT	NNP	_	5	compound
4	control	control	JJ	_	5	amod
5	subjects	subject	NNS	_	1	nmod
6	and	and	CC	_	5	cc
7	the	the	DT	_	11	det
8	combined	combined	JJ	_	11	amod
9	drug5	drug5	NN	_	11	compound
10	case	case	NN	_	11	compound
11	group	group	NN	_	5	conj
12	showed	show	VBD	_	0	ROOT
13	strong	strong	JJ	_	14	amod
14	association	association	NN	_	12	dobj
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	P	p	NN	_	21	nsubj
21	=	=	JJ	_	14	dep
22	0.008-0	0.008-0	CD	_	23	compound
23	.01	.01	CD	_	21	dobj
24	;	;	:	_	21	punct
25	OR	or	NN	_	21	dep
26	1.53-1	1.53-1	CD	_	27	compound
27	.57	.57	CD	_	25	nummod
28	-RRB-	-rrb-	-RRB-	_	21	punct
29	and	and	CC	_	14	cc
30	marginal	marginal	JJ	_	31	amod
31	association	association	NN	_	14	conj
32	with	with	IN	_	33	case
33	drug3	drug3	NN	_	31	nmod
34	and	and	CC	_	33	cc
35	drug4	drug4	NN	_	33	conj
36	-LRB-	-lrb-	-LRB-	_	38	punct
37	P	p	NN	_	38	nsubj
38	=	=	JJ	_	31	dep
39	0.07	0.07	CD	_	38	dobj
40	and	and	CC	_	38	cc
41	P	p	NN	_	42	nsubj
42	=	=	JJ	_	38	conj
43	0.04	0.04	CD	_	42	dobj
44	,	,	,	_	38	punct
45	respectively	respectively	RB	_	38	advmod
46	-RRB-	-rrb-	-RRB-	_	38	punct
47	.	.	.	_	12	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	genotyped	genotype	VBD	_	0	ROOT
4	these	these	DT	_	5	det
5	SNPs	snp	NNS	_	3	dobj
6	in	in	IN	_	3	dep
7	nondiabetic	nondiabetic	JJ	_	6	dep
8	,	,	,	_	7	punct
9	non-Amish	non-amish	JJ	_	10	amod
10	subjects	subject	NNS	_	8	root
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	n	n	NN	_	10	dep
13	=	=	JJ	_	12	amod
14	48	48	CD	_	13	dep
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	,	,	,	_	10	punct
17	in	in	IN	_	18	case
18	whom	whom	WP	_	23	nmod
19	intravenous	intravenous	JJ	_	21	amod
20	drug3	drug3	NN	_	21	compound
21	tests	test	NNS	_	23	nsubjpass
22	were	be	VBD	_	23	auxpass
23	performed	perform	VBN	_	10	acl:relcl
24	,	,	,	_	23	punct
25	and	and	CC	_	23	cc
26	found	find	VBD	_	23	conj
27	an	a	DT	_	28	det
28	association	association	NN	_	26	dobj
29	between	between	IN	_	30	case
30	drug1	drug1	NN	_	28	nmod
31	and	and	CC	_	30	cc
32	drug2	drug2	NN	_	30	conj
33	and	and	CC	_	32	cc
34	drug4	drug4	NN	_	32	conj
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	P	p	NN	_	37	nsubj
37	=	=	JJ	_	28	dep
38	0.003	0.003	CD	_	37	dobj
39	and	and	CC	_	37	cc
40	P	p	NN	_	41	nsubj
41	=	=	JJ	_	37	conj
42	0.005	0.005	CD	_	41	dobj
43	,	,	,	_	37	punct
44	respectively	respectively	RB	_	37	advmod
45	-RRB-	-rrb-	-RRB-	_	37	punct
46	and	and	CC	_	28	cc
47	drug5	drug5	NN	_	28	conj
48	-LRB-	-lrb-	-LRB-	_	49	punct
49	P	p	NN	_	47	dep
50	=	=	JJ	_	49	amod
51	0.04	0.04	CD	_	50	dep
52	and	and	CC	_	49	cc
53	P	p	NN	_	49	conj
54	=	=	JJ	_	53	amod
55	0.007	0.007	CD	_	54	dep
56	,	,	,	_	49	punct
57	respectively	respectively	RB	_	49	advmod
58	-RRB-	-rrb-	-RRB-	_	49	punct
59	.	.	.	_	10	punct

1	we	we	PRP	_	2	nsubj
2	examined	examine	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	association	association	NN	_	2	dobj
5	of	of	IN	_	8	case
6	a	a	DT	_	8	det
7	common	common	JJ	_	8	amod
8	variant	variant	NN	_	4	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	TCF7L2	tcf7l2	NN	_	12	compound
12	gene	gene	NN	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug1	drug1	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	with	with	IN	_	18	case
17	drug2	drug2	NN	_	18	compound
18	risk	risk	NN	_	4	nmod
19	among	among	IN	_	20	case
20	Caucasians	Caucasians	NNPS	_	18	nmod
21	.	.	.	_	2	punct

1	Over	over	IN	_	4	case
2	an	a	DT	_	4	det
3	average	average	JJ	_	4	amod
4	period	period	NN	_	19	nmod
5	of	of	IN	_	7	case
6	three	three	CD	_	7	nummod
7	years	year	NNS	_	4	nmod
8	,	,	,	_	19	punct
9	participants	participant	NNS	_	19	nsubj
10	with	with	IN	_	14	case
11	the	the	DT	_	14	det
12	risk-conferring	risk-conferring	JJ	_	14	amod
13	TT	tt	NN	_	14	compound
14	genotype	genotype	NN	_	9	nmod
15	at	at	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	were	be	VBD	_	19	cop
18	more	more	RBR	_	19	advmod
19	likely	likely	JJ	_	0	ROOT
20	to	to	TO	_	21	mark
21	have	have	VB	_	19	xcomp
22	progression	progression	NN	_	21	dobj
23	from	from	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	to	to	TO	_	26	case
26	drug3	drug3	NN	_	22	nmod
27	than	than	IN	_	28	dep
28	were	be	VBD	_	19	dep
29	CC	cc	NN	_	30	compound
30	homozygotes	homozygote	NNS	_	28	nsubj
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	hazard	hazard	NN	_	33	compound
33	ratio	ratio	NN	_	30	dep
34	,	,	,	_	33	punct
35	1.55	1.55	CD	_	33	amod
36	;	;	:	_	33	punct
37	95	95	CD	_	40	nummod
38	percent	percent	NN	_	40	compound
39	confidence	confidence	NN	_	40	compound
40	interval	interval	NN	_	33	dep
41	,	,	,	_	40	punct
42	1.20	1.20	CD	_	44	compound
43	to	to	TO	_	44	dep
44	2.01	2.01	CD	_	40	appos
45	;	;	:	_	33	punct
46	P	p	NN	_	33	dep
47	<	<	JJR	_	46	amod
48	0.001	0.001	CD	_	47	dep
49	-RRB-	-rrb-	-RRB-	_	33	punct
50	.	.	.	_	19	punct

1	Common	common	JJ	_	2	amod
2	variants	variant	NNS	_	5	nsubj
3	in	in	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	seem	seem	VBP	_	0	ROOT
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	associated	associate	VBN	_	5	xcomp
9	with	with	IN	_	12	case
10	an	a	DT	_	12	det
11	increased	increase	VBN	_	12	amod
12	risk	risk	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	among	among	IN	_	16	case
16	persons	person	NNS	_	12	nmod
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	SNP	snp	NN	_	3	compound
3	drug1	drug1	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	nominally	nominally	RB	_	6	advmod
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	in	in	IN	_	6	dep
10	the	the	DT	_	9	root
11	initial	initial	JJ	_	10	dep
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	p	p	NN	_	14	nsubj
14	=	=	JJ	_	11	dep
15	0.08	0.08	CD	_	14	dobj
16	-RRB-	-rrb-	-RRB-	_	14	punct
17	and	and	CC	_	11	cc
18	two	two	CD	_	21	nummod
19	replication	replication	NN	_	21	compound
20	sample	sample	NN	_	21	compound
21	sets	set	NNS	_	11	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	p	p	NN	_	24	nsubj
24	=	=	JJ	_	21	dep
25	0.05	0.05	CD	_	24	dobj
26	and	and	CC	_	25	cc
27	0.06	0.06	CD	_	25	conj
28	-RRB-	-rrb-	-RRB-	_	24	punct
29	.	.	.	_	11	punct

1	For	for	IN	_	5	case
2	the	the	DT	_	5	det
3	combined	combined	JJ	_	5	amod
4	sample	sample	NN	_	5	compound
5	set	set	NN	_	11	nmod
6	,	,	,	_	11	punct
7	in	in	IN	_	8	case
8	which	which	WDT	_	11	nmod
9	we	we	PRP	_	11	nsubj
10	successfully	successfully	RB	_	11	advmod
11	genotyped	genotype	VBD	_	0	ROOT
12	1,174	1,174	CD	_	16	nummod
13	type	type	NN	_	16	compound
14	2	2	CD	_	16	nummod
15	diabetes	diabetes	NN	_	16	compound
16	patients	patient	NNS	_	11	dobj
17	and	and	CC	_	16	cc
18	823	823	CD	_	20	nummod
19	control	control	JJ	_	20	amod
20	subjects	subject	NNS	_	16	conj
21	,	,	,	_	16	punct
22	drug1	drug1	NN	_	23	nsubj
23	showed	show	VBD	_	16	acl:relcl
24	a	a	DT	_	26	det
25	significant	significant	JJ	_	26	amod
26	association	association	NN	_	23	dobj
27	with	with	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	odds	odds	NNS	_	31	compound
31	ratio	ratio	NN	_	28	dep
32	=	=	JJ	_	31	amod
33	1.69	1.69	CD	_	32	dep
34	-LSB-	-lsb-	-LRB-	_	43	punct
35	95	95	CD	_	36	nummod
36	%	%	NN	_	43	dep
37	CI	ci	NN	_	36	amod
38	1.21-2	1.21-2	CD	_	39	nummod
39	.36	.36	CD	_	37	dep
40	-RSB-	-rsb-	-RRB-	_	36	punct
41	,	,	,	_	43	punct
42	p	p	NN	_	43	nsubj
43	=	=	JJ	_	33	dep
44	0.002	0.002	CD	_	43	dobj
45	-RRB-	-rrb-	-RRB-	_	43	punct
46	with	with	IN	_	49	case
47	the	the	DT	_	49	det
48	same	same	JJ	_	49	amod
49	direction	direction	NN	_	31	nmod
50	as	as	IN	_	53	case
51	the	the	DT	_	53	det
52	previous	previous	JJ	_	53	amod
53	reports	report	NNS	_	49	nmod
54	in	in	IN	_	55	case
55	samples	sample	NNS	_	53	nmod
56	from	from	IN	_	60	case
57	European	european	JJ	_	60	amod
58	and	and	CC	_	57	cc
59	European-origin	european-origin	JJ	_	57	conj
60	populations	population	NNS	_	55	nmod
61	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	rest	rest	NN	_	16	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	five	five	CD	_	6	nummod
6	SNPs	snp	NNS	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug1	drug1	NN	_	6	dep
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	and	and	CC	_	8	cc
12	drug3	drug3	NN	_	8	conj
13	-RRB-	-rrb-	-RRB-	_	8	punct
14	did	do	VBD	_	16	aux
15	not	not	RB	_	16	neg
16	show	show	VB	_	0	ROOT
17	any	any	DT	_	19	det
18	significant	significant	JJ	_	19	amod
19	associations	association	NNS	_	16	dobj
20	with	with	IN	_	21	case
21	drug4	drug4	NN	_	19	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	consistent	consistent	JJ	_	3	amod
3	association	association	NN	_	20	nsubj
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	in	in	IN	_	7	case
7	TCF7L2	tcf7l2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	in	in	IN	_	13	case
11	different	different	JJ	_	13	amod
12	ethnic	ethnic	JJ	_	13	amod
13	groups	group	NNS	_	3	nmod
14	,	,	,	_	13	punct
15	including	include	VBG	_	18	case
16	the	the	DT	_	18	det
17	Japanese	japanese	JJ	_	18	amod
18	population	population	NN	_	13	nmod
19	,	,	,	_	13	punct
20	suggests	suggest	VBZ	_	0	ROOT
21	that	that	IN	_	27	mark
22	TCF7L2	tcf7l2	NN	_	27	nsubj
23	is	be	VBZ	_	27	cop
24	a	a	DT	_	27	det
25	common	common	JJ	_	27	amod
26	susceptibility	susceptibility	NN	_	27	compound
27	gene	gene	NN	_	20	ccomp
28	for	for	IN	_	31	case
29	type	type	NN	_	31	compound
30	2	2	CD	_	31	nummod
31	diabetes	diabetes	NN	_	27	nmod
32	.	.	.	_	20	punct

1	The	the	DT	_	3	det
2	minor	minor	JJ	_	3	amod
3	alleles	allele	NNS	_	58	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	TCF7L2	tcf7l2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	5	punct
10	drug2	drug2	NN	_	5	conj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	TCF7L2	tcf7l2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	,	,	,	_	5	punct
15	drug3	drug3	NN	_	5	conj
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	-30	-30	CD	_	18	nummod
18	G/A	g/a	NN	_	15	dep
19	,	,	,	_	18	punct
20	GCK	gck	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	,	,	,	_	5	punct
23	drug4	drug4	NN	_	5	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	E23K	e23k	NN	_	23	dep
26	,	,	,	_	25	punct
27	KCNJ11	kcnj11	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	25	punct
29	,	,	,	_	5	punct
30	drug5	drug5	NN	_	5	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	CDKAL1	cdkal1	NN	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	,	,	,	_	5	punct
35	drug6	drug6	NN	_	5	conj
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	IGF2BP2	igf2bp2	NN	_	35	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	,	,	,	_	5	punct
40	drug7	drug7	NN	_	5	conj
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	MTNR1B	mtnr1b	NN	_	40	appos
43	-RRB-	-rrb-	-RRB-	_	42	punct
44	,	,	,	_	5	punct
45	drug8	drug8	NN	_	5	conj
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	MTNR1B	mtnr1b	NN	_	45	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	and	and	CC	_	5	cc
50	drug9	drug9	NN	_	5	conj
51	-LRB-	-lrb-	-LRB-	_	52	punct
52	Gly972Arg	gly972arg	NN	_	50	dep
53	,	,	,	_	52	punct
54	IRS1	irs1	NN	_	52	appos
55	-RRB-	-rrb-	-RRB-	_	52	punct
56	were	be	VBD	_	58	auxpass
57	significantly	significantly	RB	_	58	advmod
58	associated	associate	VBN	_	0	ROOT
59	with	with	IN	_	62	case
60	a	a	DT	_	62	det
61	higher	higher	JJR	_	62	amod
62	risk	risk	NN	_	58	nmod
63	of	of	IN	_	64	case
64	drug10	drug10	NN	_	62	nmod
65	.	.	.	_	58	punct

1	In	in	IN	_	2	case
2	summary	summary	NN	_	20	nmod
3	,	,	,	_	20	punct
4	by	by	IN	_	5	mark
5	pooling	pool	VBG	_	20	advcl
6	all	all	DT	_	9	det
7	available	available	JJ	_	9	amod
8	qualified	qualified	JJ	_	9	amod
9	data	datum	NNS	_	5	dobj
10	from	from	IN	_	12	case
11	genetic	genetic	JJ	_	12	amod
12	studies	study	NNS	_	5	nmod
13	on	on	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	20	punct
18	we	we	PRP	_	20	nsubj
19	have	have	VBP	_	20	aux
20	confirmed	confirm	VBN	_	0	ROOT
21	that	that	IN	_	25	mark
22	drug2	drug2	NN	_	25	nsubjpass
23	is	be	VBZ	_	25	auxpass
24	significantly	significantly	RB	_	25	advmod
25	associated	associate	VBN	_	20	ccomp
26	with	with	IN	_	27	case
27	susceptibility	susceptibility	NN	_	25	nmod
28	to	to	TO	_	29	case
29	drug4	drug4	NN	_	27	nmod
30	in	in	IN	_	33	case
31	the	the	DT	_	33	det
32	global	global	JJ	_	33	amod
33	population	population	NN	_	27	nmod
34	.	.	.	_	20	punct

1	In	in	IN	_	3	case
2	recent	recent	JJ	_	3	amod
3	years	year	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	it	it	PRP	_	9	nsubjpass
6	has	have	VBZ	_	9	aux
7	been	be	VBN	_	9	auxpass
8	widely	widely	RB	_	9	advmod
9	accepted	accept	VBN	_	0	ROOT
10	that	that	IN	_	19	mark
11	transcription	transcription	NN	_	12	compound
12	factor	factor	NN	_	19	nsubjpass
13	7-like	7-like	JJ	_	16	amod
14	2	2	CD	_	16	nummod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	TCF7L2	tcf7l2	NN	_	12	dep
17	-RRB-	-rrb-	-RRB-	_	12	punct
18	is	be	VBZ	_	19	auxpass
19	associated	associate	VBN	_	9	ccomp
20	with	with	IN	_	25	case
21	type	type	NN	_	25	compound
22	2	2	CD	_	25	nummod
23	diabetes	diabetes	NN	_	25	compound
24	mellitus	mellitus	NN	_	25	compound
25	drug3	drug3	NN	_	19	nmod
26	in	in	IN	_	29	case
27	multiple	multiple	JJ	_	29	amod
28	ethnic	ethnic	JJ	_	29	amod
29	groups	group	NNS	_	25	nmod
30	,	,	,	_	25	punct
31	especially	especially	RB	_	35	advmod
32	its	its	PRP$	_	35	nmod:poss
33	single	single	JJ	_	35	amod
34	nucleotide	nucleotide	NN	_	35	compound
35	polymorphisms	polymorphism	NNS	_	25	appos
36	of	of	IN	_	37	case
37	drug1	drug1	NN	_	35	nmod
38	,	,	,	_	37	punct
39	drug2	drug2	NN	_	37	conj
40	and	and	CC	_	37	cc
41	rs290487T/C	rs290487t/c	NN	_	37	conj
42	.	.	.	_	9	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	6	nmod
3	,	,	,	_	6	punct
4	this	this	DT	_	5	det
5	study	study	NN	_	6	nsubj
6	indicated	indicate	VBD	_	0	ROOT
7	that	that	IN	_	15	mark
8	the	the	DT	_	10	det
9	drug1	drug1	NN	_	10	compound
10	polymorphism	polymorphism	NN	_	15	nsubj
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	TCF7L2	tcf7l2	NN	_	14	compound
14	gene	gene	NN	_	10	nmod
15	had	have	VBD	_	6	ccomp
16	a	a	DT	_	18	det
17	significant	significant	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	on	on	IN	_	21	case
20	drug4	drug4	NN	_	21	compound
21	risk	risk	NN	_	18	nmod
22	in	in	IN	_	25	case
23	Chinese	chinese	JJ	_	25	amod
24	Han	Han	NNP	_	25	compound
25	population	population	NN	_	15	nmod
26	,	,	,	_	15	punct
27	with	with	IN	_	28	case
28	drug2	drug2	NN	_	15	nmod
29	and	and	CC	_	28	cc
30	drug3	drug3	NN	_	31	compound
31	polymorphisms	polymorphism	NNS	_	28	conj
32	showing	show	VBG	_	28	acl
33	no	no	DT	_	35	neg
34	significant	significant	JJ	_	35	amod
35	effect	effect	NN	_	32	dobj
36	.	.	.	_	6	punct

1	Subgroups	subgroup	NNS	_	2	compound
2	analyses	analysis	NNS	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	significant	significant	JJ	_	6	amod
6	associations	association	NNS	_	9	nsubjpass
7	are	be	VBP	_	9	auxpass
8	not	not	RB	_	9	neg
9	found	find	VBN	_	3	ccomp
10	between	between	IN	_	13	case
11	the	the	DT	_	13	det
12	six	six	CD	_	13	nummod
13	SNPs	snp	NNS	_	9	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug1	drug1	NN	_	13	dep
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug3	drug3	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug4	drug4	NN	_	15	conj
22	,	,	,	_	15	punct
23	drug5	drug5	NN	_	15	conj
24	,	,	,	_	15	punct
25	and	and	CC	_	15	cc
26	drug6	drug6	NN	_	15	conj
27	-RRB-	-rrb-	-RRB-	_	15	punct
28	and	and	CC	_	13	cc
29	the	the	DT	_	30	det
30	drug7	drug7	NN	_	13	conj
31	in	in	IN	_	34	case
32	some	some	DT	_	34	det
33	ethnic	ethnic	JJ	_	34	amod
34	populations	population	NNS	_	30	nmod
35	.	.	.	_	3	punct

1	The	the	DT	_	5	det
2	four	four	CD	_	5	nummod
3	tested	test	VBN	_	5	amod
4	TCF7L2	tcf7l2	NN	_	5	compound
5	variants	variant	NNS	_	9	nsubj
6	were	be	VBD	_	9	cop
7	in	in	IN	_	9	case
8	linkage	linkage	NN	_	9	compound
9	disequilibrium	disequilibrium	NN	_	0	ROOT
10	,	,	,	_	9	punct
11	and	and	CC	_	9	cc
12	4-locus	4-locus	NN	_	23	compound
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug1	drug1	NN	_	12	dep
15	,	,	,	_	14	punct
16	drug2	drug2	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug3	drug3	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug4	drug4	NN	_	14	appos
21	-RRB-	-rrb-	-RRB-	_	14	punct
22	haplotype	haplotype	NN	_	23	compound
23	analysis	analysis	NN	_	24	nsubj
24	demonstrated	demonstrate	VBD	_	9	conj
25	that	that	IN	_	30	mark
26	haplotype	haplotype	NN	_	30	nsubjpass
27	1111	1111	CD	_	26	nummod
28	was	be	VBD	_	30	auxpass
29	negatively	negatively	RB	_	30	advmod
30	associated	associate	VBN	_	24	ccomp
31	-LRB-	-lrb-	-LRB-	_	34	punct
32	Pc	pc	NN	_	34	nsubj
33	<	<	JJR	_	34	dep
34	0.001	0.001	CD	_	30	dep
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	30	punct
37	while	while	IN	_	54	mark
38	haplotypes	haplotype	NNS	_	54	nsubjpass
39	2222	2222	CD	_	38	nummod
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	Pc	pc	NN	_	38	dep
42	=	=	JJ	_	41	amod
43	0.008	0.008	CD	_	42	dep
44	-RRB-	-rrb-	-RRB-	_	41	punct
45	and	and	CC	_	38	cc
46	2211	2211	CD	_	38	conj
47	-LRB-	-lrb-	-LRB-	_	48	punct
48	Pc	pc	NN	_	46	dep
49	=	=	JJ	_	48	amod
50	0.020	0.020	CD	_	49	dep
51	-RRB-	-rrb-	-RRB-	_	48	punct
52	were	be	VBD	_	54	auxpass
53	positively	positively	RB	_	54	advmod
54	associated	associate	VBN	_	30	advcl
55	with	with	IN	_	57	case
56	drug5	drug5	NN	_	57	compound
57	risk	risk	NN	_	54	nmod
58	,	,	,	_	54	punct
59	after	after	IN	_	60	mark
60	controlling	control	VBG	_	54	advcl
61	for	for	IN	_	63	case
62	a	a	DT	_	63	det
63	number	number	NN	_	60	nmod
64	of	of	IN	_	65	case
65	covariates	covariate	NNS	_	63	nmod
66	.	.	.	_	9	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	the	the	DT	_	5	det
4	published	publish	VBN	_	5	amod
5	evidence	evidence	NN	_	2	dobj
6	for	for	IN	_	7	case
7	association	association	NN	_	5	nmod
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	k	k	NN	_	9	dep
12	=	=	JJ	_	11	amod
13	27	27	CD	_	14	nummod
14	samples	sample	NNS	_	12	dep
15	-RRB-	-rrb-	-RRB-	_	11	punct
16	and	and	CC	_	9	cc
17	drug2	drug2	NN	_	24	compound
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	k	k	NN	_	20	nsubj
20	=	=	JJ	_	17	dep
21	44	44	CD	_	22	nummod
22	samples	sample	NNS	_	20	dobj
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	SNPs	snp	NNS	_	9	conj
25	with	with	IN	_	26	case
26	drug3	drug3	NN	_	7	nmod
27	using	use	VBG	_	2	xcomp
28	meta-analytic	meta-analytic	JJ	_	29	amod
29	techniques	technique	NNS	_	27	dobj
30	.	.	.	_	2	punct

1	Meta-analysis	meta-analysis	NN	_	2	nsubj
2	indicated	indicate	VBD	_	0	ROOT
3	compelling	compelling	JJ	_	4	amod
4	evidence	evidence	NN	_	2	dobj
5	of	of	IN	_	7	case
6	an	a	DT	_	7	det
7	association	association	NN	_	4	nmod
8	between	between	IN	_	11	case
9	the	the	DT	_	11	det
10	drug1	drug1	NN	_	11	compound
11	variants	variant	NNS	_	7	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	fixed	fixed	JJ	_	16	amod
16	effects	effect	NNS	_	13	dep
17	:	:	:	_	16	punct
18	B	b	NN	_	16	dep
19	=	=	JJ	_	18	amod
20	0.91	0.91	CD	_	19	dep
21	,	,	,	_	18	punct
22	95	95	CD	_	23	compound
23	%	%	NN	_	24	amod
24	CI	ci	NN	_	18	appos
25	=	=	JJ	_	24	amod
26	0.77	0.77	CD	_	25	dep
27	,	,	,	_	18	punct
28	1.06	1.06	CD	_	18	amod
29	,	,	,	_	18	punct
30	p	p	NN	_	18	appos
31	<	<	JJR	_	30	amod
32	.001	.001	CD	_	31	dep
33	;	;	:	_	16	punct
34	random	random	JJ	_	35	amod
35	effects	effect	NNS	_	16	dep
36	:	:	:	_	35	punct
37	B	b	NN	_	35	dep
38	=	=	JJ	_	37	amod
39	1.01	1.01	CD	_	38	dep
40	,	,	,	_	37	punct
41	95	95	CD	_	42	compound
42	%	%	NN	_	43	amod
43	CI	ci	NN	_	37	appos
44	=	=	JJ	_	43	amod
45	0.81	0.81	CD	_	44	dep
46	,	,	,	_	37	punct
47	1.22	1.22	CD	_	37	amod
48	,	,	,	_	37	punct
49	p	p	NN	_	51	dep
50	<	<	JJR	_	51	dep
51	.001	.001	CD	_	37	appos
52	-RRB-	-rrb-	-RRB-	_	51	punct
53	,	,	,	_	37	punct
54	equivalent	equivalent	JJ	_	37	amod
55	to	to	TO	_	58	case
56	a	a	DT	_	58	det
57	per-allele	per-allele	JJ	_	58	amod
58	effect	effect	NN	_	54	nmod
59	of	of	IN	_	62	case
60	approximately	approximately	RB	_	61	advmod
61	1	1	CD	_	62	nummod
62	cigarette/day	cigarette/day	NN	_	58	nmod
63	.	.	.	_	16	punct

1	Among	among	IN	_	2	case
2	women	woman	NNS	_	14	nmod
3	with	with	IN	_	5	case
4	a	a	DT	_	5	det
5	history	history	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	14	punct
9	the	the	DT	_	11	det
10	TT	tt	NN	_	11	compound
11	genotype	genotype	NN	_	14	nsubj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	increased	increase	VBD	_	0	ROOT
15	drug3	drug3	NN	_	16	compound
16	risk	risk	NN	_	14	dobj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	OR	or	NN	_	16	dep
19	,	,	,	_	18	punct
20	2.46	2.46	CD	_	18	amod
21	;	;	:	_	18	punct
22	95	95	CD	_	23	compound
23	%	%	NN	_	24	amod
24	CI	ci	NN	_	18	dep
25	1.28-4	1.28-4	CD	_	26	compound
26	.73	.73	CD	_	24	nummod
27	-RRB-	-rrb-	-RRB-	_	18	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Donor	donor	NN	_	6	compound
4	TCF7L2	tcf7l2	NN	_	6	compound
5	drug1	drug1	NN	_	6	compound
6	polymorphism	polymorphism	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	associated	associate	VBN	_	1	appos
9	with	with	IN	_	12	case
10	an	a	DT	_	12	det
11	increased	increase	VBN	_	12	amod
12	risk	risk	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	after	after	IN	_	16	case
16	LT	lt	NN	_	12	nmod
17	and	and	CC	_	8	cc
18	has	have	VBZ	_	8	conj
19	a	a	DT	_	22	det
20	potential	potential	JJ	_	22	amod
21	clinical	clinical	JJ	_	22	amod
22	value	value	NN	_	18	dobj
23	for	for	IN	_	25	case
24	the	the	DT	_	25	det
25	prediction	prediction	NN	_	22	nmod
26	of	of	IN	_	27	case
27	NODM	nodm	NN	_	25	nmod
28	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	minor	minor	JJ	_	4	amod
3	T	t	NN	_	4	compound
4	allele	allele	NN	_	9	nsubjpass
5	of	of	IN	_	7	case
6	TCF7L2	tcf7l2	NN	_	7	compound
7	drug1	drug1	NN	_	4	nmod
8	was	be	VBD	_	9	auxpass
9	found	find	VBN	_	0	ROOT
10	to	to	TO	_	12	mark
11	significantly	significantly	RB	_	12	advmod
12	increase	increase	VB	_	9	xcomp
13	the	the	DT	_	14	det
14	risk	risk	NN	_	12	dobj
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	12	punct
18	with	with	IN	_	22	case
19	an	a	DT	_	22	det
20	allelic	allelic	JJ	_	22	amod
21	odds	odds	NNS	_	22	compound
22	ratio	ratio	NN	_	12	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	OR	or	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	of	of	IN	_	27	case
27	1.458	1.458	CD	_	22	nmod
28	-LRB-	-lrb-	-LRB-	_	31	punct
29	95	95	CD	_	30	compound
30	%	%	NN	_	31	amod
31	CI	ci	NN	_	27	dep
32	1.108-1	1.108-1	CD	_	33	compound
33	.918	.918	CD	_	31	nummod
34	,	,	,	_	31	punct
35	p	p	NN	_	36	nsubj
36	=	=	JJ	_	31	dep
37	0.007	0.007	CD	_	36	dobj
38	-RRB-	-rrb-	-RRB-	_	31	punct
39	.	.	.	_	9	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	found	find	VBD	_	0	ROOT
4	a	a	DT	_	6	det
5	strong	strong	JJ	_	6	amod
6	correlation	correlation	NN	_	3	dobj
7	between	between	IN	_	9	case
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	the	the	DT	_	12	det
12	presence	presence	NN	_	9	conj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	P	p	NN	_	17	nsubj
17	=	=	JJ	_	3	parataxis
18	0.02	0.02	CD	_	17	dobj
19	with	with	IN	_	22	case
20	a	a	DT	_	22	det
21	high	high	JJ	_	22	amod
22	OR	or	NN	_	17	nmod
23	=	=	JJ	_	22	amod
24	8.28	8.28	CD	_	23	dep
25	-RRB-	-rrb-	-RRB-	_	17	punct
26	.	.	.	_	3	punct

1	We	we	PRP	_	2	nsubj
2	conclude	conclude	VBP	_	0	ROOT
3	that	that	IN	_	8	mark
4	drug1	drug1	NN	_	6	compound
5	GTCF7L2	gtcf7l2	NN	_	6	compound
6	variant	variant	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	associated	associate	VBN	_	2	ccomp
9	with	with	IN	_	11	case
10	peripheral	peripheral	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	in	in	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	but	but	CC	_	8	cc
15	this	this	DT	_	16	det
16	effect	effect	NN	_	19	nsubjpass
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	seen	see	VBN	_	8	conj
20	in	in	IN	_	22	case
21	control	control	NN	_	22	compound
22	women	woman	NNS	_	19	nmod
23	.	.	.	_	2	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	TCF7L2	tcf7l2	NN	_	5	compound
4	drug1	drug1	NN	_	5	compound
5	polymorphism	polymorphism	NN	_	6	nsubj
6	protects	protect	VBZ	_	1	appos
7	Mexican	mexican	JJ	_	8	amod
8	children	child	NNS	_	6	dobj
9	from	from	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	.	.	.	_	1	punct

1	THADA	thada	NN	_	2	compound
2	variant	variant	NN	_	7	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug1	drug1	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	was	be	VBD	_	7	auxpass
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	OR	or	NN	_	9	dep
12	1.5	1.5	CD	_	11	nummod
13	;	;	:	_	11	punct
14	95	95	CD	_	15	compound
15	%	%	NN	_	16	amod
16	CI	ci	NN	_	11	dep
17	1.04	1.04	CD	_	16	nummod
18	,	,	,	_	16	punct
19	2.22	2.22	CD	_	16	nummod
20	;	;	:	_	11	punct
21	p	p	NN	_	22	nsubj
22	=	=	JJ	_	11	dep
23	0.03	0.03	CD	_	22	dobj
24	-RRB-	-rrb-	-RRB-	_	11	punct
25	.	.	.	_	7	punct

1	If	if	IN	_	14	mark
2	the	the	DT	_	3	det
3	application	application	NN	_	14	nsubjpass
4	of	of	IN	_	7	case
5	TCF7L2	tcf7l2	NN	_	7	compound
6	drug1	drug1	NN	_	7	compound
7	SNPs	snp	NNS	_	3	nmod
8	as	as	IN	_	10	case
9	a	a	DT	_	10	det
10	marker	marker	NN	_	3	nmod
11	for	for	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	is	be	VBZ	_	14	auxpass
14	confirmed	confirm	VBN	_	27	advcl
15	by	by	IN	_	18	case
16	further	further	JJ	_	18	amod
17	independent	independent	JJ	_	18	amod
18	studies	study	NNS	_	14	nmod
19	,	,	,	_	27	punct
20	replacing	replace	VBG	_	27	nsubjpass
21	tacrolimus	tacrolimus	NN	_	20	dobj
22	with	with	IN	_	24	case
23	other	other	JJ	_	24	amod
24	immunosuppressants	immunosuppressant	NNS	_	20	nmod
25	could	could	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	warranted	warrant	VBN	_	0	ROOT
28	in	in	IN	_	29	case
29	patients	patient	NNS	_	27	nmod
30	at	at	IN	_	32	case
31	high	high	JJ	_	32	amod
32	risk	risk	NN	_	29	nmod
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	32	nmod
35	,	,	,	_	27	punct
36	as	as	IN	_	37	mark
37	diagnosed	diagnose	VBN	_	27	advcl
38	by	by	IN	_	40	case
39	TCF7L2	tcf7l2	NN	_	40	compound
40	genotyping	genotyping	NN	_	37	nmod
41	.	.	.	_	27	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	16	nmod
3	,	,	,	_	16	punct
4	an	a	DT	_	5	det
5	association	association	NN	_	16	nsubjpass
6	of	of	IN	_	8	case
7	two	two	CD	_	8	nummod
8	SNPs	snp	NNS	_	5	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	TCF7L2	tcf7l2	NN	_	12	compound
12	gene	gene	NN	_	8	nmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	5	nmod
15	was	be	VBD	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	in	in	IN	_	19	case
18	both	both	CC	_	19	cc:preconj
19	cities	city	NNS	_	16	nmod
20	:	:	:	_	19	punct
21	drug1	drug1	NN	_	19	dep
22	,	,	,	_	21	punct
23	-LRB-	-lrb-	-LRB-	_	21	punct
24	for	for	IN	_	26	case
25	Guerrero	Guerrero	NNP	_	26	compound
26	OR	or	NN	_	23	root
27	=	=	JJ	_	26	amod
28	1.98	1.98	CD	_	29	compound
29	CI95	ci95	CD	_	30	nummod
30	%	%	NN	_	27	dobj
31	1.02-3	1.02-3	CD	_	32	compound
32	.89	.89	CD	_	30	nummod
33	and	and	CC	_	27	cc
34	for	for	IN	_	36	case
35	Mexico	Mexico	NNP	_	36	compound
36	OR	or	NN	_	27	conj
37	=	=	JJ	_	36	amod
38	1.94	1.94	CD	_	39	compound
39	CI95	ci95	CD	_	40	nummod
40	%	%	NN	_	42	dep
41	1.31-2	1.31-2	CD	_	42	nummod
42	.88	.88	CD	_	37	dep
43	-RRB-	-rrb-	-RRB-	_	26	punct
44	and	and	CC	_	26	cc
45	drug2	drug2	NN	_	26	conj
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	OR	or	NN	_	45	dep
48	=	=	JJ	_	47	amod
49	1.79	1.79	CD	_	50	compound
50	CI95	ci95	CD	_	51	nummod
51	%	%	NN	_	48	dep
52	1.08-2	1.08-2	CD	_	53	compound
53	.97	.97	CD	_	51	nummod
54	,	,	,	_	47	punct
55	OR	or	NN	_	47	appos
56	=	=	JJ	_	61	case
57	1.78	1.78	CD	_	58	compound
58	CI95	ci95	CD	_	59	nummod
59	%	%	NN	_	61	dep
60	1.17-2	1.17-2	CD	_	61	nummod
61	.71	.71	CD	_	55	nmod
62	respectively	respectively	RB	_	61	advmod
63	-RRB-	-rrb-	-RRB-	_	47	punct
64	.	.	.	_	26	punct

1	No	no	DT	_	2	neg
2	interaction	interaction	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	between	between	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	HLA-DQB1	hla-dqb1	NN	_	6	conj
9	*	*	SYM	_	10	dep
10	0602	0602	CD	_	4	nmod
11	,	,	,	_	10	punct
12	which	which	WDT	_	14	nsubjpass
13	was	be	VBD	_	14	auxpass
14	shown	show	VBN	_	10	acl:relcl
15	to	to	TO	_	18	mark
16	be	be	VB	_	18	auxpass
17	negatively	negatively	RB	_	18	advmod
18	associated	associate	VBN	_	14	xcomp
19	with	with	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	in	in	IN	_	22	case
22	mothers	mother	NNS	_	20	nmod
23	born	bear	VBN	_	22	acl
24	in	in	IN	_	25	case
25	Sweden	Sweden	NNP	_	23	nmod
26	-LRB-	-lrb-	-LRB-	_	28	punct
27	P	p	NN	_	28	nsubj
28	=	=	JJ	_	18	parataxis
29	0.010	0.010	CD	_	28	dobj
30	-RRB-	-rrb-	-RRB-	_	28	punct
31	.	.	.	_	4	punct

1	A	a	DT	_	3	det
2	genetic	genetic	JJ	_	3	amod
3	variant	variant	NN	_	20	nsubjpass
4	within	within	IN	_	7	case
5	the	the	DT	_	7	det
6	CHRNA5-CHRNA3-CHRNB4	chrna5-chrna3-chrnb4	NN	_	7	compound
7	region	region	NN	_	3	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug1	drug1	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	3	punct
12	previously	previously	RB	_	13	advmod
13	associated	associate	VBN	_	3	acl
14	with	with	IN	_	16	case
15	drug2	drug2	NN	_	16	compound
16	quantity	quantity	NN	_	13	nmod
17	,	,	,	_	3	punct
18	was	be	VBD	_	20	auxpass
19	recently	recently	RB	_	20	advmod
20	shown	show	VBN	_	0	ROOT
21	to	to	TO	_	22	mark
22	interact	interact	VB	_	20	xcomp
23	with	with	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	on	on	IN	_	27	case
26	drug4	drug4	NN	_	27	compound
27	predisposition	predisposition	NN	_	22	nmod
28	.	.	.	_	20	punct

1	The	the	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	variant	variant	NN	_	7	nsubjpass
4	was	be	VBD	_	7	auxpass
5	not	not	RB	_	7	neg
6	significantly	significantly	RB	_	7	advmod
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	drug2	drug2	NN	_	10	compound
10	status	status	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	snus	snus	NN	_	13	compound
13	use	use	NN	_	10	conj
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	P	p	NN	_	16	dep
16	>	>	JJR	_	7	parataxis
17	0.05	0.05	CD	_	16	nummod
18	-RRB-	-rrb-	-RRB-	_	16	punct
19	;	;	:	_	7	punct
20	the	the	DT	_	22	det
21	T	t	NN	_	22	compound
22	allele	allele	NN	_	24	nsubjpass
23	was	be	VBD	_	24	auxpass
24	associated	associate	VBN	_	7	parataxis
25	with	with	IN	_	27	case
26	lower	lower	JJR	_	27	amod
27	BMI	bmi	NN	_	24	nmod
28	in	in	IN	_	31	case
29	the	the	DT	_	31	det
30	overall	overall	JJ	_	31	amod
31	cohort	cohort	NN	_	27	nmod
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	b	b	NN	_	34	nsubj
34	=	=	JJ	_	27	dep
35	-0.10	-0.10	CD	_	36	nummod
36	kg/m	kg/m	NN	_	34	dobj
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	2	2	CD	_	34	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	,	,	,	_	34	punct
41	SE	se	NN	_	42	nsubj
42	=	=	JJ	_	34	parataxis
43	0.05	0.05	CD	_	42	dobj
44	;	;	:	_	34	punct
45	P	p	NN	_	46	nsubj
46	=	=	JJ	_	34	parataxis
47	0.03	0.03	CD	_	46	dobj
48	-RRB-	-rrb-	-RRB-	_	34	punct
49	and	and	CC	_	27	cc
50	with	with	IN	_	52	case
51	drug3	drug3	NN	_	52	compound
52	quantity	quantity	NN	_	27	conj
53	in	in	IN	_	54	case
54	those	those	DT	_	52	nmod
55	in	in	IN	_	56	case
56	whom	whom	WP	_	59	nmod
57	this	this	DT	_	59	nsubjpass
58	was	be	VBD	_	59	auxpass
59	measured	measure	VBN	_	54	acl:relcl
60	-LRB-	-lrb-	-LRB-	_	61	punct
61	n	n	NN	_	59	dep
62	=	=	JJ	_	61	amod
63	5,304	5,304	CD	_	62	dep
64	-RRB-	-rrb-	-RRB-	_	61	punct
65	-LRB-	-lrb-	-LRB-	_	67	punct
66	b	b	NN	_	67	nsubj
67	=	=	JJ	_	59	parataxis
68	0.08	0.08	CD	_	67	dobj
69	,	,	,	_	67	punct
70	SE	se	NN	_	71	nsubj
71	=	=	JJ	_	67	parataxis
72	0.01	0.01	CD	_	71	dobj
73	;	;	:	_	67	punct
74	P	p	NN	_	67	dep
75	<	<	JJR	_	74	amod
76	0.0001	0.0001	CD	_	75	dep
77	-RRB-	-rrb-	-RRB-	_	67	punct

1	The	the	DT	_	7	det
2	drug1	drug1	NN	_	7	compound
3	-LRB-	-lrb-	-LRB-	_	7	punct
4	T	t	NN	_	7	compound
5	-RRB-	-rrb-	-RRB-	_	7	punct
6	allele	allele	NN	_	7	compound
7	genotype	genotype	NN	_	10	nsubjpass
8	was	be	VBD	_	10	auxpass
9	significantly	significantly	RB	_	10	advmod
10	associated	associate	VBN	_	27	csubjpass
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	P	p	NN	_	15	nsubj
15	=	=	JJ	_	12	dep
16	0.003	0.003	CD	_	15	dobj
17	-RRB-	-rrb-	-RRB-	_	15	punct
18	but	but	CC	_	12	cc
19	drug2	drug2	NN	_	24	compound
20	-LRB-	-lrb-	-LRB-	_	24	punct
21	T	t	NN	_	24	compound
22	-RRB-	-rrb-	-RRB-	_	24	punct
23	allele	allele	NN	_	24	compound
24	genotype	genotype	NN	_	12	conj
25	was	be	VBD	_	27	auxpass
26	not	not	RB	_	27	neg
27	associated	associate	VBN	_	0	ROOT
28	with	with	IN	_	31	case
29	the	the	DT	_	31	det
30	clinico-pathologic	clinico-pathologic	JJ	_	31	amod
31	characteristics	characteristic	NNS	_	27	nmod
32	.	.	.	_	27	punct

1	Thus	thus	RB	_	5	advmod
2	,	,	,	_	5	punct
3	we	we	PRP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	17	mark
7	the	the	DT	_	11	det
8	drug1	drug1	NN	_	11	compound
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	markers	marker	NNS	_	17	nsubj
12	are	be	VBP	_	17	cop
13	independent	independent	JJ	_	17	amod
14	genetic	genetic	JJ	_	17	amod
15	drug3	drug3	NN	_	17	compound
16	risk	risk	NN	_	17	compound
17	factors	factor	NNS	_	5	ccomp
18	in	in	IN	_	21	case
19	a	a	DT	_	21	det
20	Russian	russian	JJ	_	21	amod
21	population	population	NN	_	17	nmod
22	.	.	.	_	5	punct

1	Thus	thus	RB	_	5	advmod
2	,	,	,	_	5	punct
3	we	we	PRP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	17	mark
7	the	the	DT	_	11	det
8	drug1	drug1	NN	_	11	compound
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	markers	marker	NNS	_	17	nsubj
12	are	be	VBP	_	17	cop
13	independent	independent	JJ	_	17	amod
14	genetic	genetic	JJ	_	17	amod
15	drug3	drug3	NN	_	17	compound
16	risk	risk	NN	_	17	compound
17	factors	factor	NNS	_	5	ccomp
18	in	in	IN	_	21	case
19	a	a	DT	_	21	det
20	Russian	russian	JJ	_	21	amod
21	population	population	NN	_	17	nmod
22	.	.	.	_	5	punct

1	The	the	DT	_	4	det
2	non-synonymous	non-synonymous	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	polymorphism	polymorphism	NN	_	10	nsubjpass
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	ADRB3	adrb3	NN	_	8	compound
8	gene	gene	NN	_	4	nmod
9	was	be	VBD	_	10	auxpass
10	associated	associate	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	Trpallele	Trpallele	NNP	_	12	dep
15	,	,	,	_	14	punct
16	OR	or	NN	_	14	appos
17	=	=	JJ	_	16	amod
18	0.62	0.62	CD	_	17	dep
19	,	,	,	_	14	punct
20	p	p	NN	_	14	appos
21	=	=	JJ	_	20	amod
22	0.001	0.001	CD	_	21	dep
23	-RRB-	-rrb-	-RRB-	_	14	punct
24	and	and	CC	_	12	cc
25	drug3	drug3	NN	_	28	compound
26	-LRB-	-lrb-	-LRB-	_	28	punct
27	Trp	trp	NN	_	28	compound
28	allele	allele	NN	_	12	conj
29	,	,	,	_	28	punct
30	OR	or	NN	_	28	appos
31	=	=	JJ	_	30	amod
32	0.74	0.74	CD	_	31	dep
33	,	,	,	_	28	punct
34	p	p	NN	_	35	nsubj
35	=	=	JJ	_	28	acl:relcl
36	0.018	0.018	CD	_	35	dobj
37	-RRB-	-rrb-	-RRB-	_	28	punct
38	.	.	.	_	10	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Single	single	JJ	_	5	amod
4	nucleotide	nucleotide	NN	_	5	compound
5	polymiorphisms	polymiorphism	NNS	_	18	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	SNPs	snp	NNS	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	drug1	drug1	NN	_	5	dep
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	located	located	JJ	_	5	amod
13	within	within	IN	_	15	case
14	TCF7L2	tcf7l2	NN	_	15	compound
15	gene	gene	NN	_	12	nmod
16	have	have	VBP	_	18	aux
17	been	be	VBN	_	18	auxpass
18	identified	identify	VBN	_	1	appos
19	as	as	IN	_	25	case
20	the	the	DT	_	25	det
21	strongest	strongest	JJS	_	25	amod
22	common	common	JJ	_	25	amod
23	genetic	genetic	JJ	_	25	amod
24	risk	risk	NN	_	25	compound
25	factors	factor	NNS	_	18	nmod
26	for	for	IN	_	27	case
27	development	development	NN	_	25	nmod
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	T2D	t2d	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Although	although	IN	_	19	mark
4	the	the	DT	_	5	det
5	biology	biology	NN	_	19	nsubj
6	of	of	IN	_	10	case
7	the	the	DT	_	10	det
8	Wnt/beta-catenin	wnt/beta-catenin	NN	_	10	compound
9	signaling	signaling	NN	_	10	compound
10	pathway	pathway	NN	_	5	nmod
11	and	and	CC	_	5	cc
12	prior	prior	JJ	_	13	amod
13	association	association	NN	_	5	conj
14	between	between	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	numerous	numerous	JJ	_	18	amod
18	phenotypes	phenotype	NNS	_	15	conj
19	warranted	warrant	VBD	_	36	advcl
20	examination	examination	NN	_	19	dobj
21	of	of	IN	_	24	case
22	this	this	DT	_	24	det
23	TCF7L2	tcf7l2	NN	_	24	compound
24	SNP	snp	NN	_	20	nmod
25	,	,	,	_	36	punct
26	no	no	DT	_	28	neg
27	compelling	compelling	JJ	_	28	amod
28	evidence	evidence	NN	_	36	nsubjpass
29	for	for	IN	_	30	case
30	association	association	NN	_	28	nmod
31	with	with	IN	_	32	case
32	breast	breast	NN	_	30	nmod
33	or	or	CC	_	32	cc
34	drug2	drug2	NN	_	32	conj
35	was	be	VBD	_	36	auxpass
36	observed	observe	VBN	_	1	dep
37	.	.	.	_	1	punct

1	However	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	5	det
4	risk	risk	NN	_	5	compound
5	allele	allele	NN	_	11	nsubj
6	at	at	IN	_	8	case
7	TCF7L2	tcf7l2	NN	_	8	compound
8	drug1	drug1	NN	_	5	nmod
9	was	be	VBD	_	11	cop
10	more	more	RBR	_	11	advmod
11	frequent	frequent	JJ	_	0	ROOT
12	in	in	IN	_	14	case
13	drug2	drug2	NN	_	14	compound
14	subjects	subject	NNS	_	11	nmod
15	than	than	IN	_	17	case
16	in	in	IN	_	17	case
17	controls	control	NNS	_	11	nmod
18	when	when	WRB	_	20	advmod
19	we	we	PRP	_	20	nsubj
20	restricted	restrict	VBD	_	11	advcl
21	the	the	DT	_	22	det
22	analysis	analysis	NN	_	20	dobj
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	subjects	subject	NNS	_	20	nmod
26	with	with	IN	_	28	case
27	lower	lower	JJR	_	28	amod
28	weight-for-height	weight-for-height	NN	_	25	nmod
29	than	than	IN	_	31	case
30	the	the	DT	_	31	det
31	median	median	NN	_	28	nmod
32	of	of	IN	_	35	case
33	the	the	DT	_	35	det
34	PA	pa	NN	_	35	compound
35	subjects	subject	NNS	_	31	nmod
36	-LRB-	-lrb-	-LRB-	_	11	punct

1	To	to	TO	_	2	mark
2	investigate	investigate	VB	_	0	ROOT
3	the	the	DT	_	4	det
4	expression	expression	NN	_	2	dobj
5	of	of	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	protein	protein	NN	_	4	nmod
8	in	in	IN	_	11	case
9	normal	normal	JJ	_	11	amod
10	breast	breast	NN	_	11	compound
11	tissue	tissue	NN	_	4	nmod
12	,	,	,	_	2	punct
13	and	and	CC	_	2	cc
14	examine	examine	VB	_	2	conj
15	the	the	DT	_	16	det
16	difference	difference	NN	_	14	dobj
17	in	in	IN	_	19	case
18	ABCC11	abcc11	NN	_	19	compound
19	mRNA	mrna	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	proteinexpression	proteinexpression	NN	_	19	conj
22	between	between	IN	_	24	case
23	normal	normal	JJ	_	24	amod
24	breast	breast	NN	_	16	nmod
25	and	and	CC	_	24	cc
26	drug3	drug3	NN	_	27	compound
27	tissues	tissue	NNS	_	24	conj
28	taking	take	VBG	_	24	acl
29	into	into	IN	_	32	case
30	account	account	NN	_	32	compound
31	ABCC11	abcc11	NN	_	32	compound
32	genotype	genotype	NN	_	28	nmod
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	a	a	DT	_	36	det
35	functional	functional	JJ	_	36	amod
36	SNP	snp	NN	_	32	dep
37	,	,	,	_	36	punct
38	drug1	drug1	NN	_	36	appos
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	and	and	CC	_	32	cc
41	estrogen	estrogen	NN	_	42	compound
42	receptor	receptor	NN	_	32	conj
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	ER	er	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	status	status	NN	_	2	dobj

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	,	,	,	_	7	punct
6	to	to	TO	_	7	mark
7	determine	determine	VB	_	0	ROOT
8	whether	whether	IN	_	12	mark
9	the	the	DT	_	10	det
10	SNP	snp	NN	_	12	nsubj
11	can	can	MD	_	12	aux
12	serve	serve	VB	_	7	ccomp
13	as	as	IN	_	16	case
14	a	a	DT	_	16	det
15	diagnostic	diagnostic	JJ	_	16	amod
16	marker	marker	NN	_	12	nmod
17	for	for	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	AO	ao	JJ	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	7	punct
23	we	we	PRP	_	24	nsubj
24	examined	examine	VBD	_	7	parataxis
25	genotypes	genotype	NNS	_	24	dobj
26	at	at	IN	_	27	case
27	drug1	drug1	NN	_	25	nmod
28	in	in	IN	_	32	case
29	79	79	CD	_	32	nummod
30	Japanese	japanese	JJ	_	32	amod
31	AO	ao	JJ	_	32	amod
32	individuals	individual	NNS	_	25	nmod
33	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	Europeans	Europeans	NNPS	_	11	nmod
3	,	,	,	_	11	punct
4	three	three	CD	_	5	nummod
5	haplotypes	haplotype	NNS	_	11	nsubjpass
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	region	region	NN	_	5	nmod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	shown	show	VBN	_	0	ROOT
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	auxpass
14	associated	associate	VBN	_	11	xcomp
15	with	with	IN	_	17	case
16	eye	eye	NN	_	17	compound
17	pigmentation	pigmentation	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	a	a	DT	_	21	det
20	missense	missense	NN	_	21	compound
21	SNP	snp	NN	_	17	conj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug1	drug1	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	has	have	VBZ	_	27	aux
26	been	be	VBN	_	27	auxpass
27	associated	associate	VBN	_	11	ccomp
28	with	with	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod

1	Our	we	PRP$	_	2	nmod:poss
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	13	mark
5	the	the	DT	_	6	det
6	haplotype	haplotype	NN	_	13	nsubj
7	restricted	restricted	JJ	_	6	amod
8	to	to	TO	_	9	case
9	Europe	Europe	NNP	_	7	nmod
10	is	be	VBZ	_	13	cop
11	the	the	DT	_	13	det
12	strongest	strongest	JJS	_	13	amod
13	marker	marker	NN	_	3	ccomp
14	for	for	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	globally	globally	RB	_	13	advmod
17	and	and	CC	_	13	cc
18	add	add	VB	_	13	conj
19	further	further	JJ	_	21	amod
20	inferential	inferential	JJ	_	21	amod
21	evidence	evidence	NN	_	18	dobj
22	that	that	IN	_	33	mark
23	the	the	DT	_	25	det
24	derived	derive	VBN	_	25	amod
25	allele	allele	NN	_	33	nsubj
26	of	of	IN	_	27	case
27	drug1	drug1	NN	_	25	nmod
28	is	be	VBZ	_	33	cop
29	an	a	DT	_	33	det
30	East	east	JJ	_	33	amod
31	Asian	asian	JJ	_	33	amod
32	drug3	drug3	NN	_	33	compound
33	allele	allele	NN	_	21	ccomp
34	.	.	.	_	3	punct

1	Moreover	moreover	RB	_	23	advmod
2	,	,	,	_	23	punct
3	the	the	DT	_	5	det
4	TT	tt	NN	_	5	compound
5	genotype	genotype	NN	_	23	nsubjpass
6	of	of	IN	_	10	case
7	the	the	DT	_	10	det
8	nicotinic	nicotinic	JJ	_	10	amod
9	acetylcholine	acetylcholine	NN	_	10	compound
10	receptor	receptor	NN	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	nAChR	nachr	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	a3-subunit	a3-subunit	NN	_	19	compound
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	CHRNA3	chrna3	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	drug1	drug1	NN	_	19	compound
19	polymorphism	polymorphism	NN	_	10	dep
20	has	have	VBZ	_	23	aux
21	previously	previously	RB	_	23	advmod
22	been	be	VBN	_	23	auxpass
23	associated	associate	VBN	_	0	ROOT
24	with	with	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	drug3	drug3	NN	_	25	conj
28	.	.	.	_	23	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	that	that	IN	_	14	mark
4	the	the	DT	_	6	det
5	variant	variant	JJ	_	6	amod
6	allele	allele	NN	_	14	nsubjpass
7	of	of	IN	_	9	case
8	OCA2	oca2	NN	_	9	compound
9	R419Q	r419q	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug1	drug1	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	was	be	VBD	_	14	auxpass
14	associated	associate	VBN	_	2	ccomp
15	with	with	IN	_	17	case
16	increased	increase	VBN	_	17	amod
17	risk	risk	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	2	punct

1	We	we	PRP	_	4	nsubj
2	were	be	VBD	_	4	cop
3	also	also	RB	_	4	advmod
4	able	able	JJ	_	0	ROOT
5	to	to	TO	_	6	mark
6	demonstrate	demonstrate	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	OCA2	oca2	NN	_	9	compound
9	R419Q	r419q	NN	_	6	dobj
10	,	,	,	_	9	punct
11	drug1	drug1	NN	_	9	conj
12	,	,	,	_	9	punct
13	coding	code	VBG	_	14	compound
14	SNP	snp	NN	_	15	nsubj
15	acts	act	VBZ	_	9	acl:relcl
16	as	as	IN	_	19	case
17	a	a	DT	_	19	det
18	penetrance	penetrance	NN	_	19	compound
19	modifier	modifier	NN	_	15	nmod
20	of	of	IN	_	24	case
21	this	this	DT	_	24	det
22	new	new	JJ	_	24	amod
23	drug2	drug2	NN	_	24	compound
24	SNP	snp	NN	_	19	nmod
25	for	for	IN	_	27	case
26	eye	eye	NN	_	27	compound
27	color	color	NN	_	19	nmod
28	,	,	,	_	9	punct
29	and	and	CC	_	9	cc
30	somewhat	somewhat	RB	_	31	advmod
31	independently	independently	RB	_	9	conj
32	,	,	,	_	31	punct
33	of	of	IN	_	35	case
34	drug3	drug3	NN	_	35	compound
35	risk	risk	NN	_	31	nmod
36	.	.	.	_	4	punct

1	Conclusions	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Genetic	genetic	JJ	_	4	amod
4	variation	variation	NN	_	14	nsubj
5	of	of	IN	_	6	case
6	DRD2	drd2	NN	_	4	nmod
7	,	,	,	_	4	punct
8	specifically	specifically	RB	_	11	advmod
9	the	the	DT	_	11	det
10	drug1	drug1	NN	_	11	compound
11	polymorphism	polymorphism	NN	_	4	appos
12	,	,	,	_	4	punct
13	may	may	MD	_	14	aux
14	produce	produce	VB	_	1	appos
15	an	a	DT	_	18	det
16	earlier	earlier	JJR	_	18	amod
17	clinical	clinical	JJ	_	18	amod
18	presentation	presentation	NN	_	14	dobj
19	of	of	IN	_	23	case
20	drug2	drug2	NN	_	23	compound
21	disease	disease	NN	_	23	compound
22	neuropsychiatric	neuropsychiatric	JJ	_	23	amod
23	symptoms	symptom	NNS	_	18	nmod
24	and	and	CC	_	18	cc
25	signs	sign	NNS	_	18	conj
26	that	that	IN	_	27	nsubj
27	occur	occur	VBP	_	25	acl:relcl
28	in	in	IN	_	30	case
29	the	the	DT	_	30	det
30	course	course	NN	_	27	nmod
31	of	of	IN	_	34	case
32	dopaminergic	dopaminergic	JJ	_	34	amod
33	system	system	NN	_	34	compound
34	impairment	impairment	NN	_	30	nmod
35	due	due	JJ	_	38	case
36	to	to	TO	_	35	mwe
37	copper	copper	NN	_	38	compound
38	accumulation	accumulation	NN	_	34	nmod
39	in	in	IN	_	41	case
40	the	the	DT	_	41	det
41	brain	brain	NN	_	38	nmod
42	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	investigated	investigate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	relationship	relationship	NN	_	2	dobj
5	between	between	IN	_	7	case
6	drug4	drug4	NN	_	7	compound
7	symptoms	symptom	NNS	_	4	nmod
8	and	and	CC	_	7	cc
9	dopamine	dopamine	NN	_	16	compound
10	receptor	receptor	NN	_	16	compound
11	2	2	CD	_	16	nummod
12	DRD2	drd2	NN	_	16	compound
13	gene	gene	NN	_	16	compound
14	polymorphisms-141	polymorphisms-141	NN	_	16	compound
15	C	c	NN	_	16	compound
16	I/D	i/d	NN	_	7	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	exon	exon	NN	_	22	compound
21	8	8	CD	_	22	nummod
22	G/A	g/a	NN	_	16	dep
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug2	drug2	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	and	and	CC	_	16	cc
27	ANKK1	ankk1	NN	_	30	compound
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	Ankyrin	ankyrin	NN	_	30	compound
30	Repeat	repeat	NN	_	16	conj
31	and	and	CC	_	30	cc
32	Kinase	kinase	NN	_	33	compound
33	Domain	domain	NN	_	30	conj
34	Containing	contain	VBG	_	30	acl
35	1	1	LS	_	34	dobj
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	gene	gene	NN	_	39	compound
38	polymorphism	polymorphism	NN	_	39	compound
39	Taq1A	taq1a	NN	_	35	root
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	drug3	drug3	NN	_	39	appos
42	-RRB-	-rrb-	-RRB-	_	41	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	strongly	strongly	RB	_	4	advmod
4	suggested	suggest	VBD	_	0	ROOT
5	that	that	IN	_	14	mark
6	A1	a1	NN	_	14	nsubj
7	+	+	CC	_	6	cc
8	variants	variant	NNS	_	6	conj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	drug1	drug1	NN	_	12	compound
12	allele	allele	NN	_	6	nmod
13	do	do	VBP	_	14	aux
14	confer	confer	VB	_	4	ccomp
15	an	a	DT	_	17	det
16	associated	associated	JJ	_	17	amod
17	risk	risk	NN	_	14	dobj
18	for	for	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	inpatients	inpatient	NNS	_	17	nmod
21	who	who	WP	_	23	nsubjpass
22	were	be	VBD	_	23	auxpass
23	treated	treat	VBN	_	20	acl:relcl
24	with	with	IN	_	25	case
25	SGAs	sga	NNS	_	23	nmod
26	,	,	,	_	14	punct
27	and	and	CC	_	14	cc
28	these	these	DT	_	29	det
29	variants	variant	NNS	_	31	nsubj
30	may	may	MD	_	31	aux
31	explain	explain	VB	_	14	conj
32	inconsistencies	inconsistency	NNS	_	31	dobj
33	found	find	VBN	_	32	acl
34	across	across	IN	_	36	case
35	prior	prior	JJ	_	36	amod
36	studies	study	NNS	_	33	nmod
37	,	,	,	_	32	punct
38	when	when	WRB	_	39	advmod
39	comparing	compare	VBG	_	31	advcl
40	FGAs	fga	NNS	_	39	dobj
41	and	and	CC	_	40	cc
42	SGAs	sga	NNS	_	40	conj
43	.	.	.	_	4	punct

1	Eleven	eleven	CD	_	5	nummod
2	tag	tag	NN	_	5	compound
3	single	single	JJ	_	5	amod
4	nucleotide	nucleotide	NN	_	5	compound
5	polymorphisms	polymorphism	NNS	_	26	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	SNPs	snp	NNS	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	in	in	IN	_	12	case
10	the	the	DT	_	12	det
11	PRCP	prcp	NN	_	12	compound
12	gene	gene	NN	_	5	nmod
13	and	and	CC	_	5	cc
14	four	four	CD	_	16	nummod
15	tag	tag	NN	_	16	compound
16	SNPs	snp	NNS	_	5	conj
17	and	and	CC	_	16	cc
18	G-1903A	g-1903a	NN	_	20	compound
19	drug1	drug1	NN	_	20	compound
20	polymorphism	polymorphism	NN	_	16	conj
21	in	in	IN	_	24	case
22	the	the	DT	_	24	det
23	CMA1	cma1	NN	_	24	compound
24	gene	gene	NN	_	16	nmod
25	were	be	VBD	_	26	auxpass
26	genotyped	genotype	VBN	_	0	ROOT
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	drug2	drug2	NN	_	26	nmod
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	n	n	NN	_	29	dep
32	=	=	JJ	_	31	amod
33	1020	1020	CD	_	32	dep
34	-RRB-	-rrb-	-RRB-	_	31	punct
35	using	use	VBG	_	26	xcomp
36	a	a	DT	_	43	det
37	polymerase	polymerase	NN	_	43	compound
38	chain	chain	NN	_	43	compound
39	reaction-restriction	reaction-restriction	NN	_	43	compound
40	fragment	fragment	NN	_	43	compound
41	length	length	NN	_	43	compound
42	polymorphism	polymorphism	NN	_	43	compound
43	method	method	NN	_	35	dobj

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	present	present	JJ	_	5	amod
5	results	result	NNS	_	6	nsubj
6	indicated	indicate	VBD	_	1	appos
7	PRCP	prcp	NN	_	8	compound
8	drug1	drug1	NN	_	11	nsubjpass
9	can	can	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	considered	consider	VBN	_	6	ccomp
12	as	as	IN	_	14	case
13	a	a	DT	_	14	det
14	marker	marker	NN	_	31	nmod
15	for	for	IN	_	16	case
16	EH	eh	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	Hap3	hap3	NN	_	19	compound
19	GAGCACTAACA	gagcactaaca	NN	_	16	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	PRCP	prcp	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	and	and	CC	_	16	cc
24	Hap16	hap16	NN	_	25	compound
25	TTTA	ttta	NN	_	16	conj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	CMA1	cma1	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	might	might	MD	_	31	aux
30	be	be	VB	_	31	auxpass
31	associated	associate	VBN	_	11	xcomp
32	with	with	IN	_	33	case
33	drug2	drug2	NN	_	31	nmod
34	in	in	IN	_	37	case
35	Chinese	chinese	JJ	_	37	amod
36	Han	Han	NNP	_	37	compound
37	population	population	NN	_	33	nmod
38	.	.	.	_	1	punct

1	Previous	previous	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	indicated	indicate	VBN	_	0	ROOT
5	that	that	IN	_	12	mark
6	CMA1	cma1	NN	_	9	compound
7	promoter	promoter	NN	_	9	compound
8	polymorphism	polymorphism	NN	_	9	compound
9	drug1	drug1	NN	_	12	nsubjpass
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	involved	involve	VBN	_	4	ccomp
13	in	in	IN	_	14	mark
14	regulating	regulate	VBG	_	12	advcl
15	immunoglobulin	immunoglobulin	NN	_	16	compound
16	E	e	NN	_	20	compound
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	IgE	ige	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	levels	level	NNS	_	14	dobj
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	with	with	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	,	,	,	_	4	punct
26	and	and	CC	_	4	cc
27	it	it	PRP	_	29	nsubjpass
28	is	be	VBZ	_	29	auxpass
29	associated	associate	VBN	_	4	conj
30	with	with	IN	_	32	case
31	the	the	DT	_	32	det
32	progression	progression	NN	_	29	nmod
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	32	nmod
35	.	.	.	_	4	punct

1	Polymorphism	polymorphism	NN	_	2	compound
2	drug1	drug1	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	CMA1	cma1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	11	case
9	serum	serum	NN	_	11	compound
10	IgE	ige	NN	_	11	compound
11	level	level	NN	_	7	nmod
12	in	in	IN	_	14	case
13	drug2	drug2	NN	_	14	compound
14	subjects	subject	NNS	_	11	nmod
15	,	,	,	_	11	punct
16	but	but	CC	_	17	cc
17	not	not	RB	_	11	cc
18	with	with	IN	_	20	case
19	chymase	chymase	NN	_	20	compound
20	level	level	NN	_	11	conj
21	in	in	IN	_	23	case
22	both	both	DT	_	23	det
23	groups	group	NNS	_	20	nmod
24	.	.	.	_	7	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Our	we	PRP$	_	4	nmod:poss
4	results	result	NNS	_	5	nsubj
5	suggest	suggest	VBP	_	1	appos
6	that	that	IN	_	12	mark
7	the	the	DT	_	10	det
8	CMA	CMA	NNP	_	10	compound
9	drug1	drug1	NN	_	10	compound
10	polymorphism	polymorphism	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	associated	associate	VBN	_	5	ccomp
13	with	with	IN	_	15	case
14	the	the	DT	_	15	det
15	progression	progression	NN	_	12	nmod
16	of	of	IN	_	19	case
17	drug2	drug2	NN	_	19	compound
18	inKorean	inkorean	NN	_	19	compound
19	patients	patient	NNS	_	15	nmod
20	.	.	.	_	1	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	LEUVEN	LEUVEN	NNP	_	4	compound
4	cohort	cohort	NN	_	11	nmod
5	,	,	,	_	11	punct
6	drug1	drug1	NN	_	7	compound
7	AA-carriers	aa-carrier	NNS	_	11	nsubj
8	and	and	CC	_	7	cc
9	rs8034191	rs8034191	NN	_	10	compound
10	GG-carriers	gg-carrier	NNS	_	7	conj
11	had	have	VBD	_	0	ROOT
12	a	a	DT	_	15	det
13	two-fold	two-fold	RB	_	14	advmod
14	increased	increase	VBN	_	15	amod
15	risk	risk	NN	_	11	dobj
16	to	to	TO	_	17	mark
17	suffer	suffer	VB	_	15	acl
18	from	from	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	GOLD	gold	NN	_	17	nmod
21	IV	iv	CD	_	20	nummod
22	-LRB-	-lrb-	-LRB-	_	11	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Results	result	NNS	_	4	nsubj
4	confirm	confirm	VBP	_	1	appos
5	previous	previous	JJ	_	6	amod
6	observations	observation	NNS	_	4	dobj
7	of	of	IN	_	10	case
8	a	a	DT	_	10	det
9	significant	significant	JJ	_	10	amod
10	association	association	NN	_	6	nmod
11	between	between	IN	_	16	case
12	the	the	DT	_	16	det
13	CMA1	cma1	NN	_	16	compound
14	promoter	promoter	NN	_	16	compound
15	polymorphism	polymorphism	NN	_	16	compound
16	drug1	drug1	NN	_	10	nmod
17	and	and	CC	_	16	cc
18	atopic	atopic	JJ	_	19	amod
19	drug2	drug2	NN	_	16	conj
20	,	,	,	_	10	punct
21	but	but	CC	_	22	cc
22	not	not	RB	_	10	cc
23	with	with	IN	_	26	case
24	serum	serum	NN	_	26	compound
25	IgE	ige	NN	_	26	compound
26	levels	level	NNS	_	10	conj
27	,	,	,	_	4	punct
28	and	and	CC	_	4	cc
29	support	support	VBP	_	4	conj
30	the	the	DT	_	31	det
31	hypothesis	hypothesis	NN	_	29	dobj
32	that	that	IN	_	34	mark
33	CMA1	cma1	NN	_	34	nsubj
34	serves	serve	VBZ	_	31	ccomp
35	as	as	IN	_	37	case
36	candidate	candidate	NN	_	37	compound
37	gene	gene	NN	_	34	nmod
38	for	for	IN	_	40	case
39	atopic	atopic	JJ	_	40	amod
40	eczema	eczema	NN	_	37	nmod
41	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	increased	increase	VBN	_	3	amod
3	risk	risk	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	brain	brain	NN	_	6	compound
6	drug5	drug5	NN	_	3	nmod
7	was	be	VBD	_	8	cop
8	evident	evident	JJ	_	0	ROOT
9	for	for	IN	_	11	case
10	CYP1A1	cyp1a1	NN	_	11	compound
11	drug1	drug1	NN	_	8	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	P	p	NN	_	14	nsubj
14	=	=	JJ	_	11	dep
15	0.0028	0.0028	CD	_	14	dobj
16	;	;	:	_	14	punct
17	OR	or	NN	_	18	nsubj
18	=	=	JJ	_	14	parataxis
19	2.06	2.06	CD	_	18	dobj
20	;	;	:	_	14	punct
21	95	95	CD	_	22	compound
22	%	%	NN	_	23	amod
23	CI	ci	NN	_	14	conj
24	,	,	,	_	23	punct
25	1.27-3	1.27-3	CD	_	26	compound
26	.34	.34	CD	_	23	nummod
27	-RRB-	-rrb-	-RRB-	_	23	punct
28	and	and	CC	_	14	cc
29	minor	minor	JJ	_	31	amod
30	haplotypes	haplotype	NNS	_	31	compound
31	drug2	drug2	NN	_	14	conj
32	-	-	:	_	14	punct
33	drug3	drug3	NN	_	35	compound
34	-	-	:	_	35	punct
35	drug4	drug4	NN	_	14	dep
36	in	in	IN	_	37	case
37	females	female	NNS	_	35	nmod
38	-LRB-	-lrb-	-LRB-	_	42	punct
39	global	global	JJ	_	42	amod
40	haplotypeassociation	haplotypeassociation	NN	_	42	compound
41	P	p	NN	_	42	compound
42	value	value	NN	_	35	dep
43	,	,	,	_	42	punct
44	0.0011	0.0011	CD	_	42	amod
45	-RRB-	-rrb-	-RRB-	_	42	punct
46	.	.	.	_	8	punct

1	Only	only	RB	_	3	amod
2	STK39	stk39	NN	_	3	compound
3	drug1	drug1	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	significantly	significantly	RB	_	6	advmod
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	higher	higher	JJR	_	9	amod
9	DBP	dbp	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	P	p	NN	_	9	dep
12	=	=	JJ	_	11	amod
13	0.02	0.02	CD	_	12	dep
14	-RRB-	-rrb-	-RRB-	_	11	punct
15	in	in	IN	_	18	case
16	the	the	DT	_	18	det
17	drug2	drug2	NN	_	18	compound
18	subjects	subject	NNS	_	9	nmod
19	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	association	association	NN	_	11	nsubjpass
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	7	compound
7	susceptibility	susceptibility	NN	_	4	conj
8	has	have	VBZ	_	11	aux
9	been	be	VBN	_	11	auxpass
10	widely	widely	RB	_	11	advmod
11	studied	study	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	4	compound
4	polymorphism	polymorphism	NN	_	9	nsubj
5	of	of	IN	_	7	case
6	MTHFR	mthfr	NN	_	7	compound
7	gene	gene	NN	_	4	nmod
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	1	dep
10	the	the	DT	_	11	det
11	risk	risk	NN	_	9	dobj
12	of	of	IN	_	14	case
13	drug2	drug2	NN	_	14	compound
14	cancer	cancer	NN	_	11	nmod
15	in	in	IN	_	19	case
16	the	the	DT	_	19	det
17	complete	complete	JJ	_	19	amod
18	over-dominant	over-dominant	JJ	_	19	amod
19	model	model	NN	_	9	nmod
20	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	ACTN3	actn3	NN	_	3	compound
3	R577X	r577x	NN	_	7	compound
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug1	drug1	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	polymorphism	polymorphism	NN	_	8	nsubj
8	determines	determine	VBZ	_	0	ROOT
9	the	the	DT	_	10	det
10	presence	presence	NN	_	8	dobj
11	or	or	CC	_	10	cc
12	absence	absence	NN	_	10	conj
13	of	of	IN	_	15	case
14	functional	functional	JJ	_	15	amod
15	ACTN3	actn3	NN	_	10	nmod
16	,	,	,	_	15	punct
17	which	which	WDT	_	19	nsubj
18	may	may	MD	_	19	aux
19	influence	influence	VB	_	15	acl:relcl
20	the	the	DT	_	21	det
21	extent	extent	NN	_	19	dobj
22	of	of	IN	_	24	case
23	exercise-induced	exercise-induced	JJ	_	24	amod
24	drug2	drug2	NN	_	21	nmod
25	.	.	.	_	8	punct

1	We	we	PRP	_	2	nsubj
2	conclude	conclude	VBP	_	0	ROOT
3	that	that	IN	_	11	mark
4	HIF1A	hif1a	NN	_	6	compound
5	drug1	drug1	NN	_	6	compound
6	polymorphism	polymorphism	NN	_	11	nsubj
7	by	by	IN	_	8	case
8	itself	itself	PRP	_	6	nmod
9	is	be	VBZ	_	11	cop
10	not	not	RB	_	11	neg
11	critical	critical	JJ	_	2	ccomp
12	in	in	IN	_	13	mark
13	determining	determine	VBG	_	11	advcl
14	drug2	drug2	NN	_	13	dobj
15	.	.	.	_	2	punct

1	To	to	TO	_	2	case
2	best	best	JJS	_	9	nmod
3	of	of	IN	_	5	case
4	our	we	PRP$	_	5	nmod:poss
5	knowledge	knowledge	NN	_	2	nmod
6	,	,	,	_	9	punct
7	we	we	PRP	_	9	nsubj
8	first	first	RB	_	9	advmod
9	screened	screen	VBD	_	0	ROOT
10	these	these	DT	_	11	det
11	variants	variant	NNS	_	9	dobj
12	known	know	VBN	_	11	acl
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	auxpass
15	associated	associate	VBN	_	12	xcomp
16	with	with	IN	_	18	case
17	drug10	drug10	NN	_	18	compound
18	disease	disease	NN	_	15	nmod
19	,	,	,	_	18	punct
20	E46K	e46k	NN	_	18	appos
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug1	drug1	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	in	in	IN	_	25	case
25	SNCA	SNCA	NNP	_	20	nmod
26	,	,	,	_	25	punct
27	drug2	drug2	NN	_	25	appos
28	in	in	IN	_	29	case
29	LRRK2	lrrk2	NN	_	27	nmod
30	,	,	,	_	29	punct
31	drug3	drug3	NN	_	33	compound
32	n	n	NN	_	33	compound
33	PARK2	park2	NN	_	29	conj
34	,	,	,	_	29	punct
35	drug4	drug4	NN	_	29	appos
36	in	in	IN	_	37	case
37	SLC41A1	slc41a1	NN	_	35	nmod
38	,	,	,	_	37	punct
39	drug5	drug5	NN	_	37	conj
40	,	,	,	_	37	punct
41	drug6	drug6	NN	_	37	conj
42	,	,	,	_	37	punct
43	G908R	g908r	NN	_	37	conj
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	drug7	drug7	NN	_	43	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	,	,	,	_	37	punct
48	1007fs	1007f	NNS	_	37	conj
49	-LRB-	-lrb-	-LRB-	_	50	punct
50	drug8	drug8	NN	_	48	appos
51	-RRB-	-rrb-	-RRB-	_	50	punct
52	in	in	IN	_	53	case
53	NOD2	nod2	NN	_	48	nmod
54	and	and	CC	_	53	cc
55	G2385R	g2385r	NN	_	53	conj
56	-LRB-	-lrb-	-LRB-	_	57	punct
57	drug9	drug9	NN	_	55	appos
58	-RRB-	-rrb-	-RRB-	_	57	punct
59	in	in	IN	_	60	case
60	LRRK2	lrrk2	NN	_	37	nmod
61	from	from	IN	_	64	case
62	southern	southern	JJ	_	64	amod
63	China	China	NNP	_	64	compound
64	population	population	NN	_	60	nmod
65	.	.	.	_	9	punct

1	drug5	drug5	NN	_	4	nsubjpass
2	were	be	VBD	_	4	auxpass
3	positively	positively	RB	_	4	advmod
4	associated	associate	VBN	_	0	ROOT
5	with	with	IN	_	8	case
6	the	the	DT	_	8	det
7	risk	risk	NN	_	8	compound
8	alleles	allele	NNS	_	4	nmod
9	of	of	IN	_	11	case
10	IL23R	il23r	NN	_	11	compound
11	drug1	drug1	NN	_	8	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	OR	or	NN	_	11	dep
14	=	=	JJ	_	13	amod
15	2.25	2.25	CD	_	14	dep
16	-LSB-	-lsb-	-LRB-	_	18	punct
17	1.13-4	1.13-4	CD	_	18	nummod
18	.51	.51	NN	_	15	appos
19	-RSB-	-rsb-	-RRB-	_	18	punct
20	-RRB-	-rrb-	-RRB-	_	13	punct
21	and	and	CC	_	11	cc
22	6q21	6q21	JJ	_	23	amod
23	drug2	drug2	NN	_	11	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	OR	or	NN	_	23	dep
26	=	=	JJ	_	25	amod
27	1.60	1.60	CD	_	26	dep
28	-LSB-	-lsb-	-LRB-	_	30	punct
29	1.10-2	1.10-2	CD	_	30	nummod
30	.34	.34	CD	_	27	appos
31	-RSB-	-rsb-	-RRB-	_	30	punct
32	and	and	CC	_	25	cc
33	negatively	negatively	RB	_	34	advmod
34	associated	associate	VBN	_	25	conj
35	with	with	IN	_	38	case
36	the	the	DT	_	38	det
37	risk	risk	NN	_	38	compound
38	alleles	allele	NNS	_	34	nmod
39	of	of	IN	_	41	case
40	IRGM	IRGM	NNP	_	41	compound
41	drug3	drug3	NN	_	38	nmod
42	-LRB-	-lrb-	-LRB-	_	43	punct
43	OR	or	NN	_	38	dep
44	=	=	JJ	_	43	amod
45	0.29	0.29	CD	_	44	dep
46	-LSB-	-lsb-	-LRB-	_	48	punct
47	0.11-0	0.11-0	CD	_	48	nummod
48	.74	.74	CD	_	45	dep
49	-RSB-	-rsb-	-RRB-	_	48	punct
50	-RRB-	-rrb-	-RRB-	_	43	punct
51	and	and	CC	_	38	cc
52	DEFB1	defb1	NN	_	53	compound
53	drug4	drug4	NN	_	38	conj
54	-LRB-	-lrb-	-LRB-	_	55	punct
55	OR	or	NN	_	53	dep
56	=	=	JJ	_	55	amod
57	0.50	0.50	CD	_	56	dep
58	-LSB-	-lsb-	-LRB-	_	60	punct
59	0.30-0	0.30-0	CD	_	60	nummod
60	.80	.80	CD	_	57	dep
61	-RSB-	-rsb-	-RRB-	_	60	punct
62	-RRB-	-rrb-	-RRB-	_	55	punct
63	.	.	.	_	4	punct

1	In	in	IN	_	4	case
2	genotype-association	genotype-association	JJ	_	4	amod
3	SNP	snp	NN	_	4	compound
4	analysis	analysis	NN	_	23	nmod
5	,	,	,	_	23	punct
6	all	all	DT	_	8	det
7	NOD2	nod2	NN	_	8	compound
8	SNPs	snp	NNS	_	23	nsubj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug1	drug1	NN	_	8	dep
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	appos
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	appos
15	-RRB-	-rrb-	-RRB-	_	10	punct
16	and	and	CC	_	8	cc
17	the	the	DT	_	19	det
18	IL23r	il23r	NN	_	19	compound
19	SNP	snp	NN	_	8	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	drug4	drug4	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	showed	show	VBD	_	0	ROOT
24	a	a	DT	_	26	det
25	significant	significant	JJ	_	26	amod
26	association	association	NN	_	23	dobj
27	to	to	TO	_	28	case
28	drug5	drug5	NN	_	26	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	p	p	NN	_	31	dep
31	<	<	JJR	_	26	dep
32	0.03	0.03	CD	_	31	nummod
33	-RRB-	-rrb-	-RRB-	_	31	punct
34	.	.	.	_	23	punct

1	Three	three	CD	_	3	nummod
2	NOD2/CARD15	nod2/card15	NN	_	3	compound
3	variants	variant	NNS	_	21	nsubjpass
4	,	,	,	_	3	punct
5	namely	namely	RB	_	9	advmod
6	two	two	CD	_	9	nummod
7	missense	missense	NN	_	9	compound
8	polymorphisms	polymorphism	NNS	_	9	compound
9	drug1	drug1	NN	_	3	appos
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	3	punct
13	and	and	CC	_	3	cc
14	a	a	DT	_	18	det
15	frame	frame	NN	_	18	compound
16	shift	shift	NN	_	18	compound
17	polymorphism	polymorphism	NN	_	18	compound
18	drug3	drug3	NN	_	3	conj
19	,	,	,	_	3	punct
20	were	be	VBD	_	21	auxpass
21	associated	associate	VBN	_	0	ROOT
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	in	in	IN	_	26	case
25	Caucasian	caucasian	JJ	_	26	amod
26	populations	population	NNS	_	23	nmod
27	.	.	.	_	21	punct

1	Our	we	PRP$	_	2	nmod:poss
2	analysis	analysis	NN	_	3	nsubj
3	revealed	reveal	VBD	_	0	ROOT
4	that	that	IN	_	3	dobj
5	effects	effect	NNS	_	4	root
6	of	of	IN	_	9	case
7	two	two	CD	_	9	nummod
8	linked	link	VBN	_	9	amod
9	variants	variant	NNS	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug1	drug1	NN	_	9	dep
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	-RRB-	-rrb-	-RRB-	_	11	punct
15	in	in	IN	_	18	case
16	the	the	DT	_	18	det
17	AGPHD1/CHRNA3	agphd1/chrna3	NN	_	18	compound
18	cluster	cluster	NN	_	5	nmod
19	on	on	IN	_	21	case
20	drug3	drug3	NN	_	21	compound
21	development	development	NN	_	18	nmod
22	are	be	VBP	_	5	dep
23	significantly	significantly	RB	_	27	advmod
24	,	,	,	_	27	punct
25	yet	yet	RB	_	27	advmod
26	not	not	RB	_	27	neg
27	entirely	entirely	RB	_	22	advmod
28	,	,	,	_	27	punct
29	mediated	mediate	VBN	_	27	dep
30	by	by	IN	_	33	case
31	the	the	DT	_	33	det
32	smoking-related	smoking-related	JJ	_	33	amod
33	phenotypes	phenotype	NNS	_	29	nmod

1	In	in	IN	_	3	case
2	association	association	NN	_	3	compound
3	analysis	analysis	NN	_	6	nmod
4	,	,	,	_	6	punct
5	we	we	PRP	_	6	nsubj
6	found	find	VBD	_	0	ROOT
7	statistically	statistically	RB	_	8	advmod
8	significant	significant	JJ	_	9	amod
9	association	association	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	p	p	NN	_	14	nsubj
14	=	=	JJ	_	9	dep
15	0.001	0.001	CD	_	14	dobj
16	,	,	,	_	14	punct
17	OR	or	NN	_	18	nsubj
18	=	=	JJ	_	14	parataxis
19	3.011	3.011	CD	_	18	dobj
20	,	,	,	_	14	punct
21	CI95	ci95	CD	_	22	nummod
22	%	%	NN	_	23	nsubj
23	=	=	JJ	_	14	parataxis
24	1.494-6	1.494-6	CD	_	25	nummod
25	.071	.071	CD	_	23	dobj
26	-RRB-	-rrb-	-RRB-	_	14	punct
27	and	and	CC	_	9	cc
28	drug2	drug2	NN	_	52	compound
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	p	p	NN	_	31	nsubj
31	=	=	JJ	_	28	dep
32	2.62	2.62	CD	_	31	dobj
33	*	*	SYM	_	35	dep
34	10	10	CD	_	35	nummod
35	<formula>	<formula>	NN	_	31	dep
36	^	^	CD	_	35	nummod
37	-LCB-	-lcb-	-LRB-	_	38	punct
38	-4	-4	CD	_	35	dep
39	-RCB-	-rcb-	-RRB-	_	38	punct
40	</formula>	</formula>	RB	_	35	dep
41	,	,	,	_	31	punct
42	OR	or	NN	_	43	nsubj
43	=	=	JJ	_	31	parataxis
44	14.117	14.117	CD	_	43	dobj
45	,	,	,	_	31	punct
46	CI95	ci95	CD	_	47	nummod
47	%	%	NN	_	48	nsubj
48	=	=	JJ	_	31	parataxis
49	1.884-105	1.884-105	CD	_	50	nummod
50	.799	.799	CD	_	48	dobj
51	-RRB-	-rrb-	-RRB-	_	31	punct
52	polymorphisms	polymorphism	NNS	_	9	conj
53	with	with	IN	_	55	case
54	drug3	drug3	NN	_	55	compound
55	patients	patient	NNS	_	52	nmod
56	.	.	.	_	6	punct

1	Whereas	whereas	IN	_	9	mark
2	the	the	DT	_	4	det
3	NOD2	nod2	NN	_	4	compound
4	genotype	genotype	NN	_	9	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	9	auxpass
8	positively	positively	RB	_	9	advmod
9	associated	associate	VBN	_	18	advcl
10	with	with	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	,	,	,	_	18	punct
13	the	the	DT	_	15	det
14	drug1	drug1	NN	_	15	compound
15	genotype	genotype	NN	_	18	nsubjpass
16	is	be	VBZ	_	18	auxpass
17	positively	positively	RB	_	18	advmod
18	associated	associate	VBN	_	0	ROOT
19	with	with	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	L2	l2	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	disease	disease	NN	_	20	dep
25	.	.	.	_	18	punct

1	The	the	DT	_	2	det
2	association	association	NN	_	19	nsubj
3	between	between	IN	_	6	case
4	the	the	DT	_	6	det
5	Serine/threonine	serine/threonine	NN	_	6	compound
6	kinase	kinase	NN	_	2	nmod
7	15	15	CD	_	6	nummod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	STK15	stk15	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	F31I	f31i	NN	_	12	compound
12	polymorphism	polymorphism	NN	_	6	dep
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug1	drug1	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	and	and	CC	_	6	cc
17	drug2	drug2	NN	_	18	compound
18	susceptibility	susceptibility	NN	_	6	conj
19	remains	remain	VBZ	_	0	ROOT
20	controversial	controversial	JJ	_	19	xcomp
21	.	.	.	_	19	punct

1	Stratified	stratified	JJ	_	2	amod
2	analysis	analysis	NN	_	6	nsubj
3	by	by	IN	_	5	case
4	drug2	drug2	NN	_	5	compound
5	type	type	NN	_	2	nmod
6	revealed	reveal	VBD	_	0	ROOT
7	that	that	IN	_	13	mark
8	the	the	DT	_	11	det
9	STK	STK	NNP	_	11	compound
10	drug1	drug1	NN	_	11	compound
11	polymorphism	polymorphism	NN	_	13	nsubj
12	may	may	MD	_	13	aux
13	contribute	contribute	VB	_	6	ccomp
14	to	to	TO	_	16	case
15	the	the	DT	_	16	det
16	risk	risk	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	AA	aa	NN	_	18	dep
21	vs.	vs.	CC	_	20	cc
22	TT	tt	NN	_	20	conj
23	:	:	:	_	20	punct
24	OR	or	NN	_	20	dep
25	=	=	JJ	_	24	amod
26	1.21	1.21	CD	_	25	dep
27	,	,	,	_	24	punct
28	95	95	CD	_	29	compound
29	%	%	NN	_	30	amod
30	CI	ci	NN	_	24	appos
31	=	=	JJ	_	30	amod
32	1.01-1	1.01-1	CD	_	33	nummod
33	.44	.44	CD	_	31	dep
34	,	,	,	_	24	punct
35	Pheterogeneity	pheterogeneity	NN	_	24	appos
36	=	=	JJ	_	35	amod
37	0.002	0.002	CD	_	36	dep
38	-RRB-	-rrb-	-RRB-	_	20	punct
39	,	,	,	_	18	punct
40	drug4	drug4	NN	_	18	conj
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	AA	aa	NN	_	40	dep
43	vs.	vs.	CC	_	42	cc
44	UNASSIGNED	UNASSIGNED	NNP	_	42	conj
45	:	:	:	_	42	punct
46	OR	or	NN	_	42	dep
47	=	=	JJ	_	46	amod
48	1.24	1.24	CD	_	47	dep
49	,	,	,	_	46	punct
50	95	95	CD	_	51	compound
51	%	%	NN	_	52	amod
52	CI	ci	NN	_	46	appos
53	=	=	JJ	_	52	amod
54	1.05-1	1.05-1	CD	_	55	nummod
55	.47	.47	CD	_	53	dep
56	,	,	,	_	46	punct
57	Pheterogeneity	pheterogeneity	NN	_	46	appos
58	=	=	JJ	_	57	amod
59	0.124	0.124	CD	_	58	dep
60	-RRB-	-rrb-	-RRB-	_	42	punct
61	,	,	,	_	18	punct
62	and	and	CC	_	18	cc
63	drug5	drug5	NN	_	18	conj
64	-LRB-	-lrb-	-LRB-	_	65	punct
65	AA	aa	NN	_	63	dep
66	vs.	vs.	CC	_	65	cc
67	UNASSIGNED	UNASSIGNED	NNP	_	65	conj
68	:	:	:	_	65	punct
69	OR	or	NN	_	65	dep
70	=	=	JJ	_	69	amod
71	1.19	1.19	CD	_	70	dep
72	,	,	,	_	69	punct
73	95	95	CD	_	74	compound
74	%	%	NN	_	75	amod
75	CI	ci	NN	_	69	appos
76	=	=	JJ	_	75	amod
77	1.02-1	1.02-1	CD	_	78	nummod
78	.39	.39	CD	_	76	dep
79	,	,	,	_	69	punct
80	Pheterogeneity	pheterogeneity	NN	_	69	appos
81	=	=	JJ	_	80	amod
82	0.148	0.148	CD	_	81	dep
83	-RRB-	-rrb-	-RRB-	_	65	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	showed	show	VBD	_	0	ROOT
4	that	that	IN	_	3	dobj
5	four	four	CD	_	6	nummod
6	SNPs	snp	NNS	_	4	root
7	in	in	IN	_	8	case
8	AURKA	AURKA	NNP	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	data	datum	NNS	_	6	dep
11	in	in	IN	_	13	case
12	recessive	recessive	JJ	_	13	amod
13	model	model	NN	_	10	nmod
14	,	,	,	_	13	punct
15	drug1	drug1	NN	_	13	appos
16	:	:	:	_	10	punct
17	OR	or	NN	_	10	dep
18	=	=	JJ	_	17	amod
19	2.19	2.19	CD	_	18	dep
20	,	,	,	_	17	punct
21	95	95	CD	_	22	compound
22	%	%	NN	_	23	amod
23	CI	ci	NN	_	17	appos
24	=	=	JJ	_	23	amod
25	1.03-4	1.03-4	CD	_	26	nummod
26	.66	.66	CD	_	24	dep
27	,	,	,	_	17	punct
28	p	p	NN	_	17	appos
29	=	=	JJ	_	28	amod
30	0.0422	0.0422	CD	_	29	dep
31	;	;	:	_	17	punct
32	drug2	drug2	CD	_	35	dep
33	:	:	:	_	35	punct
34	OR	or	NN	_	35	nsubj
35	=	=	JJ	_	17	dep
36	0.38	0.38	CD	_	35	dep
37	,	,	,	_	36	punct
38	95	95	CD	_	39	compound
39	%	%	NN	_	40	amod
40	CI	ci	NN	_	36	appos
41	=	=	JJ	_	40	amod
42	0.18-0	0.18-0	CD	_	43	nummod
43	.82	.82	CD	_	41	dep
44	,	,	,	_	36	punct
45	p	p	NN	_	46	nsubj
46	=	=	JJ	_	36	acl:relcl
47	0.0141	0.0141	CD	_	46	dobj
48	;	;	:	_	17	punct
49	drug3	drug3	CD	_	52	dep
50	:	:	:	_	52	punct
51	OR	or	NN	_	52	nsubj
52	=	=	JJ	_	17	dep
53	1.54	1.54	CD	_	52	dep
54	,	,	,	_	53	punct
55	95	95	CD	_	56	compound
56	%	%	NN	_	57	amod
57	CI	ci	NN	_	53	appos
58	=	=	JJ	_	57	amod
59	1.18-2	1.18-2	CD	_	60	nummod
60	.00	.00	CD	_	58	dep
61	,	,	,	_	53	punct
62	p	p	NN	_	63	nsubj
63	=	=	JJ	_	53	acl:relcl
64	0.0014	0.0014	CD	_	63	dobj
65	;	;	:	_	17	punct
66	drug4	drug4	CD	_	69	dep
67	:	:	:	_	69	punct
68	OR	or	NN	_	69	nsubj
69	=	=	JJ	_	109	dep
70	0.68	0.68	CD	_	80	punct
71	,	,	,	_	70	punct
72	95	95	CD	_	73	compound
73	%	%	NN	_	74	amod
74	CI	ci	NN	_	70	appos
75	=	=	JJ	_	74	amod
76	0.47-0	0.47-0	CD	_	77	nummod
77	.98	.98	CD	_	75	dep
78	,	,	,	_	70	punct
79	p	p	NN	_	80	nsubj
80	=	=	JJ	_	69	dep
81	0.0380	0.0380	CD	_	80	dobj
82	-RRB-	-rrb-	-RRB-	_	80	punct
83	and	and	CC	_	69	cc
84	one	one	CD	_	85	nummod
85	SNP	snp	NN	_	69	conj
86	in	in	IN	_	87	case
87	BRCA1	brca1	NN	_	85	nmod
88	-LRB-	-lrb-	-LRB-	_	89	punct
89	drug5	drug5	NN	_	85	dep
90	,	,	,	_	89	punct
91	dominant	dominant	JJ	_	93	amod
92	model	model	NN	_	93	compound
93	OR	or	NN	_	89	appos
94	=	=	JJ	_	93	amod
95	1.35	1.35	CD	_	94	dep
96	,	,	,	_	89	punct
97	95	95	CD	_	98	compound
98	%	%	NN	_	99	amod
99	CI	ci	NN	_	89	appos
100	=	=	JJ	_	99	amod
101	1.11-1	1.11-1	CD	_	102	nummod
102	.64	.64	CD	_	100	dep
103	,	,	,	_	89	punct
104	p	p	NN	_	89	appos
105	=	=	JJ	_	104	amod
106	0.0030	0.0030	CD	_	105	dep
107	-RRB-	-rrb-	-RRB-	_	89	punct
108	were	be	VBD	_	109	auxpass
109	associated	associate	VBN	_	17	dep
110	with	with	IN	_	112	case
111	drug6	drug6	NN	_	112	compound
112	susceptibility	susceptibility	NN	_	109	nmod
113	.	.	.	_	10	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Six	six	CD	_	6	nummod
4	single	single	JJ	_	6	amod
5	nucleotide	nucleotide	NN	_	6	compound
6	polymorphisms	polymorphism	NNS	_	44	nsubjpass
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	SNPs	snp	NNS	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	in	in	IN	_	42	case
11	the	the	DT	_	42	det
12	AURKA	AURKA	NNP	_	42	compound
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug1	drug1	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	12	punct
17	ERBB2	erbb2	NN	_	12	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug2	drug2	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	12	punct
22	MDM2	mdm2	NN	_	12	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug3	drug3	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	12	punct
27	CDH1	cdh1	NN	_	12	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug4	drug4	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	12	punct
32	CDKN2A	cdkn2a	NN	_	12	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	drug5	drug5	NN	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	12	punct
37	and	and	CC	_	12	cc
38	TP73	tp73	NN	_	12	conj
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	drug6	drug6	NN	_	38	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	genes	gene	NNS	_	6	nmod
43	were	be	VBD	_	44	auxpass
44	genotyped	genotype	VBN	_	1	appos
45	in	in	IN	_	48	case
46	a	a	DT	_	48	det
47	consecutive	consecutive	JJ	_	48	amod
48	cohort	cohort	NN	_	44	nmod
49	of	of	IN	_	52	case
50	346	346	CD	_	52	nummod
51	drug7	drug7	NN	_	52	compound
52	patients	patient	NNS	_	48	nmod
53	,	,	,	_	52	punct
54	who	who	WP	_	56	nsubj
55	had	have	VBD	_	56	aux
56	underwent	undergo	VBN	_	52	acl:relcl
57	surgical	surgical	JJ	_	58	amod
58	resection	resection	NN	_	56	dobj
59	with	with	IN	_	61	case
60	curative	curative	JJ	_	61	amod
61	intent	intent	NN	_	56	nmod
62	.	.	.	_	1	punct

1	However	however	RB	_	22	advmod
2	,	,	,	_	22	punct
3	in	in	IN	_	6	case
4	a	a	DT	_	6	det
5	multivariate	multivariate	JJ	_	6	amod
6	analysis	analysis	NN	_	22	nmod
7	,	,	,	_	22	punct
8	patients	patient	NNS	_	22	nsubj
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	carrying	carry	VBG	_	10	acl
12	the	the	DT	_	14	det
13	heterozygous	heterozygous	JJ	_	14	amod
14	MDM2	mdm2	NN	_	11	dobj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug1	drug1	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	T/G	t/g	NN	_	19	compound
19	genotype	genotype	NN	_	14	dep
20	had	have	VBD	_	22	aux
21	significantly	significantly	RB	_	22	advmod
22	improved	improve	VBN	_	0	ROOT
23	DFS	dfs	NN	_	22	dobj
24	compared	compare	VBN	_	26	case
25	with	with	IN	_	26	case
26	patients	patient	NNS	_	22	advcl
27	carrying	carry	VBG	_	26	acl
28	the	the	DT	_	30	det
29	wild-type	wild-type	JJ	_	30	amod
30	genotype	genotype	NN	_	27	dobj
31	-LRB-	-lrb-	-LRB-	_	34	punct
32	adjusted	adjust	VBN	_	34	amod
33	hazard	hazard	NN	_	34	compound
34	ratio	ratio	NN	_	30	dep
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	AHR	ahr	NN	_	34	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	,	,	,	_	34	punct
39	0.63	0.63	CD	_	34	amod
40	;	;	:	_	34	punct
41	95	95	CD	_	42	compound
42	%	%	NN	_	44	amod
43	confidence	confidence	NN	_	44	compound
44	interval	interval	NN	_	34	dep
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	CI	ci	NN	_	44	appos
47	-RRB-	-rrb-	-RRB-	_	46	punct
48	-LSB-	-lsb-	-LRB-	_	50	punct
49	0.45-0	0.45-0	CD	_	50	nummod
50	.88	.88	CD	_	44	dep
51	-RSB-	-rsb-	-RRB-	_	50	punct
52	-RRB-	-rrb-	-RRB-	_	34	punct
53	.	.	.	_	22	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	45	nmod
3	,	,	,	_	45	punct
4	higher	higher	JJR	_	5	amod
5	frequencies	frequency	NNS	_	45	nsubjpass
6	of	of	IN	_	11	case
7	the	the	DT	_	11	det
8	MMP1	mmp1	NN	_	11	compound
9	drug1	drug1	NN	_	11	compound
10	2G	2g	NN	_	11	compound
11	allele	allele	NN	_	5	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	p	p	NN	_	14	nsubj
14	=	=	JJ	_	5	dep
15	0.017	0.017	CD	_	14	dobj
16	,	,	,	_	14	punct
17	OR	or	NN	_	14	dep
18	1.49	1.49	CD	_	17	nummod
19	,	,	,	_	14	punct
20	95	95	CD	_	21	nummod
21	%	%	NN	_	24	dep
22	CI	ci	NN	_	24	dep
23	1.06-2	1.06-2	CD	_	24	nummod
24	.08	.08	CD	_	14	parataxis
25	-RRB-	-rrb-	-RRB-	_	14	punct
26	and	and	CC	_	5	cc
27	the	the	DT	_	29	det
28	MMP1/MMP3	mmp1/mmp3	NN	_	29	compound
29	drug2	drug2	NN	_	5	conj
30	/	/	:	_	29	punct
31	drug3	drug3	NN	_	33	compound
32	2G/G	2g/g	NN	_	33	compound
33	haplotype	haplotype	NN	_	29	dep
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	OR	or	NN	_	33	dep
36	1.45	1.45	CD	_	35	nummod
37	,	,	,	_	35	punct
38	95	95	CD	_	39	compound
39	%	%	NN	_	40	amod
40	CI	ci	NN	_	35	appos
41	1.01-2	1.01-2	CD	_	42	compound
42	.10	.10	CD	_	40	nummod
43	-RRB-	-rrb-	-RRB-	_	35	punct
44	were	be	VBD	_	45	auxpass
45	detected	detect	VBN	_	0	ROOT
46	in	in	IN	_	48	case
47	drug4	drug4	NN	_	48	compound
48	patients	patient	NNS	_	45	nmod
49	than	than	IN	_	51	case
50	in	in	IN	_	51	case
51	controls	control	NNS	_	45	nmod
52	-LRB-	-lrb-	-LRB-	_	53	punct
53	n	n	NN	_	51	dep
54	=	=	JJ	_	53	amod
55	295	295	CD	_	54	dep
56	-RRB-	-rrb-	-RRB-	_	53	punct
57	.	.	.	_	45	punct

1	The	the	DT	_	2	det
2	presence	presence	NN	_	13	nsubjpass
3	of	of	IN	_	8	case
4	the	the	DT	_	8	det
5	variant	variant	JJ	_	8	amod
6	allele	allele	NN	_	8	compound
7	TNFA	tnfa	NN	_	8	compound
8	c.-238A	c.-238a	NN	_	2	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug1	drug1	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	was	be	VBD	_	13	auxpass
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	17	case
15	lower	lower	JJR	_	17	amod
16	serum	serum	NN	_	17	compound
17	levels	level	NNS	_	13	nmod
18	of	of	IN	_	19	case
19	TNF-a	tnf-a	NN	_	17	nmod
20	,	,	,	_	13	punct
21	and	and	CC	_	13	cc
22	with	with	IN	_	25	case
23	significantly	significantly	RB	_	24	advmod
24	decreased	decrease	VBN	_	25	amod
25	risk	risk	NN	_	13	conj
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	in	in	IN	_	30	case
29	both	both	CC	_	30	det
30	cohorts	cohort	NNS	_	25	nmod
31	.	.	.	_	13	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Evidence	evidence	NN	_	5	nsubj
4	has	have	VBZ	_	5	aux
5	suggested	suggest	VBN	_	1	dep
6	that	that	IN	_	5	dobj
7	tumour	tumour	NN	_	9	compound
8	necrosis	necrosis	NN	_	9	compound
9	factor	factor	NN	_	6	root
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	TNF	tnf	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	-	-	:	_	9	punct
14	a	a	DT	_	17	nsubjpass
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	involved	involve	VBN	_	9	acl:relcl
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	aetiology	aetiology	NN	_	17	nmod
21	of	of	IN	_	22	case
22	psoriasis	psoriasis	NN	_	20	nmod
23	,	,	,	_	17	punct
24	but	but	CC	_	17	cc
25	the	the	DT	_	27	det
26	underlying	underlying	JJ	_	27	amod
27	association	association	NN	_	50	nsubj
28	of	of	IN	_	31	case
29	the	the	DT	_	31	det
30	TNF-a	tnf-a	NN	_	31	compound
31	polymorphisms	polymorphism	NNS	_	27	nmod
32	-238	-238	CD	_	33	nummod
33	G/A	g/a	NN	_	31	dep
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	drug1	drug1	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	and	and	CC	_	31	cc
38	-308	-308	CD	_	39	nummod
39	G/A	g/a	NN	_	31	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	drug2	drug2	NN	_	39	appos
42	-RRB-	-rrb-	-RRB-	_	41	punct
43	with	with	IN	_	45	case
44	the	the	DT	_	45	det
45	risk	risk	NN	_	27	nmod
46	of	of	IN	_	47	case
47	drug3	drug3	NN	_	45	nmod
48	is	be	VBZ	_	50	cop
49	still	still	RB	_	50	advmod
50	unconfirmed	unconfirmed	JJ	_	17	conj
51	.	.	.	_	9	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Risk	risk	NN	_	4	compound
4	alleles	allele	NNS	_	16	nsubjpass
5	previously	previously	RB	_	6	advmod
6	associated	associate	VBN	_	4	acl
7	with	with	IN	_	8	case
8	drug5	drug5	NN	_	6	nmod
9	were	be	VBD	_	16	auxpass
10	significantly	significantly	RB	_	16	advmod
11	-LRB-	-lrb-	-LRB-	_	16	punct
12	P	p	NN	_	16	dep
13	<	<	JJR	_	12	amod
14	0.05	0.05	CD	_	13	dep
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	associated	associate	VBN	_	1	appos
17	with	with	IN	_	19	case
18	reduced	reduce	VBN	_	19	amod
19	abstinence	abstinence	NN	_	16	nmod
20	in	in	IN	_	24	case
21	the	the	DT	_	24	det
22	PLA	PLA	NNP	_	24	compound
23	pharmacotherapy	pharmacotherapy	NN	_	24	compound
24	group	group	NN	_	19	nmod
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	PG	pg	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	at	at	IN	_	29	case
29	6MO	6mo	NN	_	19	nmod
30	-LSB-	-lsb-	-LRB-	_	19	punct
31	for	for	IN	_	32	case
32	drug1	drug1	NN	_	30	root
33	,	,	,	_	32	punct
34	odds	odds	NNS	_	35	compound
35	ratio	ratio	NN	_	33	root
36	-LRB-	-lrb-	-LRB-	_	40	punct
37	95	95	CD	_	38	compound
38	%	%	NN	_	40	amod
39	confidence	confidence	NN	_	40	compound
40	interval	interval	NN	_	35	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	0.41	0.41	CD	_	35	dep
43	-LRB-	-lrb-	-LRB-	_	45	punct
44	0.17-0	0.17-0	CD	_	45	nummod
45	.99	.99	CD	_	42	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	-RSB-	-rsb-	-RRB-	_	35	punct
48	,	,	,	_	35	punct
49	and	and	CC	_	35	cc
50	at	at	IN	_	51	case
51	end	end	NN	_	35	conj
52	of	of	IN	_	53	case
53	treatment	treatment	NN	_	51	nmod
54	and	and	CC	_	35	cc
55	at	at	IN	_	56	case
56	6MO	6mo	NN	_	35	conj
57	-LSB-	-lsb-	-LRB-	_	59	punct
58	for	for	IN	_	59	case
59	drug2	drug2	NN	_	56	nmod
60	,	,	,	_	59	punct
61	0.42	0.42	CD	_	59	conj
62	-LRB-	-lrb-	-LRB-	_	64	punct
63	0.19-0	0.19-0	CD	_	64	nummod
64	.93	.93	CD	_	61	appos
65	-RRB-	-rrb-	-RRB-	_	64	punct
66	and	and	CC	_	59	cc
67	0.31	0.31	CD	_	59	conj
68	-LRB-	-lrb-	-LRB-	_	70	punct
69	0.12-0	0.12-0	CD	_	70	nummod
70	.80	.80	CD	_	67	appos
71	-RRB-	-rrb-	-RRB-	_	70	punct
72	-RSB-	-rsb-	-RRB-	_	59	punct
73	,	,	,	_	35	punct
74	and	and	CC	_	35	cc
75	with	with	IN	_	77	case
76	increased	increase	VBN	_	77	amod
77	abstinence	abstinence	NN	_	35	conj
78	in	in	IN	_	81	case
79	the	the	DT	_	81	det
80	NRT	NRT	NNP	_	81	compound
81	PG	pg	NN	_	77	nmod
82	at	at	IN	_	83	case
83	6MO	6mo	NN	_	77	nmod
84	-LSB-	-lsb-	-LRB-	_	86	punct
85	for	for	IN	_	86	case
86	drug3	drug3	NN	_	77	nmod
87	,	,	,	_	86	punct
88	2.07	2.07	CD	_	86	conj
89	-LRB-	-lrb-	-LRB-	_	91	punct
90	1.11-3	1.11-3	CD	_	91	nummod
91	.87	.87	CD	_	88	appos
92	-RRB-	-rrb-	-RRB-	_	91	punct
93	and	and	CC	_	86	cc
94	for	for	IN	_	95	case
95	drug4	drug4	NN	_	86	conj
96	,	,	,	_	95	punct
97	2.54	2.54	CD	_	95	appos
98	-LRB-	-lrb-	-LRB-	_	100	punct
99	1.29-4	1.29-4	CD	_	100	nummod
100	.99	.99	CD	_	97	dep
101	-RRB-	-rrb-	-RRB-	_	100	punct
102	-RSB-	-rsb-	-RRB-	_	86	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	This	this	DT	_	4	det
4	meta-analysis	meta-analysis	NN	_	5	nsubj
5	suggests	suggest	VBZ	_	1	appos
6	that	that	IN	_	14	mark
7	the	the	DT	_	8	det
8	drug1	drug1	NN	_	14	nsubj
9	and	and	CC	_	8	cc
10	-308	-308	CD	_	12	nummod
11	promoter	promoter	NN	_	12	compound
12	polymorphisms	polymorphism	NNS	_	8	conj
13	may	may	MD	_	14	aux
14	play	play	VB	_	5	ccomp
15	different	different	JJ	_	16	amod
16	roles	role	NNS	_	14	dobj
17	in	in	IN	_	18	mark
18	conferring	confer	VBG	_	14	advcl
19	susceptibility	susceptibility	NN	_	18	dobj
20	to	to	TO	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	genotyped	genotype	VBD	_	0	ROOT
3	and	and	CC	_	2	cc
4	analyzed	analyze	VBD	_	2	conj
5	4	4	CD	_	6	nummod
6	SNPs	snp	NNS	_	4	dobj
7	in	in	IN	_	9	case
8	3	3	CD	_	9	nummod
9	genes	gene	NNS	_	6	nmod
10	:	:	:	_	2	punct
11	PTPN22	ptpn22	NN	_	12	compound
12	C1858T	c1858t	NN	_	2	dep
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug1	drug1	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	12	punct
17	TNFA	tnfa	NN	_	18	compound
18	G-308A	g-308a	NN	_	12	appos
19	,	,	,	_	12	punct
20	G-238A	g-238a	NN	_	12	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug2	drug2	NN	_	20	dep
23	,	,	,	_	22	punct
24	drug3	drug3	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	22	punct
26	and	and	CC	_	12	cc
27	MIF	mif	NN	_	28	compound
28	G-173C	g-173c	NN	_	12	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	drug4	drug4	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	in	in	IN	_	35	case
33	647	647	CD	_	35	nummod
34	drug5	drug5	NN	_	35	compound
35	cases	case	NNS	_	12	nmod
36	and	and	CC	_	35	cc
37	751	751	CD	_	39	nummod
38	healthy	healthy	JJ	_	39	amod
39	controls	control	NNS	_	35	conj
40	.	.	.	_	2	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	We	we	PRP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	confirmed	confirm	VBN	_	1	appos
6	associations	association	NNS	_	5	dobj
7	between	between	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug1	drug1	NN	_	8	conj
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	1	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	drug1	drug1	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	found	find	VBN	_	1	dep
7	to	to	TO	_	9	mark
8	be	be	VB	_	9	cop
9	predictive	predictive	JJ	_	6	xcomp
10	of	of	IN	_	12	case
11	clinical	clinical	JJ	_	12	amod
12	response	response	NN	_	9	nmod
13	and	and	CC	_	6	cc
14	was	be	VBD	_	16	cop
15	more	more	RBR	_	16	advmod
16	likely	likely	JJ	_	6	conj
17	to	to	TO	_	18	mark
18	predict	predict	VB	_	16	xcomp
19	long-term	long-term	JJ	_	20	amod
20	survival	survival	NN	_	18	dobj
21	in	in	IN	_	24	case
22	Japanese	japanese	JJ	_	24	amod
23	drug2	drug2	NN	_	24	compound
24	patients	patient	NNS	_	20	nmod
25	receiving	receive	VBG	_	24	acl
26	definitive	definitive	JJ	_	28	amod
27	5-FU/CDDP-based	5-fu/cddp-based	JJ	_	28	amod
28	CRT	CRT	NNP	_	25	dobj
29	.	.	.	_	1	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	8	nsubj
4	compared	compare	VBN	_	3	acl
5	to	to	TO	_	7	case
6	healthy	healthy	JJ	_	7	amod
7	individuals	individual	NNS	_	4	nmod
8	demonstrated	demonstrate	VBD	_	1	appos
9	a	a	DT	_	12	det
10	statistically	statistically	RB	_	11	advmod
11	significant	significant	JJ	_	12	amod
12	increase	increase	NN	_	8	dobj
13	in	in	IN	_	15	case
14	drug1	drug1	NN	_	15	compound
15	allele	allele	NN	_	12	nmod
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	p	p	NN	_	18	nsubj
18	=	=	JJ	_	12	dep
19	0.037	0.037	CD	_	18	dobj
20	,	,	,	_	18	punct
21	OR	or	NN	_	22	nsubj
22	=	=	JJ	_	18	parataxis
23	2.12	2.12	CD	_	22	dobj
24	,	,	,	_	18	punct
25	95	95	CD	_	26	compound
26	%	%	NN	_	27	amod
27	CI	ci	NN	_	18	dep
28	1.29-3	1.29-3	CD	_	29	nummod
29	.4	.4	NN	_	27	dep
30	-RRB-	-rrb-	-RRB-	_	18	punct
31	.	.	.	_	1	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Genome-wide	genome-wide	JJ	_	4	amod
4	significance	significance	NN	_	21	nsubjpass
5	in	in	IN	_	8	case
6	fully	fully	RB	_	7	advmod
7	adjusted	adjust	VBN	_	8	amod
8	models	model	NNS	_	4	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	sex	sex	NN	_	8	dep
11	,	,	,	_	10	punct
12	age	age	NN	_	10	conj
13	,	,	,	_	10	punct
14	APOE	APOE	NNP	_	15	compound
15	genotype	genotype	NN	_	10	conj
16	,	,	,	_	10	punct
17	population	population	NN	_	18	compound
18	stratification	stratification	NN	_	10	appos
19	-RRB-	-rrb-	-RRB-	_	10	punct
20	was	be	VBD	_	21	auxpass
21	observed	observe	VBN	_	1	dep
22	for	for	IN	_	24	case
23	a	a	DT	_	24	det
24	SNP	snp	NN	_	21	nmod
25	in	in	IN	_	26	case
26	drug1	drug1	NN	_	24	nmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	drug2	drug2	NN	_	24	dep
29	,	,	,	_	28	punct
30	allele	allele	NN	_	28	appos
31	=	=	JJ	_	30	amod
32	G	g	NN	_	31	dep
33	;	;	:	_	28	punct
34	frequency	frequency	NN	_	40	compound
35	,	,	,	_	34	punct
36	0.09	0.09	CD	_	37	nummod
37	cases	case	NNS	_	34	conj
38	and	and	CC	_	34	cc
39	0.06	0.06	CD	_	34	conj
40	controls	control	NNS	_	28	dep
41	;	;	:	_	40	punct
42	odds	odds	NNS	_	43	compound
43	ratio	ratio	NN	_	40	dep
44	-LSB-	-lsb-	-LRB-	_	45	punct
45	OR	or	NN	_	43	appos
46	-RSB-	-rsb-	-RRB-	_	45	punct
47	,	,	,	_	43	punct
48	1.79	1.79	CD	_	52	nummod
49	-LSB-	-lsb-	-LRB-	_	52	punct
50	95	95	CD	_	51	compound
51	%	%	NN	_	52	amod
52	CI	ci	NN	_	43	appos
53	,	,	,	_	52	punct
54	1.47-2	1.47-2	CD	_	55	nummod
55	.12	.12	CD	_	52	appos
56	-RSB-	-rsb-	-RRB-	_	52	punct
57	;	;	:	_	28	punct
58	P	p	NN	_	59	nsubj
59	=	=	JJ	_	28	dep
60	2.2	2.2	CD	_	62	nummod
61	*	*	SYM	_	62	dep
62	10	10	CD	_	59	dobj
63	-LRB-	-lrb-	-LRB-	_	64	punct
64	-9	-9	CD	_	59	dep
65	-RRB-	-rrb-	-RRB-	_	64	punct
66	-RRB-	-rrb-	-RRB-	_	28	punct
67	,	,	,	_	24	punct
68	which	which	WDT	_	72	nsubj
69	is	be	VBZ	_	72	cop
70	in	in	IN	_	72	case
71	linkage	linkage	NN	_	72	compound
72	disequilibrium	disequilibrium	NN	_	24	acl:relcl
73	with	with	IN	_	74	case
74	SNPs	snp	NNS	_	72	nmod
75	previously	previously	RB	_	76	advmod
76	associated	associate	VBN	_	74	acl
77	with	with	IN	_	79	case
78	drug3	drug3	NN	_	79	compound
79	disease	disease	NN	_	76	nmod
80	in	in	IN	_	81	case
81	Europeans	european	NNS	_	79	nmod
82	-LRB-	-lrb-	-LRB-	_	87	punct
83	0.8	0.8	CD	_	87	dep
84	<	<	JJR	_	87	dep
85	D'	d'	NN	_	87	dep
86	<	<	JJR	_	87	dep
87	0.9	0.9	CD	_	72	dep
88	-RRB-	-rrb-	-RRB-	_	87	punct
89	.	.	.	_	1	punct

1	Genotyping	genotype	VBG	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	performed	perform	VBN	_	0	ROOT
4	for	for	IN	_	7	case
5	five	five	CD	_	7	nummod
6	single-nucleotide	single-nucleotide	JJ	_	7	amod
7	polymorphisms	polymorphism	NNS	_	3	nmod
8	that	that	WDT	_	11	nsubjpass
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	associated	associate	VBN	_	7	acl:relcl
12	with	with	IN	_	13	case
13	drug6	drug6	NN	_	11	nmod
14	:	:	:	_	3	punct
15	drug1	drug1	NN	_	3	dep
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug3	drug3	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug4	drug4	NN	_	15	conj
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	CLSTN2	clstn2	NN	_	15	conj
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	drug5	drug5	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	.	.	.	_	3	punct

1	Three	three	CD	_	2	nummod
2	SNPs	snp	NNS	_	80	nsubjpass
3	-LSB-	-lsb-	-LRB-	_	4	punct
4	drug1	drug1	NN	_	2	dep
5	in	in	IN	_	6	case
6	APOE	APOE	NNP	_	4	nmod
7	:	:	:	_	4	punct
8	odds	odds	NNS	_	9	compound
9	ratio	ratio	NN	_	4	dep
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	OR	or	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	=	=	JJ	_	9	amod
14	4.24	4.24	CD	_	13	dep
15	,	,	,	_	4	punct
16	95	95	CD	_	17	compound
17	%	%	NN	_	19	amod
18	confidence	confidence	NN	_	19	compound
19	interval	interval	NN	_	4	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	CI	ci	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	=	=	JJ	_	19	amod
24	3.01-5	3.01-5	CD	_	25	nummod
25	.96	.96	CD	_	23	dep
26	,	,	,	_	4	punct
27	P	p	NN	_	28	nsubj
28	=	=	JJ	_	4	dep
29	1.23	1.23	CD	_	31	compound
30	*	*	SYM	_	31	dep
31	10	10	CD	_	28	dobj
32	;	;	:	_	4	punct
33	drug2	drug2	NN	_	4	dep
34	in	in	IN	_	35	case
35	APOE	APOE	NNP	_	33	nmod
36	:	:	:	_	4	punct
37	OR	or	NN	_	4	dep
38	=	=	JJ	_	37	amod
39	3.57	3.57	CD	_	38	dep
40	,	,	,	_	37	punct
41	95	95	CD	_	42	compound
42	%	%	NN	_	43	amod
43	CI	ci	NN	_	37	appos
44	=	=	JJ	_	43	amod
45	2.51-5	2.51-5	CD	_	46	nummod
46	.06	.06	CD	_	44	dep
47	,	,	,	_	37	punct
48	P	p	NN	_	49	nsubj
49	=	=	JJ	_	37	acl:relcl
50	1.23	1.23	CD	_	51	nummod
51	*	*	SYM	_	49	dobj
52	10	10	CD	_	51	nummod
53	;	;	:	_	4	punct
54	and	and	CC	_	4	cc
55	drug3	drug3	NN	_	4	conj
56	in	in	IN	_	57	case
57	PICALM	PICALM	NNP	_	55	nmod
58	:	:	:	_	4	punct
59	OR	or	NN	_	4	dep
60	=	=	JJ	_	59	amod
61	0.63	0.63	CD	_	60	dep
62	,	,	,	_	59	punct
63	95	95	CD	_	64	compound
64	%	%	NN	_	65	amod
65	CI	ci	NN	_	59	appos
66	=	=	JJ	_	65	amod
67	0.49-0	0.49-0	CD	_	68	nummod
68	.81	.81	CD	_	66	dep
69	,	,	,	_	59	punct
70	P	p	NN	_	71	nsubj
71	=	=	JJ	_	59	dep
72	0.00036	0.00036	CD	_	71	dobj
73	,	,	,	_	59	punct
74	log	log	NN	_	76	compound
75	additive	additive	JJ	_	76	amod
76	model	model	NN	_	59	appos
77	-RSB-	-rsb-	-RRB-	_	4	punct
78	were	be	VBD	_	80	auxpass
79	significantly	significantly	RB	_	80	advmod
80	associated	associate	VBN	_	0	ROOT
81	with	with	IN	_	83	case
82	drug4	drug4	NN	_	83	compound
83	susceptibility	susceptibility	NN	_	80	nmod
84	after	after	IN	_	85	case
85	correction	correction	NN	_	83	nmod
86	for	for	IN	_	88	case
87	multiple	multiple	JJ	_	88	amod
88	testing	testing	NN	_	85	nmod
89	.	.	.	_	80	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Single	single	JJ	_	5	amod
4	nucleotide	nucleotide	NN	_	5	compound
5	polymorphisms	polymorphism	NNS	_	38	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	SNPs	snp	NNS	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	drug1	drug1	NN	_	5	dep
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	e4	e4	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	and	and	CC	_	9	cc
14	drug2	drug2	NN	_	9	conj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	e2	e2	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	5	punct
19	both	both	DT	_	21	det
20	invoking	invoke	VBG	_	21	amod
21	changes	change	NNS	_	5	appos
22	in	in	IN	_	25	case
23	the	the	DT	_	25	det
24	amino-acid	amino-acid	JJ	_	25	amod
25	sequence	sequence	NN	_	21	nmod
26	of	of	IN	_	33	case
27	the	the	DT	_	33	det
28	apolipoprotein	apolipoprotein	NN	_	29	compound
29	E	e	NN	_	33	compound
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	APOE	apoe	NN	_	33	compound
32	-RRB-	-rrb-	-RRB-	_	33	punct
33	gene	gene	NN	_	25	nmod
34	,	,	,	_	5	punct
35	have	have	VBP	_	38	aux
36	previously	previously	RB	_	38	advmod
37	been	be	VBN	_	38	auxpass
38	tested	test	VBN	_	1	dep
39	for	for	IN	_	40	case
40	association	association	NN	_	38	nmod
41	with	with	IN	_	42	case
42	drug3	drug3	NN	_	40	nmod
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	MS	ms	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	risk	risk	NN	_	42	dep
47	.	.	.	_	1	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Despite	despite	IN	_	5	case
4	sufficient	sufficient	JJ	_	5	amod
5	power	power	NN	_	23	nmod
6	to	to	TO	_	7	mark
7	detect	detect	VB	_	5	acl
8	associations	association	NNS	_	7	dobj
9	at	at	IN	_	12	case
10	genome-wide	genome-wide	JJ	_	12	amod
11	significance	significance	NN	_	12	compound
12	thresholds	threshold	NNS	_	7	nmod
13	across	across	IN	_	15	case
14	a	a	DT	_	15	det
15	range	range	NN	_	12	nmod
16	of	of	IN	_	17	case
17	ORs	or	NNS	_	15	nmod
18	,	,	,	_	23	punct
19	our	we	PRP$	_	20	nmod:poss
20	analyses	analysis	NNS	_	23	nsubj
21	did	do	VBD	_	23	aux
22	not	not	RB	_	23	neg
23	support	support	VB	_	1	appos
24	a	a	DT	_	25	det
25	role	role	NN	_	23	dobj
26	of	of	IN	_	27	case
27	drug1	drug1	NN	_	25	nmod
28	or	or	CC	_	27	cc
29	drug2	drug2	NN	_	27	conj
30	on	on	IN	_	32	case
31	drug3	drug3	NN	_	32	compound
32	susceptibility	susceptibility	NN	_	25	nmod

1	The	the	DT	_	2	det
2	distributions	distribution	NNS	_	55	nsubj
3	of	of	IN	_	4	case
4	SNPs	snp	NNS	_	2	nmod
5	relating	relate	VBG	_	4	acl
6	to	to	TO	_	10	case
7	the	the	DT	_	10	det
8	amyloid	amyloid	NN	_	10	compound
9	cascade	cascade	NN	_	10	compound
10	hypothesis	hypothesis	NN	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	TOMM40	tomm40	NN	_	14	compound
13	drug1	drug1	NN	_	14	compound
14	G	g	NN	_	10	dep
15	and	and	CC	_	14	cc
16	TOMM40	tomm40	NN	_	18	compound
17	drug2	drug2	NN	_	18	compound
18	G	g	NN	_	14	conj
19	-RRB-	-rrb-	-RRB-	_	14	punct
20	,	,	,	_	2	punct
21	to	to	TO	_	23	case
22	the	the	DT	_	23	det
23	drug8	drug8	NN	_	2	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	ApoE	apoe	NN	_	27	compound
26	drug3	drug3	NN	_	27	compound
27	C	c	NN	_	23	dep
28	,	,	,	_	27	punct
29	LDLR	ldlr	NN	_	31	compound
30	drug4	drug4	NN	_	31	compound
31	G	g	NN	_	27	conj
32	and	and	CC	_	27	cc
33	CH25H	ch25h	NN	_	35	compound
34	drug5	drug5	NN	_	35	compound
35	T	t	NN	_	27	conj
36	and	and	CC	_	27	cc
37	PLAU	plau	NN	_	39	compound
38	drug6	drug6	NN	_	39	compound
39	CT	ct	NN	_	27	conj
40	-RRB-	-rrb-	-RRB-	_	27	punct
41	and	and	CC	_	23	cc
42	to	to	TO	_	45	case
43	the	the	DT	_	45	det
44	tau	tau	NN	_	45	compound
45	hypothesis	hypothesis	NN	_	23	conj
46	-LRB-	-lrb-	-LRB-	_	49	punct
47	MAPT/STH	mapt/sth	NN	_	49	compound
48	drug7	drug7	NN	_	49	compound
49	GG	gg	NNS	_	45	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	in	in	IN	_	52	case
52	aMCI	amci	NN	_	45	nmod
53	were	be	VBD	_	55	cop
54	significantly	significantly	RB	_	55	advmod
55	different	different	JJ	_	0	ROOT
56	than	than	IN	_	57	case
57	those	those	DT	_	55	nmod
58	in	in	IN	_	60	case
59	normal	normal	JJ	_	60	amod
60	controls	control	NNS	_	57	nmod
61	.	.	.	_	55	punct

1	The	the	DT	_	2	det
2	authors	author	NNS	_	4	nsubj
3	then	then	RB	_	4	advmod
4	performed	perform	VBD	_	0	ROOT
5	a	a	DT	_	7	det
6	large	large	JJ	_	7	amod
7	meta-analysis	meta-analysis	NN	_	4	dobj
8	of	of	IN	_	10	case
9	36	36	CD	_	10	nummod
10	studies	study	NNS	_	7	nmod
11	examining	examine	VBG	_	10	acl
12	the	the	DT	_	13	det
13	association	association	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug5	drug5	NN	_	13	nmod
16	with	with	IN	_	17	case
17	polymorphisms	polymorphism	NNS	_	13	nmod
18	in	in	IN	_	21	case
19	the	the	DT	_	21	det
20	TCF7L2	tcf7l2	NN	_	21	compound
21	gene	gene	NN	_	17	nmod
22	in	in	IN	_	24	case
23	various	various	JJ	_	24	amod
24	ethnicities	ethnicity	NNS	_	21	nmod
25	,	,	,	_	4	punct
26	containing	contain	VBG	_	4	advcl
27	drug1	drug1	NN	_	26	dobj
28	C-to-T	c-to-t	JJ	_	27	dep
29	-LRB-	-lrb-	-LRB-	_	32	punct
30	IVS3C	ivs3c	NN	_	32	compound
31	>	>	JJR	_	32	dep
32	T	t	NN	_	28	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	,	,	,	_	27	punct
35	drug2	drug2	NN	_	36	compound
36	T-to-C	t-to-c	NN	_	27	conj
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	IVS3T	ivs3t	NN	_	40	compound
39	>	>	JJR	_	40	amod
40	C	c	NN	_	36	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	,	,	,	_	27	punct
43	a	a	DT	_	45	det
44	drug3	drug3	NN	_	45	compound
45	G-to-T	g-to-t	NN	_	27	conj
46	-LRB-	-lrb-	-LRB-	_	49	punct
47	IVS4G	ivs4g	NN	_	49	dep
48	>	>	JJR	_	49	dep
49	T	t	NN	_	45	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	,	,	,	_	27	punct
52	and	and	CC	_	27	cc
53	drug4	drug4	NN	_	54	compound
54	G-to-C	g-to-c	NN	_	27	conj
55	-LRB-	-lrb-	-LRB-	_	60	punct
56	IVS4G	ivs4g	NN	_	60	compound
57	>	>	JJR	_	60	amod
58	C	c	NN	_	60	compound
59	-RRB-	-rrb-	-RRB-	_	60	punct
60	polymorphisms	polymorphism	NNS	_	54	dep
61	and	and	CC	_	60	cc
62	toevaluate	toevaluate	VB	_	60	conj
63	the	the	DT	_	64	det
64	size	size	NN	_	62	dobj
65	of	of	IN	_	67	case
66	gene	gene	NN	_	67	compound
67	effect	effect	NN	_	64	nmod
68	and	and	CC	_	64	cc
69	the	the	DT	_	72	det
70	possible	possible	JJ	_	72	amod
71	genetic	genetic	JJ	_	72	amod
72	mode	mode	NN	_	64	conj
73	of	of	IN	_	74	case
74	action	action	NN	_	72	nmod

1	Carbohydrate	carbohydrate	JJ	_	2	amod
2	quality	quality	NN	_	5	nsubj
3	and	and	CC	_	2	cc
4	quantity	quantity	NN	_	2	conj
5	modified	modify	VBN	_	0	ROOT
6	risk	risk	NN	_	5	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	associated	associate	VBN	_	8	acl
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	11	punct
13	which	which	WDT	_	14	nsubj
14	suggests	suggest	VBZ	_	11	acl:relcl
15	that	that	IN	_	25	mark
16	changes	change	NNS	_	25	nsubjpass
17	in	in	IN	_	18	case
18	risk	risk	NN	_	16	nmod
19	attributable	attributable	JJ	_	16	amod
20	to	to	TO	_	23	case
21	the	the	DT	_	23	det
22	TCF7L2	tcf7l2	NN	_	23	compound
23	variant	variant	NN	_	19	nmod
24	are	be	VBP	_	25	auxpass
25	magnified	magnify	VBN	_	14	ccomp
26	under	under	IN	_	27	case
27	conditions	condition	NNS	_	25	nmod
28	of	of	IN	_	31	case
29	increased	increase	VBN	_	31	amod
30	insulin	insulin	NN	_	31	compound
31	demand	demand	NN	_	27	nmod
32	.	.	.	_	5	punct

1	We	we	PRP	_	2	nsubj
2	genotyped	genotype	VBD	_	0	ROOT
3	the	the	DT	_	7	det
4	TCF7L2	tcf7l2	NN	_	7	compound
5	single	single	JJ	_	7	amod
6	nucleotide	nucleotide	NN	_	7	compound
7	polymorphisms	polymorphism	NNS	_	2	dobj
8	drug1	drug1	NN	_	7	dep
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	previously	previously	RB	_	13	advmod
13	associated	associate	VBN	_	7	dep
14	with	with	IN	_	15	case
15	drug5	drug5	NN	_	13	nmod
16	-RRB-	-rrb-	-RRB-	_	13	punct
17	and	and	CC	_	7	cc
18	drug3	drug3	NN	_	20	compound
19	nd	nd	NN	_	20	compound
20	drug4	drug4	NN	_	7	conj
21	-LRB-	-lrb-	-LRB-	_	20	punct
22	which	which	WDT	_	23	nsubj
23	tag	tag	VBP	_	20	acl:relcl
24	haplotype	haplotype	NN	_	25	compound
25	A	a	NN	_	23	dobj
26	-LSB-	-lsb-	-LRB-	_	27	punct
27	HapA	hapa	NN	_	25	appos
28	-RSB-	-rsb-	-RRB-	_	27	punct
29	,	,	,	_	25	punct
30	a	a	DT	_	31	det
31	haplotype	haplotype	NN	_	25	appos
32	reported	report	VBD	_	31	acl
33	to	to	TO	_	35	mark
34	be	be	VB	_	35	auxpass
35	associated	associate	VBN	_	32	xcomp
36	with	with	IN	_	37	case
37	drug6	drug6	NN	_	35	nmod
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	in	in	IN	_	42	case
40	2,512	2,512	CD	_	42	nummod
41	FHS	fhs	NN	_	42	compound
42	participants	participant	NNS	_	37	nmod
43	.	.	.	_	2	punct

1	As	as	IN	_	2	mark
2	expected	expect	VBN	_	11	advcl
3	,	,	,	_	11	punct
4	the	the	DT	_	7	det
5	T	t	NN	_	7	compound
6	risk	risk	NN	_	7	compound
7	allele	allele	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	associated	associate	VBN	_	0	ROOT
12	with	with	IN	_	14	case
13	higher	higher	JJR	_	14	amod
14	drug2	drug2	NN	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	p	p	NN	_	17	nsubj
17	=	=	JJ	_	14	dep
18	0.01	0.01	CD	_	17	dobj
19	-RRB-	-rrb-	-RRB-	_	17	punct
20	.	.	.	_	11	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	association	association	NN	_	2	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	p	p	NN	_	11	nsubj
11	=	=	JJ	_	8	dep
12	0.98	0.98	CD	_	11	dobj
13	-RRB-	-rrb-	-RRB-	_	11	punct
14	,	,	,	_	8	punct
15	drug3	drug3	NN	_	8	conj
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	p	p	NN	_	18	nsubj
18	=	=	JJ	_	15	dep
19	0.89	0.89	CD	_	18	dobj
20	-RRB-	-rrb-	-RRB-	_	18	punct
21	,	,	,	_	8	punct
22	drug4	drug4	NN	_	8	conj
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	p	p	NN	_	25	nsubj
25	=	=	JJ	_	22	dep
26	0.32	0.32	CD	_	25	dobj
27	-RRB-	-rrb-	-RRB-	_	25	punct
28	or	or	CC	_	8	cc
29	drug5	drug5	NN	_	8	conj
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	p	p	NN	_	32	nsubj
32	=	=	JJ	_	29	dep
33	0.92	0.92	CD	_	32	dobj
34	-RRB-	-rrb-	-RRB-	_	32	punct
35	.	.	.	_	2	punct

1	We	we	PRP	_	2	nsubj
2	confirmed	confirm	VBD	_	0	ROOT
3	that	that	IN	_	10	mark
4	the	the	DT	_	6	det
5	risk	risk	NN	_	6	compound
6	allele	allele	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	is	be	VBZ	_	10	auxpass
10	associated	associate	VBN	_	2	ccomp
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	a	a	DT	_	15	det
15	drug3	drug3	NN	_	12	conj
16	.	.	.	_	2	punct

1	We	we	PRP	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	detect	detect	VB	_	0	ROOT
5	any	any	DT	_	6	det
6	association	association	NN	_	4	dobj
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	6	nmod
12	,	,	,	_	4	punct

1	We	we	PRP	_	2	nsubj
2	investigated	investigate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	effect	effect	NN	_	2	dobj
5	of	of	IN	_	8	case
6	single	single	JJ	_	8	amod
7	nucleotide	nucleotide	NN	_	8	compound
8	polymorphisms	polymorphism	NNS	_	4	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	SNP	snp	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	8	punct
13	drug1	drug1	NN	_	8	appos
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	8	punct
17	within	within	IN	_	20	case
18	the	the	DT	_	20	det
19	TCF7L2	tcf7l2	NN	_	20	compound
20	locus	locus	NN	_	4	nmod
21	on	on	IN	_	22	case
22	drug3	drug3	NN	_	4	nmod
23	and	and	CC	_	22	cc
24	other	other	JJ	_	25	amod
25	drug4	drug4	NN	_	22	conj
26	and	and	CC	_	4	cc
27	their	they	PRP$	_	28	nmod:poss
28	modulation	modulation	NN	_	4	conj
29	by	by	IN	_	31	case
30	dietary	dietary	JJ	_	31	amod
31	fat	fat	NN	_	28	nmod
32	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	summary	summary	NN	_	16	nmod
3	,	,	,	_	16	punct
4	drug2	drug2	NN	_	16	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	10	punct
6	>	>	JJR	_	10	dep
7	or	or	CC	_	6	cc
8	=	=	JJ	_	6	conj
9	6.62	6.62	CD	_	10	nummod
10	%	%	NN	_	4	dep
11	of	of	IN	_	13	case
12	energy	energy	NN	_	13	compound
13	intake	intake	NN	_	10	nmod
14	-RRB-	-rrb-	-RRB-	_	10	punct
15	were	be	VBD	_	16	auxpass
16	associated	associate	VBN	_	0	ROOT
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	in	in	IN	_	20	case
20	carriers	carrier	NNS	_	18	nmod
21	of	of	IN	_	25	case
22	the	the	DT	_	25	det
23	minor	minor	JJ	_	25	amod
24	T	t	NN	_	25	compound
25	allele	allele	NN	_	20	nmod
26	at	at	IN	_	30	case
27	the	the	DT	_	30	det
28	TCF7L2	tcf7l2	NN	_	30	compound
29	drug1	drug1	NN	_	30	compound
30	SNP	snp	NN	_	25	nmod
31	and	and	CC	_	16	cc
32	may	may	MD	_	33	aux
33	predispose	predispose	VB	_	16	conj
34	them	they	PRP	_	33	dobj
35	to	to	TO	_	36	case
36	MetS	mets	NN	_	33	nmod
37	,	,	,	_	36	punct
38	diabetes	diabetes	NN	_	36	conj
39	,	,	,	_	36	punct
40	and	and	CC	_	36	cc
41	cardiovascular	cardiovascular	JJ	_	42	amod
42	disease	disease	NN	_	36	conj
43	.	.	.	_	16	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	that	that	IN	_	18	mark
4	SNPs	snp	NNS	_	18	nsubjpass
5	drug1	drug1	NN	_	4	dep
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug3	drug3	NN	_	5	conj
10	and	and	CC	_	5	cc
11	drug4	drug4	NN	_	5	conj
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	TCF7L2	tcf7l2	NN	_	15	compound
15	gene	gene	NN	_	4	nmod
16	were	be	VBD	_	18	auxpass
17	strongly	strongly	RB	_	18	advmod
18	associated	associate	VBN	_	2	ccomp
19	with	with	IN	_	20	case
20	drug5	drug5	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	p	p	NN	_	23	dep
23	<	<	JJR	_	20	dep
24	0.004	0.004	CD	_	23	nummod
25	-RRB-	-rrb-	-RRB-	_	23	punct
26	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	drug1	drug1	NN	_	11	nmod
3	,	,	,	_	11	punct
4	T2D	t2d	NN	_	5	compound
5	patients	patient	NNS	_	11	nsubj
6	carrying	carry	VBG	_	5	acl
7	genotypes	genotype	NNS	_	8	compound
8	CT	ct	NN	_	6	dobj
9	or	or	CC	_	8	cc
10	TT	tt	NN	_	8	conj
11	had	have	VBD	_	0	ROOT
12	drug2	drug2	NN	_	16	compound
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	FPG	fpg	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	levels	level	NNS	_	11	dobj
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	p	p	NN	_	19	nsubj
19	=	=	JJ	_	16	dep
20	0.042	0.042	CD	_	19	dobj
21	-RRB-	-rrb-	-RRB-	_	19	punct
22	and	and	CC	_	16	cc
23	drug3	drug3	NN	_	16	conj
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	p	p	NN	_	26	nsubj
26	=	=	JJ	_	23	dep
27	0.015	0.015	CD	_	26	dobj
28	-RRB-	-rrb-	-RRB-	_	26	punct
29	and	and	CC	_	23	cc
30	drug4	drug4	NN	_	23	conj
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	p	p	NN	_	33	nsubj
33	=	=	JJ	_	30	dep
34	0.015	0.015	CD	_	33	dobj
35	-RRB-	-rrb-	-RRB-	_	33	punct
36	compared	compare	VBN	_	16	acl
37	to	to	TO	_	39	case
38	the	the	DT	_	39	det
39	patients	patient	NNS	_	36	nmod
40	carrying	carry	VBG	_	39	acl
41	CC	cc	NN	_	42	compound
42	genotype	genotype	NN	_	40	dobj
43	.	.	.	_	11	punct

1	Furthermore	furthermore	RB	_	38	advmod
2	,	,	,	_	38	punct
3	the	the	DT	_	5	det
4	risk	risk	NN	_	5	compound
5	alleles	allele	NNS	_	38	nsubjpass
6	from	from	IN	_	9	case
7	TCF7L2	tcf7l2	NN	_	9	compound
8	drug1	drug1	NN	_	9	compound
9	polymorphism	polymorphism	NN	_	5	nmod
10	either	either	CC	_	13	cc:preconj
11	with	with	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	polymorphism	polymorphism	NN	_	5	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	p	p	NN	_	16	nsubj
16	=	=	JJ	_	13	dep
17	0.0257	0.0257	CD	_	16	dobj
18	,	,	,	_	16	punct
19	OR	or	NN	_	20	nsubj
20	=	=	JJ	_	16	parataxis
21	1.398	1.398	CD	_	20	dobj
22	-RRB-	-rrb-	-RRB-	_	16	punct
23	or	or	CC	_	13	cc
24	with	with	IN	_	26	case
25	drug3	drug3	NN	_	26	compound
26	polymorphism	polymorphism	NN	_	13	conj
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	p	p	NN	_	29	nsubj
29	=	=	JJ	_	26	dep
30	0.0024	0.0024	CD	_	29	dobj
31	,	,	,	_	29	punct
32	OR	or	NN	_	29	dep
33	=	=	JJ	_	32	amod
34	1.514	1.514	CD	_	33	dep
35	-RRB-	-rrb-	-RRB-	_	29	punct
36	were	be	VBD	_	38	auxpass
37	significantly	significantly	RB	_	38	advmod
38	associated	associate	VBN	_	0	ROOT
39	with	with	IN	_	40	case
40	drug4	drug4	NN	_	38	nmod
41	.	.	.	_	38	punct

1	The	the	DT	_	2	det
2	allele	allele	NN	_	12	nsubj
3	and	and	CC	_	2	cc
4	genotype	genotype	NN	_	5	compound
5	frequencies	frequency	NNS	_	2	conj
6	of	of	IN	_	9	case
7	two	two	CD	_	9	nummod
8	SNP	snp	NN	_	9	compound
9	drug1	drug1	NN	_	2	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	showed	show	VBD	_	0	ROOT
13	that	that	IN	_	16	mark
14	these	these	DT	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	associated	associate	VBN	_	12	ccomp
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	odds	odds	NNS	_	19	compound
19	ratio	ratio	NN	_	16	dep
20	up	up	IN	_	22	case
21	to	to	TO	_	22	case
22	4	4	CD	_	19	nmod
23	-RRB-	-rrb-	-RRB-	_	19	punct
24	with	with	IN	_	26	case
25	the	the	DT	_	26	det
26	development	development	NN	_	16	nmod
27	of	of	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	in	in	IN	_	33	case
30	the	the	DT	_	33	det
31	autoantibody-negative	autoantibody-negative	JJ	_	33	amod
32	diabetic	diabetic	JJ	_	33	amod
33	cohort	cohort	NN	_	26	nmod
34	,	,	,	_	26	punct
35	but	but	CC	_	26	cc
36	not	not	RB	_	41	neg
37	in	in	IN	_	41	case
38	the	the	DT	_	41	det
39	autoantibody-positive	autoantibody-positive	JJ	_	41	amod
40	diabetic	diabetic	JJ	_	41	amod
41	cohort	cohort	NN	_	26	conj
42	.	.	.	_	12	punct

1	In	in	IN	_	4	case
2	our	we	PRP$	_	4	nmod:poss
3	case-control	case-control	JJ	_	4	amod
4	subjects	subject	NNS	_	10	nmod
5	,	,	,	_	10	punct
6	susceptibility	susceptibility	NN	_	10	nsubjpass
7	to	to	TO	_	8	case
8	drug9	drug9	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	replicated	replicate	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	TCF7L2	tcf7l2	NN	_	13	compound
13	drug1	drug1	NN	_	10	nmod
14	,	,	,	_	13	punct
15	CDKAL1	cdkal1	NN	_	16	compound
16	drug2	drug2	NN	_	13	conj
17	,	,	,	_	13	punct
18	drug3	drug3	NN	_	13	conj
19	,	,	,	_	13	punct
20	HHEX	hhex	NN	_	13	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug4	drug4	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	13	punct
25	IGF2BP2	igf2bp2	NN	_	13	conj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	drug5	drug5	NN	_	25	dep
28	and	and	CC	_	27	cc
29	drug6	drug6	NN	_	27	conj
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	,	,	,	_	13	punct
32	CDKN2A/B	cdkn2a/b	NN	_	13	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	drug7	drug7	NN	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	13	punct
37	and	and	CC	_	13	cc
38	SLC30A8	slc30a8	NN	_	13	conj
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	drug8	drug8	NN	_	38	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	.	.	.	_	10	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	to	to	TO	_	5	case
4	these	these	DT	_	5	det
5	polymorphisms	polymorphism	NNS	_	2	nmod
6	,	,	,	_	8	punct
7	meta-analysis	meta-analysis	NN	_	8	nsubj
8	confirmed	confirm	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	association	association	NN	_	8	dobj
11	of	of	IN	_	13	case
12	drug4	drug4	NN	_	13	compound
13	susceptibility	susceptibility	NN	_	10	nmod
14	with	with	IN	_	16	case
15	KCNJ11	kcnj11	NN	_	16	compound
16	drug1	drug1	NN	_	10	nmod
17	,	,	,	_	16	punct
18	TCF7L2	tcf7l2	NN	_	19	compound
19	drug2	drug2	NN	_	16	conj
20	,	,	,	_	16	punct
21	and	and	CC	_	16	cc
22	HHEX	HHEX	NNP	_	23	compound
23	drug3	drug3	NN	_	16	conj
24	.	.	.	_	8	punct

1	The	the	DT	_	4	det
2	TCF7L2	tcf7l2	NN	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	polymorphism	polymorphism	NN	_	5	nsubj
5	showed	show	VBD	_	0	ROOT
6	the	the	DT	_	9	det
7	highest	highest	JJS	_	9	amod
8	odds	odds	NNS	_	9	compound
9	ratio	ratio	NN	_	5	dobj
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	OR	or	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	for	for	IN	_	14	case
14	drug2	drug2	NN	_	9	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	OR	or	NN	_	14	dep
17	1.714	1.714	CD	_	16	nummod
18	-LSB-	-lsb-	-LRB-	_	20	punct
19	1.298-2	1.298-2	CD	_	20	nummod
20	.263	.263	CD	_	16	appos
21	-RSB-	-rsb-	-RRB-	_	20	punct
22	-RRB-	-rrb-	-RRB-	_	16	punct
23	.	.	.	_	5	punct

1	Odds	odds	NNS	_	2	compound
2	ratio	ratio	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	other	other	JJ	_	5	amod
5	polymorphisms	polymorphism	NNS	_	2	nmod
6	ranged	range	VBD	_	0	ROOT
7	from	from	IN	_	8	case
8	1.13	1.13	CD	_	6	nmod
9	to	to	TO	_	10	dep
10	1.41	1.41	CD	_	8	nmod
11	.	.	.	_	6	punct
12	The	the	DT	_	14	det
13	risk	risk	NN	_	14	compound
14	allele	allele	NN	_	20	nsubjpass
15	of	of	IN	_	17	case
16	CDKAL1	cdkal1	NN	_	17	compound
17	drug1	drug1	NN	_	14	nmod
18	was	be	VBD	_	20	auxpass
19	significantly	significantly	RB	_	20	advmod
20	associated	associate	VBN	_	6	parataxis
21	with	with	IN	_	23	case
22	drug2	drug2	NN	_	23	compound
23	patients	patient	NNS	_	20	nmod
24	after	after	IN	_	25	case
25	adjustment	adjustment	NN	_	20	nmod
26	for	for	IN	_	29	case
27	other	other	JJ	_	29	amod
28	confounding	confounding	JJ	_	29	amod
29	factors	factor	NNS	_	25	nmod
30	.	.	.	_	6	punct

1	Compared	compare	VBN	_	3	case
2	with	with	IN	_	3	case
3	controls	control	NNS	_	13	advcl
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	men	man	NNS	_	3	dep
6	and	and	CC	_	5	cc
7	women	woman	NNS	_	5	conj
8	combined	combine	VBN	_	5	acl
9	-RRB-	-rrb-	-RRB-	_	5	punct
10	,	,	,	_	13	punct
11	drug10	drug10	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	OR	or	NN	_	17	dep
20	1.55	1.55	CD	_	19	nummod
21	,	,	,	_	19	punct
22	95	95	CD	_	23	compound
23	%	%	NN	_	24	amod
24	CI	ci	NN	_	19	appos
25	1.34-1	1.34-1	CD	_	26	compound
26	.79	.79	CD	_	24	nummod
27	,	,	,	_	19	punct
28	p	p	NN	_	34	dep
29	=	=	JJ	_	34	dep
30	4.17	4.17	CD	_	34	nummod
31	x	x	CC	_	30	cc
32	10	10	CD	_	30	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	-9	-9	CD	_	19	dep
35	-RRB-	-rrb-	-RRB-	_	19	punct
36	-RRB-	-rrb-	-RRB-	_	15	punct
37	in	in	IN	_	38	case
38	CDKAL1	cdkal1	NN	_	15	conj
39	;	;	:	_	15	punct
40	drug3	drug3	NN	_	15	dep
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	OR	or	NN	_	40	dep
43	1.49	1.49	CD	_	42	nummod
44	,	,	,	_	42	punct
45	95	95	CD	_	46	compound
46	%	%	NN	_	47	amod
47	CI	ci	NN	_	42	appos
48	1.29-1	1.29-1	CD	_	49	compound
49	.72	.72	CD	_	47	nummod
50	,	,	,	_	42	punct
51	p	p	NN	_	57	dep
52	=	=	JJ	_	57	dep
53	1.05	1.05	CD	_	57	nummod
54	x	x	CC	_	53	cc
55	10	10	CD	_	53	conj
56	-LRB-	-lrb-	-LRB-	_	57	punct
57	-7	-7	CD	_	42	dep
58	-RRB-	-rrb-	-RRB-	_	42	punct
59	-RRB-	-rrb-	-RRB-	_	15	punct
60	in	in	IN	_	63	case
61	the	the	DT	_	63	det
62	CDKN2A-CDKN2B	cdkn2a-cdkn2b	JJ	_	63	amod
63	region	region	NN	_	15	nmod
64	;	;	:	_	15	punct
65	drug4	drug4	NN	_	15	conj
66	-LRB-	-lrb-	-LRB-	_	67	punct
67	OR	or	NN	_	65	dep
68	1.27	1.27	CD	_	67	nummod
69	,	,	,	_	67	punct
70	95	95	CD	_	71	compound
71	%	%	NN	_	72	amod
72	CI	ci	NN	_	67	appos
73	1.09-1	1.09-1	CD	_	74	compound
74	.49	.49	CD	_	72	nummod
75	,	,	,	_	67	punct
76	p	p	NN	_	77	nsubj
77	=	=	JJ	_	67	dep
78	0.003	0.003	CD	_	77	dobj
79	-RRB-	-rrb-	-RRB-	_	67	punct
80	,	,	,	_	65	punct
81	drug5	drug5	NN	_	65	conj
82	,	,	,	_	65	punct
83	and	and	CC	_	65	cc
84	drug6	drug6	NN	_	65	conj
85	in	in	IN	_	86	case
86	HHEX	hhex	NN	_	65	nmod
87	;	;	:	_	15	punct
88	drug7	drug7	NN	_	15	conj
89	-LRB-	-lrb-	-LRB-	_	90	punct
90	OR	or	NN	_	88	dep
91	1.18	1.18	CD	_	90	nummod
92	,	,	,	_	90	punct
93	95	95	CD	_	94	compound
94	%	%	NN	_	95	amod
95	CI	ci	NN	_	90	appos
96	1.01-1	1.01-1	CD	_	97	compound
97	.38	.38	CD	_	95	nummod
98	,	,	,	_	90	punct
99	p	p	NN	_	100	nsubj
100	=	=	JJ	_	90	dep
101	0.03	0.03	CD	_	100	dobj
102	-RRB-	-rrb-	-RRB-	_	90	punct
103	in	in	IN	_	104	case
104	IGF2BP2	igf2bp2	NN	_	88	nmod
105	;	;	:	_	15	punct
106	drug8	drug8	NN	_	15	conj
107	-LRB-	-lrb-	-LRB-	_	108	punct
108	OR	or	NN	_	106	dep
109	1.24	1.24	CD	_	108	nummod
110	,	,	,	_	108	punct
111	95	95	CD	_	112	compound
112	%	%	NN	_	113	amod
113	CI	ci	NN	_	108	appos
114	1.07-1	1.07-1	CD	_	115	compound
115	.43	.43	CD	_	113	nummod
116	,	,	,	_	108	punct
117	p	p	NN	_	118	nsubj
118	=	=	JJ	_	108	dep
119	0.005	0.005	CD	_	118	dobj
120	-RRB-	-rrb-	-RRB-	_	108	punct
121	in	in	IN	_	122	case
122	SLC30A8	slc30a8	NN	_	106	nmod
123	;	;	:	_	15	punct
124	and	and	CC	_	15	cc
125	drug9	drug9	NN	_	15	conj
126	-LRB-	-lrb-	-LRB-	_	127	punct
127	OR	or	NN	_	125	dep
128	1.58	1.58	CD	_	127	nummod
129	,	,	,	_	127	punct
130	95	95	CD	_	131	compound
131	%	%	NN	_	132	amod
132	CI	ci	NN	_	127	appos
133	1.03-2	1.03-2	CD	_	134	compound
134	.43	.43	CD	_	132	nummod
135	,	,	,	_	127	punct
136	p	p	NN	_	137	nsubj
137	=	=	JJ	_	127	dep
138	0.038	0.038	CD	_	137	dobj
139	-RRB-	-rrb-	-RRB-	_	127	punct
140	in	in	IN	_	141	case
141	TCF7L2	tcf7l2	NN	_	125	nmod
142	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	risk	risk	NN	_	3	compound
3	alleles	allele	NNS	_	28	nsubjpass
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	SNPs	snp	NNS	_	3	nmod
7	drug1	drug1	NN	_	6	dep
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	in	in	IN	_	11	case
11	CDKAL1	cdkal1	NN	_	3	nmod
12	;	;	:	_	3	punct
13	drug3	drug3	NN	_	3	conj
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	CDKN2A-CDKN2B	cdkn2a-cdkn2b	JJ	_	17	amod
17	region	region	NN	_	13	nmod
18	;	;	:	_	3	punct
19	and	and	CC	_	3	cc
20	drug4	drug4	NN	_	3	conj
21	,	,	,	_	20	punct
22	drug5	drug5	NN	_	20	conj
23	and	and	CC	_	20	cc
24	drug6	drug6	NN	_	20	conj
25	in	in	IN	_	26	case
26	HHEX	HHEX	NNP	_	20	nmod
27	were	be	VBD	_	28	auxpass
28	associated	associate	VBN	_	0	ROOT
29	with	with	IN	_	31	case
30	drug7	drug7	NN	_	31	compound
31	AUC	auc	NN	_	28	nmod
32	during	during	IN	_	36	case
33	a	a	DT	_	36	det
34	100	100	CD	_	35	compound
35	g	g	NN	_	36	amod
36	OGTT	ogtt	NN	_	28	nmod
37	performed	perform	VBN	_	36	acl
38	at	at	IN	_	40	case
39	the	the	DT	_	40	det
40	time	time	NN	_	37	nmod
41	of	of	IN	_	42	case
42	diagnosis	diagnosis	NN	_	40	nmod
43	of	of	IN	_	44	case
44	drug8	drug8	NN	_	42	nmod
45	.	.	.	_	28	punct

1	The	the	DT	_	3	det
2	risk	risk	NN	_	3	compound
3	alleles	allele	NNS	_	15	nsubjpass
4	of	of	IN	_	7	case
5	the	the	DT	_	7	det
6	TCF7L2	tcf7l2	NN	_	7	compound
7	gene	gene	NN	_	3	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug1	drug1	NN	_	7	dep
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	were	be	VBD	_	15	auxpass
14	strongly	strongly	RB	_	15	advmod
15	associated	associate	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	,	,	,	_	15	punct
19	even	even	RB	_	21	advmod
20	after	after	IN	_	21	mark
21	controlling	control	VBG	_	15	advcl
22	for	for	IN	_	25	case
23	traditional	traditional	JJ	_	25	amod
24	risk	risk	NN	_	25	compound
25	factors	factor	NNS	_	21	nmod
26	in	in	IN	_	32	case
27	both	both	CC	_	32	dep
28	a	a	DT	_	32	det
29	cross-sectional	cross-sectional	JJ	_	32	amod
30	and	and	CC	_	29	cc
31	prospective	prospective	JJ	_	29	conj
32	setting	setting	NN	_	25	nmod
33	.	.	.	_	15	punct

1	The	the	DT	_	4	det
2	minor	minor	JJ	_	4	amod
3	allele	allele	NN	_	4	compound
4	frequency	frequency	NN	_	13	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	conj
9	and	and	CC	_	6	cc
10	drug3	drug3	NN	_	6	conj
11	was	be	VBD	_	13	cop
12	significantly	significantly	RB	_	13	advmod
13	higher	higher	JJR	_	0	ROOT
14	in	in	IN	_	16	case
15	drug4	drug4	NN	_	16	compound
16	patients	patient	NNS	_	13	nmod
17	compared	compare	VBN	_	19	case
18	with	with	IN	_	19	case
19	that	that	DT	_	13	advcl
20	in	in	IN	_	22	case
21	non-diabetic	non-diabetic	JJ	_	22	amod
22	individuals	individual	NNS	_	19	nmod
23	.	.	.	_	13	punct

1	The	the	DT	_	6	det
2	T	t	NN	_	6	compound
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	minor	minor	JJ	_	2	dep
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	allele	allele	NN	_	13	nsubjpass
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	variant	variant	JJ	_	10	amod
10	drug1	drug1	NN	_	6	nmod
11	was	be	VBD	_	13	auxpass
12	significantly	significantly	RB	_	13	advmod
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	17	case
15	a	a	DT	_	17	det
16	greater	greater	JJR	_	17	amod
17	OR	or	NN	_	13	nmod
18	for	for	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	adjusted	adjust	VBN	_	19	acl
21	for	for	IN	_	22	case
22	age	age	NN	_	20	nmod
23	,	,	,	_	22	punct
24	sex	sex	NN	_	22	conj
25	and	and	CC	_	22	cc
26	BMI	bmi	NN	_	22	conj
27	in	in	IN	_	30	case
28	logistic	logistic	JJ	_	30	amod
29	regression	regression	NN	_	30	compound
30	analysis	analysis	NN	_	20	nmod
31	:	:	:	_	13	punct

1	No	no	DT	_	4	neg
2	statistically	statistically	RB	_	3	advmod
3	significant	significant	JJ	_	4	amod
4	association	association	NN	_	9	nsubjpass
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	SNPs	snp	NNS	_	4	nmod
8	was	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	or	or	CC	_	11	cc
15	between	between	IN	_	16	case
16	carriers	carrier	NNS	_	11	conj
17	and	and	CC	_	16	cc
18	non-carriers	non-carrier	NNS	_	16	conj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	16	nmod
21	and	and	CC	_	20	cc
22	drug2	drug2	NN	_	23	compound
23	mutations	mutation	NNS	_	20	conj
24	.	.	.	_	9	punct

1	while	while	IN	_	4	mark
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	showed	show	VBD	_	0	ROOT
5	a	a	DT	_	8	det
6	statistically	statistically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	association	association	NN	_	4	dobj
9	between	between	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	13	compound
13	patients	patient	NNS	_	10	conj
14	carrying	carry	VBG	_	8	acl
15	the	the	DT	_	17	det
16	26V	26v	NN	_	17	compound
17	allele	allele	NN	_	14	dobj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	OR	or	NN	_	17	dep
20	=	=	JJ	_	19	amod
21	1.69	1.69	CD	_	20	dep
22	,	,	,	_	19	punct
23	95	95	CD	_	24	compound
24	%	%	NN	_	25	amod
25	CI	ci	NN	_	19	appos
26	=	=	JJ	_	25	amod
27	1.11-2	1.11-2	CD	_	28	nummod
28	.56	.56	CD	_	26	dep
29	,	,	,	_	19	punct
30	P	p	NN	_	31	nsubj
31	=	=	JJ	_	19	dep
32	0.013	0.013	CD	_	31	dobj
33	-RRB-	-rrb-	-RRB-	_	19	punct
34	.	.	.	_	4	punct

1	The	the	DT	_	5	det
2	drug1	drug1	NN	_	5	compound
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	variants	variant	NNS	_	11	nsubjpass
6	of	of	IN	_	7	case
7	TCF7L2	tcf7l2	NN	_	5	nmod
8	have	have	VBP	_	11	aux
9	been	be	VBN	_	11	auxpass
10	strongly	strongly	RB	_	11	advmod
11	associated	associate	VBN	_	0	ROOT
12	with	with	IN	_	14	case
13	drug3	drug3	NN	_	14	compound
14	risk	risk	NN	_	11	nmod
15	in	in	IN	_	17	case
16	most	most	JJS	_	17	amod
17	populations	population	NNS	_	14	nmod
18	studied	study	VBN	_	17	acl
19	to	to	TO	_	20	case
20	date	date	NN	_	18	nmod
21	.	.	.	_	11	punct

1	Comparison	comparison	NN	_	14	nsubj
2	between	between	IN	_	3	case
3	allele	allele	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	genotype	genotype	NN	_	6	compound
6	frequencies	frequency	NNS	_	3	conj
7	of	of	IN	_	9	case
8	these	these	DT	_	9	det
9	SNPs	snp	NNS	_	3	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	and	and	CC	_	11	cc
13	controls	control	NNS	_	11	conj
14	showed	show	VBD	_	0	ROOT
15	marginal	marginal	JJ	_	16	amod
16	association	association	NN	_	14	dobj
17	for	for	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	16	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	p	p	NN	_	25	nsubj
25	=	=	JJ	_	16	dep
26	0.063	0.063	CD	_	25	dobj
27	,	,	,	_	25	punct
28	OR	or	NN	_	25	dep
29	1.982	1.982	CD	_	28	nummod
30	,	,	,	_	25	punct
31	95	95	CD	_	32	compound
32	%	%	NN	_	33	amod
33	CI	ci	NN	_	25	dep
34	1.128-3	1.128-3	CD	_	35	nummod
35	.485	.485	NN	_	33	dep
36	;	;	:	_	25	punct
37	p	p	NN	_	38	nsubj
38	=	=	JJ	_	25	parataxis
39	0.071	0.071	CD	_	38	dobj
40	,	,	,	_	25	punct
41	OR	or	NN	_	25	dep
42	1.237	1.237	CD	_	41	nummod
43	,	,	,	_	41	punct
44	95	95	CD	_	45	compound
45	%	%	NN	_	46	amod
46	CI	ci	NN	_	41	appos
47	0.983-1	0.983-1	CD	_	48	compound
48	.557	.557	CD	_	46	nummod
49	,	,	,	_	41	punct
50	respectively	respectively	RB	_	41	advmod
51	-RRB-	-rrb-	-RRB-	_	25	punct
52	.	.	.	_	14	punct

1	No	no	DT	_	2	neg
2	association	association	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	found	find	VBN	_	0	ROOT
5	for	for	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	appos
9	,	,	,	_	6	punct
10	c.	c.	VBP	_	6	acl
11	1,637	1,637	CD	_	12	nummod
12	C	c	NN	_	10	dobj
13	>	>	JJR	_	12	amod
14	A	a	DT	_	13	dep
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	p	p	NN	_	19	nsubj
19	=	=	JJ	_	12	dep
20	0.278-1	0.278-1	CD	_	21	nummod
21	.000	.000	CD	_	19	dobj
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	.	.	.	_	4	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	association	association	NN	_	2	dobj
5	of	of	IN	_	7	case
6	a	a	DT	_	7	det
7	polymorphism	polymorphism	NN	_	4	nmod
8	in	in	IN	_	10	case
9	TCF7L2	tcf7l2	NN	_	10	compound
10	drug1	drug1	NN	_	7	nmod
11	in	in	IN	_	15	case
12	the	the	DT	_	15	det
13	WNT	wnt	JJ	_	15	amod
14	signaling	signaling	NN	_	15	compound
15	pathway	pathway	NN	_	4	nmod
16	,	,	,	_	15	punct
17	which	which	WDT	_	22	nsubjpass
18	previously	previously	RB	_	22	advmod
19	has	have	VBZ	_	22	aux
20	been	be	VBN	_	22	auxpass
21	strongly	strongly	RB	_	22	advmod
22	associated	associate	VBN	_	15	acl:relcl
23	with	with	IN	_	24	case
24	risk	risk	NN	_	22	nmod
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	,	,	,	_	15	punct
28	with	with	IN	_	29	case
29	drug3	drug3	NN	_	15	nmod
30	and	and	CC	_	29	cc
31	drug4	drug4	NN	_	29	conj
32	in	in	IN	_	38	case
33	the	the	DT	_	35	det
34	prospective	prospective	JJ	_	35	amod
35	Nurses	nurse	NNS	_	38	nmod:poss
36	'	'	POS	_	35	case
37	Health	Health	NNP	_	38	compound
38	Study	Study	NNP	_	29	nmod
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	NHS	NHS	NNP	_	38	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	and	and	CC	_	38	cc
43	Health	Health	NNP	_	45	compound
44	ProfessionalsFollow-up	ProfessionalsFollow-up	NNP	_	45	compound
45	Study	Study	NNP	_	49	compound
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	HPFS	hpf	NNS	_	45	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	cohorts	cohort	NNS	_	38	conj
50	.	.	.	_	2	punct

1	Overall	overall	RB	_	10	advmod
2	,	,	,	_	10	punct
3	in	in	IN	_	5	case
4	the	the	DT	_	5	det
5	NHS	NHS	NNP	_	10	nmod
6	and	and	CC	_	5	cc
7	HPFS	HPFS	NNP	_	5	conj
8	,	,	,	_	10	punct
9	there	there	EX	_	10	expl
10	was	be	VBD	_	0	ROOT
11	suggestive	suggestive	JJ	_	12	amod
12	evidence	evidence	NN	_	10	nsubj
13	for	for	IN	_	16	case
14	an	a	DT	_	16	det
15	inverse	inverse	JJ	_	16	amod
16	association	association	NN	_	12	nmod
17	associated	associate	VBN	_	16	acl
18	with	with	IN	_	19	case
19	homozygosity	homozygosity	NN	_	17	nmod
20	for	for	IN	_	23	case
21	the	the	DT	_	23	det
22	minor	minor	JJ	_	23	amod
23	allele	allele	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	drug2	drug2	NN	_	25	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	conditional	conditional	JJ	_	23	dep
30	and	and	CC	_	29	cc
31	covariate	covariate	JJ	_	33	amod
32	adjusted	adjusted	JJ	_	33	amod
33	OR	or	NN	_	29	conj
34	=	=	JJ	_	29	amod
35	0.63	0.63	CD	_	34	dep
36	,	,	,	_	29	punct
37	95	95	CD	_	38	compound
38	%	%	NN	_	39	amod
39	CI	ci	NN	_	29	appos
40	:	:	:	_	29	punct
41	0.37-1	0.37-1	CD	_	42	compound
42	.08	.08	CD	_	29	dep
43	;	;	:	_	29	punct
44	P	p	NN	_	29	dep
45	for	for	IN	_	46	case
46	heterogeneity	heterogeneity	NN	_	44	nmod
47	0.52	0.52	CD	_	46	nummod
48	for	for	IN	_	50	case
49	the	the	DT	_	50	det
50	association	association	NN	_	46	nmod
51	in	in	IN	_	52	case
52	women	woman	NNS	_	50	nmod
53	and	and	CC	_	52	cc
54	men	man	NNS	_	52	conj
55	-RRB-	-rrb-	-RRB-	_	29	punct
56	.	.	.	_	10	punct

1	This	this	DT	_	2	det
2	result	result	NN	_	3	nsubj
3	suggests	suggest	VBZ	_	0	ROOT
4	that	that	IN	_	13	mark
5	the	the	DT	_	7	det
6	increased	increase	VBN	_	7	amod
7	drug2	drug2	NN	_	13	nsubj
8	associated	associate	VBN	_	7	acl
9	with	with	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	genotype	genotype	NN	_	8	nmod
12	is	be	VBZ	_	13	cop
13	specific	specific	JJ	_	3	ccomp
14	to	to	TO	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	3	punct

1	Specifically	specifically	RB	_	27	advmod
2	,	,	,	_	27	punct
3	the	the	DT	_	6	det
4	same	same	JJ	_	6	amod
5	risk	risk	NN	_	6	compound
6	allele	allele	NN	_	27	nsubjpass
7	of	of	IN	_	10	case
8	single	single	JJ	_	10	amod
9	nucleotide	nucleotide	NN	_	10	compound
10	polymorphism	polymorphism	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	SNP	snp	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	drug1	drug1	NN	_	10	dep
15	that	that	WDT	_	17	nsubjpass
16	is	be	VBZ	_	17	auxpass
17	associated	associate	VBN	_	10	acl:relcl
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	T	t	NN	_	22	compound
22	allele	allele	NN	_	19	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	has	have	VBZ	_	27	aux
25	recently	recently	RB	_	27	advmod
26	been	be	VBN	_	27	auxpass
27	associated	associate	VBN	_	0	ROOT
28	with	with	IN	_	31	case
29	an	a	DT	_	31	det
30	increased	increase	VBN	_	31	amod
31	risk	risk	NN	_	27	nmod
32	of	of	IN	_	33	case
33	drug3	drug3	NN	_	31	nmod
34	.	.	.	_	27	punct

1	The	the	DT	_	3	det
2	minor	minor	JJ	_	3	amod
3	allele	allele	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	each	each	DT	_	6	det
6	variant	variant	NN	_	3	nmod
7	was	be	VBD	_	9	auxpass
8	significantly	significantly	RB	_	9	advmod
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	;	;	:	_	9	punct
13	the	the	DT	_	15	det
14	greatest	greatest	JJS	_	15	amod
15	risk	risk	NN	_	21	nsubjpass
16	of	of	IN	_	17	mark
17	developing	develop	VBG	_	15	acl
18	the	the	DT	_	19	det
19	disease	disease	NN	_	17	dobj
20	was	be	VBD	_	21	auxpass
21	conferred	confer	VBN	_	9	parataxis
22	by	by	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	,	,	,	_	21	punct
25	with	with	IN	_	29	case
26	an	a	DT	_	29	det
27	allelic	allelic	JJ	_	29	amod
28	odds	odds	NNS	_	29	compound
29	ratio	ratio	NN	_	21	nmod
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	OR	or	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	of	of	IN	_	34	case
34	1.31	1.31	CD	_	29	nmod
35	-LRB-	-lrb-	-LRB-	_	38	punct
36	95	95	CD	_	37	compound
37	%	%	NN	_	38	amod
38	CI	ci	NN	_	34	dep
39	:	:	:	_	38	punct
40	1.11	1.11	CD	_	45	dep
41	-	-	:	_	45	punct
42	1.56	1.56	CD	_	45	dep
43	,	,	,	_	45	punct
44	p	p	NN	_	45	nsubj
45	=	=	JJ	_	38	dep
46	1.96	1.96	CD	_	50	nummod
47	x	x	CC	_	46	cc
48	10	10	CD	_	46	conj
49	-LRB-	-lrb-	-LRB-	_	50	punct
50	-3	-3	CD	_	45	dobj
51	-RRB-	-rrb-	-RRB-	_	38	punct
52	-RRB-	-rrb-	-RRB-	_	29	punct
53	.	.	.	_	9	punct

1	drug3	drug3	NN	_	3	compound
2	disease	disease	NN	_	3	compound
3	stage	stage	NN	_	7	nsubjpass
4	was	be	VBD	_	7	auxpass
5	marginally	marginally	RB	_	6	advmod
6	significantly	significantly	RB	_	7	advmod
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	the	the	DT	_	10	det
10	frequency	frequency	NN	_	7	nmod
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	T	t	NN	_	14	compound
14	variant	variant	NN	_	10	nmod
15	at	at	IN	_	16	case
16	drug1	drug1	NN	_	10	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	p	p	NN	_	19	nsubj
19	=	=	JJ	_	10	dep
20	0.057	0.057	CD	_	19	dobj
21	;	;	:	_	19	punct
22	adjusted	adjust	VBN	_	23	amod
23	p	p	NN	_	24	nsubj
24	=	=	JJ	_	19	parataxis
25	0.017	0.017	CD	_	24	dobj
26	-RRB-	-rrb-	-RRB-	_	19	punct
27	but	but	CC	_	10	cc
28	not	not	RB	_	30	neg
29	at	at	IN	_	30	case
30	drug2	drug2	NN	_	10	conj
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	p	p	NN	_	33	nsubj
33	=	=	JJ	_	30	dep
34	0.5	0.5	CD	_	33	dobj
35	;	;	:	_	33	punct
36	adjusted	adjust	VBN	_	37	amod
37	p	p	NN	_	38	nsubj
38	=	=	JJ	_	33	parataxis
39	0.2	0.2	CD	_	38	dobj
40	-RRB-	-rrb-	-RRB-	_	33	punct
41	.	.	.	_	7	punct

1	Comparison	comparison	NN	_	10	nsubj
2	between	between	IN	_	3	case
3	subjects	subject	NNS	_	1	nmod
4	with	with	IN	_	5	case
5	drug3	drug3	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	the	the	DT	_	9	det
8	combined	combined	JJ	_	9	amod
9	drug4	drug4	NN	_	5	conj
10	showed	show	VBD	_	0	ROOT
11	a	a	DT	_	13	det
12	significant	significant	JJ	_	13	amod
13	association	association	NN	_	10	dobj
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	OR	or	NN	_	15	dep
18	1.47	1.47	CD	_	17	nummod
19	,	,	,	_	17	punct
20	CI	ci	NN	_	17	appos
21	1.04-2	1.04-2	CD	_	22	compound
22	.08	.08	CD	_	20	nummod
23	;	;	:	_	17	punct
24	p	p	NN	_	25	nsubj
25	=	=	JJ	_	17	dep
26	0.03	0.03	CD	_	25	dobj
27	-RRB-	-rrb-	-RRB-	_	17	punct
28	but	but	CC	_	15	cc
29	not	not	RB	_	31	neg
30	with	with	IN	_	31	case
31	drug2	drug2	NN	_	15	conj
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	OR	or	NN	_	31	dep
34	1.16	1.16	CD	_	33	nummod
35	,	,	,	_	33	punct
36	CI	ci	NN	_	33	appos
37	0.81-1	0.81-1	CD	_	38	compound
38	.64	.64	CD	_	36	nummod
39	;	;	:	_	33	punct
40	p	p	NN	_	41	nsubj
41	=	=	JJ	_	33	dep
42	0.4	0.4	CD	_	41	dobj
43	-RRB-	-rrb-	-RRB-	_	33	punct
44	.	.	.	_	10	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubjpass
6	are	be	VBP	_	7	auxpass
7	associated	associate	VBN	_	3	ccomp
8	with	with	IN	_	10	case
9	increased	increase	VBN	_	10	amod
10	risk	risk	NN	_	7	nmod
11	for	for	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	in	in	IN	_	15	case
14	Emirati	emirati	JJ	_	15	amod
15	subjects	subject	NNS	_	12	nmod
16	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	minor	minor	JJ	_	3	amod
3	alleles	allele	NNS	_	11	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	drug3	drug3	NN	_	5	conj
11	showed	show	VBD	_	0	ROOT
12	significant	significant	JJ	_	13	amod
13	associations	association	NNS	_	11	dobj
14	with	with	IN	_	15	case
15	drug6	drug6	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	OR	or	NN	_	15	dep
18	=	=	JJ	_	17	amod
19	1.48	1.48	CD	_	18	dep
20	,	,	,	_	17	punct
21	P	p	NN	_	22	nsubj
22	=	=	JJ	_	17	dep
23	2.7	2.7	CD	_	22	dobj
24	x	x	CC	_	23	cc
25	10	10	CD	_	23	conj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	-4	-4	CD	_	22	dep
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	;	;	:	_	17	punct
30	OR	or	NN	_	17	dep
31	=	=	JJ	_	30	amod
32	1.39	1.39	CD	_	31	dep
33	,	,	,	_	30	punct
34	P	p	NN	_	35	nsubj
35	=	=	JJ	_	30	dep
36	4.6	4.6	CD	_	35	dobj
37	x	x	CC	_	36	cc
38	10	10	CD	_	36	conj
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	-4	-4	CD	_	35	dep
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	;	;	:	_	17	punct
43	OR	or	NN	_	17	dep
44	=	=	JJ	_	43	amod
45	1.70	1.70	CD	_	44	dep
46	,	,	,	_	43	punct
47	P	p	NN	_	48	nsubj
48	=	=	JJ	_	43	dep
49	9.8	9.8	CD	_	48	dobj
50	x	x	CC	_	49	cc
51	10	10	CD	_	49	conj
52	-LRB-	-lrb-	-LRB-	_	53	punct
53	-5	-5	CD	_	48	dep
54	-RRB-	-rrb-	-RRB-	_	53	punct
55	,	,	,	_	48	punct
56	respectively	respectively	RB	_	48	advmod
57	-RRB-	-rrb-	-RRB-	_	17	punct
58	in	in	IN	_	62	case
59	the	the	DT	_	62	det
60	combined	combined	JJ	_	62	amod
61	sample	sample	NN	_	62	compound
62	sets	set	NNS	_	13	nmod
63	,	,	,	_	11	punct
64	However	however	RB	_	11	advmod
65	,	,	,	_	11	punct
66	neither	neither	CC	_	67	cc:preconj
67	drug4	drug4	NN	_	70	nsubj
68	nor	nor	CC	_	67	cc
69	drug5	drug5	NN	_	67	conj
70	showed	show	VBD	_	11	dep
71	a	a	DT	_	73	det
72	significant	significant	JJ	_	73	amod
73	association	association	NN	_	70	dobj
74	.	.	.	_	11	punct

1	Significant	significant	JJ	_	2	amod
2	evidence	evidence	NN	_	6	nsubjpass
3	for	for	IN	_	4	case
4	association	association	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	for	for	IN	_	9	case
8	high	high	JJ	_	9	amod
9	TG	tg	NN	_	6	nmod
10	for	for	IN	_	13	case
11	the	the	DT	_	13	det
12	T	t	NN	_	13	compound
13	alleles	allele	NNS	_	9	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	p	p	NN	_	20	nsubj
20	=	=	JJ	_	9	dep
21	0.005	0.005	CD	_	20	dobj
22	and	and	CC	_	20	cc
23	p	p	NN	_	24	nsubj
24	=	=	JJ	_	20	conj
25	0.01	0.01	CD	_	24	dobj
26	-RRB-	-rrb-	-RRB-	_	20	punct
27	in	in	IN	_	30	case
28	Mexican	mexican	JJ	_	30	amod
29	drug3	drug3	NN	_	30	compound
30	families	family	NNS	_	9	nmod
31	,	,	,	_	6	punct
32	No	no	DT	_	33	neg
33	evidence	evidence	NN	_	37	nsubjpass
34	for	for	IN	_	35	case
35	association	association	NN	_	33	nmod
36	was	be	VBD	_	37	auxpass
37	observed	observe	VBN	_	6	ccomp
38	for	for	IN	_	39	case
39	drug4	drug4	NN	_	37	nmod
40	,	,	,	_	39	punct
41	drug5	drug5	NN	_	39	conj
42	,	,	,	_	39	punct
43	drug6	drug6	NN	_	39	appos
44	in	in	IN	_	45	case
45	Mexicans	Mexicans	NNPS	_	43	nmod
46	.	.	.	_	6	punct

1	When	when	WRB	_	0	ROOT
2	testing	testing	NN	_	3	compound
3	drug1	drug1	NN	_	1	dep
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	for	for	IN	_	7	case
7	replication	replication	NN	_	3	nmod
8	in	in	IN	_	11	case
9	Finnish	finnish	JJ	_	11	amod
10	drug3	drug3	NN	_	11	compound
11	families	family	NNS	_	7	nmod
12	,	,	,	_	3	punct
13	these	these	DT	_	16	det
14	single	single	JJ	_	16	amod
15	nucleotide	nucleotide	NN	_	16	compound
16	polymorphisms	polymorphism	NNS	_	18	nsubjpass
17	were	be	VBD	_	18	auxpass
18	associated	associate	VBN	_	3	acl:relcl
19	with	with	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	p	p	NN	_	23	nsubj
23	=	=	JJ	_	20	dep
24	0.01	0.01	CD	_	23	dobj
25	and	and	CC	_	23	cc
26	p	p	NN	_	27	nsubj
27	=	=	JJ	_	23	conj
28	0.007	0.007	CD	_	27	dobj
29	-RRB-	-rrb-	-RRB-	_	23	punct
30	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	drug1	drug1	NN	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	are	be	VBP	_	10	auxpass
9	significantly	significantly	RB	_	10	advmod
10	associated	associate	VBN	_	3	ccomp
11	with	with	IN	_	13	case
12	high	high	JJ	_	13	amod
13	drug3	drug3	NN	_	10	nmod
14	in	in	IN	_	16	case
15	drug4	drug4	NN	_	16	compound
16	families	family	NNS	_	13	nmod
17	from	from	IN	_	20	case
18	two	two	CD	_	20	nummod
19	different	different	JJ	_	20	amod
20	populations	population	NNS	_	13	nmod
21	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	11	mark
5	the	the	DT	_	9	det
6	TCF7L2	tcf7l2	NN	_	9	compound
7	drug1	drug1	NN	_	9	compound
8	genetic	genetic	JJ	_	9	amod
9	variation	variation	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	associated	associate	VBN	_	3	ccomp
12	with	with	IN	_	15	case
13	an	a	DT	_	15	det
14	increased	increase	VBN	_	15	amod
15	risk	risk	NN	_	11	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	3	punct

1	One	one	CD	_	3	nummod
2	representative	representative	NN	_	3	compound
3	variant	variant	NN	_	9	nsubjpass
4	,	,	,	_	3	punct
5	drug1	drug1	NN	_	3	appos
6	,	,	,	_	3	punct
7	was	be	VBD	_	9	auxpass
8	nominally	nominally	RB	_	9	advmod
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	in	in	IN	_	15	case
13	a	a	DT	_	15	det
14	general	general	JJ	_	15	amod
15	model	model	NN	_	9	nmod
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	additive	additive	JJ	_	18	amod
18	P	p	NN	_	15	dep
19	=	=	JJ	_	18	amod
20	0.03	0.03	CD	_	19	dep
21	,	,	,	_	18	punct
22	dominant	dominant	JJ	_	23	amod
23	P	p	NN	_	24	nsubj
24	=	=	JJ	_	18	dep
25	0.005	0.005	CD	_	24	dobj
26	-RRB-	-rrb-	-RRB-	_	18	punct
27	but	but	CC	_	15	cc
28	not	not	RB	_	32	neg
29	in	in	IN	_	32	case
30	a	a	DT	_	32	det
31	within-family	within-family	NN	_	32	compound
32	analysis	analysis	NN	_	15	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	additive	additive	JJ	_	35	amod
35	P	p	NN	_	36	nsubj
36	=	=	JJ	_	32	dep
37	0.2	0.2	CD	_	36	dobj
38	,	,	,	_	36	punct
39	dominant	dominant	JJ	_	40	amod
40	P	p	NN	_	41	nsubj
41	=	=	JJ	_	36	parataxis
42	0.07	0.07	CD	_	41	dobj
43	-RRB-	-rrb-	-RRB-	_	36	punct
44	.	.	.	_	9	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	several	several	JJ	_	4	amod
4	variants	variant	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	;	;	:	_	6	punct
10	in	in	IN	_	11	case
11	particular	particular	JJ	_	15	nmod
12	,	,	,	_	15	punct
13	drug1	drug1	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	associated	associate	VBN	_	6	parataxis
16	in	in	IN	_	18	case
17	both	both	CC	_	18	cc:preconj
18	general	general	JJ	_	15	nmod
19	and	and	CC	_	18	cc
20	within-family	within-family	NN	_	18	conj
21	analyses	analysis	NNS	_	18	dep
22	-LRB-	-lrb-	-LRB-	_	25	punct
23	both	both	DT	_	24	det
24	P	p	NN	_	25	nsubj
25	=	=	JJ	_	15	parataxis
26	0.0007	0.0007	CD	_	25	dobj
27	-RRB-	-rrb-	-RRB-	_	25	punct
28	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	association	association	NN	_	2	nsubj
5	between	between	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	in	in	IN	_	13	case
10	the	the	DT	_	13	det
11	UK	UK	NNP	_	13	compound
12	case-control	case-control	JJ	_	13	amod
13	study	study	NN	_	2	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	Cochran-Armitage	cochran-armitage	JJ	_	16	amod
16	test	test	NN	_	13	dep
17	,	,	,	_	16	punct
18	p	p	NN	_	19	nsubj
19	=	=	JJ	_	16	dep
20	0.51	0.51	CD	_	19	dobj
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	;	;	:	_	2	punct
23	nor	nor	CC	_	2	cc
24	with	with	IN	_	26	case
25	symptomatic	symptomatic	JJ	_	26	amod
26	status	status	NN	_	2	conj
27	in	in	IN	_	30	case
28	the	the	DT	_	30	det
29	Finnish	finnish	JJ	_	30	amod
30	cohort	cohort	NN	_	26	nmod
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	p	p	NN	_	33	nsubj
33	=	=	JJ	_	26	dep
34	0.36	0.36	CD	_	33	dobj
35	-RRB-	-rrb-	-RRB-	_	33	punct
36	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	5	nmod
3	,	,	,	_	5	punct
4	there	there	EX	_	5	expl
5	were	be	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	relationships	relationship	NNS	_	5	nsubj
8	between	between	IN	_	14	case
9	the	the	DT	_	14	det
10	TCF7L2	tcf7l2	NN	_	14	compound
11	single	single	JJ	_	14	amod
12	nucleotide	nucleotide	NN	_	14	compound
13	polymorphism	polymorphism	NN	_	14	compound
14	drug1	drug1	NN	_	7	nmod
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	UK	UK	NNP	_	19	compound
19	cases	case	NNS	_	7	dep
20	,	,	,	_	19	punct
21	p	p	NN	_	19	appos
22	=	=	JJ	_	21	amod
23	0.99	0.99	CD	_	22	dep
24	;	;	:	_	19	punct
25	Finnish	finnish	JJ	_	26	amod
26	controls	control	NNS	_	19	conj
27	,	,	,	_	26	punct
28	p	p	NN	_	26	appos
29	=	=	JJ	_	28	amod
30	0.57	0.57	CD	_	29	dep
31	;	;	:	_	19	punct
32	Finnish	finnish	JJ	_	34	amod
33	symptomatic	symptomatic	JJ	_	34	amod
34	cases	case	NNS	_	19	dep
35	,	,	,	_	34	punct
36	p	p	NN	_	37	nsubj
37	=	=	JJ	_	34	acl:relcl
38	0.80	0.80	CD	_	37	dobj
39	-RRB-	-rrb-	-RRB-	_	19	punct
40	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	frequency	frequency	NN	_	15	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	T	t	NN	_	6	compound
6	allele	allele	NN	_	2	nmod
7	of	of	IN	_	9	case
8	both	both	CC	_	9	cc:preconj
9	drug1	drug1	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	12	compound
12	polymorphisms	polymorphism	NNS	_	9	conj
13	was	be	VBD	_	15	cop
14	significantly	significantly	RB	_	15	advmod
15	higher	higher	JJR	_	0	ROOT
16	in	in	IN	_	18	case
17	drug3	drug3	NN	_	18	compound
18	subjects	subject	NNS	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	23	23	CD	_	21	nummod
21	%	%	NN	_	15	dep
22	and	and	CC	_	21	cc
23	33	33	CD	_	24	nummod
24	%	%	NN	_	21	conj
25	-RRB-	-rrb-	-RRB-	_	21	punct
26	compared	compare	VBN	_	28	case
27	to	to	TO	_	28	case
28	that	that	DT	_	15	advcl
29	in	in	IN	_	32	case
30	normal	normal	JJ	_	32	amod
31	glucose-tolerant	glucose-tolerant	JJ	_	32	amod
32	subjects	subject	NNS	_	28	nmod
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	19	19	CD	_	35	nummod
35	%	%	NN	_	32	dep
36	and	and	CC	_	35	cc
37	28	28	CD	_	38	nummod
38	%	%	NN	_	35	conj
39	;	;	:	_	35	punct
40	P	p	NN	_	41	nsubj
41	=	=	JJ	_	35	dep
42	.001	.001	CD	_	41	dobj
43	and	and	CC	_	41	cc
44	P	p	NN	_	45	nsubj
45	=	=	JJ	_	41	conj
46	.0001	.0001	CD	_	45	dobj
47	,	,	,	_	41	punct
48	respectively	respectively	RB	_	41	advmod
49	-RRB-	-rrb-	-RRB-	_	35	punct
50	.	.	.	_	15	punct

1	Normal	normal	JJ	_	3	amod
2	glucose-tolerant	glucose-tolerant	JJ	_	3	amod
3	subjects	subject	NNS	_	10	nsubj
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	TT	tt	NN	_	7	compound
7	genotype	genotype	NN	_	3	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	had	have	VBD	_	0	ROOT
11	significantly	significantly	RB	_	12	advmod
12	higher	higher	JJR	_	13	amod
13	drug2	drug2	NN	_	10	dobj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	mean	mean	NN	_	13	dep
16	+	+	CC	_	15	cc
17	/	/	:	_	15	punct
18	-	-	:	_	15	punct
19	SD	sd	NN	_	15	dep
20	,	,	,	_	15	punct
21	6.1	6.1	CD	_	15	dep
22	+	+	CC	_	21	cc
23	/	/	:	_	26	punct
24	-	-	:	_	26	punct
25	1.4	1.4	CD	_	26	nummod
26	mmol/L	mmol/l	NN	_	21	dep
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	than	than	IN	_	29	case
29	those	those	DT	_	21	nmod
30	with	with	IN	_	33	case
31	the	the	DT	_	33	det
32	GG	gg	NNS	_	33	compound
33	genotype	genotype	NN	_	29	nmod
34	-LRB-	-lrb-	-LRB-	_	33	punct
35	5.6	5.6	CD	_	34	root
36	+	+	CC	_	35	cc
37	/	/	:	_	35	conj
38	-	-	:	_	37	punct
39	1.0	1.0	CD	_	40	nummod
40	mmol/L	mmol/l	NN	_	38	root
41	,	,	,	_	40	punct
42	P	p	NN	_	43	nsubj
43	=	=	JJ	_	40	dep
44	.011	.011	CD	_	43	dobj
45	-RRB-	-rrb-	-RRB-	_	40	punct
46	.	.	.	_	40	punct

1	Normal	normal	JJ	_	3	amod
2	glucose-tolerant	glucose-tolerant	JJ	_	3	amod
3	subjects	subject	NNS	_	11	nsubj
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	TT	tt	NN	_	7	compound
7	genotype	genotype	NN	_	3	nmod
8	of	of	IN	_	10	case
9	drug1	drug1	NN	_	10	compound
10	polymorphism	polymorphism	NN	_	7	nmod
11	had	have	VBD	_	0	ROOT
12	significantly	significantly	RB	_	13	advmod
13	higher	higher	JJR	_	14	amod
14	drug2	drug2	NN	_	11	dobj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	mean	mean	NN	_	14	dep
17	+	+	CC	_	16	cc
18	/	/	:	_	16	punct
19	-	-	:	_	16	punct
20	SD	sd	NN	_	16	dep
21	,	,	,	_	16	punct
22	6.0	6.0	CD	_	16	dep
23	+	+	CC	_	22	cc
24	/	/	:	_	27	punct
25	-	-	:	_	27	punct
26	1.3	1.3	CD	_	27	nummod
27	mmol/L	mmol/l	NN	_	22	dep
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	than	than	IN	_	30	case
30	those	those	DT	_	22	nmod
31	with	with	IN	_	34	case
32	the	the	DT	_	34	det
33	CC	cc	NN	_	34	compound
34	genotype	genotype	NN	_	30	nmod
35	-LRB-	-lrb-	-LRB-	_	34	punct
36	5.6	5.6	CD	_	35	root
37	+	+	CC	_	36	cc
38	/	/	:	_	36	conj
39	-	-	:	_	38	punct
40	1.0	1.0	CD	_	41	nummod
41	mmol/L	mmol/l	NN	_	39	root
42	,	,	,	_	41	punct
43	P	p	NN	_	44	nsubj
44	=	=	JJ	_	41	dep
45	.004	.004	CD	_	44	dobj
46	-RRB-	-rrb-	-RRB-	_	41	punct
47	.	.	.	_	41	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	16	nmod
3	,	,	,	_	16	punct
4	the	the	DT	_	6	det
5	T	t	NN	_	6	compound
6	allele	allele	NN	_	16	nsubj
7	of	of	IN	_	12	case
8	the	the	DT	_	12	det
9	drug1	drug1	NN	_	12	compound
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	polymorphisms	polymorphism	NNS	_	6	nmod
13	of	of	IN	_	15	case
14	TCF7L2	tcf7l2	NN	_	15	compound
15	gene	gene	NN	_	12	nmod
16	confer	confer	VBP	_	0	ROOT
17	susceptibility	susceptibility	NN	_	16	dobj
18	to	to	TO	_	19	mark
19	drug3	drug3	VB	_	17	acl
20	in	in	IN	_	22	case
21	Asian	asian	JJ	_	22	amod
22	Indians	Indians	NNPS	_	19	nmod
23	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	CT/TT	ct/tt	NN	_	3	compound
3	genotypes	genotype	NNS	_	8	nsubj
4	of	of	IN	_	6	case
5	SNP	snp	NN	_	6	compound
6	drug1	drug1	NN	_	3	nmod
7	strongly	strongly	RB	_	8	advmod
8	predicted	predict	VBD	_	0	ROOT
9	future	future	JJ	_	10	amod
10	drug2	drug2	NN	_	8	dobj
11	in	in	IN	_	14	case
12	2	2	CD	_	14	nummod
13	independent	independent	JJ	_	14	amod
14	cohorts	cohort	NNS	_	10	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	Swedish	swedish	JJ	_	14	dep
17	and	and	CC	_	16	cc
18	Finnish	finnish	JJ	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	.	.	.	_	8	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	extend	extend	VBP	_	0	ROOT
4	previous	previous	JJ	_	5	amod
5	observations	observation	NNS	_	3	dobj
6	to	to	TO	_	9	case
7	other	other	JJ	_	9	amod
8	ethnic	ethnic	JJ	_	9	amod
9	groups	group	NNS	_	5	nmod
10	,	,	,	_	3	punct
11	and	and	CC	_	3	cc
12	strongly	strongly	RB	_	13	advmod
13	confirm	confirm	VBP	_	3	conj
14	that	that	IN	_	21	mark
15	drug1	drug1	NN	_	16	compound
16	genotype	genotype	NN	_	21	nsubj
17	is	be	VBZ	_	21	cop
18	a	a	DT	_	21	det
19	major	major	JJ	_	21	amod
20	risk	risk	NN	_	21	compound
21	factor	factor	NN	_	13	ccomp
22	for	for	IN	_	23	case
23	development	development	NN	_	21	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	.	.	.	_	3	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	GLP-1-infusion	glp-1-infusion	NN	_	9	nsubj
4	combined	combine	VBN	_	3	acl
5	with	with	IN	_	8	case
6	a	a	DT	_	8	det
7	hyperglycaemic	hyperglycaemic	JJ	_	8	amod
8	clamp	clamp	NN	_	4	nmod
9	showed	show	VBD	_	0	ROOT
10	a	a	DT	_	12	det
11	significant	significant	JJ	_	12	amod
12	reduction	reduction	NN	_	9	dobj
13	in	in	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	in	in	IN	_	16	case
16	carriers	carrier	NNS	_	12	nmod
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	risk	risk	NN	_	20	compound
20	allele	allele	NN	_	16	nmod
21	in	in	IN	_	23	case
22	two	two	CD	_	23	nummod
23	variants	variant	NNS	_	20	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	drug1	drug1	NN	_	27	compound
26	drug2	drug2	NN	_	27	compound
27	p	p	NN	_	23	dep
28	<	<	JJR	_	27	amod
29	0.02	0.02	CD	_	28	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	,	,	,	_	9	punct

1	we	we	PRP	_	2	nsubj
2	analysed	analyse	VBD	_	0	ROOT
3	two	two	CD	_	6	nummod
4	single	single	JJ	_	6	amod
5	nucleotide	nucleotide	NN	_	6	compound
6	polymorphisms	polymorphism	NNS	_	2	dobj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	SNPs	snp	NNS	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	6	punct
11	drug1	drug1	NN	_	6	appos
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	6	punct
15	in	in	IN	_	18	case
16	the	the	DT	_	18	det
17	transcription	transcription	NN	_	18	compound
18	factor	factor	NN	_	2	nmod
19	7-like	7-like	JJ	_	21	amod
20	2	2	CD	_	21	nummod
21	gene	gene	NN	_	18	dep
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	TCF7L2	tcf7l2	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	,	,	,	_	18	punct
26	which	which	WDT	_	28	nsubjpass
27	are	be	VBP	_	28	auxpass
28	associated	associate	VBN	_	18	acl:relcl
29	with	with	IN	_	32	case
30	an	a	DT	_	32	det
31	increased	increase	VBN	_	32	amod
32	risk	risk	NN	_	28	nmod
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	32	nmod
35	.	.	.	_	2	punct

1	Both	both	DT	_	3	cc:preconj
2	TCF7L2	tcf7l2	NN	_	3	compound
3	SNPs	snp	NNS	_	10	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug1	drug1	NN	_	3	dep
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	were	be	VBD	_	10	auxpass
10	found	find	VBN	_	0	ROOT
11	to	to	TO	_	14	mark
12	be	be	VB	_	14	auxpass
13	significantly	significantly	RB	_	14	advmod
14	associated	associate	VBN	_	10	xcomp
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	when	when	WRB	_	18	advmod
18	adjusting	adjust	VBG	_	14	advcl
19	for	for	IN	_	21	case
20	insulin	insulin	NN	_	21	compound
21	sensitivity	sensitivity	NN	_	18	nmod
22	,	,	,	_	14	punct
23	both	both	CC	_	27	cc:preconj
24	in	in	IN	_	27	case
25	the	the	DT	_	27	det
26	whole	whole	JJ	_	27	amod
27	cohort	cohort	NN	_	14	nmod
28	and	and	CC	_	27	cc
29	when	when	WRB	_	34	advmod
30	the	the	DT	_	32	det
31	diabetic	diabetic	JJ	_	32	amod
32	subjects	subject	NNS	_	34	nsubjpass
33	were	be	VBD	_	34	auxpass
34	excluded	exclude	VBN	_	27	conj
35	.	.	.	_	10	punct

1	The	the	DT	_	4	det
2	most	most	RBS	_	3	advmod
3	significant	significant	JJ	_	4	amod
4	associations	association	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	with	with	IN	_	12	case
8	TCF7L2	tcf7l2	NN	_	12	compound
9	intron	intron	NN	_	12	compound
10	3	3	CD	_	12	nummod
11	SNPs	snp	NNS	_	12	compound
12	drug1	drug1	NN	_	6	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	additive	additive	JJ	_	15	amod
15	P	p	NN	_	12	dep
16	=	=	JJ	_	15	amod
17	4.10	4.10	CD	_	21	nummod
18	x	x	CC	_	17	cc
19	10	10	CD	_	17	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	-6	-6	CD	_	16	dep
22	-RRB-	-rrb-	-RRB-	_	15	punct
23	,	,	,	_	12	punct
24	odds	odds	NNS	_	25	compound
25	ratio	ratio	NN	_	12	conj
26	-LSB-	-lsb-	-LRB-	_	27	punct
27	OR	or	NN	_	25	appos
28	-RSB-	-rsb-	-RRB-	_	27	punct
29	1.51	1.51	CD	_	25	nummod
30	;	;	:	_	12	punct
31	admixture-adjusted	admixture-adjusted	JJ	_	32	amod
32	P	p	NN	_	12	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	a	a	DT	_	36	dep
35	-RRB-	-rrb-	-RRB-	_	36	punct
36	=	=	JJ	_	32	dep
37	3.77	3.77	CD	_	36	dobj
38	x	x	CC	_	37	cc
39	10	10	CD	_	37	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	-6	-6	CD	_	36	dep
42	-RRB-	-rrb-	-RRB-	_	41	punct
43	-RRB-	-rrb-	-RRB-	_	36	punct
44	and	and	CC	_	32	cc
45	drug2	drug2	NN	_	32	conj
46	-LRB-	-lrb-	-LRB-	_	48	punct
47	P	p	NN	_	48	nsubj
48	=	=	JJ	_	45	dep
49	0.001	0.001	CD	_	48	dobj
50	,	,	,	_	48	punct
51	OR	or	NN	_	48	dep
52	1.30	1.30	CD	_	51	nummod
53	;	;	:	_	48	punct
54	P	p	NN	_	70	nsubjpass
55	-LRB-	-lrb-	-LRB-	_	58	punct
56	a	a	DT	_	58	dep
57	-RRB-	-rrb-	-RRB-	_	58	punct
58	=	=	JJ	_	54	dep
59	0.003	0.003	CD	_	58	dobj
60	-RRB-	-rrb-	-RRB-	_	58	punct
61	,	,	,	_	54	punct
62	The	the	DT	_	64	det
63	2-SNP	2-snp	JJ	_	64	amod
64	haplotype	haplotype	NN	_	54	appos
65	containing	contain	VBG	_	64	acl
66	these	these	DT	_	67	det
67	SNPs	snp	NNS	_	65	dobj
68	was	be	VBD	_	70	auxpass
69	also	also	RB	_	70	advmod
70	associated	associate	VBN	_	48	parataxis
71	with	with	IN	_	72	case
72	drug3	drug3	NN	_	70	nmod
73	-LRB-	-lrb-	-LRB-	_	75	punct
74	P	p	NN	_	75	nsubj
75	=	=	JJ	_	72	dep
76	3	3	CD	_	75	dobj
77	x	x	CC	_	76	cc
78	10	10	CD	_	76	conj
79	-LRB-	-lrb-	-LRB-	_	80	punct
80	-5	-5	CD	_	75	parataxis
81	-RRB-	-rrb-	-RRB-	_	80	punct
82	-RRB-	-rrb-	-RRB-	_	75	punct

1	The	the	DT	_	5	det
2	previously	previously	RB	_	3	advmod
3	reported	report	VBN	_	5	amod
4	SNPs	snp	NNS	_	5	compound
5	drug1	drug1	NN	_	13	nsubj
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	TCF7L2	tcf7l2	NN	_	11	compound
11	gene	gene	NN	_	5	nmod
12	were	be	VBD	_	13	cop
13	rare	rare	JJ	_	0	ROOT
14	and	and	CC	_	13	cc
15	were	be	VBD	_	17	auxpass
16	not	not	RB	_	17	neg
17	associated	associate	VBN	_	13	conj
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	in	in	IN	_	23	case
21	a	a	DT	_	23	det
22	Chinese	chinese	JJ	_	23	amod
23	population	population	NN	_	17	nmod
24	,	,	,	_	23	punct
25	which	which	WDT	_	27	nsubj
26	may	may	MD	_	27	aux
27	attribute	attribute	VB	_	23	acl:relcl
28	to	to	TO	_	31	case
29	the	the	DT	_	31	det
30	low	low	JJ	_	31	amod
31	frequencies	frequency	NNS	_	27	nmod
32	of	of	IN	_	35	case
33	these	these	DT	_	35	det
34	two	two	CD	_	35	nummod
35	SNPs	snp	NNS	_	31	nmod
36	.	.	.	_	13	punct

1	SNP	snp	NN	_	2	compound
2	drug1	drug1	NN	_	18	nsubjpass
3	located	located	JJ	_	2	amod
4	in	in	IN	_	7	case
5	an	a	DT	_	7	det
6	LD	ld	NN	_	7	compound
7	block	block	NN	_	3	nmod
8	close	close	NN	_	7	amod
9	to	to	TO	_	13	case
10	the	the	DT	_	13	det
11	3	3	CD	_	13	nummod
12	'	'	''	_	13	punct
13	end	end	NN	_	8	nmod
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	gene	gene	NN	_	13	nmod
17	was	be	VBD	_	18	auxpass
18	associated	associate	VBN	_	0	ROOT
19	with	with	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	allele-specific	allele-specific	JJ	_	23	amod
23	P	p	NN	_	20	dep
24	=	=	JJ	_	23	amod
25	0.0021	0.0021	CD	_	24	dep
26	;	;	:	_	23	punct
27	permuted	permuted	JJ	_	28	amod
28	P	p	NN	_	29	nsubj
29	=	=	JJ	_	23	dep
30	0.03	0.03	CD	_	29	dobj
31	-RRB-	-rrb-	-RRB-	_	23	punct
32	.	.	.	_	18	punct

1	We	we	PRP	_	2	nsubj
2	studied	study	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	effect	effect	NN	_	2	dobj
5	of	of	IN	_	7	case
6	TCF7L2	tcf7l2	NN	_	7	compound
7	drug1	drug1	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	10	compound
10	genotypes	genotype	NNS	_	7	conj
11	on	on	IN	_	12	case
12	drug3	drug3	NN	_	4	nmod

1	We	we	PRP	_	2	nsubj
2	observed	observe	VBD	_	0	ROOT
3	a	a	DT	_	5	det
4	significant	significant	JJ	_	5	amod
5	association	association	NN	_	2	dobj
6	between	between	IN	_	9	case
7	the	the	DT	_	9	det
8	single-nucleotide	single-nucleotide	JJ	_	9	amod
9	polymorphism	polymorphism	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	SNP	snp	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	drug1	drug1	NN	_	9	dep
14	and	and	CC	_	9	cc
15	the	the	DT	_	17	det
16	microsatellite	microsatellite	NN	_	17	compound
17	drug2	drug2	NN	_	9	conj
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	Mexican	mexican	JJ	_	23	amod
23	sample	sample	NN	_	17	nmod

1	The	the	DT	_	3	det
2	SNP	snp	NN	_	3	compound
3	drug1	drug1	NN	_	4	nsubj
4	shows	show	VBZ	_	0	ROOT
5	similar	similar	JJ	_	6	amod
6	trends	trend	NNS	_	4	dobj
7	,	,	,	_	4	punct
8	but	but	CC	_	4	cc
9	its	its	PRP$	_	10	nmod:poss
10	association	association	NN	_	16	nsubj
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	is	be	VBZ	_	16	cop
14	not	not	RB	_	16	neg
15	as	as	RB	_	16	advmod
16	strong	strong	JJ	_	4	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	OR	or	NN	_	16	dep
19	=	=	JJ	_	18	amod
20	1.39	1.39	CD	_	19	dep
21	,	,	,	_	18	punct
22	p	p	NN	_	23	nsubj
23	=	=	JJ	_	18	dep
24	0.152	0.152	CD	_	23	dobj
25	-RRB-	-rrb-	-RRB-	_	18	punct
26	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	DPS	DPS	NNP	_	12	nmod
4	,	,	,	_	12	punct
5	the	the	DT	_	7	det
6	TT	tt	NN	_	7	compound
7	genotype	genotype	NN	_	12	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	was	be	VBD	_	12	auxpass
11	significantly	significantly	RB	_	12	advmod
12	associated	associate	VBN	_	0	ROOT
13	with	with	IN	_	17	case
14	an	a	DT	_	17	det
15	adjusted	adjusted	JJ	_	17	amod
16	2.85-fold	2.85-fold	JJ	_	17	amod
17	risk	risk	NN	_	12	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	95	95	CD	_	20	compound
20	%	%	NN	_	21	amod
21	CI	ci	NN	_	17	dep
22	1.17-6	1.17-6	CD	_	23	compound
23	.95	.95	CD	_	21	nummod
24	,	,	,	_	21	punct
25	p	p	NN	_	26	nsubj
26	=	=	JJ	_	21	dep
27	0.021	0.021	CD	_	26	dobj
28	-RRB-	-rrb-	-RRB-	_	21	punct
29	of	of	IN	_	31	case
30	incident	incident	NN	_	31	compound
31	drug2	drug2	NN	_	17	nmod
32	in	in	IN	_	35	case
33	the	the	DT	_	35	det
34	control	control	NN	_	35	compound
35	group	group	NN	_	17	nmod
36	,	,	,	_	17	punct
37	but	but	CC	_	17	cc
38	not	not	RB	_	42	neg
39	in	in	IN	_	42	case
40	the	the	DT	_	42	det
41	intervention	intervention	NN	_	42	compound
42	group	group	NN	_	17	conj
43	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	T	t	NN	_	3	compound
3	allele	allele	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	was	be	VBD	_	8	auxpass
7	significantly	significantly	RB	_	8	advmod
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	decreased	decrease	VBN	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	Studies	study	NNS	_	11	appos
14	II	ii	CD	_	13	nummod
15	,	,	,	_	13	punct
16	III	iii	CD	_	13	nummod
17	-RRB-	-rrb-	-RRB-	_	13	punct
18	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	variant	variant	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	of	of	IN	_	6	case
6	TCF7L2	tcf7l2	NN	_	4	nmod
7	was	be	VBD	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	incident	incident	NN	_	11	compound
11	drug2	drug2	NN	_	8	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	DPS	dps	NN	_	11	nmod
15	and	and	CC	_	14	cc
16	in	in	IN	_	21	case
17	a	a	DT	_	21	det
18	separate	separate	JJ	_	21	amod
19	population-based	population-based	JJ	_	21	amod
20	cross-sectional	cross-sectional	JJ	_	21	amod
21	study	study	NN	_	14	conj
22	.	.	.	_	8	punct

1	We	we	PRP	_	2	nsubj
2	genotyped	genotype	VBD	_	0	ROOT
3	6,516	6,516	CD	_	4	nummod
4	participants	participant	NNS	_	2	dobj
5	for	for	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	and	and	CC	_	2	cc
10	analysed	analyse	VBD	_	2	conj
11	the	the	DT	_	12	det
12	role	role	NN	_	10	dobj
13	in	in	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	susceptibility	susceptibility	NN	_	12	nmod
16	using	use	VBG	_	10	xcomp
17	binary	binary	JJ	_	19	amod
18	logistic	logistic	JJ	_	19	amod
19	regression	regression	NN	_	16	dobj
20	.	.	.	_	2	punct
21	Age	Age	NNP	_	26	compound
22	,	,	,	_	21	punct
23	sex	sex	NN	_	21	conj
24	and	and	CC	_	21	cc
25	obesity	obesity	NN	_	21	conj
26	status	status	NN	_	28	nsubjpass
27	were	be	VBD	_	28	auxpass
28	examined	examine	VBN	_	2	parataxis
29	as	as	IN	_	30	case
30	covariates	covariate	NNS	_	28	nmod

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	All	all	DT	_	5	det
4	investigated	investigate	VBN	_	5	amod
5	polymorphisms	polymorphism	NNS	_	8	nsubjpass
6	were	be	VBD	_	8	auxpass
7	significantly	significantly	RB	_	8	advmod
8	associated	associate	VBN	_	1	dep
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	drug1	drug1	NN	_	14	nsubj
14	showed	show	VBD	_	8	conj
15	the	the	DT	_	17	det
16	strongest	strongest	JJS	_	17	amod
17	association	association	NN	_	14	dobj
18	-LRB-	-lrb-	-LRB-	_	24	punct
19	T	t	NN	_	24	dep
20	vs	vs	CC	_	19	cc
21	G	g	NN	_	19	conj
22	,	,	,	_	24	punct
23	chi2	chi2	NN	_	24	nsubj
24	=	=	JJ	_	17	dep
25	9.20	9.20	CD	_	24	dobj
26	,	,	,	_	24	punct
27	p	p	NN	_	28	nsubj
28	=	=	JJ	_	24	parataxis
29	0.0024	0.0024	CD	_	28	dobj
30	,	,	,	_	24	punct
31	odds	odds	NNS	_	32	compound
32	ratio	ratio	NN	_	33	nsubj
33	=	=	JJ	_	24	parataxis
34	1.70	1.70	CD	_	33	dobj
35	,	,	,	_	24	punct
36	95	95	CD	_	37	compound
37	%	%	NN	_	38	amod
38	CI	ci	NN	_	24	dep
39	=	=	JJ	_	38	amod
40	1.20-2	1.20-2	CD	_	41	nummod
41	.41	.41	CD	_	39	dep
42	-RRB-	-rrb-	-RRB-	_	24	punct
43	,	,	,	_	8	punct

1	However	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	showed	show	VBD	_	0	ROOT
5	association	association	NN	_	4	dobj
6	with	with	IN	_	9	case
7	30	30	CD	_	9	nummod
8	'	'	''	_	9	punct
9	Deltainsulin	Deltainsulin	NNP	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug2	drug2	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	in	in	IN	_	15	case
14	an	a	DT	_	15	det
15	interaction	interaction	NN	_	5	nmod
16	with	with	IN	_	17	case
17	percentage	percentage	NN	_	15	nmod
18	of	of	IN	_	20	case
19	body	body	NN	_	20	compound
20	fat	fat	NN	_	17	nmod
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	Bonferroni-corrected	bonferroni-corrected	JJ	_	23	amod
23	P	p	NN	_	20	dep
24	=	=	JJ	_	23	amod
25	0.027	0.027	CD	_	24	dep
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	also	also	RB	_	3	advmod
3	showed	show	VBD	_	0	ROOT
4	an	a	DT	_	5	det
5	association	association	NN	_	3	dobj
6	with	with	IN	_	8	case
7	beta-cell	beta-cell	NN	_	8	compound
8	compensation	compensation	NN	_	5	nmod
9	for	for	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	based	base	VBN	_	5	acl
12	on	on	IN	_	15	case
13	30	30	CD	_	15	nummod
14	'	'	''	_	15	punct
15	Deltainsulin	Deltainsulin	NNP	_	11	nmod
16	in	in	IN	_	18	case
17	an	a	DT	_	18	det
18	interaction	interaction	NN	_	11	nmod
19	with	with	IN	_	20	case
20	percentage	percentage	NN	_	18	nmod
21	of	of	IN	_	23	case
22	body	body	NN	_	23	compound
23	fat	fat	NN	_	20	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	Bonferroni-corrected	bonferroni-corrected	JJ	_	26	amod
26	P	p	NN	_	23	dep
27	=	=	JJ	_	26	amod
28	0.014	0.014	CD	_	27	dep
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	also	also	RB	_	4	advmod
4	associated	associate	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	odds	odds	NNS	_	9	compound
9	ratio	ratio	NN	_	6	dep
10	-LSB-	-lsb-	-LRB-	_	11	punct
11	OR	or	NN	_	9	appos
12	-RSB-	-rsb-	-RRB-	_	11	punct
13	2.49	2.49	CD	_	9	nummod
14	-LSB-	-lsb-	-LRB-	_	17	punct
15	95	95	CD	_	16	compound
16	%	%	NN	_	17	amod
17	CI	ci	NN	_	9	appos
18	1.17-5	1.17-5	CD	_	19	nummod
19	.31	.31	NN	_	17	dep
20	-RSB-	-rsb-	-RRB-	_	17	punct
21	;	;	:	_	9	punct
22	P	p	NN	_	23	nsubj
23	=	=	JJ	_	9	dep
24	0.018	0.018	CD	_	23	dobj
25	-RRB-	-rrb-	-RRB-	_	9	punct
26	in	in	IN	_	29	case
27	our	we	PRP$	_	29	nmod:poss
28	case-control	case-control	JJ	_	29	amod
29	sample	sample	NN	_	6	nmod
30	.	.	.	_	4	punct

1	We	we	PRP	_	2	nsubj
2	observed	observe	VBD	_	0	ROOT
3	nominal	nominal	JJ	_	4	amod
4	association	association	NN	_	2	dobj
5	between	between	IN	_	7	case
6	four	four	CD	_	7	nummod
7	SNPs	snp	NNS	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug1	drug1	NN	_	7	dep
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug3	drug3	NN	_	9	conj
14	,	,	,	_	9	punct
15	and	and	CC	_	9	cc
16	drug4	drug4	NN	_	9	conj
17	-RRB-	-rrb-	-RRB-	_	9	punct
18	in	in	IN	_	21	case
19	three	three	CD	_	21	nummod
20	haplotype	haplotype	NN	_	21	compound
21	blocks	block	NNS	_	4	nmod
22	and	and	CC	_	21	cc
23	drug5	drug5	NN	_	21	conj
24	,	,	,	_	4	punct
25	age	age	NN	_	4	conj
26	at	at	IN	_	27	case
27	diagnosis	diagnosis	NN	_	25	nmod
28	,	,	,	_	4	punct
29	and	and	CC	_	4	cc
30	2-h	2-h	JJ	_	32	amod
31	glucose	glucose	NN	_	32	compound
32	levels	level	NNS	_	4	conj
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	P	p	NN	_	35	nsubj
35	=	=	JJ	_	32	dep
36	0.001-0	0.001-0	CD	_	37	nummod
37	.055	.055	CD	_	35	dobj
38	-RRB-	-rrb-	-RRB-	_	35	punct
39	.	.	.	_	2	punct

